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1 1  .SYMPTOMS
The medical history is the cornerstone of the evaluation of the urologic patient and 
a well-taken history will frequently elucidate the probable diagnosis. The urologist 
must lead the patient through detailed and appropriate questioning to obtain accu-
rate information.
1 1 1  .Systemic .manifestations
Symptoms of fever and weight loss should be checked. The presence of fever 
associated with other symptoms of UTIs may be helpful in evaluating the site of 
the infection. Acute pyelonephritis or prostatitis will lead to high temperatures, 
often accompanied by chills. Infants and children who have acute pyelonephritis 
may have high temperatures without other localizing symptoms or signs. A history 
of unexplained attacks of fever occurring even years before may represent other-
wise asymptomatic pyelonephritis. The absence of fever does not rule out renal 
infection. Chronic pyelonephritis does not cause fever. Weight loss is expected in 
the advanced stages of cancer, but it may be noticed also when there is CRF. In 
children who have low weight and less than average height, chronic obstruction, 
UTis or both should be suspected. General malaise may be noted with tumors, 
chronic pyelonephritis or CRF. The presence of many of these symptoms may be 
compatible with HIV infection. RCC sometimes causes fever.
Paraneoplastic .syndromes
Paraneoplastic syndromes are defined as a collection of symptoms and clinical 
signs occurring in cancer patients and involving systemic effects taking place re-
motely from the tumor. They are not related either to its local invasion or distant 
meastasis and are not caused by infection, nutritional deficiency or treatment. 
A paraneoplastic syndrome etiology:
• Bilogically active substances (hormonal peptides or hormone-like substances, 
biologic amines, growth factors) aberrantly produced by the tumor;
• Stimulation of the immune system via autoimmunity, immune complexes pro-
duction and immune suppression;
Detection of this syndrome can lead to the diagnosis of a previously undetected 
neoplasm. It can dominate the clinical picture and thus lead to errors with respect 
to the origin and type of primary tumor. It can follow the clinical course of the 
tumor and thus be useful for monitoring its evolution. 
All GUT tumors may cause this syndrome, even though RCC is the most frequent 
urological malignancy involved. Although some syndromes, such as polycythemia 
and hypertension, are more typical of RCC, others, such as hypercalcemia and 
Cushing’s syndrome, are common to other GUT cancers. PC is the second urologi-
cal tumor associated with paraneoplastic syndrome. This syndrome is uncommon in 
BC and rare in TC. Paraneoplastic hypercalcemia represents the most common case.
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When evaluating an individual with new onset nonurological symptoms sug-
gestive of paraneoplastic syndrome, clinicians should consider the presence of an 
underlying malignancy, including GUT carcinomas. Imaging studies may be use-
ful to detect the primary tumor in patients. The most effective treatment strategy 
is represented by the radical therapy of the underlying cancer.
Gynecomastia
Often idiopathic, gynecomastia is common in elderly men, particularly those tak-
ing estrogens for PC. It is also seen in association with TC. Certain endocrinologic 
diseases, for example, Klinefelter syndrome, may also cause gynecomastia. Male 
patients with obesity have false gynecomastia.
Urosepsis
Patients with urosepsis should be diagnosed at an early stage, especially in the case of 
a complicated UTI. The systemic inflammatory response syndrome, known as SIRS 
(temperature (>38°C or <36°C)), hyperleukocytosis or leukopenia (WBC >12000 
cells/mm3 or <4000 cells/mm3 or >10% immature forms), tachycardia (>90 bpm), 
tachypnoea (respiratory rate >20 breaths/min or PaCO2 <32 mmHg), is recognised 
as the first event in a cascade to multi-organ failure. SIRS is response to a wide 
variety of clinical insults, which can be infectious, as in sepsis but may be non-in-
fectious in etiology (e.g. burns or pancreatitis). The prognosis of urosepsis is globally 
better than that of sepsis from other infectious sites.
The clinical evidence of UTI is based on symptoms, physical examination, 
sonographic and radiological features and laboratory data, such as bacteriuria 
and leukocyturia. Infection is presence of organisms in a normally sterile site that 
is usually, but not necessarily, accompanied by an inflammatory host response. 
Bacteraemia is presens of bacteria in blood as confirmed by culture, which may be 
transient and not nesessary for diagnosis of urosepsis.
Sepsis is activation of the inflammatory process due to infection. 
Severe sepsis is associated with organ dysfunction, hypoperfusion or hypoten-
sion. Hypoperfusion and perfusion abnormalities may include but are not limited 
to lactic acidosis, oliguria or acute alteration of mental status.
Septic shock is sepsis with hypotension despite adequate fluid resuscitation along 
with the presence of perfusion abnormalities. Patients who are on inotropic or va-
sopressor agents may not be hypotensive at the time that perfusion abnormalities 
are measured. Refractory septic shock lasts for >1h and does not respond to fluid 
administration or pharmacological intervention. Mortality is considerably increased 
when severe sepsis or septic shock are present.
There are combination of treatment options for management of urosepsis. The 
drainage of any obstruction in the urinary tract is essential as first-line treatment. Urol-
ogists are recommended to treat patients in collaboration with ICU. Most nosocomial 
urosepsis can be avoided by reduction of hospital stay, early removal of indwelling 
urethral catheters and avoidance of unnecessary catheterisations, using of closed cath-
eter systems and attention to simple daily aseptic techniques to avoid cross-infection.
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1 1 2  .Flank .pain
This can present suddenly as severe acute pain in the flank reaching a peak within 
minutes or hours. Alternatively, it may have a slower course of onset as a chronic 
loin pain, developing over weeks or months. Loin pain is frequently presumed to 
be urological in origin. However, other non-urologic organs are located in this 
region. Diseases of non-urological organs may be the source of the pain and pain 
arising from extra-abdominal organs may radiate to the loins as a “referred” pain. 
The most common cause of sudden onset of severe acute loin pain in the flank 
is the passage of a stone formed in the kidney, down through the ureter. Ureteric 
stone pain characteristically starts very suddenly. This pain is colicky in nature. 
Waves of increasing severity are followed by a reduction in severity, although sel-
dom going away completely. It radiates to the groin as the stone passes into the 
lower ureter. The pain may change in location, from flank to groin, but its location 
does not provide a good indication of the position of the stone, except where the 
patient has pain or discomfort in the penis and a strong desire to void, which sug-
gests that the stone has moved into the distal part of the ureter. The patient cannot 
get comfortable. They often roll around in agony. Those with peritonitis lie still.
Flank .pain: .non-stone .urological .causes
A clot may form from a bleeding source within the kidney (e.g. RCC and injury). 
Similarly, a ureteric cancer may cause ureteric obstruction and acute loin pain. 
Loin pain and hematuria are often assumed to be due to a stone, but it is im-
portant to do investigation of such patients from the perspective of  upper urinary 
tract cancer.
PUJO may present acutely with flank pain severe enough to mimic a ureteric 
stone. Investigations will demonstrate hydronephrosis, with a normal calibre ureter 
below the PUJ and no stone. 
Patient may have acute loin pain if there is UTIs (acute pyelonephritis or pyo-
nephrosis). These patients have a high fever and no signs of obstruction. On the 
contrary, ureteric stone patients with obstructive pyelonephritis are often system-
ically very unwell. History, physical examination, US and radiological methods 
are clearly important for distinguishing urological from non-urological loin pain. 
Palpate the abdomen for signs of peritonitis (abdominal tenderness and/or guard-
ing) and examine for abdominal masses. Examine the patient’s back, chest and 
testicles. In women, do a pregnancy test and gynecological exam.
Flank .pain: .non-urological .causes
There are many causes for non-urological pain syndrome:
• Pneumonia;
• Myocardial infarction;
• Ovarian pathology (e.g. twisted ovarian cyst, adnexitis);
• Ectopic pregnancy;
• Leaking abdominal aortic aneurysm;
• Acute appendicitis;
• Inflammatory bowel disease (Crohn’s, ulcerative colitis);
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• Diverticulitis;
• Burst peptic ulcer;
• Bowel obstruction;
• Spinal cord disease.
1 1 3  .Scrotal .symptoms
Scrotal pain may be observed by torsion of the testicles and testicular appendages, 
epididymo-orchitis, testicular tumours and as a referred pain by ureteric colic and 
prostatitis.
Ischaemic pain by testicular torsion is severe. Torsion presents with sudden 
onset of pain in the hemiscrotum. Pain may radiate to the groin and/or loin. 
There is sometimes a history of mild trauma to the testis. Similar episodes may 
have occurred in the past, with spontaneous resolution of the pain, suggesting 
torsion/spontaneous detorsion. The testis is very tender and “high-riding”, lying 
at a higher than normal position in the testis. Testis may lie horizontally and there 
is scrotal erythema.
Patient with epididymo-orchitis has similar presenting symptoms as testicular 
torsion. Tenderness is usually localized to the epididymis (posterior part of the 
testis).
Patient with testicular tumour rare present with testicular pain. Testicular swell-
ing may occur rapidly. An secondary hydrocele is common. A hydrocele in a 
young person should always be investigated with an US to determine whether 
the underlying testis is normal. Approximately 10-15% of testis tumours present 
with signs suggesting inflammation. Often there are signs suggesting a diagnosis 
of epididymo-orchitis with a tender, swollen testis, with redness in the overlying 
scrotal skin and a fever.
Lumps in the scrotum and in the groin  may be observed in patients with hy-
drocele, epididymal cyst, testicular tumour, varicocele, TB, epididymo-orchitis 
and inguinal hernia.
A hydrocele is an abnormal collection of peritoneal fluid between the pari etal 
and visceral layers of the tunica vaginalis. Normally the processus vaginalis be-
comes obliterated along its entire length, apart from where it surrounds the testis. 
Hydrocele may be primary and secondary. Primary hydrocele usually painless. A 
hydrocele has a smooth surface and it is difficult or impossible to feel the testis 
which is surrounded by the tense, fluid collection. Unless, rarely, the hydrocele 
is very lax. The superior margin can be palpated. It is possible to transilluminate 
a hydrocele. The light from a torch applied on one side can be seen on the other 
side of the hydrocele. Primary hydroceles develop slowly and there is no precipi-
tating event such as epididymoorchitis or trauma and the underlying testis appears 
normal on US. Secondary hydro celes may be due to infection, tumour and trauma 
represent an effusion between the layers of the tunica vaginalis. In filariasis, ob-
struction of the lymphatics of the spermatic cord give rise to the hydrocele.
Epididymal cyst also known as a spermatocele. Derived from the collecting 
tubules of the epididymis and contain clear fluid. They develop slowly, lie within 
the scrotum  and usually lie above and behind the testis. They are often multiple.
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In the absence of involvement of the epididymitis, inflammation of the testis is 
due to a viral infection e.g. mumps. Often occurs with enlargement of the salivary 
glands.
Tuberculous epididymo-orchitis is infection of the epididymis by ТВ, which has 
spread from the blood or urinary tract. The absence of pain and tenderness is no-
ticeable. The epididymis is hard and has an irregular surface. The spermatic cord is 
thickened and the vas deferens also feels hard and irregular as a “string of beads”.
Testicular tumour is a solid mass, arising from within the scrotum and may extend 
up into the spermatic cord. They may present with symptoms of an acute epididy-
mo-orchitis. They may have undergone an orchidopexy for UDT. The lump is usually 
hard and may have a smooth or irregular surface. Abdominal and supraclavicular 
lymph nodes are examined.
Varicocele is the dilatation of the pampiniform plexus more common on the 
left side. They may cause a dragging sensation or ache in the scrotum. Patients 
with III stage of the disease feel like a “bag of worms” in the scrotum. Primary 
varicocele disappears when the patient lies down.
An indirect inguinal hernia often extends into the scrotum. It usually expands 
on coughing. This hernia usually reduces with direct pressure or on lying down. 
It is not possible to get above the lump. Since inguinal and femoral hernias arise 
from within the abdomen and descend into the groin, it is not possible to get 
above them. For lumps that arise from within the scrotum, the superior edge 
can be palpated. Once a hernia has protruded through the abdominal wall, it can 
expand in any direction in the subcutaneous tissues and therefore the position of 
the unreduced hernia cannot be used to establish whether it is inguinal or femoral. 
Inguinal hernia reduces through the abdominal wall at a point above and medial 
to the pubic tubercle. An indirect inguinal hernia often descends into the scrotum, 
but direct inguinal hernia rarely does. Femoral hernia reduces through the abdom-
inal wall at a point below and lateral to the pubic tubercle.
1 1 4  .Penile .and .urethral .symptoms
Phimosis is a condition in which the contracted foreskin cannot be retracted over 
the glans. Chronic infection from poor local hygiene is its most common cause of 
secondary phimosis. Calculi and SCC may develop under the foreskin. Phimosis 
can occur at any age. In diabetic older men, chronic balanoposthitis may lead to 
phimosis and may be the initial presenting complaint. Children under 2 years of 
age seldom have true phimosis. Their relatively narrow preputial opening gradually 
widens and allows for normal retraction of foreskin over the glans. Edema, erythe-
ma and tenderness of the prepuce and the presence of purulent discharge usually 
cause the patient to seek medical care.  
Paraphimosis is the condition in which the foreskin, once retracted over the 
glans, cannot be replaced in its normal position. This is complication of the phi-
mosis. The skin ring causes venous congestion leading to edema and enlargement 
of the glans with significant risk of necrosis.
Peyronie’s disease is plastic induration of the penis and is a well-recognized 
clinical problem affecting middle-aged and older men. Patients present with com-
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plaints of painful erection and curvature of the penis. The penile deformity may 
be so severe that it prevents satisfactory vaginal penetration. The patient has no 
pain and no curvature when the penis is non-erect. Examination of the penile 
shaft reveals a palpable dense, fibrous plaque of varying size involving the tunica 
albuginea. Multiple plaques are sometimes seen. In severe cases, calcification and 
ossification are noted. Although the cause of Peyronie’s disease remains obscure, 
the dense fibrous plaque is microscopically consistent with findings of Dupuytren’s 
contracture of the tendons of the hand.
Priapism – is painful, persistent, prolonged erection of the penis mre than 4 
hours and not related to sexual stimulation. There are two broad categories - low-
flow (most common) and high-flow. Low-flow priapism may be due to hemato-
logical disease and malignant infiltration of the corpora cavernosa or papaverine 
injection intracavernosly. Priapism is painful because the corpora are ischaemic. 
High-flow priapism is painless and may arise due to perineal trauma, which cre-
ates an arteriovenous fistula. Diagnosis is usually obvious from the history and 
examination of the erect, tender penis in low-flow priapism. Characteristically, the 
corpora cavernosa are rigid and the glans is flaccid.
Acquired urethral stricture is common in men but rare in women. Most ac-
quired strictures are due to infection or trauma. Although GU is seldom a cause of 
stricture today, UTIs remains a major cause, particularly infection from long-term 
use of indwelling urethral catheters. Large catheters and instruments are more 
likely to cause ischemia and internal trauma. External trauma, for example, pelvic 
fractures can partially or completely sever the membranous urethra and cause se-
vere and complex urethral obliterations. Straddle injuries can produce bulbar stric-
tures. These narrowings restrict urine flow and cause dilation of the proximal ure-
thra and prostatitis. The bladder muscle may become hypertrophic and increased 
PVR may be noted. Severe, prolonged obstruction can result in VUR, UHN and 
CRF. Chronic urinary stasis makes UTIs likely. Urethral fistulas and periurethral 
abscesses commonly develop in association with chronic, severe strictures.
Condylomata acuminata are uncommon in the urethra and are almost always 
preceded by lesions on the penile skin. They are wart-like papillomas caused by 
a papilloma virus and are usually transmitted by direct sexual contact but may be 
transmitted nonsexually. Patients commonly complain of bloody spotting from the 
urethra and occasionally have dysuria and urethral discharge. Examination of the 
urethral meatus often reveals a small, protruding papilloma. If a lesion is not found 
in this location, the meatus should be separated with the examining fingers so that 
the distal urethra can be inspected. The sexual partner must also be examined and 
treated if necessary.
1 1 5  .Urinary .incontinence
Stress urinary incontinence is the complaint of involuntary leakage of urine on 
effort of exertion, sneezing or coughing. A diagnosis of urodynamic SUI is made 
during filling cystometry when there is involuntary leakage of urine during a rise 
in abdominal pressure induced by coughing, in the absence of a detrusor contrac-
tion. SUI occurs as a result of bladder neck/urethral hypermobility and/or neuro-
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muscular defects causing ISD. It is called sphincter weakness incontinence. As a 
consequence, urine leaks whenever ure thral resistance is exceeded by an increased 
abdominal pressure.
Urge urinary incontinence is the complaint of any involuntary leakage of urine 
accompanied by or immediately preceded by urgency. UUI may be due to neu-
rogenic or idiopathic OAB or more commonly due to pathology that irritates the 
bladder (infection, tumour, stone).
Mixed urinary incontinence is a combination of SUI and UUI. 
Overflow incontinence is bedwetting in an elderly man usually indicates high 
pressure chronic retention due to presence of BOO.
A constant leak of urine suggests a fistulous communication between the blad-
der and vagina due to surgical injury at the time of hysterectomy or caesarian 
section or, rarely, the presence of an ectopic ureter draining into the vagina. In 
this case the urine leak is usually low in volume, but lifelong. It is called false 
incontinence.
1 1 6  .Nocturia .and .nicturia
Nicturia is empirically defined as the production of more than one-third of 24-h 
urine output between midnight and 8 a.m. Nicturia may lead to sleep disturbance. 
Nicturia is associatiated with endocrine, renal and cardiovascular disease (CRF, 
DM, central and nephrogenic diabetes insipidus, primary polydipsia, hypercalcae-
mia, drugs, autonomic failure).
Nocturia can be due to urological disease and this is a frequent urinations 
during the night due to BPH, OAB or incomplete bladder emptying.
Ask the patient to complete a FVC, which is a voiding diary that records time 
and volume of each void over a 24-h period for 7 days. Polyuria is defined em-
pirically as >3 L of urine output per 24 h. Polyuria may be due to either a solute 
diuresis or a water diuresis. Measure urine osmolality: <250 mOsm/kg = water 
diuresis, >300 mOsm/kg = solute diuresis. Excess levels of various solutes in the 
urine, such as glucose in the poorly controlled diabetic, lead to a solute diuresis. A 
water diuresis occurs in patients with primary polydipsia as an apropriate physio-
logical response to high water intake and diabetes insipidus de to ADH deficiency 
or resistance.
1 2  .PHYSICAL .EXAMINATION .OF .THE .UROLOGICAL .PATIENT
1 2 1  .Abdominal .examination .of .the .patient .with .urological .disease
Because of their retroperitoneal (kidneys, ureters) or pelvic location (bladder 
and prostate) these organs are relatively inaccessible to the examining hand when 
compared with, for example, the spleen, liver or bowel. For the same reason, for 
the kidneys and bladder to be palpable implies a fairly advanced disease state.
It is important that the urologist appreciates the characteristics of other in-
tra-abdominal organs when involved with disease, so that they may be distin-
guished from urological organs.
Characteristics and causes of an enlarged kidney (RCC, hydronephrosis, pyo-
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nephrosis, perinephric abscess, polycystic disease): the mass lies in a paracolic 
gutter, it moves with respiration, is dull to percussion and can be felt bimanually. 
It can also be balloted between your hands, one placed on the anterior abdominal 
wall and one on the posterior abdominal wall.
Characteristics and causes of an enlarged bladder (BPH, PC, urethral stricture): 
arises out of the pelvis, dull to percussion, pressure of examining hand may cause 
a desire to void.
Enlarged inguinal lymph nodes are palpated as a firm, non-compressible, nod-
ular lump in the groin and abdomen. Look for pathology in the skin of the scro-
tum and penis, the peri-anal area and anus, the skin and superficial tissues of the 
thigh and leg.
Testis may be on the correct anatomical path, but may have failed to reach 
the scrotum if there are abdominal or inguinal UDT. Testis have descended away 
from the normal anatomical path is called ectopic testis. The lump is smooth, 
oval, tender to palpation, non-compressible and there is no testis in the scrotum.
1 2 2  .Digital .rectal .examination
Prostate is located on the anterior part of the rectum. The DRE is the mainstay 
of prostatic examination.
Rules of the DRE. The anal region is examined for fistulae and fissures. Lubri-
cant gel is applied to the gloved finger. Index finger is inserted gently and slowly 
into the anal canal, then into the rectum. Prostate is palpated anteriorly with the 
pulp of finger. Consistency (normal or firm), surface (smooth or irregular) are 
noted and size is estimated. It can be helpful to relate its size to common objects. 
A normal prostate is the size of a walnut. A moderately enlarged prostate has the 
appearance of a tangerine. A big prostate has the size of an apple or orange. The 
normal bilobed prostate has a median sulcus between the two lobes and in PC this 
groove may be obscured. Prostatic tenderness is best elicited by gentle pressure on 
the prostate with the examining finger. If there is acute prostatitis, prostate glad 
is very tender. By prostatic abscess there is a hole and fluctuation. DRE should 
be avoided in acute prostatitis becouse of septicaemia risk and in patients with an 
anal fissure, where DRE would be very painful.
The integrity of the sacral nerves that innervate the bladder and of the sacral 
spinal cord can be established by eliciting the bulbocavernosus reflex during a 
DRE. The sensory side of the reflex is elicited by squeezing the glans of the penis 
or the clitoris. In catheterized patients reflex is estimated by gently pulling the bal-
loon of the catheter onto the bladder neck. The motor side of the reflex is tested by 
feeling for contraction of the anus during this sensory stimulus. Contraction of the 
anus represents a positive reflex and indicates that the afferent and efferent nerves 
of the sacral spinal cord (S2-S4) and the sacral cord are intact.
1 3  .URINE .EXAMINATION
1 3 1  .Dipstick .testing
Analysis for pH, blood, protein, glucose and WBC can be done with dipstick test-
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ing. Urinary pH varies between 4.5 and 8, averaging between 5.5 and 6.5. Normal 
urine contains <3 RBCs per HPF. Positive dipstick for blood indicates the pres-
ence of hemoglobin in the urine. Sensitivity of urine dipsticks for identifying he-
maturia is >3 RBCs/HPF is >90%. Specificity is lower. Higher false positive rate 
with the dipstick may be due to contamination with menstrual blood, dehydration.
Hematuria due to a urological cause does not elevate urinary protein. Hema-
turia of nephrological origin often occurs in association with casts and there is 
almost always significant proteinuria. Normal, healthy adults excrete about 80-150 
mg of protein per day in their urine. Normal protein concentration <20 mg/dl. 
Proteinuria suggests the presence of renal disease (glomerular, tubulo-interstitial, 
renal vascular) or multiple myeloma, but it can occur following strenuous exercise. 
Dipstick test is based on a tetrabromophenol blue dye colour change and green 
colour develops in the presence of protein of >20 mg/dL. 
Leukocyte esterase activity detects the presence of WBC in the urine. Leuko-
cyte esterase is produced by neutrophils and causes a color change in a chromogen 
salt on the dipstick. Not all patients with bacteriuria have significant pyuria. False 
negatives causes: concentrated urine, glycosuria, presence of urobilinogen, con-
sumption of large amounts of ascorbic acid. False positives causes: contamination.
Nitrites in the urine suggest the possibility of bacteriuria. They are not nor-
mally found in the urine. Many species of gram negative bacteria can convert 
nitrates to nitrites and these are detected in urine by a reaction with the reagents 
on the dipstick, which form a red azo dye. The specificity of the nitrite dipstick 
for detecting bacteriuria is >90%. False positive nitrite testing may be due to 
contamination. Sensitivity is 35-85%. Test is less accurate in urine containing 
fewer than 105 organisms/ml. Cloudy urine that is positive for WBC and nitrite is 
very likely to be infected.
1 3 2  .Urine .microscopy .
Urine microscopy is performed with help of phase-contrast microscopy. RBCs 
derived from the glomerulus are dysmorphic because of their passage through the 
glomerulus. RBCs derived from tubular bleeding by tubulointerstitial disease and 
those due to urinary tract diseases have a normal shape. Glomerular bleeding is 
suggested by the presence of dysmorphic RBCs, casts and proteinuria.
A protein coagulum formed in the renal tubule has an appearance of “cast” in 
the shape of the tubule. The protein matrix traps tubular luminal contents. If the 
cast contains only mucoproteins it is called a hyaline cast seen after exercise, heat 
exposure, pyelonephritis or CRD. RBCs casts contain trapped erythrocytes and 
are diagnostic of glomerular bleeding, most often due to GN. WBCs casts are seen 
in acute GN, acute pyelonephritis and acute tubulointerstitial nephritis.
Specific crystal types may be seen in urine and help diagnose stone disease. 
Cystine crystals establish the diagnosis of cystinuria. Calcium oxalate, uric acid 
and cystine are precipitated in acidic urine. Crystals precipitated in alkaline urine 
include calcium phosphate and triple-phosphate.
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1 3 3  .Urine .cytology
Exfoliated cells lying in urine for several hours are degenerated. Such urine spec-
imens are not suitable for cytological interpretation. Cytological examination can 
be performed on bladder washings with normal saline obtained from the bladder 
at cystoscopy or following catheterization or from the ureter via a ureteric catheter 
or ureteroscope. The urine is centrifuged and the specimen obtained is fixed in 
alcohol and stained by the Papanicolaou technique. Normal urothelial cells are 
shed into the urine and under the microscope their nuclei appear regular and 
monomorphic with diffuse, fine chromatin pattern and single nucleolus.
Causes of a positive cytology report may be by urothelial malignancy (TCC, 
SCC, adenocarcinoma), previous radiotherapy, previous cytotoxic drug (e.g. cyclo-
phosphamide, busulfan, ciclosporin) treatment and urinary tract stones.
High-grade TCC and CIS exfoliate cells, which look very abnormal. Abnormal 
urothelial cells have high nuclear/cytoplasmic ratio, hyperchromatic and promi-
nent nuclei.
1 4  .ENDOSCOPY
1 4 1  .Urethroscopy
To identify and aid in treating urethral pathology, endoscopic inspection via 
a urethrocystoscope with a 0° lens is helpful. Strictures are characterized by 
circumferential narrowing. It is difficult to identify the true extent and depth 
of a stricture solely by vision because scarring can involve deeper tissues. Ure-
thral diverticulum, BPH, bladder neck sclerosis, chronic inflammation can be 
identified with urethroscopy. Urethroscopy can be used for identification and 
extraction of foreign bodies or calculi and to access biopsy-suspicious lesions. 
Urethroscopy allows endoscopic treatment of urethral condylomata.
1 4 2  .Cystoscopy
Endoscopic inspection of the bladder requires irrigation, illumination and optics. 
To optimize a complete examination, the rigid endoscope should be rotated and 
0°, 30°, 70° lenses may be required. Suprapubic pressure facilitates inspection of 
the anterior wall of the bladder. Bladder dome frequently has an air bubble. A 
systematic approach is required when evaluating the urethra, prostate, bladder 
walls, dome and neck and ureteral orifices, including location, number, shape and 
character of efflux. The bladder should be evaluated at different levels of filling. 
It is only after full distention of the bladder characteristic glomerulations and ec-
chymoses are seen in patients with interstitial cystitis. Cystoscopy is informative, 
especially in assessing prostate size and length of prostatic urethra. Rigid endosco-
py results in discomfort, which can be minimized with 1% lidocaine per urethra 
as a local anesthetic. 
Flexible endoscopes decrease patient discomfort and allow for instrumentation 
in the supine rather than the dorsal lithotomy position. They are now used rou-
tinely in an office setting for hematuria/tumor surveillance and double-J stent 
retrieval. Videoendoscopy with flexible scopes allows patients to visualize normal 
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and abnormal anatomy and thus helps them understand their pathology. Videoen-
doscopy reduces fluid contact to the urologist. However, there are disadvantages. 
Flexible scopes have smaller irrigating ports. As a result, changing lenses, assess-
ing residual urine and repeat evacuation of irrigant cannot be completed without 
entirely removing the endoscope. Rigid endoscopy allows for a greater variety of 
instrumentation, better optics and increased durability. Endoscopic inspection al-
lows for identification of calculi, foreign bodies and tumors and also is used for 
catheterization of ureters.
1 4 3  .Ureterorenoscopy
URS is endoscopy of the ureter up to the renal pelvis for both diagnostic evaluation 
and therapeutic intervention. Ureterorenoscopes are endoscopes for retrograde in-
sertion into the ureter. However, they also may be used in an antegrade fashion 
via a percutaneously established nephrostomy tract. Technical improvements in 
the last decade have led to the introduction of smaller caliber, more versatile 
instruments. Rigid ureterorenoscopes are available in sizes 6.9-12.6F and semi-
rigid fiberoptic ureterorenoscopes and flexible ureterorenoscopes may be found 
in sizes 6.2-9.3F. The smallest instruments are for diagnostic procedures only. 
Larger instruments, with a 3-6F working channel, can accept stone baskets, wire 
graspers, stone forceps, biopsy forceps and probes for stone disintegration. Flexible 
ureterorenoscopes follow the topographic anatomy of the ureter more easily and 
facilitate inspection of middle and lower renal calyces if a deflecting mechanism 
for the tip of the instrument is provided. Newer flexible ureterorenoscopes have 
270° deflecting tips, that allow access to virtually every calyx of the collecting 
system. However, the use of instrumentation through flexible nephroscopes is 
limited by the size and flexibility of working instruments such as stone forceps and 




• Lesions of ureter or renal pelvis;
• Hematuria from upper tract;
Therapeutic indications: 
• Ureteral stone treatment;
• Direct vision internal ureterotomy of ureteral strictures;
• Endoscopic resection and coagulation of ureteral tumors.
1 5  .ULTRASOUND
Sound is the mechanical propagation of pressure changes or waves, through a deform-
able medium. A wave frequency of 1 cycle/s (cps) is called a Hz. Sound frequencies 
greater than 20 kHz are beyond the range of human hearing and are called US. 
Medical sonography uses US to produce images. The frequencies commonly used in 
medical sonography are between 3.5 and 15 MHz. US waves for imaging are generated 
by transducers, devices that convert electrical energy to sound energy and vice versa. 
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These transducers are special piezoelectric crystals that emit US waves when they are 
deformed by an electrical voltage and, conversely, generate an electrical potential when 
struck by reflected sound waves. Thus, they act as both sonic transmitters and detec-
tors. In general concept, medical sonography resembles naval submarine sonar. US 
images are reflection images formed when part of the sound that was emitted by the 
transducer bounces back from tissue interfaces to the transducer. The sound, reflected 
by stationary tissues forms the data set for anatomic gray-scale images. The sound 
reflected by moving structures (eg, flowing blood in a vessel) has an altered frequency 
due to the Doppler effect. By determining the Doppler shift, vascular flow direction 
and velocity can be encoded graphically with spectral Doppler or by color Doppler. 
A more sensitive method of detecting flow, called power mode Doppler, is available 
on modern equipment. This technique displays the integrated power of the Doppler 
signal rather than the mean Doppler frequency shift. Direction or velocity of flow is not 
displayed in the power mode. Reflected sound received by the transducer is converted 
into electrical signals that are analyzed by computer algorithms and rapidly converted 
into video images viewed directly on a real-time display. Images are rapidly updated on 
the display, giving an integrated cross-sectional anatomic depiction of the site studied. 
Individual frames may be frozen during an examination for motion-free analysis and 
recording or continuous images may be recorded as digital or conventional video.
US is commonly used for the evaluation of the GUT organs. US is useful for 
assessing renal size and growth. For example, small echogenic kidneys suggest 
renal parenchymal disease, whereas a dilated pelvocaliceal system indicates an ob-
struction. Renal US is useful in detection and characterization of renal masses. US 
provides an effective method of distinguishing benign cortical cysts from potential-
ly malignant solid renal lesions. US may also be used to follow up mildly compli-
cated cysts detected on CT, for example, hyperdense cysts or cysts with thin sep-
tations. The differential diagnosis for echogenic renal masses includes renal stones, 
AML, renal cortical neoplasms, abscesses and hematomas. All echogenic renal 
masses should be correlated with clinical history and, if necessary, confirmed with 
another imaging modality or follow-up US. Thin-section CT showing fat within 
the renal lesion characterizes it as a benign AML and no further investigation is 
required. Echogenic lesions smaller than 1 cm are more difficult to characterize 
by CT owing to partial volume averaging. In the correct clinical setting, follow-up 
US rather than repeat CT may be more useful.
Doppler sonography is useful for the evaluation of renal vessels, vascularity of 
renal masses and complications following renal transplant. It can detect renal vein 
thrombosis, renal artery stenosis and ureteral obstruction prior to the development 
of hydronephrosis, arteriovenous fistulas and pseudoaneurysms. Perinephric fluid 
collections following renal transplantation, ESWL or acute obstructions are reli-
ably detected by US.
Applications of bladder sonography include assessment of bladder volume, wall 
thickness, detection of bladder calculi and tumors. The suprapubic transabdominal 
approach is most commonly used.
US of the testis has become an extension of the physical examination. The 
location of the testis allows the use of a high-frequency transducer (10-15 MHz), 
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which produces excellent spatial resolution. The addition of color Doppler so-
nography provides simultaneous display of morphology and blood flow. Normal 
low-resistance intratesticular arterial blood flow is consistently detected with pow-
er or color Doppler. US is highly accurate in differentiating intratesticular from 
extratesticular disease and in the detection of intratesticular pathology. US is 
commonly used to evaluate acute scrotum syndrome. It can distinguish between 
inflammatory processes, inguinal hernias and testicular torsion. In addition, ep-
ididymitis not responding to antibiotics within 2 weeks should be investigated 
further with scrotal US to exclude TC.
Developments in other imaging modalities have decreased the use of US in 
several clinical scenarios. Most patients with suspected renovascular hypertension 
are evaluated with CT or MRT rather than Doppler US. Unenhanced helical 
CT is now the initial procedure of choice for the evaluation of the patient with 
acute flank pain and suspected urolithiasis. In addition to rapidly and sensitively 
detecting renal stones without the need for i.v. contrast medium, helical CT also 
has the potential for identifying other causes of flank pain such as appendicitis 
and diverticulitis. In the past, a combination of KUB and US was advocated for 
the evaluation of hematuria, but recent studies indicate that, CT with IVU are the 
preferred modalities to evaluate this common clinical problem.
The main advantages of US are ease of use, high patient tolerance, non-inva-
siveness, lack of ionizing radiation, low relative cost and wide availability. Disad-
vantages include a relatively low signal-to-noise level, tissue non-specificity, lim-
ited field of view and dependence on the operator’s skill and the patient’s habitus.
Indications:
• Assessment of hematuria;
• Determination of nature of renal masses: US can differentiate simple benign 
cysts (smooth, well-demarcated wall, reflecting no echoes) from solid masses 
(almost always malignant cystic masses with solid components or multiple sep-
tae or calcificatione are malignant), from those casting an ‘acoustic shadow’;
• The presence/absence of hydronephrosis in patients with abnormal renal func-
tion;
• US guided nephrostomy insertion in patients with hydronephrosis and renal 
impairment or with infected, obstructed kidneys;
• US guided placement of a suprapubic catheter;
• TRUS investigation of prostate size and pathology;
• To assist prostate biopsy;
• Investigation of azoospermia;
• To image the urethra and establish the depth and extent of spongiofibrosis in 
urethral stricture disease;
• To differentiate benign lesions (hydrocele, epididymal cyst) from malignant 
testicular tumours (solid, echo poor or with abnormal echo pattern);
• To establish the presence/absence of testicular blood flow when combined with 
power Doppler in suspected torsion;
• Assessment of testicular trauma;
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• Investigation of infertility in the patients with varicoceles and testicular atrophy;
•  PVR urine volume measurement.
1 6  .RADIOLOGICAL .IMAGING
1 6 1  .A .plain .film
A plain film of the abdomen, frequently called a KUB film, is the simplest urora-
diologic examination. It is generally the preliminary film in extended radiologic 
examinations. It may demonstrate osseous abnormalities, abnormal calcifications 
or large soft-tissue masses. Kidney outlines usually can be seen on the plain film, 
so that their size, number, shape and position can be assessed. The length of the 
kidney is the most widely used and most convenient radiographic measurement. 
The average adult kidney is about 12-14 cm long. In children older than 2 years 
of age, the length of a normal kidney is approximately equal to the distance from 
the top of the first to the bottom of the fourth lumbar vertebral body. Patterns of 
calcification in the urinary tract may help to identify specific diseases.
KUB is used for detection of stones and determination of their size and their 
location within the kidneys, ureters and bladder. If there is intrarenal calcification 
and it moves with the kidney, this is renal stone. If in doubt get an US. Stone has 
the characteristic ‘acoustic shadow’ within the kidney. IVU or CT will confirm 
diagnosis. CTU or IVU, which relate the position of the opacity to the anatomical 
location of the ureters, are required to make a definitive diagnosis of a ureteric 
stone. However, once the presence of a ureteric stone has been confirmed by an-
other imaging study (CTU or IVU) and as long as it is radio-opaque enough and 
large enough to be seen, plain radiography is a good way of following the patient 
to establish whether the stone is progressing distally, down the ureter. It is not 
useful for ‘following’ uret eric stones that are radiolucent, small (generally a stone 
must be 3-4 mm to be visible on plain X-ray) or when the stones pass through 
the ureter as it lies over the sacrum. Ability of KUB X-ray to ‘see’ stones is also 
dependent on amount of overlying bowel gas. Opacities that may be confused 
with stones on plain radiography are: calcified lymph nodes and pelvic phleboliths 
(round, lucent centre, usually below the ischial spines).
1 6 2  .Intravenous .urography
A KUB is obtained before contrast is given to look for calcification overlying 
the region of  GUT organs. Intravascular contrast is administered followed by a 
series of examinations, to image their anatomy and pathology and to give some 
indication of renal function. Nephrogram phase is first phase of IVU. Film tak-
en immediately following i.v. administration of contrast shows peak nephrogram 
density. The contrast medium is concentrated in the pelvicalyceal system and thus 
this ‘pyelogram’ phase is much denser than the nephrogram phase. The pyelo-
gram phase can be made more dense by dehydrating the patient prior to contrast 
administration. 
Side-effects of administration of i.v. contrast media occur in 1% of patients 
given non-ionic and 5% given ionic contrast media. The most serious reactions 
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represent an anaphylactic reaction - hypotension with flushing of the skin (marked 
peripheral vasodilatation), edema (face, neck, body and limbs), bronchospasm, 
urticaria. Rarely, cardiac arrest can occur. A contrast reaction is more likely to 
occur in patients with an iodine allergy, previous contrast reaction, asthma, mul-
tiple other allergies and heart disease and is less likely with non-ionic contrast 
media. Steroid premedication at least 12 h before can reduce the risk of a contrast 
reaction. Contrast media are also nephrotoxic. 10% of patients with a raised Cr 
will develop an increase in Cr after an IVU. This is more likely in DM, with 
dehydration and with large contrast doses. The increase in Cr usually resolves 
spontaneously.
Indications for imaging:
• Investigation of hematuria: detection of renal masses, filling defects within the 
collecting system of the kidney and within the ureters, which may be stones or 
TCCs;
• Localization and confirmation of calcification overlying the urinary tract;
• Investigation of patients with loin pain and suspected ureteric colic;
• Identification of congenital urinary tract abnormalities;
• Identifying of strictures. 
1 6 3  .Retrograde .urography
This is a invasive procedure that requires cystoscopy and the placement of cath-
eters in the ureters. A radiopaque contrast medium is introduced into the ureters 
or renal collecting structures through the ureteral catheters and radiographs of 
the abdomen are taken. Some type of local or general anesthesia should be used. 
Retrograde urograms may be necessary if IVU or CT urogram are unsatisfactory, 
if the patient has a history of adverse reaction to i.v. contrast media or if other 
methods of imaging are unavailable or inappropriate.
1 6 4  .Antegrade .urography
Outlining the renal collecting structures and ureters by percutaneous urography is 
occasionally done when excretory or retrograde urography has failed or is contra-
indicated or when there is a PNS tube in place and delineation of the collecting 
system is desired.
1 6 5  .Cystography
Retrograde filling of the bladder, via a catheter, with contrast. Identifies vesicocolic 
and vesicovaginal fistulae, extraperitoneal and/or intraperitoneal bladder injuries.
1 6 6  .Urethrography .
The urethra can be imaged radiographically by retrograde injection of radiopaque 
fluid or in antegrade fashion with VCUG. The antegrade technique is required 
when lesions of the posterior urethra, for example, posterior urethral valves, are 
suspected. The retrograde technique is more useful for examining the anterior 
urethra in the patients with anterior urethral stricture.
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1 7  .COMPUTED .TOMOGRAPHY
In CT scanning, a thin, collimated beam of X-rays is passed through the patient 
and captured by an array of solid-state or gas detectors. 
The interconnected X-ray source and detector system are rapidly rotated in the 
gantry around the patient. Computers integrate the collected X-ray transmission 
data to reconstruct and show a cross-sectional tomogram.
Spiral CT uses a slip-ring gantry that rotates continuously while the pa-
tient moves constantly through the collimated X-ray beam. Spiral CT tech-
nology affords the ability to image during specific phases of contrast bolus 
enhancement, including the ability to perform CT angiography and allows im-
proved image reformations. Multidetector or multislice, helical CT scanners have 
an array of multiple rows of detectors in a helical scanner such that multiple scan 
images can be acquired per gantry rotation and as a by-product thinner sections 
and higher resolution achieved. Such systems are optimally paired with powerful 
computer workstations so that high-quality 3D and multiplanar reformations can 
be quickly generated and analyzed.
Renal CT is most commonly used in the evaluation of acute flank pain, hema-
turia, renal abscess and trauma and in the characterization and staging of renal 
neoplasm. CT evaluation of renal anatomy and pathology generally requires i.v. 
injection of iodinated contrast media. Noncontrast scans are needed, however, 
when renal or perirenal calcification, hemorrhage or urine extravasation is sus-
pected, since scans obtained after the administration of contrast media may mask 
these abnormalities. Also, pre- and postcontrast scans are required to determine 
whether a mass is solid or cystic. A nephrogram phase with medullary enhance-
ment is reached within 60 seconds. Excretion of contrast material into the col-
lecting structures can be expected within 2–3 minutes after initiation of contrast 
administration. 
Although CT can detect ureteral tumors, the current role of CT in the evalua-
tion of the ureters is predominantly for tumor staging and evaluation of the cause 
and level of obstruction. Helical CT without oral or i.v. contrast is the preferred 
imaging modality for patients with renal colic or suspected urolithiasis. 
In the evaluation of the urinary bladder, CT is used primarily in staging bladder 
tumors and in diagnosing bladder rupture following trauma. Performing CT after 
filling the bladder with dilute contrast medium (CT cystography) improves the 
sensitivity of this modality for detecting tumors and bladder rupture.
For prostate diseases, CT is used for detection of lymphadenopathy and to de-
lineate prostatic abscesses. CT is used for detection of the abdominal location of 
suspected UDT, for staging of testicular tumors and in the search for nodal or distant 
metastasis. The addition of delayed CT imaging 10-15 minutes post i.v. contrast-en-
hanced CT shows high sensitivity and specificity in characterizing adrenal lesions. 
Benign adenomas, including lipid poor adenomas, show brisk contrast washout. CT 
or MRT are replacing conventional angiography for diagnostic examinations. 
The main advantages of CT include a wide field of view, the ability to detect 
subtle differences in the X-ray attenuation properties of various tissues, good spa-
tial resolution, anatomical cross-sectional images and operator independence. A 
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considerable amount of diagnostic information available from CT scans depends 
on patterns of contrast enhancement, so a carefully tailored examination is es-
sential. Reformatted helical image data in different planes and in 3D has made 
renal CT imaging, with renal angiography and urography, valuable in preoperative 
planning, such as for partial nephrectomy.
Limitations of CT include restriction to the transaxial plane for direct imaging, 
tissue nonspecificity, low soft-tissue contrast resolution and the need for contrast 
media. Finally, radiation exposure is a consideration with multisequence CT im-
aging. On average, current CT urography technique exposes the patient to approx-
imately 1.5 times the radiation dose of conventional urography. Ongoing studies 
evaluating reduced exposure and modifying protocols are under way.
1 8  .MAGNETIC .RESONANCE .TOMOGRAPHY
Clinical MRT has its basis in the nuclear properties of the hydrogen atoms in the 
body. Hydrogen nuclei, when considered as aggregates, sometimes referred to 
as “protons,” behave like tiny magnets, with net polarity (positive and negative) 
oriented along an axis at any given point in space. Ordinarily, the axes of the 
hydrogen nuclei in the body are randomly oriented. However, if the nuclei are 
placed in a strong magnetic field, like that produced in an MRT scanner, they 
precess and wobble like a spinning top around the lines of magnetic force. When 
hydrogen nuclei in a strong magnetic field are additionally stimulated by short, 
pulsed radio waves of appropriate frequency, they absorb energy and invert their 
orientation with respect to the magnetic field. At the termination of radiofrequen-
cy pulses, the hydrogen nuclei return at various rates to their original orientation 
within the magnetic field, emitting energy in the form of radio waves. This phe-
nomenon is called nuclear magnetic resonance. The emitted weak radio signals 
from the resonating hydrogen nuclei are received by sophisticated antenna or coils 
and transformed with various computer programs into cross-sectional images. Dif-
ferent MR signal intensities reflect different hydrogen densities in body tissues, as 
well as differing physical, cellular and chemical microenvironments and also flow 
characteristics. 
Applications for MR in renal imaging include demonstration of congenital 
anomalies, diagnosis of renal vein thrombosis and diagnosis and staging of RCC. 
MR angiography is useful in evaluating renal transplant vessels, renal vein tumor 
or thrombosis and renal artery stenosis. The use of contrast media in MRT of the 
kidney has broadened clinical applications. Using bolus injection of gadolinium and 
rapid sequence imaging, both anatomy and function of the kidney can be assessed. 
Gadolinium, similar to iodine contrast media, is an extracellular contrast agent 
primarily excreted by glomerular filtration. Compared to iodinated contrast media, 
gadolinium has superior renal tolerance in patients with preexisting CRF. Iodinat-
ed contrast agents used in radiography and CT increase attenuation linearly with 
their concentration. The effect of gadolinium on MR tissue signal intensity is more 
complex, though in general at lower concentrations gadolinium causes an increase 
in signal intensity. The use of gadolinium has extended the application of MRT to 
the evaluation of renal obstruction and the detection and characterization of renal 
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tumors. Gadolinium enhanced MRT is useful for assessing renal artery stenosis and 
for evaluating potential renal donors. MRT is used primarily to stage bladder tumors 
and to differentiate between benign bladder wall hypertrophy and infiltrating ma-
lignant neoplasm. In imaging the prostate gland, MRT is principally used to stage 
patients with PC. MRT of the testis is appropriate when other imaging studies are 
inconclusive and is applicable to the evaluation of UDT, trauma, epididymoorchitis 
and tumors. This technique is commonly used to characterize adrenal masses.
Advantages of MRT include direct imaging in any plane desired, choice of large 
or small field of view, excellent soft-tissue contrast, imaging without exposure to 
ionizing radiation and less operator dependence. MRT can image blood vessels 
and the GUT without contrast material. MR scanning, however, is not without 
drawbacks. The scanning time is relatively slow and as a result image clarity is 
often inferior compared with CT. Absolute contraindications to MRT include the 
presence of intracranial aneurysm clips, unless the referring physician is certain 
that the clip is made of a nonferromagnetic material, intraorbital metal fragments 
and any electrically, magnetically or mechanically activated implants. Relative 
contraindications such as pregnancy should always be viewed in the light of risk 
versus benefit of the examination.
1 9  .RADIOISOTOPE .IMAGING .AND .RENAL .FUNCTION .ASSESSEMENT
Glomerular .filtration .rate
When we talk about measuring kidney function, what we mean is measurement of 
GFR. This is regarded as the best measure of kidney function and we grade the 
degree of renal impairment and renal failure according to the GFR. Normal GFR 
in young men is approximately 130 ml/min per 1.73 m2` of body surface area. In 
young women it is 120 ml/min per 1.73 m2` of body surface area.
The ideal filtration marker is excreted by filtration alone. Exogenous markers 
that can be used to measure include inulin, iothalamate, EDTA, iohexol. Mea-
surement of GFR using exogenously administered markers is complex and expen-
sive and is difficult to do in routine clinical practice.
Urinary clearance of endogenous markers, such as Cr, can be used to estimate 
GFR. Cr is freely filtered at the glomerulus. A timed urine collection and mea-
surement of serum Cr concentration allows calculation of GFR according to the 
formula:
Clearance (GFR) = UЅV/P,
where U is the concentration of Cr in urine, P the concentration in plasma and 
V is the urine flow.
As an alternative, estimation of GFR can be made from simple measurement of 
serum Cr, since the main mechanism of Cr excretion is by glomerular filtration and 
GFR has a reciprocal relationship with serum Cr. Thus, as GFR falls, indicating wors-
ening renal function, Cr rises. However, Cr is not the ideal filtration marker, since it 
is also excreted by proximal tubular secretion, as well as by glomerular filtration and 
therefore Cr clearance exceeds GFR, i.e. Cr clearance tends to overestimate GFR.
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A variety of organic compounds can be “labeled” with a radioactive isotope 
that emits gamma rays, allowing the radiation to penetrate through tissues and 
reach a “gamma” camera placed adjacent to the patient The most commonly 
used radioisotope is technetium 99Tc. The excretion characteristics of the or-
ganic compound to which the 99Tc is bound determine the clinical use. 99Tc is 
bound to mercaptoacetyl triglycine. Over 90% MAG3 becomes bound to plasma 
proteins following i.v. injection. It is excreted from the kidneys principally by 
tubular secretion. Following i.v. injection MAG3 is very rapidly excreted. Ap-
pearing in the kidney within 15 s. of the injection and starting to appear in the 
bladder within about 3 min. Approximately 2/3 of the injected dose of MAG3 
is taken up by the kidneys with each passage of blood through the kidney. The 
radioactivity over each kidney thus increases rapidly. The peak of radioactivity 
represents the point at which delivery of MAG3 to the kidney from the renal 
artery is equivalent to excretion of MAG3. The radioactivity starts to decline as 
excretion outstrips supply. Thus, a time-activity curve can be recorded for each 
kidney. This time-activity curve is known as a renogram.
Images are collected onto a film at 30 s. intervals for the first 3 min and then at 
5 min intervals for the remainder of the study (usually a total of 30 min).
A normal renogram has 3 phases. First phase: a steeply rising curve lasting 20-
30 s. Second phase: a more slowly rising curve, rising to a peak. If the curve does 
not reach a peak the second phase is said to rise continually. A normal second 
phase ends with a sharp peak. Third phase: a curve that descends after the peak. 
There can be no third phase if there is no peak. No comment is made about the 
first phase. The second phase is described as being absent, impaired or normal. 
The third phase is described as being absent, impaired or normal.
The time to the peak depends on urine flow and level of hydration and is a 
crude measure of the time it takes the tracer to travel through the parenchyma 
of the kidney and through the renal pelvis. The time to the peak of the renogram 
normally varies between 2 and 4.5 min.
If the renogram continues beyond the time at which the peak should normally 
occur, then there may be a distal obstruction. In this situation, an injection of 
40mg of furosemide is given and if the curves start to fall rapidly, this is taken as 
proof that there is no obstruction. If it continues to rise, there is obstruction. If it 
remains flat (neither rising or falling), this is described as an “equivocal” result.
Renography is used to characterize “split” renal function. This is % of function 
contributed by each kidney. Determination of presence of renal obstruction based 
on shape of renogram curve.
There is also radioisotope imaging with DMSA, which is labelled with 99Tc. 
It is taken up by the proximal tubules and retained there, with very little being 
excreted in the urine. A “static” image of the kidneys is thus obtained. It demon-
strates whether a “lesion” contains functioning nephrons or not.
Renography with DMSA is used also to characterize “split” renal function and 
detection of scars in the kidney. These appear as defects in the cortical outline, 
representing areas in which the radioisotope is not taken up.
Radioisotope imaging with 99Tc -labelled MDP is used in clinical situa-
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tions, where there is increased blood supply and increased osteoblastic activity 
in areas of bone. There are many causes of a focal increase in isotope uptake 
- bone metastases, site of fractures, osteomyelitis, ТВ, benign bone lesions. 
Metastases from PC are characterized by their predilection for the spine and 
the fact that they are multiple.
1 10  .UROFLOWMETRY
Uroflowmetry is used for measurement of flow rate. Provides a visual image of 
the “strength” of a patient’s urinary stream. Urine flow rate is measured in ml/s 
and is determined using electronic flowmeters. These flowmeters are able to pro-
vide a print-out recording the voided volume, Qmax and time taken to complete 
the void, together with a record of the flow pattern. Maximum flow rate, Qmax, 
is influenced by the volume of urine voided, by the contractility of the patient’s 
bladder and by the resistance of their urethra.
Uroflowmetry alone cannot tell you why the flow is abnormal. It cannot distin-
guish between low flow due to BOO and that due to a poorly contractile bladder.
1 11  .CYSTOMETRY, .PRESSURE .FLOW .STUDIES .AND .VIDEOCYSTOMETRY
Cystometry is the recording of bladder pressure during bladder filling. PFS is the 
simultaneous recording of bladder pressure during voiding. Videocystometry is 
fluoroscopy (X-ray screening) combined with PFS during voiding. 
These techniques provide the most precise measurements of bladder and ure-
thral sphincter behaviour during bladder filling and during voiding. Cystometry 
precedes the PFS. Bladder pressure (Pves, measured by a urethral or suprapubic 
catheter) and abdominal pressure (Pabd, measured by a pressure line inserted 
into the rectum) are recorded as the bladder fills (cystometric phase) and emp-
ties (voiding phase) and flow rate is simultaneously measured during the voiding 
phase. The pressure developed by the bladder muscle (Pdet), cannot be direct-
ly measured, but it can be derived by subtracting abdominal pres sure from the 
pressure measured within the bladder (the intravesical pressure). This allows the 
effect of rises in intra-abdominal pressure caused by coughing or straining to be 
subtracted from the total (intravesical) pressure, so that a “pure” detrusor pressure 
is obtained.
All pressures are recorded in cm H2O and flow rate is measured in ml/s. The 
pressure lines are small-bore, fluid-filled catheters attached to an external pressure 
transducer or catheter-tip pressure transducers can be used.
A computerized print-out of intravesical pressure (Pves), intra-abdominal pres-
sure (Pabd) and detrusor pressure (Pdet) and flow rate (Qmax) is obtained. During 
bladder filling, the presence of OAB contractions can be detected. During void-
ing, the key parameters are Qmax and the detrusor pressure at the point at which 
Qmax is reached, Pdet Qmax. This pressure, relative to Qmax, can be used to 
define the presence of BOO by using a variety of nomograms.
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1 12  .PSA
PSA is a 34KD glycoprotein enzyme produced by the columnar acinar and ductal 
prostatic epithelial cells. It is a member of the human kallikrein family and its 
function is to liquefy the ejaculate, enabling fertilization. PSA is present in both 
benign and malignant cells, although the expression of PSA tends to be reduced in 
malignant cells and may be absent in poorly differentiated tumors. Large amounts 
are secreted into the semen and small quantities are found in the urine and blood.
The function of serum PSA is unclear, although it is known to liberate the in-
sulin-like growth factor type 1 from one of its binding proteins. 75% of circulating 
PSA is bound to plasma proteins (complexed PSA) and metabolized in the liver, 
while 25% is free and excreted in the urine. Complexed PSA is stable, bound to 
alpha-1 antichymotrypsin and alpha-2 macroglobulin. Free PSA is unstable, re-
cently found to consist of two iso-forms: pro-PSA is a peripheral zone precursor, 
apparently elevated in the presence of PC and BPSA is the TZ precursor and as-
sociated with BPH. The current normal range for the serum PSA assay in men is 
2,5-3,0 ng/mL. Though this varies with age, prostatitis, BPH, ejaculation, prostate 
massage. In the absence of PC, serum PSA concentrations also vary physiological-
ly, according to race and prostate volume.
STONE DISEASE
2 1  .KIDNEY .STONES
The prevalence of renal stone disease is determined by endogenous and environ-
mental factors. A combination of factors and genetic predisposition often contrib-
ute to risk of stone formation.
Endogenous .factors: .
• The peak incidence of stones occurs between the ages of 20-50 years;
• Males are affected 3 times as frequently as females;
• Urinary tract abnormalities with urine stasis;
• UTIs;
• Genetic factors and metabolic abnormalities. It is reported that 1/4 of patients 
with kidney stones has a family history of stone disease.
Environmental .factors:
• Geographical location and climate: while renal stone disease is more common 
in hot climates, some endogenous populations of hot climates have a low in-
cidence of stones and many temperate areas have a high incidence of stones. 
Ureteric stones become more prevalent during the summer, presumably be-
cause of higher urinary concentration in the summer encourages crystallization. 
Concentrated urine has a lower pH, encouraging cystine and uric acid stone 
formation. Exposure to sunlight may also increase endogenous vitamin D pro-
duction, leading to hypercalciuria;
• Low fluid intake (<1000 ml/day) predisposes to stone formation. Increasing 
water “hardness” with high calcium content may reduce risk of stone forma-
tion, by decreasing urinary oxalate;
• High animal protein intake increases risk of stone disease due to high urinary 
oxalate and uric acid, low pH and low urinary citrate. 
• High salt intake causes hypercalciuria.
• Contrary to conventional teaching, low calcium diets predispose to calcium 
stone disease and high calcium intake is protective;
• Sedentary lifestyle predispose to stones compared with active life.
Types .and .predisposing .factors .of .the .kidney .stones
Stones may be classified according to composition, X-Ray appearance, size and 
shape.
Other rare radiolucent stone types: indinavir (a protease inhibitor used for treat-
ment of HIV), triamterene (a relatively insoluble potassium sparing diuretic, most 
of which is excreted in urine), xanthine stones.
Three broad categories of stones are described, based on their X-Ray appear-
ance. This gives some indication of the likely stone composition and helps, to 




Opacity implies the presence of substantial amounts of calcium within the stone. 
Calcium phosphate stones are the most radiodense stones, being almost as dense 
as bone. Calcium oxalate stones are slightly less radiodense.
Relatively radiolucent
Cystine stones are relatively radiodense because they contain sulphur. Magnesium 
ammonium phosphate (struvite) stones are less radiodense than calcium contain-
ing stones.
Completely radiolucent
Uric acid, cystine, triamterene, xanthine and indinavir stones are radiolucent. 
Stones can be characterized by their size. Stones which grow to occupy the renal 
collecting system are known as staghorn calculi. They are most commonly com-
posed of struvite - magnesium ammonium phosphate and being caused by UTIs 
and forming under the alkaline conditions induced by urea-splitting bacteria. They 
may be composed of uric acid, cystine or calcium oxalate monohydrate.
Mechanisms .of .formation
Most common urine is saturated with calcium and oxalate, when the product of 
the concentrations of calcium and oxalate exceeds the solubility product. Above 
the solubility product, crystals of calcium and oxalate should form, but they do 
not because of the presence of inhibitors of crystalization. However, above a high 
concentration of calcium and oxalate, inhibitors of crystallization become ineffec-
tive and crystals of calcium oxalate start to form. The concentration of calcium 
and oxalate at which crystallization starts is known as the formation product and 
the urine is said to be supersaturated with the substances.
The ability of urine to hold more solute in solution than can pure water is due 
to the presence of various inhibitors of crystallization. Citrate forms a soluble com-
plex with calcium, preventing it from combining with oxalate or phosphate to form 
stones. Other inhibitors of crystallization include magnesium, glycosaminoglycans 
and Tamm-Horsfall protein.
Periods of intermittent supersaturation of urine with various substances can 
occur as a consequence of dehydration and following meals.
Table 2.1. Stones classification
Stones Frequency
Calcium oxalate 80-85%
Uric acid stones 5-10%
Calcium phosphate + calcium oxalate 8-10%
Pure calcium phosphate Rare
Struvite (infection stones) 5-20%
Cystine stones 1%
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The earliest phase of crystal formation is known as nucleation. Crystal nuclei usual-
ly form on the surfaces of epithelial cells and proteins or on other crystals. Aggregation 
- is formaton of clumps. Citrate and magnesium not only inhibit crystallization but 
also inhibit aggregation.
Symptoms, .signs .and .diagnosis
Kidney stones may present with acute or chronic symptoms or be found inciden-
tally during investigation of other problems. Presenting symptoms include pain 
or hematuria (microscopic or macroscopic). Struvite staghorn calculi classically 
present with recurrent UTIs. Malaise, weakness and loss of appetite can also occur 
if patient has CRF. Less commonly, struvite stones present with infective compli-
cations (abscess, purulent pyelonephritis, pyonephrosis, urosepsis).
Plain X-Ray: calculi that contain calcium are radiodense. 15-20% of stones are 
radiolucent.
Sensitivity of renal US for detecting of renal calculi is ~90-95%. A combina-
tion of plain X-Ray and renal US is a useful screening test for detection of renal 
calculi.
IVU will detect “filling defect, but increasingly being replaced by CT.
CT is a very accurate method of diagnosing all stones. Allows accurate determi-
nation of stone size, location and good definition of pelvicalyceal anatomy.
Treatment
Watchful waiting
The traditional indications for intervention are pain, UTIs and obstruction. It is 
not necessary to treat every kidney stone. As a rule, the younger the patient, the 
larger the stone and the more symptoms it is causing, the more inclined are we to 
recommend treatment. “Silent” stones could drop into the ureter causing ureteric 
colic or it could increase in size and affect kidney function or cause pain.
Another factor determining the need for treatment is the patient’s job. It is 
sensible to warn any one whose job entrusts them with the safety of others (pilots, 
drivers) that they are not fit to carry out these occupations until stone free.
Some stones are definitely not suitable for watchful waiting. Untreated struvite 
staghorn calculi will eventually destroy the kidney if untreated and are a signif-
icant risk to the patient’s life. Watchful waiting is therefore not recommended 
for staghorn calculi unless patient co-morbidity is such that surgery would be a 
higher risk than watchful waiting. Historical series suggest that many patients with 
staghorn calculi who did not undergo surgical removal died of CRF, urosepsis, 
pyonephrosis, perinephric abscess.
Medical therapy
Uric acid and cystine stones are potentially suitable for dissolution therapy, but 
calcium within either stone type reduces the chances of successful dissolution.
Urine of patients with purine - rich diet is frequently supersaturated with uric 
acid. Many patients who form uric acid stones have gout. The other do so because 
of a high protein and low fluid intake.
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Uric acid stones form in concentrated, acid urine. Dissolution therapy is based 
on hydration, urine alkalinization, allopurinol and diet. The aim being to reduce 
urinary uric acid saturation. It is recommended to maintain a high fluid intake 
with urine output 2-3L per day, “alkalinization” the urine to pH 6.5-7. In those 
with hyperuricemia or urinary uric acid excretion >1200 mg/day, allopurinol 300-
600 mg/day is used, which inhibits conversion of hypoxanthin and xanthine to 
uric acid. Dissolution of large stones is possible with this regimen.
Cystinuria is an inherited defect for the amino acids cystine ornithine, argi-
nine and lysine transport, leading to excessive urinary excretion of cystine. Most 
cystinuric patients excrete about 1g of cystine per day, which is well above the 
solubility of cystine by acidic pH.  Patients with cystinuria most common present 
with renal calculi. It is recommended the reduction of cystine excretion.  Dietary 
restriction of the cystine precursor amino acid methionine and also of sodium 
intake to excretion <100 mg/day. Options are: alkalinization of the urine to >pH 
7,5 to increase solubility of cystine, maintenance of a high fluid intake and use of 
drugs which convert cystine to more soluble compounds. Cystine stones are very 
hard and are therefore relatively resistant to ESWL. Nonetheless, for small cystine 
stones, a substantial proportion will still respond to ESWL. Flexible URS and 
PCNL are used where ESWL fragmentation has failed.
ESWL
This is technique of focusing externally generated shock waves at a stone. There 
are many methods of shock waves generations.
By electromagnetic method there are two electrically conducting cylindrical 
plates, which are separated by a thin membrane of insulating material. Passage of 
an electrical current through the plates generates a strong magnetic field between 
them, the subsequent movement of which generates a shock wave. An “acoustic” 
lens is used to focus the shock waves.
X-ray and US or a combination of both are used to locate the stone on which 
the shock waves are focused.
Likelihood of fragmentation with ESWL depends on stone size and location, anato-
my of renal collecting system, degree of obesity and stone composition. ESWL is most 
effective for stones <2 cm in diameter and less effective for stones >2 cm diameter, 
lower pole stones, stone in a calyceal diverticulum with absent drainage and those very 
hard cystine or calcium oxalate monohydrate stones.
Stone free rates for solitary kidney stones are app. 80% for stones <1 cm in 
diameter, 60% for those between 1-2 cm and 50% for those >2 cm in diameter. 
Lower stone free rates as compared with open surgery or PCNL are accepted be-
cause of the minimal morbidity of ESWL.
ESWL causes a certain amount of structural and functional renal damage. Micro-
scopic or macroscopic hematuria and edema are common, perirenal hematoma less so.
Absolute contraindications: pregnancy, uncorrected blood clotting disorders, 
UTIs, obstruction, high blood pressure.
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Flexible URS and laser lithotripsy
The development of small-calibre ureteroscopes with active deflecting mecha-
nisms and instrument channels, in combination with the development of laser 
technology, small-diameter laser fibres and stone baskets and graspers, has opened 
the way for intracorporeal, endoscopic treatment of kidney and uretheral stones. 
Access to the entire collecting system is possible with modern instruments. The 
holmium: YAG laser has a minimal effect on tissues at distances of 2-3 mm from 
the laser tip and so “collateral” tissue damage is minimal with this laser type.
Flexible URS and laser fragmentation offers a more effective treatment option com-
pared with ESWL, with a lower morbidity than PCNL, but usually requires a general 
anaesthetic. It can also allow access to areas of the kidney where ESWL is less efficient 
or where PCNL cannot reach. It is most suited to stones <2 cm in diameter.
PCNL
PCNL is the removal of a kidney stone via a “track’, developed between the 
surface of the skin and the collecting system of the kidney. The first step requires 
“inflation” of the renal collecting system (pelvis and calyces) with fluid or air in-
stilled via a ureteric catheter inserted cystoscopically. This makes subsequent per-
cutaneous puncture of a renal calyx with a nephrostomy needle easier. Once the 
nephrostomy needle is in the calyx, a guide wire is inserted into the renal pelvis to 
act as a guide over which the “track” is dilated. An access sheath is passed down 
the track and into the calyx and through this a nephroscope can be advanced into 
the kidney. An ultrasonic or laser lithotripsy probe is used to fragment the stone 
and remove the debris.
A posterior approach is most commonly used: below the 12th rib to avoid the 
pleura and far enough away from the rib to avoid the intercostal vessels and nerve. 
The preferred approach is through a posterior calyx, rather than into the renal 
pelvis, because this avoids damage to posterior branches of the renal artery which 
are closely associated with the renal pelvis. General anaesthesia is usual, though 
regional or even local anaesthesia can be used.
PCNL is generally recommended for stones >3 cm in diameter, those that have 
failed ESWL and/or an attempt at flexible URS and laser treatment. It is the first-
line option for staghorn calculi, with ESWL and/or repeat PCNL being used for 
residual stone fragments.
For stones 2-3 cm in diameter, options include ESWL with a JJ stent in situ, 
flexible URS with laser treatment and PCNL. PCNL gives the best chance of 
complete stone clearance with a single procedure, but this is achieved at a higher 
risk of morbidity. Some patients will opt for several sessions of ESWL or flexible 
URS/laser treatment and the possible risk of ultimately requiring PCNL because of 
failure of ESWL or laser treatment, rather than proceeding with PCNL “up front”.
For small stones, the stone-free rate after PCNL is in the order of 90-95%. For 
staghorn stones, the stone-free rate of PCNL, when combined with post-operative 
ESWL for residual stone fragments, is in the order of 80-85%.
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Open stone surgery
Indications are very limited:
• Complex stone burden;
• Failure of endoscopic treatment;
• Anatomic abnormality that precludes endoscopic surgery;
• Body habitus that precludes endoscopic surgery;
• Patient request for a single procedure where multiple PCNLs might be required 
for stone clearance;
• Non-functioning kidney, nephrosclerosis and pyonephrosis (nephrectomy).
2 2  .URETERIC .STONES
Symptoms .and .signs
Ureteric stones usually present with sudden onset of severe flank pain which is 
colicky in nature. It may radiate to the groin as the stone passes into the lower 
ureter. The patient moves around, trying to find a comfortable position. Patients 
with conditions causing peritonitis (e.g. appendicitis, a ruptured ectopic pregnan-
cy) lie very still: movement and abdominal palpation are very painful.
Many patients with ureteric stones have microscopic or macroscopic hematu-
ria, but 10-30% have no blood in their urine (complete unilateral block). Remem-
ber, blood in the urine on dipstick testing or microscopy may be a coincidental 
finding because of non-stone urological disease (e.g. neoplasm, UTIs).
The most important aspect of examination in a patient with a ureteric stone con-
firmed on imaging is to measure their temperature. If the patient has a stone and a 
fever, they have obstructive pyelonephritis. A fever in the presence of an obstructing 
stone is an indication for urine and blood culture, i.v. fluids and antibiotics and drain-
age (stenting or nephrostomy) if the fever does not resolve within a matter of hours.
Diagnosis
The IVU for many years the mainstay of imaging in patients with flank pain. Cur-
rently IVU has been replaced by CT urography.
If you only have access to IVU, remember that it is contraindicated in patients 
with a history of previous contrast reactions and should be avoided in those with 
high fever, a strong history of allergies or asthma. Patients with alleggies will re-
quire high-dose steroids 24h before the IVU. Patients taking metformin for DM 
should stop this for 48h prior to an IVU. Clearly, being able to perform an alter-
native test, such as CT in such patients, is very useful.
Abdominal US is used in all patients, who present with flank pain suggestive of a 
possible stone, to exclude serious pathology such as a leaking abdominal aortic aneu-
rysm and to demonstrate any other gross abnormalities due to non-stone associated 
flank pain. There is hydronephrosis due to ureteric obstruction. 
Plain abdominal X-Ray and renal US are not sufficiently sensitive or specific 
for their routine use for diagnosing ureteric stones.
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Treatment
While appropriate imaging studies are being organized, pain relief should be given: 
NSAIDs (e.g. diclofenac) by intramuscular or i.v. injection, by mouth or per rec-
tum. This drug provides rapid and effective pain control. Analgesic effect may be 
partly anti-inflammatory, partly by reducing ureteric peristalsis. Where NSAIDs are 
inadequate, opiate analgesics are added. There is no need to encourage the patient 
to drink copious amounts of fluids, nor to give them large volumes of fluids i.v. in 
the hope that this will “flush” the stone out. Excess urine output will tend to cause 
a greater degree of hydronephrosis in the affected kidney, which may make ureteric 
peristalsis even less efficient than it already is.
Watchfull waiting
In many instances, small ureteric stones (3-5 mm) will pass spontaneously within 
days or a few weeks, with analgesic supplements for exacerbations of pain. Chanc-
es of spontaneous stone passage depend principally on stone size. 68% of stones 5 
mm or less will pass spontaneously and 47% of stones 6-10 mm in diameter will 
pass spontaneously. Average time for spontaneous stone passage for stones 4-6 mm 
in diameter is 3-4 weeks. Stones that have not passed in 1 months are unlikely to 
do so. Therefore, accurate determination of stone size on plain abdominal X-Ray 
or by CT helps predict chances of spontaneous stone passage.
Medical expulsive therapy
There is growing evidence for the efficacy of alpha adrenoreceptor blockers in pa-
tients with lower ureteric stones. These increase spontaneous stone passage rates, 
reduce stone passage time and reduce frequency of ureteric colic. MET is contra-
indicated where there is clinical evidence of obstructive pyelonephritis and urosep-
sis or deteriorating renal function. If a trial of MET is used, warn patients of the 
risks (drug side effects, possible need for intervention in the form of ESWL, URS 
or JJ-stenting). Arrange periodic plain X-Ray or US to monitor stone position.
Relieving of the obstruction
Temporary relief of the obstruction can be obtained by insertion of a JJ stent or 
PNS tube. JJ stent insertion or PNS tube can be done quickly, but the stone is 
still present. It may pass down and out of the ureter with a stent or nephrostomy 
in situ, but in many instances it simply sits where it is and subsequent definitive 
treatment is still required. While JJ stents can relieve stone pain, they can cause 
bothersome irritative bladder symptoms with pain in the bladder, frequency and 
urgency. JJ stents do make subsequent stone treatment in the form of URS tech-
nically easier by causing passive dilatation of the ureter.
Indications for drainage:
• Pain that fails to respond to analgesics or recurs and cannot be controlled with 
additional pain relief;
• Bacteriuria in the presence of an obstructing stone can lead to the development 
of pyelonephritis and urosepsis. Where intervention is planned (ESWL or ure-
teroscopy), appropriate antibiotics should be given in advance of the treatment
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• Obstructive pyelonephritis: have a low threshold for draining the kidney (both 
stenting and PNS);
• Impaired renal function and anyria due to solitary kidney obstructed by a stone, 
bilateral ureteric stones or pre-existing renal impairment which gets worse as a 
consequence of a ureteric stone;
• Prolonged unrelieved obstruction: this can result in long-term loss of renal 
function. Generally speaking the period of watchful waiting for spontaneous 
stone passage tends to be limited to 4-6 weeks;
• Social reasons: young, active patients may be very keen to opt for surgical treat-
ment because they need to get back to work or their childcare duties. Airline 
pilots and some other professions are unable to work until they are stone free.
Treatment options for ureteric stones:




• Percutaneous antegrade URS
Nowadays, the advent of ESWL and of smaller ureteroscopes with efficient 
stone fragmentation devices has made stone treatment and removal a far less mor-
bid procedure, with a far smoother and faster post-treatment recovery. It is easier 
for both the patient and the surgeon to opt for intervention, in the form of ESWL 
or surgery, as a quicker way of relieving them of their pain.
It is clearly important for the surgeon to inform the patient of the outcomes 
and potential complications of intervention, particularly given the fact that many 
of stones would pass spontaneously if left a little longer, particularly now there is 
evidence for MET.
Blind or under radiographic “basketing of stones” is a historical treatments 
because of the potential for serious ureteric injury is significant.
Smaller ureteroscopes with improved optics and larger instrument channels and 
the advent of holmium laser lithotripsy have improved the efficacy of ureteroscop-
ic stone fragmentation and reduced its morbidity. As a consequence, many sur-
geons and patients will opt for URS, with its potential for a “one-off” treatment, 
over ESWL where more than one treatment will be required and post-treatment 
imaging is required to confirm stone clearance.
There are no great differences in stone free rates between ESWL and URS. Pre-
cisely which technique one uses will depend to a considerable degree on local re-
sources and local expertise at performing URS, particularly for upper tract stones. 
Open and laparoscopic ureterolithotomy are used in the rare cases for very 
impacted stones, where ESWL or URS have been tried and failed or were not 
feasible.
2 3  .BLADDER .STONES
There are struvite (infection stones) or uric acid (in non-infected urine). Bladder 
calculi are predominantly a disease of men aged >50 and with BOO due to BPE. 
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They also occur in the chronically catheterized patient with  spinal cord injury 
patients.
Bladder stones may be symptomless in patients with incidental finding on in-
vestigations. This is the common presentation in spinal patients who have limited 
or no bladder sensation. In the neurologically intact patient there are suprapubic 
or perineal pain, hematuria, urgency and/or urge incontinence, recurrent UTIs, 
LUTS. If a bladder stone is suspected, they will be visible on KUB X-ray, renal 
US or cystoscopy.
Most stones are small enough to be removed cystoscopically with the help of 
endoscopic cystolitholapaxy, using stone - fragmenting forceps for stones that can 
be engaged by the jaws of the forceps and electrohydraulic or pneumatic lithotripsy 
for those that cannot. Multiple and large stone/es (>3cm) can be also removed by 
open surgery.
Etiology .and .pathophysiology
BPH is characterized by an increase in epithelial and stromal cell numbers in the 
periurethral area. New epithelial gland formation is normally only seen during 
fetal development. The development of new glands in the adult prostate has given 
rise to the concept of “reawakening” of the inductive effect of the prostatic stroma 
on the prostatic epithelium cells.
The increase in prostate cell number could reflect proliferation of epithelial and 
stromal cells, impairment of apoptosis or a combination of both. During the early 
phases of development of BPH, cell proliferation occurs rapidly. In established 
BPH, cell proliferation slows down and there is impairment of programmed cell 
death. Androgens and oestrogens imbalance actively inhibit apoptosis.
The role of androgens in BPH
Testosterone can bind directly to the androgen receptor or may be converted to 
a more potent form, DHT, by the enzyme 5AR. There are two isoforms of 5AR. 
Type I or “extra-prostatic” 5AR, which is absent in prostatic tissue and present in, 
for example, skin and liver. Type II or “prostatic” 5AR, which is found exclusively 
on the nuclear membrane of stromal cells, but not within prostatic epithelial cells. 
Type I 5AR is not inhibited by finasteride, whereas type II 5AR is.
Testosterone diffuses into prostate gland. Within epithelial cells it binds di-
rectly to the androgen receptor. In prostate stromal cells a small proportion binds 
directly to the androgen receptor, but the majority binds to type II 5AR on the 
nuclear membrane, is converted to DHT and then binds with greater affinity and 
therefore greater potency than testosterone to the androgen receptor in the stro-
mal cell. The androgen receptor/testosterone or androgen receptor/DHT complex 
then binds to specific binding sites in the nucleus, thereby inducing transcription 
of androgen-dependent genes and subsequent protein synthesis.
It is thought that stromal/epithelial interactions may be mediated by soluble 
growth factors that stimulate or inhibit cell division and differentiation. Most com-
mon growth stimulating factors are bFGF, EGF and other. TGF normally inhibit 
epithelial cell proliferation and it is possible that in BPH, TGF is downregulated.
The principle cause of BOO in men is BPH. Less common causes are urethral 
stricture and PC. BOO in women is altogether less common, the causes including 
pelvic prolapse, urethral stricture, urethral diverticulum and pelvic masses. In 
either sex, neurological disease (DM, spinal cord injury, spina bifida…) can cause 
failure of relaxation of the external sphincter during voiding.
The pathophysiological basis of BOO due to BPE secondary to BPH has been 
studied more than any other type of obstruction.
BPO has dynamic and static components:
• Dynamic component of BPO: alfa-1-adrenoceptors mediated prostatic smooth 
muscle contraction. Smooth muscle accounts for approximately 40% of the 
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area density of the hyperplastic prostate and human prostate contracts follow-
ing administration of alpha adrenergic agonists. This effect is the rationale for 
alfa-blockers treatment for symptomatic BPO;
• Static component of BPO: mediated by the volume effect of BPE.
The disease of the bladder arising from BOO is increased irritability and its 
consequences, by which it admits of little distension, becomes quick in its action 
and thick and strong in its coats. BOO causes thickening of the bladder wall. Mi-
croscopically smooth muscle cells enlarge and there is an increase in connective 
tissue between the smooth muscle bundles. In some cases this may lead to poor 
compliance, with development of high bladder and intrarenal pressures. Progres-
sive UHN can develop, with impairment of renal function and even CRF due to 
high pressure chronic urinary retention.
Experimentally created BOO causes development of OAB with  unstable blad-
der contractions during bladder filling. This may be due to prolonged increased 
intravesical pressure during voiding causing ischaemia and leading to ischaemic 
damage to neurons within the bladder. Symptomatically, many patients with BOO 
develop LUTS.
Symptoms .and .signs
There are many guidelines, developed to standardize the approach to diagnosis 
and treatment of men presenting with symptoms suggestive of BPH.
The classic “prostatic” symptoms of frequency, urgency, nocturia, hesitancy, 
poor and intermittent flow, terminal dribbling traditionally said to indicate the 
presence of BOO due to BPE were shown to bear little relationship to prostate 
size, flow rate, PVR or indeed urodynamic evidence of BOO. Age-matched elderly 
men and also women have similar LUTS, despite the fact that women have no 
prostate and rarely have BOO.
The term “Prostatism” has therefore been replaced by the term “LUTS” which 
avoids any implication about the cause of these symptoms. Urinary symptoms may 
have non-prostatic causes.
There are many symptoms in patients with BPH:
• Marked frequency and urgency, particularly when also combined with bladder 
pain;
• Bedwetting: suggests the presence of high pressure chronic retention. Look for 
distension of the abdomen due to a grossly enlarged bladder which is tense on 
palpation and dull to percussion;
• Macroscopic hematuria: sometimes due to a large vascular prostate, but exclude 
other causes (bladder and kidney cancer and stones);
• Back pain and neurological symptoms (sciatica, lower limb weakness or tin-
gling). Rarely, LUTS can be due to neurological disease.
High pressure chronic renal failure
This is maintenance of voiding, with a bladder volume of >800ml, accompanied 
by UHN. Over time this leads to CRF. When the patient is suddenly unable to 
pass urine, acute-on-chronic high pressure retention of urine has occurred.
UROLOGY 43
A man with high pressure retention who continues to void spontaneously may 
be unaware that there is anything wrong. He will often have no sensation of in-
complete emptying and his bladder seems to be insensitive to the gross distension. 
Often the first presenting symptom is that of bedwetting. This is such an unpleas-
ant and disruptive symptom that it will cause most people to visit their doctor. 
Visual inspection of the patient’s abdomen may show marked distension due to a 
grossly enlarged bladder. The diagnosis of chronic retention can be confirmed by 
palpation of the enlarged, tense bladder, which is dull to percussion.
The serum Cr is elevated and an US will show UHN with a grossly distended 
bladder if the scan is done before relief of retention.
Diagnosis
As mentioned above, a history should be taken and an examination performed 
and all recommend assessment of symptom severity using the IPSS. High-quality 
guidelines, based on results of randomized trials, recommend few diagnostic tests: 
urine analysis, completion of a voiding diary, measurement of serum Cr. They re-
gard flow rate measurement and assessment of PVR as optional tests.
Digital rectal examination and PSA
Done to detect nodules which may indicate an underlying PC and to provide a 
rough indication of prostate size. Size alone is not an indication for treatment, 
but if surgical treatment is contemplated, marked prostatic enlargement can be 
confirmed by TRUS. Prostate volume in the order of 80 ml or more increases the 
likelihood of an open prostatectomy. Discuss the pros and cons of PSA testing 
with the patient.
Serum Cr
Baseline measure of renal function and to detect renal failure secondary to high 
pressure urinary retention.
Post-void residual urine volume
Varies considerably on the same or on different days. Along with serum Cr it in-
dicates whether watchful waiting is safe. It is safe not to operate where the PVR 
volume is <150-200 ml, since the majority of men show no worsening of Cr, no 
increase in PVR, no worsening of symptoms and do not require TURP.
Flow rate measurement
This is variously regarded as optional, recommended and obligatory prior to un-
dertaking surgical treatment for BPH. Qmax>15 ml/s in norm. Like PVR, mea-
surement flow rate varies substantially on a given day, cannot distinguish between 
BOO and a poorly contractile bladder.
Renal ultrasonography
To detect UHN and kidney disease if serum Cr is elevated, measurement of PVR 
and prostate volume.
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Treatment
Watchful waiting
No particular early symptoms are specific for PC. Even if it later turns out that 
he does have PC, a patient’s symptoms might be due to coexistent BPH or some 
other pathology. If patient is concerned about the possibility of PC, PSA testing 
and prostate biopsy are performed.
Many patients are understandably concerned that their urinary symptoms may 
be a harbinger for the development of AUR. This may influence their decision to 
seek help for symptoms which they may perceive as indicating a risk of subsequent 
retention and it may affect the type of treatment they choose.
Once reassured that the likelihood of urinary retention and PC is low, patient 
may not want treatment for symptoms which on the surface may appear quite bad 
and he may be happy to adopt a policy of watchful waiting.
A number of studies have shown that in a substantial proportion of men, symp-
toms do not progress, even for those with severe symptoms. Almost a quarter of 
men who initially presented with severe symptoms noted an improvement in their 
symptoms, to mild or moderate.
On the basis of these studies we can say that symptoms, even if severe, do not 
necessarily get worse even over fairly long periods of time. This forms the foun-
dation of watchful waiting as an option for many patients, even if the symptoms 
at baseline are severe.
Conservative treatment
As described earlier, BOO is caused partly by alpha-1 adrenoceptors mediated 
prostatic smooth muscle contraction and this is the rationale treatment of symp-
tomatic BPH.
Alpha blockers are categorized by their selectivity (non-selective or selective) 
for adrenoceptors and by their elimination half-life. Indications for treatment: 
bothersome LUTS where WW has failed or the patient wishes to have treatment. 
Most studies describe response rates of 30-40%. A some proportion of men stop 
taking their medication either because of side-effects or because of a perceived 
lack of effectiveness. Side-effects: asthenia and weakness, dizziness, headache and 
postural hypotension and retrograde ejaculation.
5 ARI blocks the conversion of testosterone to DHT, the more potent androgen in 
the prostate. This causes shrinkage of the prostatic epithelium and therefore a reduction 
in prostate volume, thereby reducing the “mechanic” component of BPH. This takes 
some months to occur, so urinary symptoms will not improve initially. Finasteride is a 
competitive inhibitor of the type II 5 alpha-reductase,  which converts testosterone to 
DHT. Finasteride therefore lowers serum and intraprostatic DHT levels. Dutasteride is 
a dual inhibitor of 5 alpha-reductase. A number of large studies have shown symptom 
improvement over placebo in the IPSS scores and improvements in flow rates. The 
data also shows a small reduction in the risk of AUR. Shrinking large vascular prostates 
probably helps reduce the frequency of hematuria in men with BPH. Side-effects are 
rare sexual problems with loss of libido, impotence, reduced volume of ejaculate.
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A combination of an alpha blocker and a 5 ARI prevented progression of BPH. 
Progression being defined as a worsening of symptom score by 4 or more or the devel-
opment of complications such as UTIs or AUR.
For a man with frequency, urgency and urge incontinence symptoms suggestive 
of an OAB consider prescribing an anticholinergics (e.g. oxybutynin, tolterodine, 
trospium chloride, solifenacin). There is the concern that these drugs could pre-
cipitate urinary retention in men with BOO, but the risk of this occurring is prob-
ably very low, even in men with urodynamically proven BOO.
An alternative drug treatment for BPH symptoms is phytotherapy. 50% of 
all medications consumed for BPH symptoms are phytotherapeutic ones. These 
agents are derived from plants and include the Pygeum africanum, purple cone 
flower (Echinacea purpurea), South African star grass (Hipoxis rooperi) and saw 
palmetto berry (Serenoa Repens). These plant extracts contains an anti-inflam-
matory, antiproliferative, oestrogenic components and produces improvements in 
LUTS and flow rates. Beta-sitosterol may induce apoptosis in prostate stromal 
cells, by causing elevated levels of TGF.
Operative treatment
TURP – electrosurgical removal of the obstructing tissue of BPH or obstructing 
PC from within the prostatic urethra till prostatic capsule. An electrically heated 
wire loop is used, through a resectoscope, to cut the tissue and diathermy bleeding 
vessels. The cuted “chips” of BPH are pushed back into the bladder by the flow 
of irrigating fluid and at the end of resection are evacuated.
Indications for TURP:
• LUTS which fail to respond to changes in life style or medical therapy;
• Recurrent AUR;
• Renal impairment due to BPH;
• Recurrent hematuria due to BPE;
• Bladder stones due to prostatic obstruction.
Open prostatectomy indications:
• Large prostate (>80g):
• TURP not technically possible;
• Urethra too long for the resectoscope to gain access to the prostate;
• Presence of bladder stones which are too large for endoscopic cystolitholapaxy 
(>3 cm), combined with marked enlargement of the prostate.
Transvesical open prostatectomy is the preferred operation if there is a grossly 
enlarged prostate gland. The bladder is opened, the mucosa around the protrud-
ing BPH is incised and the finger between the node and capsule is inserted to 
enucleate this disease. A 22Ch urethral and a suprapubic catheter are left. The 
urethral catheter is removed in 3 days. Suprapubic drain can be removed on the 
10 postoperative day.
Simple retropubic prostatectomy compared with the transvesical approach allows 
more precise anatomic exposure of the prostate, thus giving better visualization of the 
prostatic cavity which allows more accurate removal of the BPH, better control of 
bleeding and more accurate division of the urethra, so reducing the risk of inconti-
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nence. The retropubic approach should not be employed when the middle lobe is very 
large because it is difficult to get behind the middle lobe and so to incise the mucosa 
distal to the ureters.The prostate is exposed by a Pfannenstiel or lower midline incision. 
Hemostasis is achieved before enucleating the prostate, by ligating the dorsal vein com-
plex with sutures placed deeply through the prostate. The prostatic capsule and BPH 
are incised transversely with the diathermy just distal to the bladder neck. The plane 
between the capsule and BPH is found with scissors and developed with a finger. Su-
tures are used for hemostasis. A wedge of bladder neck is resected. A catheter is inserted 
and left for 7-10 days and the transverse capsular incision is closed.
Minimally invasive management of BPH
It is reported a seemingly higher mortality and re-operation rate after TURP when 
compared with open prostatectomy. This, combined with other studies suggesting 
that symptomatic outcome after TURP was poor in a substantial proportion of 
patients and that TURP was associated with substantial morbidity, prompted the 
search for less invasive treatments.
The two broad categories of alternative surgical techniques are minimally invasive 
(TUNA, TUMT, HIFU) and invasive (TUVP and laser prostatectomy). All are essen-
tially heat treatments, delivered at variable temperature and power and producing vari-
able degrees of coagulative necrosis of the prostate or vaporization of prostatic tissue.
Treatment of chronic renal failure
Suprapubic catheterization relieves the pressure on the kidneys and allows nor-
malization of renal function. A large volume of urine is drained from the bladder. 
A small percentage of patients have a postural drop in SBP. It is wise to admit 
patients with such CRF for a short period of observation, until the diuresis has 
settled. Patients will require i.v. fluid replacement. Definitive treatment options are 
operation (open BPH-ectomy or TURP) or a long-term suprapubic catheter.  A 
TWC is clearly not appropriate in cases where there is back pressure on the kidneys.
4 1  .RENAL .AND .URETERAL .ANOMALIES
Abnormalities of renal fusion and ascent occur in weeks 6-9 of gestation, when the 
embryonic kidney is ‘ascending’ to its definitive lumbar position in the renal fossa.
4 1 1  .Horseshoe .kidney
Most common example of renal fusion. Prevalence 1 in 400. Male to female ratio 
2:1. The kidneys lie vertically and are joined at their lower poles by midline pa-
renchymal tissue. Consequently, the horseshoe kidney lies lower in the abdomen. 
Normal rotation of the kidney is also prevented and therefore the renal pelvis 
lies anteriorly, with the ureters also passing anteriorly over the lower part of the 
kidneys, but entering the bladder normally. Blood supply is variable, usually from 
one or more renal arteries or their branches or from branches off the aorta or in-
ferior mesenteric artery. A proportion of individuals with horseshoe kidneys have 
associated congenital urological and non-urological abnormalities.
Most patients with horseshoe kidneys remain asymptomatic. However, UTIs 
and stones may develop and cause symptoms. The diagnosis is usually suggested 
on renal US and confirmed by IVU. Renal function is usually normal or slowly 
reduced.
4 1 2  .Ectopic .kidney
The kidney fails to achieve its normal position and may be located in the thorax, 
abdomen, in iliac fossa or pelvis (on the contralateral side or crossed). The preva-
lence of renal ectopia is 1 in 900, with both sexes affected equally. The left kidney 
is affected more often than the right and bilateral cases are seen in <10%. The 
affected kidney is smaller, with the renal pelvis positioned anteriorly and the ureter 
is short, but enters the bladder normally. Pelvic kidneys occur in 1 in 2000–3000 
and lie opposite the sacrum and below the aortic bifurcation and are supplied by 
adjacent vessels. Renal ectopia has an increased risk of congenital anomalies in-
cluding contralateral renal agenesis and genital malformations.
Most are asymptomatic. Diagnosis is made on renal US, IVU or renography. 
Complications include hydronephrosis secondary to VUR or PUJO, stones and  UTIs.
4 1 3  .Renal .agenesis
Unilateral renal agenesis is the absence of one kidney due to embryological ab-
normality or absence of the ureteric bud. This results in failure of the ureteric 
bud to contact the metanephric blastema with failed induction of nephrogenesis. 
The incidence is 1 in 1000, left side > right, males > females. Absence of a kid-
ney may also be caused by involution of a multicystic dysplastic kidney in utero 
or postnatally. Many patients are asymptomatic. However, it is associated with 
other abnormalities. Often discovered as an incidental finding on US performed 
for other reasons or during investigation of associated abnormalities. Long-term 
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follow-up of renal function, urinalysis and blood pressure should be considered. 
Bilateral renal agenesis is rare, incompatible with life and is associated with severe 
other abnormalities.
4 1 4  .Cystic .kidney .disease
Autosomal recessive polycystic kidney disease
A disease of infancy and childhood, where renal collecting tubules and ducts be-
come cystically dilated and numerous small cysts form in the renal cortex and me-
dulla bilaterally. Incidence of 1 in 10.000-40.000. Severe forms present early and 
have a poor prognosis. Prenatal US demonstrates large, “bright” homogeneously 
hyperechogenic kidneys, which can cause obstructed labour and respiratory prob-
lems. Neonates have large flank masses, limb and facial anomalies. All cases are 
associated with congenital hepatic fibrosis. Infants may develop fatal uraemia and 
respiratory failure. Older children present with CRF, hypertension and portal 
hypertension. Most develop ESRD by adulthood requiring hemodialysis, nephrec-
tomy to control hypertension and subsequent renal transplantation.
Autosomal dominant polycystic kidney disease
An autosomal dominant inherited disorder involving multiple expanding renal 
parenchymal cysts. Incidence is 0.1-0.5%. 95% are bilateral. ADPKD can affect 
children and adults and accounts for 10% of all CRF, which usually manifests at 
>40 years old.
The kidneys reach an enormous size due to multiple fluid-filled cysts and can 
easily be palpated on abdominal examination. Expansion of the cysts results in 
ischaemic atrophy of the surrounding renal parenchyma and obstruction of normal 
renal tubules. Symptoms are hematuria, flank pain, flank mass, UTIs, proteinuria, 
hypertension and intracerebral bleeding, multiple cysts of other organs. The in-
cidence of renal adenoma is 20%. However, the risk of RCC is the same as the 
general population. CRF may present with nausea, vomiting, anemia, confusion 
and seizures.
Investigations depend on the presenting symptoms. For suspected UTI culture 
urinalysis are used. For hematuria urine cytology, cystoscopy and renal US are 
needed. On US the kidneys are small and hyperechoic, with multiple cysts of 
varying size, many of which show calcifications. If the nature of the cysts cannot 
be determined with certainty on US, a renal CT or MRT are used.
CRF will be managed by a nephrologist. Anemia may occur, though ADPKD 
may cause increased erythropoietin production and polycythemia.
The aim of the treatment is to preserve renal function as long as possible. It is 
indicated to monitor and to control hypertension and UTIs. Infected cysts and 
abscesses should be drained. Persistent heavy hematuria can be controlled by 
embolization or nephrectomy. ESRD requires hemodialysis and ultimately renal 
transplantation.
Due to the high risk of inheritance of ADPKD, off-spring should be offered 
genetic testing or US screening.
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Medullary cystic disease 
MCD is a autosomal dominant condition, which develops in later childhood. His-
tology shows interstitial nephritis associated with corticomedullary cysts. Disease 
progression causes a reduction in kidney size. Features include polyuria and poly-
dipsia due to a salt-losing nephropathy, anemia, growth retardation, hypertension 
and CRF. Initial treatment includes salt replacement. Hemodialysis and renal 
transplantation are later options.
Multicystic dysplastic kidney
The cysts of a “multicystic” kidney are not due to dilatation of renal collecting 
ducts as in polycystic disease, but instead, the entire kidney is dysplastic, with 
immature dysplastic stroma and cysts of various sizes. Bilateral disease is in-
compatible with life. The incidence of unilateral MCDK is 1 in 4000. Disease is 
usually detected on pre- or postnatal US. Neonates may present with an abdom-
inal mass. Unilateral disease is often associated with VUR or PUJ obstruction in 
the contralateral kidney. Affected kidneys may undergo renal aplasia, where they 
spontaneously shrink to a tiny remnant. US and renogram with DMSA help to 
distinguish this condition from hydronephrosis. Most can be treated conservatively 
with close surveillance and US follow-up for the associated risks of hypertension 
and Wilms tumour, which would be indications for nephrectomy.
Multilocular cystic nephroma
Presents in young children with a flank mass, loin pain or hematuria. Diagnosis is 
on US or CT, demonstrating multilocular cysts in the renal parenchyma, which 
may extend into the collecting system. It is included in a spectrum of disease that 
is closely associated with tumours and so the recommended treatment is partial 
or full nephrectomy.
4 1 5  .Upper .urinary .tract .duplication
A duplex kidney has an upper pole and a lower pole, each with its own separate 
pelvicalyceal system and ureter. The two ureters may join to form a single ureter at 
the PUJ or more distally as a bifid ureter before entering the bladder through one 
ureteric orifice. The two ureters may pass down individually to the bladder. This 
is called complete duplication. In this case, the Weigert-Meyer rule states that 
the upper pole ureter always opens onto the bladder medially and inferiorly to the 
ureter of the lower pole, thereby predisposing to ectopic placement of the ureteric 
orifice and obstruction due to the longer intramural course of the ureter through 
the bladder wall. The lower pole ureter opens onto the bladder laterally and supe-
riorly, reducing the intramural ureteric length, which predisposes to VUR.
Ureteric duplication occurs in 1 of 25 individuals. Female to male ratio is 2:1. 
Unilateral cases are more common than bilateral, with right and left sides affected 
equally. Risk of other congenital malformations is increased.
Patients have symptoms of UTIs, flank pain or incidental finding. Ectopic ure-
ters are associated with upper renal pole hydronephrosis secondary to obstruction, 
renal hypoplasia or dysplasia and ureteroceles. Lower pole ureters are prone to 
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VUR, resulting in UHN. Bifid ureters can get urine continuously passing from 
one collecting system to the other predisposing to urinary stasis, UTIs and stone 
formation.
Renal US demonstrates ureteric duplication and UHN. IVU shows decreased 
contrast excretion from renal upper pole and UHN. Contrast in a ureterocele 
gives the appearance of a “cobra head”. MCUG will determine whether VUR is 
present. CT and MRT reveals detailed anatomical information. Isotope renogram 
assesses renal function.
Uncomplicated complete or incomplete ureteric duplication does not require 
any intervention. In symptomatic patients, the aim is to reduce obstruction and 
VUR and improve function. Where renal function is reasonable, ureteric re-im-
plantation can treat both conditions. A poorly functioning renal unit, where upper 
pole associated with ectopic ureter and/or obstruction or lower pole associated 
with a VUR or ureterocele may require heminephrectomy and ureterectomy.
4 1 6  .Pelviureteric .junction .obstruction
A obstruction of the ureter at the PUJ resulting in a restriction of urine flow. 
Childhood incidence is estimated at 1 in 1000. Boys are affected more than girls 
with ratio 2:1. The left side is more often affected than the right side with ratio 2:1 
and there is bilateral obstruction in 10-50%.
In children, most PUJO is congenital, due to either an intrinsic narrowing 
secondary to aberrant development of ureteric/renal pelvis muscle or abnormal 
collagen or extrinsic causes with compression of the PUJ by aberrant vessels. 
Co-existing VUR is found in up to 30%.
PUJO is the most common cause of hydronephrosis found on prenatal and 
early postnatal US. Infants may also present with an abdominal mass, UTIs and 
hematuria. Older children present with flank or abdominal pain exacerbated by 
fluid consumption, UTIs. In some cases there are nausea, vomiting and hema-
turia following minor trauma.
If prenatal US has shown a large or bilateral hydronephrosis, a follow-up renal 
tract US should be performed soon after birth. If there is a prenatal unilateral 
hydronephrosis and the bladder is normal, the scan is deferred until day 3-7 to 
allow normal physiological diuresis to occur, which may spontaneously improve 
or resolve the hydronephrosis.
Children may be observed with US and renogram if they remain stable, with 
good renal function and no other complications such as persistent UTIs or stones.
Pyeloplasty is indicated if children are symptomatic, have a significant hydro-
nephrosis with >30 mm anterior-posterior renal pelvis diameter or impaired renal 
function. Techniques include open or laparoscopic Anderson-Hynes dismembered 
pyeloplasty. Post-operative follow-up is with US and MAG3 renogram. Where 
renal function is poor on the side of the PUJO, options include temporary PNS 
drainage to assess the potential for recovery. Next will be pyeloplasty if function is 
improved or nephrectomy where the impairment is severe or irreversible.
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4 1 7  .Vesicoureteric .reflux
VUR results from abnormal retrograde flow of urine from the bladder into the 
upper urinary tract. Overall incidence in children is 1-2%, younger>older with 
female:male ratio 5:1.
In normal conditions the ureter passes obliquely through the bladder wall (1-2 
cm), where it is supported by muscular attachments, which prevent VUR during 
bladder filling and voiding. The normal ratio of intramural ureteric length to 
ureteric diameter is 5:1. VUR occurs when the intramural length of ureter is too 
short. The degree of reflux is graded from I to V.
Classification:
• Primary VUR results from a congenital abnormality of the VUJ. An anatomical 
cause is seen with duplex ureters. The Weigert-Meyer rule states the lower pole 
ureter enters the bladder proximally and laterally, resulting in a shorter intra-
mural tunnel which predisposes to VUR.
• Secondary VUR results from urinary tract dysfunction associated with elevated 
intravesical pressures creating damage to the VUJ. Causes include PUV, ure-
thral stenosis, neuropathic bladder, DSD. Inflammation associated with acute 
cystitis can also distort the VUJ causing VUR.
At presentation most common patients have symptoms of UTIs. VUR asso-
ciated with UTIs can result in reflux nephropathy and nephrosclerosis, causing 
hypertension and progressive CRF.
Investigation are urinanalysis and culture to diagnose UTIs, US, DMSA reno-
gram to detect and monitor associated renal cortical scarring, MCUG to diagnose 
and grade VUR and establish reversible causes. Urodynamic investigation is used 
if there is suspicious of voiding dysfunction.
Treatment starts from eliminating of the problems contributing to secondary 
VUR. The majority (80-85%) of primary VUR grade I-II will resolve spontaneously, 
with 50% resolution in grade III-V. A period of observation with medical treatment 
is therefore initially recommended. General advice includes good fluid intake, regular 
voiding, perineal hygiene, treatment of constipation and use of probiotics. Low dose 
antibiotic prophylaxis should be given to keep the urine sterile and lower the risk 
of renal damage until VUR resolves. Anticholinergic drugs are given to treat OAB.
Surgery is indicated in limited cases. Techniques include laparoscopic or open 
ureteric re-implantation with or without antireflux technic. Endoscopic injection of 
hyaluronic acid/dextranomer bulking agent (Deflux), which is injected intramurally 
at the ureteric orifice with 80-90% success rates.
4 1 8  .Ectopic .ureter
The ureteric orifice is situated either below and medial or above and lateral to 
the normal anatomical insertion on the trigone of the bladder. Incidence is ~1 in 
1900. Female to male ratio is ≥ 3:1.
The ureteric bud arises from an abnormal position on the mesonephric duct 
during embryological development. There is a direct correlation between the loca-
tion of the ectopic ureter and the degree of ipsilateral renal hypoplasia or dyspla-
sia. 80% are associated with a duplicated collecting system. A duplex kidney has an 
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upper pole and a lower pole units, each with its own renal pelvis and ureter. The 
two ureters may join to form a single ureter or they may pass down individually 
to the bladder by complete duplication. In this case, the upper pole ureter always 
opens onto the bladder below and medial to the lower pole ureter, predisposing to 
ectopic placement of the ureteric orifice.
Sites of ectopic ureter in females include lateral in the bladder, bladder neck, 
urethra, vagina, vaginal vestibule, uterus. In male patients sites include lateral in 
the bladder, posterior urethra, seminal vesicles, ejaculatory duct, vas deferens, 
epididymis, bladder neck.
Most patients present with an antenatal diagnosis of UHN, which may present 
as an abdominal mass. Later presentations include acute or recurrent UTIs. When 
the ureteric opening is below the urethral sphincter girls present with persistent 
vaginal discharge or false incontinence, despite successful toilet training. In male 
patients the ureter is always sited above the external urethral sphincter, so boys do 
not develop incontinence. UTIs may trigger recurrent epididymitis.
US may demonstrate UHN. MRT identifies duplex systems. MCUG assesses 
VUR in lower pole ureters. Cystourethroscopy can directly identify a ureteric open-
ing in the urethra. DMSA renogram assesses renal function to help plan surgery.
Treatment is mainly expectant if there are no symptoms. Where an ectopic ure-
ter is associated with a poorly functioning renal upper pole or single-system kid-
ney, surgery is an option. This includes open or laparoscopic heminephrectomy or 
total nephrectomy with excision of the associated ureter. Uretero-pyelostomy and 
uretero-ureterostomy can be considered in duplex systems where the upper renal 
pole has reasonable function. Where some function is retained in a single-system 
kidney, the distal ureter can be resected and re-implanted into the bladder.
4 1 9  .Ureterocele
Ureterocele is a cystic dilatation of the distal ureter as it drains into the bladder. In-
cidence is 1 in 5000-12000. Female to male ratio is 4:1. 80% are associated with the 
upper pole of a duplex system. Single-system ureteroceles are more commonly found 
in males and adults. 10% of ureteroceles are bilateral. There is intravesical or orthotopic 
ureterocele, which is completely confined within the bladder. This ureterocele may be 
stenotic or non-obstructed. Second type is more common. There is ectopic ureteroce-
les, if any part extends to the bladder neck or urethra. May be sphincteric (wide orifice, 
found proximal to the bladder neck within the internal sphincter), sphincterostenotic 
(stenotic orifice, found proximal to the bladder neck), ceco-ureterocele (ectopic uret-
erocele that extends into the urethra, but the orifice is within the bladder).
Most patients present with antenatal UHN. Later presentation in infants may 
be with symptoms of UTIs. Association with ureteric duplication increases the risk 
of VUR and reflux nephropathy. Ureteroceles can also cause obstruction, which 
may be identified on antenatal US or present in children with an abdominal mass 
or pain. A prolapsing ureterocele can present as a vaginal mass in girls.
US shows a thin walled cyst in the bladder often associated with a duplex system. 
MCUG can identify ureterocele location, size and associated VUR. Cystoscopy may 
reveal a defect near the trigone. DMSA renogram assesses renal segment function.
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There are many treatment options. Endoscopic incision - this is emergen-
cy treatment for infected or obstructed ureteroceles. Also indicated for elective 
management of intravesical ureteroceles. Rarely, these may require further sur-
gery, including ureterocele excision and ureteric re-implantation to preserve renal 
function and prevent VUR. Uretero-ureterostomy or uretero-pyelostomy (from 
upper to lower pole unit): option for ectopic ureteroceles associated with a duplex 
system, with good function in the upper unit and no VUR in the lower. Upper 
pole partial nephrectomy: option for ectopic ureterocele associated with a duplex 
system with poor function in the upper unit and no VUR in the lower unit. Upper 
pole partial nephrectomy, ureterocele excision and ureteric re-implantation: op-
tion for ectopic ureterocele associated with a duplex system with poor function in 
the upper unit and VUR in the lower unit. Nephro-ureterectomy is indicated for 
significant lower pole reflux with poor function in both renal poles.
4 2  .URETHRAL .ANOMALIES
4 2 1  .Hypospadias
Hypospadias is a congenital deformity where the meatus is sited on the underside 
of the penis, anywhere from the glans to the perineum. It is often associated with a 
“hooded” foreskin and chordee, which will lead to ventral curvature of the penile 
shaft. It occurs in 1 in 250 live male births.
Hypospadias results from incomplete closure of urethral folds on the under-sur-
face of the penis during embryological development. This is related to a defect in 
production or metabolism of fetal androgens or the number and sensitivity of an-
drogen receptors in the tissues. Chordee is caused by abnormal urethral plate de-
velopment or an intrinsic abnormality of the corpora cavernosa and the “hooded” 
foreskin is due to failed fusion of the preputial folds, resulting in a lack of ventral 
foreskin. Associated anomalies are UDT, inguinal hernia, hydrocele, disorders of 
sexual development.
Classification:
• Anterior: glandular, coronal and subcoronal;
• Middle: distal penile, midshaft and proximal penile;
• Posterior: penoscrotal, scrotal and perineal;
It is indicated a full clinical examination to establish the diagnosis, assess the 
penis and urethral plate and detect associated abnormalities needing treatment. 
Patients with unilateral or bilateral absent testes and hypospadias should undergo 
chromosomal and endocrine investigation to exclude disorders of sex development. 
Posterior hypospadias can be associated with other urinary tract malformations.
Surgery is indicated where deformity is severe, interferes with voiding or is pre-
dicted to interfere with sexual function. Repair is performed between 6-18 months 
of age. Local application of testosterone for 1 month preoperative can help increase 
tissue size. Surgery aims to correct penile curvature, reconstruct a new urethra and 
bring the new meatus to the tip of the glans using urethroplasty, glanuloplasty and 
meatoplasty techniques. Some proximal defects may require a 2-stage procedure.
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4 2 2  .Posterior .urethral .valves
PUV are derived from an abnormal congenital membrane arising from the ver-
umontanum and attaching obliquely to the anterior urethra, beyond the external 
urethral sphincter, resulting in lower urinary tract obstruction. Urethral instru-
mentation or spontaneous partial rupture of the membrane is thought to cause the 
classical appearance of two valve-like folds in the prostatic urethra. Incidence is 
1 in >5000 males.
Most common PUV is diagnosed prenatally. Features include: bilateral UHN, 
dilated bladder and posterior urethra, thick walled bladder and renal dysplasia. 
Early diagnosis is associated with poor prognosis. In newborn and infants there 
are respiratory distress, palpable abdominal mass due to hydronephrotic kidneys 
or distended bladder, ascites, UTIs, renal impairment. In older children there are 
recurrent UTIs, poor urinary stream, incomplete bladder emptying, poor growth 
and incontinence. There is a risk of CRF, VUR and voiding dysfunction.
Associated features: “Pop-off valve syndrome” is seen in 20%. It describes 
mechanisms by which high urinary tract pressure is dissipated to allow normal 
renal development. It includes leaking of urine from a small bladder or renal pel-
vis rupture (urinary ascites), unilateral VUR into a non-functioning kidney and 
formation of bladder diverticuli.
Patients with PUV have long-term poor renal function, 20% develop ESRD. 
Bladder dysfunction is common despite treatment of outflow obstruction. This 
includes OAB, incontinence and bladder underactivity associated with PVR, poor 
concentration of urine and polyuria. From age 16 years, care should be transferred 
to an adult urologist or nephrologist. Problems may arise with retrograde ejacula-
tion, impotence and reduced libido due to renal impairment. There are abnormal 
prostatic or seminal vesicle secretions contributing to reduced fertility.
Assessing of the renal function are performed with MAG3 or DMSA reno-
grams. US may show thickened bladder wall, bilateral UHN and dilated posterior 
urethra. By MCUG features of PUV include a distended posterior urethra, par-
tially filled anterior urethra, bladder neck hypertrophy, thick walled bladder and 
diverticuli, incomplete bladder emptying, VUR.
Treatment include prophylactic antibiotics, check serum electrolyes and drain 
the bladder with a pediatric feeding tube. If there is improvement, cystoscopy and 
transurethral ablation of valve at 5 and 7 o’clock is recommended. A temporary 
cutaneous vesicostomy is indicated. Any underlying bladder dysfunction should be 
diagnosed and treated.
4 3  .BLADDER .EXSTROPHY .AND .EPISPADIAS
Exstrophy-epispadias complex describes a spectrum of congenital malformations 
affecting the abdominal wall, pelvis, GUT and sometimes also the spine and anus. 
It includes bladder exstrophy and epispadias.
4 3 1  .Bladder .exstrophy
The most common form, results from defective development of the anterior blad-
der and lower abdominal walls, resulting in the posterior bladder wall lying ex-
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posed on the abdomen. Incidence is 1 in 50 000 live births. Male to female ratio 
is 5:1. Increased risk in offspring of affected patients and with younger maternal 
age and increased parity.
Classically described as an embryological malformation causing abnormal over-de-
velopment of the cloacal membrane, which prevents in-growth of lower abdominal 
tissues. The cloacal membrane normally perforates to form the urogenital and anal 
openings, but in exstrophy, premature rupture results in a triangular defect below the 
umbilicus. The timing of rupture determines the type of resulting defect.
Associated anomalies:
• Bone defects: diastasis of the symphysis pubis due to outward rotation of the 
pelvic bones along the sacroiliac joints;
• Musculofascial defects: umbilical hernias, inguinal hernias, divarication of rec-
tus abdominis, abnormal pelvic floor, low lying umbilicus;
• Genital defects in male patients: short, broad penis with lateral splaying of 
the corporal cavernosa, short urethral plate, epispadias, deficiency of dorsal 
foreskin. Defects in female patients: bifid clitoris, stenotic vaginal orifice, short 
anteriorly placed vaginal canal, uterine prolapse in adult life;
• Urinary tract defects: exposed bladder plate. Majority suffer from VUR due to 
lateral displacement of the ureteric orifices;
• GUT defects: anteriorly displaced anus, rectal prolapse, abnormal anal sphinc-
ter contributes to incontinence.
Typical features seen on prenatal US include a lower abdominal wall mass, 
absent bladder filling, low-set umbilicus, small genitalia, abnormal iliac crest wid-
ening. Diagnosis can help planning of delivery in a centre with facilities to perform 
early surgical correction.
Surgery aims to provide a continent reservoir for urine storage, preserve renal 
function and create functional and cosmetically acceptable external genitalia. Se-
lected cases are suitable for a one-stage complete primary repair of bladder exstro-
phy involving closure of the bladder plate and epispadias repair.
However, many patients require staged procedures. In newborn pelvic osteot-
omy (cutting bone to correct deformity) is performed with external fixation and 
closure of bladder, abdominal wall and posterior urethra. At 6-18 months epispa-
dias repair is indicated. Bladder neck reconstruction and ureteric re-implantation 
with anti-reflux surgery is performed for 4-5 years patients when there is adequate 
bladder capacity and children can participate in voiding protocols. Where bladder 
capacity is too small, bladder augmentation or urinary diversion is required.
4 3 2  .Primary .epispadias
In epispadias, the urethra opens onto the dorsal surface of the penis, anywhere 
from the glans, penile shaft or most commonly, the penopubic region. An in-
complete urethral sphincter mechanism results in a high risk of incontinence. 
Epispadias is also associated with dorsal chordee, causing an upward curvature of 
the penis and with incomplete foreskin dorsally. Epispadias is part of the exstro-
phy-epispadias complex. Primary epispadias without exstrophy is rare.
Chapter 4. ANOMALIES OF THE GENITOURINARY TRACT56
Associated anomalies are diastasis of the symphysis pubis results in splaying of 
the corpora cavernosa and shortening of the penile shaft. Females have a bifid 
clitoris, poorly developed labia and demonstrate a spectrum of urethral deformi-
ties ranging from a patulous urethral orifice to a urethral cleft affecting the entire 
length of the urethra and sphincter. There is rare abnormality with male:female 
ratio is 5:1.
Treatment in male patients include urethroplasty with functional and cosmetic 
reconstruction of the external genitalia with penile lengthening and correction of 
chordee at 6-18 months. It describes mobilizing the urethra to the ventral aspect 
of the penis, with advancement of the urethral meatus onto the glans with a meatal 
advancement glanduloplasty. The corporal bodies are separated and rotated me-
dially above the urethra and re-approximated. From age 4-5 years, when children 
can be toilet trained, bladder neck reconstruction can be performed. with help of 
the Youngs-Dees-Leadbetter procedure. This achieves continence and any bladder 
residuals may then be emptied by urethral catheterization. If this surgery fails, 
insertion of artificial urinary sphincters or injection of peri-urethral bulking agents 
may be tried. In female patients surgery involves urethral repair reinforced with 
pubic fat, along with clitoral reconstruction and bladder neck repair.
4 4  .BLADDER .ABNORMALITIES
4 4 1  .Persistent .urachus
Embryologically, the allantois connects the urogenital sinus with the umbilicus. 
Normally, the allantois is obliterated and is represented by a fibrous cord (ura-
chus) extending from the dome of the bladder to the navel. Incomplete obliter-
ation sometimes occurs. If obliteration is complete except at the superior end, a 
draining umbilical sinus may be noted. If it becomes infected, the drainage will 
be purulent. If the inferior end remains open, it will communicate with the blad-
der, but this does not usually produce symptoms. Rarely, the entire tract remains 
patent, in which case urine drains constantly from the umbilicus. This is apt to 
become obvious within a few days of birth. If only the ends of the urachus seal 
off, a cyst of that body may form and may become quite large, presenting a low 
midline mass. If the cyst becomes infected, signs of general and local sepsis will 
develop. Adenocarcinoma may occur in a urachal cyst, particularly at its vesical 
extremity and tends to invade the tissues beneath the anterior abdominal wall. It 
may be seen cystoscopically. Stones may develop in a cyst of the urachus. These 
can be identified on a plain X-ray film. Treatment consists of excision of the ura-
chus, which lies on the peritoneal surface. If adenocarcinoma is present, radical 
resection is required. Unless other serious congenital anomalies are present, the 
prognosis is good. The complication of adenocarcinoma offers a poor prognosis.
4 4 2  .Contracture .of .the .bladder .neck
There is considerable debate about the incidence of congenital narrowing of the 
bladder neck. Some feel that its presence is a common cause of VUR, vesical 
diverticula, a hypoactive bladder and OAB associated with enuresis. The diagnosis 
UROLOGY 57
is based on endoscopic observation, which is an unreliable method. MCUG has 
been used to depict such narrowing, but interpretation of the films varies sig-
nificantly. Empirical treatment after detecting of Qmax is often employed. This 
consists of TUR or suprapubic bladder neck revision. Making the bladder neck 
incompetent in young boys may cause later retrograde ejaculation and, therefore, 
male infertility. Revision of the bladder neck in females may cause urinary incon-
tinence and is never advised. The diagnosis must therefore be made with caution. 
Genuine functional bladder neck obstruction can be detected only in the presence 
of already high voiding pressures combined with lower resistance in the external 
sphincteric segment associated with a low flow rate. This condition is highly sug-
gestive of functional bladder neck obstruction.
4 4 3  .Dilated .fetal .bladder
In the first trimester, the fetal bladder is considered to be dilated if larger than 7 
mm on US. If, on subsequent US, the bladder continues to retain urine and shows 
no evidence of urine cycling, concern regarding obstruction should be raised. If 
the amniotic fluid does not increase, this may indicate the progression to oligo-
hydramnios. Determination of the sex of the child is important because of the 
male gender predominance of certain diseases such as PUV. It can be difficult to 
distinguish in utero if the dilatation is due to obstruction. 
Dilatation caused by obstruction
Dilatations of the fetal bladder caused by anatomic obstructions are mostly due to 
urethral anomalies or external obstruction. Urethral anomalies include congenital 
urethral strictures, anterior and PUV and urethral atresia. Compression of the 
bladder outlet region can be due to obstructing pelvic tumors, an anterior sacral 
myelomeningocele, adilated vagina in a girl with a cloacal anomaly or with rectal 
anomalies. The observed bladder changes are due to mechanical obstruction and 
affect bladder development at a critical time point, which can lead to bladder wall 
hypertrophy and remodeling.
Dilatation in non-obstruction
Affected patients with neurogenic bladder do not demonstrate any sign of obstruc-
tion on postnatally performed voiding studies or cystoscopic evaluations, except 
when urethral atresia is also present. In this case the presentation is similar to 
PUV patients.
4 4 4  .Congenital .megacystis
The term megacystis is often used to describe any condition leading to a dis-
tended fetal bladder in utero, without referring to the cause of the dilation. Con-
genital megacystis is defined as a dilated, thin-walled bladder with a wide and 
poorly developed trigone. The widegaping ureteral orifices are displaced laterally, 
causing massive VUR. No neurogenic abnormalities are described. Most patients 
are recognized prenatally and should be placed on prophylactic antibiotics after 
birth. Correcting the VUR often restores normal voiding dynamics and should be 
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performed after 6 months of age. Reduction cystoplasty can be performed but is 
usually unnecessary. Although the bladder is large enough to accommodate the 
tapered ureters even in a young infant, the operation can be difficult due to the 
bladder wall’s thinness.
4 4 5  .Bladder .hypoplasia
In order to truly diagnose an fetal bladder on US, the examination has to be repeated 
after 15 to 20 minutes to rule out that the fetus has not simply emptied the bladder.
The bladder can be hypoplastic due to inadequate filling or storing of urine 
during fetal life. Although the bladder is formed during fetal development and can 
be detected on antenatal US throughout pregnancy, it never reaches an adequate 
capacity. Conditions caused by inadequate bladder outlet resistance: severe epispa-
dias, separation defects, abnormalities of renal development or urine bypassing the 
bladder by ureteral ectopia can all lead to underdevelopment of the fetal bladder.
4 4 6  .Bladder .agenesis
Embryologic development of bladder agenesis remains difficult to explain. The division 
of the cloaca into the urogenital sinus and the anorectum is apparently regular because 
the hindgut is usually normal. Therefore the defect can be due to either atrophy of the 
cranial part of the urogenital sinus or a failure to incorporate the mesonephric ducts 
and ureters into the trigone. The absence of the bladder is often associated with neu-
rologic orthopedic or other urogenital anomalies. The defect is only compatible with 
life if the ureters drain ectopically into normally developed mullerian structures in the 
female or in the rectum in males. In surviving infants, the diagnosis can be confirmed 
by retrograde ureteronephrograms via the ectopic openings. Renal function can be 
preserved after creation of an ureterosigmoidostomy or external stoma.
4 4 7  .Bladder .diverticulum
Bladder diverticula are caused by infravesical obstruction or congenital defects. 
Independent from the cause, all diverticula develop as herniation of bladder mu-
cosa between defects of bladder smooth muscle fibers. The neck of the resulting 
diverticulum depends on the size of the muscular defect. The true incidence in 
children is difficult to evaluate because many of the congenital diverticula remain 
asymptomatic and are probably never detected. 
Primary diverticula are seen in smoothwalled bladders, occur isolated with no 
other diverticula, are intermittent in presentation and happen in children with 
no infravesical obstruction. Primary diverticula arise as a localized herniation of 
bladder mucosa through the ureteral hiatus between the intravesical ureter and the 
roof of the ureteral hiatus. These primary diverticula are also known as congenital 
diverticula and are most likely caused by a congenitally deficient bladder wall. 
Congenital diverticula are often found in children with generalized connective 
tissue diseases. These diverticula can be resected if symptomatic.
Secondary diverticula are found in trabeculated bladders as one of many diver-
ticula in the bladder, are always present and are caused by infravesical obstruction. 
The resulting increased infravesical pressure forces the bladder mucosa to bulge 
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between the muscle fibers. These diverticula are usually just one of many “pop-
off” mechanisms that can occur throughout the bladder. These diverticula can also 
be caused by weakening in the bladder muscle by infection or development of a 
muscular defect after bladder surgery.
4 4 8  .Bladder .duplication
Duplication of the bladder and urethra can be complete or incomplete. It can 
occur either in the coronal or sagittal plane. In incomplete duplications, the two 
bladder halves communicate and are usually drained by a single urethra. In com-
plete duplications, the two bladders are fully separated entities with normal muco-
sa and a full-thickness musculature wall divided by a peritoneal fold. Although the 
size and quality of each entity can be different, they are usually supplied with their 
own ureter and are drained by an individual urethra and external meatus. In rare 
cases, one bladder can lack a urethra. This leads to ipsilateral renal dysplasia via 
complete obstruction. Both bladders may possess a sufficient continence mech-
anism or one side is compromised, causing incontinent episodes. Associated du-
plication anomalies have been reported. Duplicated vaginas can be connected to 
a separate unicornuate uterus. Duplicated penises are supplied with an individual 
urethra. Additional urologic abnormalities such as VUR, renal ectopia or dysplasia 
are commonly found. Complete preoperative diagnostic evaluations with karyo-
type, US, IVP, video-urodynamic studies, genitogram and GIT imaging are useful 
to determine the anatomic situation. VCUG and nuclear renal scans can supply 
additional information regarding VUR and renal function. Complete understand-
ing of the various anomalies can be difficult. Often the final treatment plan has 
to be deferred until the time of endoscopic and surgical exploration of the mal-
formation. Initial treatment is directed toward renal preservation and prevention 
of UTIs by relieving possibly obstructed GUT. Long-term goals include achieving 
continence and reconstructing the internal and external genitalia. Incomplete du-
plications may not require surgical procedures if both bladder halves are suffi-
ciently drained by a common urethra. In complete duplications, the two bladders 
can be combined into one. If both sphincter complexes are competent, the distal 
urethras are connected. If one is incompetent, the corresponding bladder neck can 
be closed and the connected urethra excised. Duplicated vaginas are combined in 
the midline and a vulvoplasty is performed. Due to the rarity of the disease and 
the large variety of presentations, the surgeries must be individualized and should 
be performed in centers experienced in complex urogenital reconstruction.
4 5  .PENILE .ABNORMALITIES
4 5 1  .Phimosis
Phimosis is a condition in which the contracted foreskin cannot be retracted over 
the glans. Chronic infection from poor local hygiene is its most common cause. 
Most cases occur in uncircumcised males, although excessive skin left after cir-
cumcision can become stenotic and cause phimosis. Calculi and SCC may develop 
under the foreskin. Phimosis can occur at any age. In diabetic older men, chronic 
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balanoposthitis may lead to phimosis and may be the initial presenting complaint. 
Children under 2 years of age seldom have true phimosis. Their relatively narrow 
preputial opening gradually widens and allows for normal retraction of foreskin 
over the glans. Circumcision for phimosis should be avoided in children requiring 
general anesthesia, except in cases with recurrent UTIs, the procedure should 
be postponed until the child reaches an age when local anesthesia can be used. 
Edema, erythema and tenderness of the prepuce and the presence of purulent 
discharge usually cause the patient to seek medical attention. The initial infection 
should be treated with broad-spectrum antimicrobial drugs. By paraphimosis if 
manual reposition fails, the dorsal foreskin can be slit. Circumcision, if indicated, 
should be done after the infection is controlled.
4 5 2  .Aphallia
Penile agenesis results from failure of development of the genital tubercle. The 
disorder is rare. The karyotype almost always is 46,XY and the usual appearance is 
that of a well-developed scrotum with descended testes and an absent penile shaft. 
The anus is usually displaced anteriorly. The urethra often opens at the anal verge 
adjacent to a small skin tag or it can open into the rectum. Associated malfor-
mations are common. Children with this lesion should be evaluated immediately 
by a multidisciplinary approach. Testing should include a karyotype and other 
appropriate studies to determine whether there are associated malformations of the 
urinary tract or other organ systems. MRT may be beneficial in determining the 
severity of the defect. Prompt gender assignment is important. Some of these pa-
tients have a male gender identity despite reconstruction as a female, presumably 
because of in-utero or postnatal sex steroid imprinting.
Consequently, the recommendation to perform gender reassignment should be 
made carefully and only after full evaluation by an ambiguous genitalia assessment 
team and parental counseling. As a male the patient would potentially be fertile, 
but currently there is an inability to construct a cosmetically acceptable phal-
lus that would allow normal urinary, sexual and reproductive function. Gender 
reassignment involves orchiectomy and feminizing genitoplasty in the neonatal 
period. At a later age, construction of a neovagina is necessary. Urinary tract 
reconstruction with simultaneous construction of an intestinal neovagina through 
a posterior sagittal and abdominal approach in patients with penile agenesis has 
been described.
4 5 3  .Diphallia
Duplication of the penis is a rare anomaly and has a range of appearances from 
a small accessory penis to complete duplication. In some cases, each phallus has 
only one corporeal body and urethra, whereas others seem to be a variant of twin-
ning, with each phallus having two corpora cavernosa and a urethra. The penises 
are usually unequal in size and lie side by side. Other associated anomalies are 
common. Evaluation should include imaging of the entire urinary tract, including 
a renal US and MCUG. US and MRT can also be done to assess penile devel-
opment. The etiology has not been delineated. Treatment must be individualized 
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with consideration of the associated anomalies with the goal of attaining a satis-
factory functional and cosmetic result.
4 5 4  .Inconspicuous .penis
An inconspicuous penis refers to a penis that appears to be small with a normal 
stretched penile length measured from the pubic symphysis to the tip of the glans 
and normal diameter of the penile shaft. This condition can be congenital or ac-
quired and is usually of great concern for parents. Several entities are included in 
this disorder, including buried penis, trapped penis and webbed penis. These con-
ditions must be differentiated from micropenis, in which the penis is abnormally 
small. When an infant has an inconspicuous penis, prompt evaluation is necessary 
for proper treatment and the family must be informed as to whether the penis is 
or is not normal. The stretched penile length should be measured from the pubic 
symphysis to the tip of the glans. In addition, the diameter of the penile shaft may 
be measured by palpation.
A buried penis, also referred to as hidden or concealed penis, is a form of 
inconspicuous penis. A buried penis is a normally developed penis that is hidden 
away by the suprapubic fat pad. The congenital form of buried penis is believed 
to be due to the inelasticity of the dartos fascia, which normally allows the penile 
skin to slide freely on the deep layers of the shaft, with restricted extension of the 
penis because the penile skin is not anchored to the deep fascia. The acquired 
form from obesity.
The other acquired form, a trapped penis, results from embedding of the penis 
in the suprapubic fat pad from scar formation over the glans. This deformity may 
occur after neonatal circumcision in an infant with significant scrotal swelling due 
to a hernia or hydrocele or after routine circumcision in an infant with a webbed 
penis. Also, in some neonates the penile shaft seems to retract naturally into the 
scrotum and if circumcision is performed in this situation, the skin at the base of 
the penis may form a cicatrix over the retracted phallus. This condition should be 
differentiated from a transient buried penis resulting from a large suprapubic fat pad 
noted in early childhood that resolves with increased age and ambulation. On exam-
ination, a buried penis must be differentiated from a micropenis, with the latter not 
having a normal penile stretched length. The clinician should determine whether 
the glans can be exposed by retracting the skin covering the glans. If so, it remains 
the surgeon’s judgment whether correction is warranted. However, if the penis is 
trapped by physiologic phimosis in the uncircumcised or cicatricial scarring in the 
circumcised penis, this increases the chance of difficulty voiding, maintaining prop-
er hygiene, balanitis, UTIs and psychosocial issues. The treatment options for chil-
dren with buried penis are based on etiology. Patients with buried penis secondary 
to obesity should have the underlying condition treated. Referral of the child back 
to the primary care provider for a weight loss and exercise program is essential, with 
surgical intervention usually not necessary. Young children with secondary cicatri-
cial scarring after penile surgery can be managed with forceful dilation of the cicatrix 
with a fine hemostat in the office after the application or injection of analgesia. 
Another option is the combination of topical betamethasone and manual retractio.
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Webbed penis, also known as penoscrotal fusion, is a congenital or acquired 
condition resulting from the scrotal skin extending onto the ventrum of the pe-
nis. The congenital form of a penoscrotal web represents an abnormality of the 
attachment between the penis and the scrotum, whereas the penis, urethra and 
remainder of the scrotum are normal. The acquired condition results from cir-
cumcision or other penile surgery due to excessive removal of ventral penile skin. 
Although the penoscrotal web is usually asymptomatic, the cosmetic appearance 
is often unacceptable.
4 5 5  .Micropenis
Micropenis is a normally formed penis that is at least 2.5 SD below the mean size 
in stretched length for age. The ratio of the length of the penile shaft to its cir-
cumference is usually normal, but occasionally the corpora cavernosa are severely 
hypoplastic. The testes are usually small and frequently cryptorchid, whereas the 
scrotum is usually fused and often diminutive. Stretched penile length is used be-
cause it correlates more closely with erectile length than does the relaxed penile 
length. The measurements should be compared with standards for penile length. 
Stretched penile length is determined by measuring the penis from its attachment 
to the pubic symphysis to the tip of the glans. One must be careful to depress the 
suprapubic fat pad completely to obtain an accurate measurement, especially in 
an obese infant or child. In general, the penis of a full-term neonate should be at 
least 1.9 cm long. One must differentiate buried penis or webbed penis from the 
micropenis, with the former having a normal penile shaft. Micropenis results from 
a hormonal abnormality that occurs after 14 weeks of gestation. Differentiation of 
the male external genitalia is complete by the 12th week of gestation and requires 
a normal testis producing testosterone, stimulated by maternal hCG. During the 
second and third trimesters, growth of the penis occurs under the direction of fetal 
androgen, which is controlled by the secretion of fetal LH. An abnormality in the 
production or use of testosterone results in a small penis and hypospadias, whereas 
a true micropenis often seems to be a consequence of a deficiency of gonadotropic 
hormones. The most common causes of micropenis are hypogonadotropic hypogo-
nadism, hypergonadotropic hypogonadism and idiopathic. Furthermore, micropenis 
is often associated with major chromosomal defects.
The initial evaluation of a child with micropenis should include a thorough 
medical history and a karyotype at birth. Accurate measurement of the penile 
length, palpation of the corporeal bodies and evaluation for cryptorchidism are 
several important aspects of the physical examination. Consultation with a pedi-
atric endocrinologist is also usually obtained to assist in the determination of the 
cause of the micropenis and to assess whether other abnormalities are also present. 
Several issues need to be addressed, including the growth potential of the penis 
and the etiology of the micropenis. The etiology may be testicular or central. 
Testicular function may be assessed by measuring serum testosterone levels before 
and after hCG stimulation. Primary testicular failure produces an absent response 
and elevated basal concentrations of LH and FSH. In some cases, a GnRH 
stimulation test is also performed. Anterior pituitary screening tests include serial 
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measurements of serum glucose, sodium, potassium and serum cortisol concen-
trations and thyroid function tests. MRT of the head should be done to determine 
the anatomic integrity of the hypothalamus and the anterior pituitary gland as well 
as the midline structures of the midbrain. Before extensive evaluation of the hypo-
thalamic pituitary-testicular axis androgen therapy should be administered to de-
termine the end organ response. In general, intramuscular testosterone is given for 
3 months. Although prolonged treatment might advance skeletal maturation, short 
courses of treatment do not affect height. Transdermal testosterone also has been 
used in these patients. If androgen treatment in a neonate successfully increases 
the penis so that its size falls within the normal range, the effects at puberty have 
not been clearly delineated. If the penis does not respond to testosterone, gender 
reassignment is an option but is controversial.  
4 5 6  .Penile .curvature
Curvature of the penis may occur along the vertical (i.e., ventral or dorsal direc-
tion) or horizontal (i.e., lateral direction) plane of the penis. Penile curvature may 
be congenital or acquired from circumcision, other penile surgery or trauma and 
has cosmetic significance and future sexual difficulties. Penile curvature is most 
commonly in the ventral direction, referred to as chordee and is commonly associ-
ated with hypospadias. However, chordee may occur without hypospadias and with 
or without a dorsal hood of prepuce and is commonly associated with a deficiency 
of the ventral skin. Ventral curvature in boys without hypospadias can generally 
be corrected by degloving of the penis, excision of fibrous tissue that is usually 
confined to the region superficial to Buck fascia and development of a Byar flap 
for penile skin coverage as necessary. Congenital dorsal penile curvature may be 
an isolated condition with or without asymmetrical penile skin or associated with 
epispadias and a ventral hood of prepuce. Some individuals may have hypospadias. 
Surgical repair of this condition without associated urethral anomalies is similar to 
chordee correction, involving degloving of the penis, excision of fibrous tissue that 
is usually confined to the region superficial to Buck fascia and development of skin 
flaps for penile skin coverage as necessary. During correction, one must be careful 
to avoid injury to the neurovascular bundles. More severe cases involve plication 
and/or excision of ellipses from the ventral corporeal bodies to correct curvature.
Lateral penile curvature is usually caused by overgrowth or hypoplasia of one 
corporeal body. Lateral penile curvature may be unrecognized until later in child-
hood because the penis is normal when flaccid and only recognized as being 
curved with an erection. Surgical repair of congenital lateral penile curvature 
involves degloving the penis and performing a plication and/or excision of ellipses 
from the corporeal bodies from the site of maximum curvature to allow straight-
ening of the penis. Secondary lateral penile curvature follows the same principles 
as for vertical curvature with degloving of the penis, excision of fibrous tissue that 
is usually confined to the region superficial to the Buck fascia and development 
of skin flaps for penile skin coverage as necessary. Intraoperative artificial erection 
may be necessary.
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4 6  .TESTICULAR .ABNORMALITIES
4 6 1  .Cryptorchidism
The testes descend into the scrotum in the third trimester. Failure of testicular 
descent results in cryptorchidism or congenital UDT. Incidence is 4% at birth for 
a full-term neonate and unilateral UDT > bilateral. About 80% will spontaneously 
descend by 6 months. The incidence at 1 year is <2%.
Etiology: abnormal testis or gubernaculum (tissue that guides the testis into the 
scrotum during development), endocrine abnormalities. Risk factors are pre-term 
infants, low birth weight or small for gestational age, twins.
Classification:
• Retractile testis: an intermittent active cremasteric reflex causes the testis to 
retract up and out of the scrotum;
• Ectopic: abnormal testis migration below the external ring of the inguinal canal 
to perineum, base of penis or femoral areas;
• Incomplete descent: atrophic testis may be intra-abdominal, intra-inguinal or 
pre-scrotal.
It is indicated full examination to elucidate if testis is palpable and to identify 
location. If neither testis is palpable, consider chromosome analysis to exclude an 
androgenized female and endocrine analysis. High LH and FSH with a low tes-
tosterone indicates anorchia, confirmed with serum inhibin B. For the impalpable 
testis, imaging with US inguinal canal may be considered, but most recommend 
proceeding directly to examination under anaesthetic and diagnostic laparoscopy.
UDT demonstrate degeneration of Sertoli cells, loss of Leydig cells, atrophy 
and abnormal spermatogenesis, which usually may be irreversible by 2 years old.
Complications:
• Relative risk of cancer is 8-fold higher in UDT. There is a 4% lifelong risk of 
TC with an intra-abdominal testis. Majority are seminomas. There is a slightly 
increased risk of cancer in the contra-lateral, normally descended testis;
• Reduced fertility;
• Increased risk of testicular torsion or trauma;
• Increased risk of indirect inguinal hernias due to a patent processus vaginalis.
Orchidopexy is recommended at 6-18 months old, but many operate within the 
first 12 months. Surgery consists of inguinal exploration, mobilization of spermatic 
cord, ligation of processus vaginalis and securing the testis into a dartos pouch 
in the scrotal wall. Risks include rare testicular atrophy. Intra-abdominal testes 
require a laparoscopic approach to mobilize the testis for orchidopexy as a single 
or 2-stage (Fowler-Stephens) procedure, involving division of spermatic vessels to 
provide extra length. The testis then relying on collateral blood flow from the vas. 
Alternatives include microvascular autotransplantation. Orchidectomy for small 
intra-abdominal testes should be considered.
5 1  .PROSTATE .CANCER
Incidence, .etiology .and .risk .factors
The diagnosis of PC is increased, probably as a result of screening for both symp-
tomatic and asymptomatic men and the use of more extensive prostatic biopsy pro-
tocols. PC is the most commonly diagnosed male cancer. The true prevalence of the 
disease is hinted at by studies carried out on men who have died of other causes. 
These have demonstrated histological evidence of PC from 10% of men in their 3rd 
decade till 70% in their 9th. This leads to the concept of “latent” PC a biologically 
non-aggressive and slow-growing form of the disease, which may be unnecessarily 
detected by PSA screening. It is estimated that 3% of men die of PC. Recent trend 
toward a reduction in PC mortality appears to be due to increased operative treat-
ment of localized disease and, perhaps, early use of hormone therapy for advanced 
disease and PSA screening programmes.
Growth of PC and also benign prostatic epithelium, is under the promotional 
influence of testosterone. Removal of androgens by castration largely results in 
programmed cell death and involution of the prostate. PC is not seen in eunuchs 
or people with congenital deficiency of 5-AR, which converts testosterone to 
DHT. Phyto-oestrogens found in foodstuffs used in Asian and Oriental cuisine, 
have a negative growth effect on PC. This probably explain why these races rarely 
develop the clinical disease or die of PC. Other dietary inhibitors of PC growth 
include vitamins E and D, lycopene and selenium.
Age is an important risk factor for development of histological PC and PIN, the 
disease being rare below 40 years and becoming increasingly common with rising 
age. However, most PC does not achieve a clinically recognizable stage.
The disease is more common in Western nations and the United States. The dis-
ease is rare in Asia and Japan, but US migrants from therese countries have increased 
risk. This suggests that the Western diet may be protective. Black men are at greater 
risk than Caucasians.
It is reported, that 5-10% of PC are inherited. Hereditary PC tends to occur in 
<60 years men who have a family history and genetic abnormalities. The risk of a 
man developing PC is doubled if there is one affected first-degree relative and is 
4-fold if there are two relatives.
Prevention
The fact that as many as 10% of men in their 3rd decade have histological PC 
suggests that there are years of opportunity for preventative strategies. There are 
many epidemiological and laboratory data supporting dietary interventions, though 
randomized prospective trials are awaited.
• High fat diets with those rich in saturated fat and omega-6 fatty acids, are 
linked to increased risk of PC diagnosis;
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• Products with phyto-oestrogens including the genistein inhibits PC cell lines;
• Lycopene, which present in tomato products, is considered to reduce risk of PC 
progression and inhibits cell lines;
• Antioxidant selenium (0.2mg/day) was shown to reduce the risk of developing 
PC;
• Antioxidant vitamin E was shown to reduce the incidence of PC;
• Vitamins A and D both inhibit growth of prostate cell lines;
• Smoking has recently been shown in population studies to be significantly as-
sociated with PC diagnosis;
• No definite link exists between alcohol consumption, vasectomy or sexual ac-
tivity with PC diagnosis.
Pathology
The most common prostatic malignancy is adenocarcinoma - carcinoma of the 
acinar or ductal epithelium. The basal cell layer is absent and the basement mem-
brane is breached by the malignant cells which invade into the prostatic fibro-
muscular stroma. Macroscopically, they tend to be hard and white. In some cases 
the prostatic urethra, ducts or stroma may be invaded by TCC of the bladder. 
Prostatic sarcomas rare but may be seen in childhood. Secondary metastases from 
other sites are rare.
Most (2/3) of adenocarcinomas occur in the peripheral zone of the prostate 
and most are multifocal. 20% appear to arise from the TZs and 5% from the em-
bryologically distinct central zone. The tumour spreads locally through the poorly 
formed prostatic capsule into surrounding tissue, at which time it is termed “lo-
cally advanced PC”. Hence, the disease may involve pelvic organs. Local spread is 
often along the course of autonomic nerves. The most frequent sites of metastasis 
are lymph nodes and bone, although lung, liver, testis and brain are involved. 
Bone metastases are characteristically sclerotic, rarely lytic.
Possible .premalignant .lesions
There are two premalignant histological lesions: PIN and ASAP. PIN consists of 
architecturally benign prostatic acini and ducts lined by cytologically atypical cells. 
The basal cell layer is present, although the basement membrane may be fragment-
ed. PIN was classified into low-grade and high-grade forms, based on the presence 
of prominent nucleoli. High-grade PIN is believed to be a precursor for intermedi-
ate or high-grade PC and its finding in sextant peripheral zone prostate biopsies car-
ries a 30-40% prediction of PC at subsequent biopsy. High-grade PIN is reported in 
5-10% of prostate needle biopsies. It does not appear to affect the serum PSA value. 
Currently, it is recommended that repeat systematic biopsies should be performed if 
isolated high-grade PIN is reported on needle biopsy or TURP.
ASAP is another histopathological prostatic lesion that pathologists report on 
needle biopsies as “suspicious for cancer”. The acini are small, lined with cy-
tologically abnormal epithelial cells. The columnar cells have prominent nuclei 
containing nucleoli, while the basal layer may be focally absent. The basement 
membrane is intact. As with PIN, studies have shown ASAP in needle biopsy pre-
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dicts PC at subsequent biopsy in over 40% of cases. Currently, it is recommended 
that repeat systematic biopsies should be performed if isolated ASAP is reported 
on needle biopsy or TURP.
Prostate .cancer .grading
Adenocarcinoma of the prostate is graded using the Gleason system (2005). Mi-
croscopically, adenocarcinoma is graded 1 to 5 according to its gland-forming 
differentiation at relatively low magnification. Since most are multifocal, an al-
lowance is made by adding the two dominant grades to give a sum score between 
2 and 10. If only one pattern is observed, the grade is simply doubled. The system 
is used with needle biopsies, TURP and radical prostatectomy specimens. Gleason 
scores 2-4 are considered well differentiated, 5-7 are moderately differentiated 
and 8-10 are poorly differentiated. Among expert pathologists there is good in-
ter-observer reproducibility with Gleason scoring. The importance of the Gleason 
score is that it correlates well with prognosis. For example, a Gleason 3+3=6 
adenocarcinoma carries a worse prognosis than a 3+2=5 cancer of equivalent 
stage. Moreover, cancers of the same Gleason score have a worse prognosis if the 
predominant grade is higher. (for example, 4+3=7 is worse than 3+4=7).
TNM .classification .of .prostate .cancer .(2009)
As with all cancer, PC staging may be considered clinical or pathological depen-
dent on available data.
T – primary tumor
TX – Primary tumor cannot be assessed
T0 – No evidence of primary tumor
T1 – Clinically inapparent tumor not palpable or visible by imaging
 T1a – Tumor incidental histological finding in <5% of tissue resected
 T1b – Tumor incidental histological finding in >5% of tissue resected
 T1c – Tumor identified by needle biopsy because of elevated PSA
T2 – Tumor confined within the prostate
 T2a – Tumor involves one half of one lobe or less
 T2b – Tumor involves more than half of one lobe, but not both lobes
 T2c – Tumor involves both lobes
T3 – Tumor extends through the prostatic capsule
 T3a – Extracapsular extension including microsc. bladder neck involv.
 T3b – Tumor invades seminal vesicle(s)
N – Regional lymph nodes
NX – Regional lymph nodes cannot be assessed
N0 – No regional lymph node metastasis
N1 – Regional lymph node metastasis
M – Distant metastasis
MX – Distant metastasis cannot be assessed
M0 – No distant metastasis
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M1 – Disant metastasis
 M1a – Non-regional lymph node(s)
 M1b – Bone(s)
 M1c – Other site(s)
Symptoms .and .signs
Since the widespread use of serum PSA testing, the majority of patients have 
non-metastatic disease at presentation. Shown below are the possible presenta-
tions, grouped by disease stage.
Localized PC (T1-T2)
• Asymptomatic, with elevated serum PSA or pathological DRE;
• LUTS (probably due to coexisting BPH and OAB);
• Hematospermia;
• Hematuria (probably due to coexisting other pathology);
• Perineal discomfort and pain (probably due to coexisting prostatitis);
Locally advanced cancer (T3-T4)




• Perineal discomfort and pain;
• Acute urinary retention;
• Symptoms of renal failure/anuria due to ureteric obstruction;
• Malignant priapism or rectal obstruction (rare).
Metastatic disease (N+, M+)
• Asymptomatic, with elevated serum PSA or incidental DRE;
• Swelling of lower limb due to lymphatic obstruction;
• Anemia, anorexia, weight loss due to toxic effects;
• Bone pain and pathological fracture;
• Neurological symptoms/signs in lower limbs due to spinal cord compression;
• Jaundice due to hepatic metastases;
• Signs of pulmonary metastases;
• Bleeding tendency due to coagulopathy.
Diagnosis
T stage is assessed by DRE, TRUS and MRT. Current imaging limits reliability in 
detection of local microscopic extraprostatic extension of PC.
Pelvic lymph node dissection is the gold-standard assessment of N stage. MRT 
or CT scanning may image enlarged nodes and most radiologists report nodes of 
>8 mm in maximal diameter. However, nodes larger than this often contain no 
cancer, while micrometastases may be present in normal-sized nodes.
M stage is assessed by physical examination, MRT or isotope bone scan, ab-
dominal and chest CT.
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DRE
Since most PC arise in the peripheral part of the prostate, they should be palpable 
on DRE. An abnormal DRE is defined by asymmetry, a nodule or a fixed craggy 
mass. ~50% of abnormal DREs are associated with PC, the remainder being BPH, 
prostatic calcifications or chronic prostatitis. An abnormal DRE in the presence 
of a normal PSA (2.5-3.0 ng/ml) carries a app. 30% incidence of predicting PC.
PSA
Until the development of commercial serum PSA assays in the late 1980s, the 
only serum marker for PC was acid phosphatase. This was highly specific for bone 
metastatic PC, but lacked sensitivity in detecting less advanced disease.
It is reported, that screening of men aged 50-70 years with PSA and DRE and 
subsequent early detection and treatment, may reduce the significant mortality 
and morbidity caused by PC. These acceptable and relatively inexpensive tests will 
detect clinically significant disease before it leaves the prostate. However, because 
of the low specificity of PSA and the high prevalence of latent PC, many men 
would suffer unnecessary anxiety, biopsies, over-diagnosis and over-treatment. 
Added to this, the treatments have morbidity and cost.
Prior to introduction of the PSA screening, most men with newly diagnosed 
PC had advanced incurable disease. PSA has revolutionized the diagnosis and 
management of PC, although its use in screening and early detection remains 
controversial. PSA may have minor (<10 ng/ml), intermediate (10-20 ng/ml) and 
major (20-100 ng/ml) elavated levels. 
In addition to its use as a serum marker for the diagnosis of PC, PSA elevations 
may help in staging, counselling and monitoring of the patients. 
PSA generally increases with advancing stage and tumour volume, although a 
small proportion of poorly differentiated tumours fail to express PSA. PSA is used, 
along with clinical T stage and Gleason score, to predict pathological tumour 
staging and outcome after radical treatments using statistically derived nomograms. 
>50% of patients have extra-prostatic disease if PSA >10ng/ml. <5% of patients 
have lymph node metastases and only 1% have bone metastases if PSA <20ng/
ml. 66% of patients have lymphatic involvement and 90% have seminal vesicle 
involvement if PSA >50ng/ml. PSA should be virtually undetectable following rad-
ical prostatectomy for organ-confined disease. PSA rise after radical prostatectomy 
precedes the development of clinical metastatic disease by a mean time of 8 years. 
PSA falls to within the normal range in 80% of patients with metastatic disease on 
hormone therapy within 4 months. The PSA rises in a mean time of 18 months 
after starting hormone therapy, signalling progressing disease. PSA is prostate-spe-
cific, but not cancer-specific. Other causes of elevated serum PSA are BPH, UTIs, 
AUR and catheterization, biopsy, TUR, DRE, ejaculation.
PSA derivatives: are free-to-total ratio, density and velocity. Measurement of 
the free-to-total (F:T) PSA ratio increases the specificity of total PSA because the 
ratio is lower in men with PC than in men with BPH. This may be helpful in de-
ciding whether to re-biopsy a patient with previous benign biopsies. An important 
limitation of this investigation is the instability of free PSA. The serum must be 
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assayed within 3h or frozen at -20°C, otherwise the free component reduces and 
a low ratio will be reported.
Consideration may be given to the prostate volume, since large benign prostates 
are the most common cause of mildly elevated PSA. Serum PSA/prostate volume 
= PSA density and serum PSA/prostate transition-zone volume = PSA-TZ density.
Short-term variations in serum PSA occur in the presence or absence of cancer, 
the cause of which may be technical or physiological. Longer term, the PSA tends 
to rise slowly due to BPH and faster due to PC. This is so-called “PSA velocity”. 
A PSA velocity >0.75ng/ml per year over at least 18 months in total PSA range 
4-10 ng/ml is suggestive of the presence of PC, given that only 5% of men without 
cancer exhibit such a velocity. A PSA velocity >20% per year should also prompt 
the recommendation of a biopsy, although a slower velocity does not exclude the 
presence of cancer. The use of PSA velocity is an option for the patient who wish-
es to avoid an initial or repeat prostatic biopsy.
Counselling is mandatory before offering a PSA and DRE to asymptomatic 
men, particularly to highlight the potential disadvantages of having an abnormal 
result, since the case for benefit to screening is not currently proven. Only men, 
who have been appropriately counselled should be tested. All patients should be 
informed when PSA testing is being considered. Sensitivity is 80%: a false neg-
ative result is possible. Specificity is 40-50%: a false positive result is possible. 
Prostatic biopsy is uncomfortable and carries a <1% risk of sepsis or significant 
rectal bleeding, hemospermia or hematuria. Repeat biopsy may be recommended 
(PIN, ASAP or rising PSA level). Treatment may not be necessary or may not be 
curative. Treatment-related morbidity could lead to a reduction in quality of life.
TRUS .and .biopsies
The most common diagnostic modality for PC is currently TRUS with guided biop-
sies. TRUS provides imaging of the prostate and seminal vesicles using a 7.5 mHz 
intra-rectal probe. It takes 5 min and is undertaken on an outpatient basis with or 
without some form of anaesthetic. A DRE precedes insertion of the probe. If biop-
sies are planned, an antiseptic rectal wall cleansing is also undertaken. Broad-spec-
trum antimicrobials are given before and after the procedure.
TRUS can image the outline of the prostate, cysts, abscesses and calcifications 
within the prostate. Hypoechoic and hyperechoic lesions in the peripheral zone 
may be due to PC or inflammatory conditions, although most PC are isoechoic 
and are not seen. It is important too that the patient appreciates that negative 
biopsies do not exclude the possibility of PC and that a positive result will not 
necessarily result in the recommendation of immediate treatment.
Biopsy protocol
6-8-10-12-18 or more trucut needle biopsies are taken in a systematic fashion, to 
include any palpable or sonographic target lesion, adding samples from the far lateral 
peripheral zones. Additional biopsies of each TZ may be taken if a TZ cancer is sus-
pected or if a patient is undergoing repeat biopsies due to a rising PSA. Seminal vesicles 
biopsies occasionally add staging information if they appear abnormal on imaging.
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It is not safe to biopsy a patient, which takes anticoagulant treatment. All such 
treatments are stopped for 10 days prior. PC may also be diagnosed by TURP 
histology or clinically in certain circumstances.
Treatment .of .localized .prostate .cancer
Watchful waiting
The statement “more men die with PC than because of it” is correct. This is be-
cause most PC are slow-growing and the majority of men diagnosed are >70 years, 
often with competing morbidities. This forms the basis for WW offering some men 
diagnosed with non-metastatic PC no initial treatment. The risks of developing 
metastatic disease and of death due to PC after 10-15 years of WW can be consid-
ered using published data, according to biopsy grade. Patients with high Gleason 
scores have poor prognosis.
WW is the best option for patients with localized PC and Gleason score 2-4 
disease, Gleason score 5-6 disease and >75 years old, significant comorbidity and 
life expectancy considered to be <10 years, stage T1a disease with normal PSA. 
WW should be considered and discussed with all who have Gleason score <7, 
when small-volume disease is predicted by DRE and the biopsy report.
Most men with localized PC on WW are seen every 6 months for clinical exam-
ination and a serum PSA test. If the disease progresses during follow-up, androgen 
ablation therapy is recommended. Treatment will start when symptoms and signs 
of advanced disease appeared. However, use of PSA, evidence of benefit with ear-
lier use of hormone therapy and involvement of patient choice, have driven earlier 
thresholds for treatment. An asymptomatic patient with a rising PSA may choose 
whether to treat his disease and accept the side-effects or whether to maintain his 
current quality of life while leaving the disease untreated.
Radical prostatectomy
RP is removing of the entire prostate with the seminal vesicles with lymph nodes 
dissection. It may be performed by open retropubic, perineal or laparoscopic ap-
proaches. Following excision of the prostate, reconstruction of the bladder neck 
and vesico-urethral anastomosis completes the procedure.
RP is indicated for the treatment of «fit» men with localized PC whose life ex-
pectancy >10 years, with curative intent. The patient should consider all available 
treatment options and the complications of RP prior to proceeding. There may be 
local guidelines on age and upper PSA cut-off for offering RP, perhaps 70 years 
and 20 ng/ml respectively.
Technic of the open retropubic procedure is discussed below. The patient is 
under anaesthetic, catheterized and positioned supine with the middle of the table. 
Through a lower extraperitoneal midline incision the retropubic space is opened. 
Obturator fossa lymphadenectomy is undertaken if the PSA >10 ng/ml or the 
Gleason score >7. Incisions in the endopelvic fascia on either side allow access to 
the prostatic apex and membranous urethra. Division and haemostatic control of 
the dorsal vein complex passing under the pubic arch allows access to the mem-
branous urethra, which is divided at the prostatic apex. The prostate is mobilized 
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retrogradely from apex to base, taking Denonvilliers fascia on its posterior surface. 
If cavernous nerve sparing is undertaken, the apical and posterior dissection is 
modified. Denonvilliers fascia is incised at the prostatic base, allowing access to 
the vasa, which are divided and seminal vesicles, which are excised. The bladder 
neck is divided, thereby freeing the prostate. The bladder neck is reconstructed to 
the approximate diameter of the membranous urethra. A sutured vesico-urethral 
anastomosis is stented by a urethral catheter, typically for 10-14 days. The wound 
is closed leaving pelvic drains, typically for 48 h. A cystogram is required only if 
there has been a documented urine leak or other catheter problem.
The nerve-sparing modification aims to reduce the risk of post-operative ED. 
The surgeon seeks to minimize injury to the cavernosal nerves passing from the 
autonomic pelvic plexus on either side in the groove between prostate and rectum, 
during mobilization of the prostate. This should not be attempted in the presence 
of palpable disease as it may compromise cancer control. The tips of the seminal 
vesicles may also be spared in cases with low risk of cancer involvement, poten-
tially reducing bleeding and cavernosal nerve injury.
There are general and specific complications of radical prostatectomy. General 
complications are those of any major surgery: bleeding requiring re-operation and/
or transfusion, infection, thromboembolism and cardiac disturbance. These are 
minimized by attention to hemostasis, prophylactic antimicrobials, pneumatic calf 
compression, low-dose heparin post-operatively and early mobilization. Chest in-
fection may be prevented by physiotherapy and encouragement of deep breathing, 
especially in smokers.
Specific complications are perioperative obturator nerve, ureteric or rectal inju-
ries. These should be managed immediately if recognized end-to-end nerve anas-
tomosis, ureteric re-implantation or primary rectal closure with or without a loop 
colostomy. Postorerative ED affects 70-90% of patients. Spontaneous erections 
may return up to 3 years post-operatively. Men >65 years or with pre-existing 
ED are more likely to suffer long term. Most patients will respond to oral PDE5 
inhibitors at 6 months, while others require intraurethral or intracavernosal pros-
taglandin E1 treatments, a vacuum device or a artificial prosthesis implantation. 
SUI affects 5% of patients beyond 6 months. This is due to injury of the external 
urethral sphincter during division and haemostatic control of the dorsal vein com-
plex. Predisposing factors include age >65 years and excessive bleeding. Pre-op-
erative teaching of pelvic floor exercises helps to regain continence. Periurethral 
bulking injections or implantation of an artificial urinary sphincter are occasional-
ly necessary. Incontinence may also develop secondary to bladder neck stenosis or 
detrusor instability. Bladder neck stenosis affects 5-8% of patients, typically occurs 
2-6 months post-operatively, rarely becoming a recurrent problem. Predisposing 
factors include heavy bleeding, post-operative urinary leak and previous TURP. 
Patients complain of new voiding difficulties and treatment is by endoscopic blad-
der neck incision.
Study comparing RP to WW has demonstrated a 50% reduction in death due 
to PC and a 66% reduction in metastatic progression in the RP group with a 
mean follow-up of only 6 years. High-grade cancers were excluded from this trial, 
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though non-randomized data suggest more patients with Gleason 7-10 localized 
disease survive 10 years following RP than with WW or radiotherapy.
Excellent long-term results are seen in well-selected patients following RP, par-
ticularly those with organ-confined disease. Serum PSA is measured a few days 
after RP, then 6-monthly and it should fall to <0.1ng/ml. The 10-year PSA pro-
gression rate following RP with a serum PSA >0.2 ng/ml is about 30%. Without 
additional treatment, the time to development of clinical disease after PSA progres-
sion averages 8 years. A 20-year clinical disease-free survival of 60% is reported.
Management .of .biochemical .relapse .post-RP
The definition of rising PSA is controversial, though most agree >0.2 ng/ml. DRE 
should be performed. Biopsy of the vesicourethral anastomosis is not widely prac-
tised unless there is a palpable abnormality. Studies have shown that MRT and 
bone scans are rarely helpful in searching for metastatic disease unless the PSA is 
>7 ng/ml. Current management options include observation, pelvic radiotherapy 
or hormone therapy.
External beam radiotherapy
Advances in radiotherapy for localized PC have included the advent of linear 
conformal accelerators and intensity-modulated techniques to minimize toxicity 
to the rectum and bladder. EBRT is administered with curative intent, often 
accompanied by 3 months of neoadjuvant hormone therapy in high-risk cases. 
There is benefit in terms of progression and survival for patients treated with 6 
months androgen ablation, in addition to radiotherapy, compared with radio-
therapy alone.
Indications are clinically localized PC, life expectancy >5 years. Patients with 
Gleason score 2-4 disease appear to do as well with WW as with any other treat-
ment with 15-year follow-up. Contraindications are severe LUTS, inflammatory 
bowel disease, previous pelvic irradiation
Protocol: a 6-week course of daily treatments amounting to a dose of 60-72Gr. 
Side-effects of such treatment options are transient LUTS and GIT symptoms, 
hematuria, contracted bladder, pain, ED and the risk of a second solid pelvic 
malignancy.
Brachytherapy
This is US-guided transperineal implantation of radioactive seeds of I125 into the 
prostate gand. BT is minimally invasive, requires general anaesthesia and is com-
pleted in one or two stages. Either way, approximately 150 Gr is delivered and 
this may be augmented by an EBRT boost. Another approach is to use Iridium192 
wires, left for several hours in situ in a series of applications, either before or after 
EBRT. The treatment is expensive due to the cost of the consumables.
Indications are: localized T1-2 PC with Gleason <7, PSA <10 ng/ml, life ex-
pectancy >5 years. Contraindications are previous TURP because of incontinence 
risk, large volume prostate causes difficulty with seed placement, moderate to 
severe LUTS. Complications are: perineal hematoma, LUTS, urinary retention, 
incontinence. ED affects up to 50% of patients.
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Cryotherapy
This is minimally invasive treatment for localized PC. This is viable alternatives 
to radical surgery or ERBT and the only current options for salvage treatment of 
organ-confined recurrent disease following radical radiotherapy.
Transperineal US-guided cryoprobes delivering argon or liquid nitrogen at a tem-
perature of -20 to -40°C. When applied in two cycles of “freezing - thawing”, cellular 
necrosis occurs. The diameter of the ice-ball is monitored with help of US. Precau-
tions must be taken to protect the urethra, external sphincter and rectal wall, such as 
warming devices. An anaesthetic is required; this is a day-case procedure which can 
be repeated.
PSA nadir is usually achieved within 3 months. 1/4-1/2 of men with localized 
disease achieve a PSA nadir of <0.1ng/ml in 3 months and 96% of men achieve 
PSA <0.2ng/ml within 6 months. Positive biopsies are observed. Long-term results 
are awaited.
Complications are: ED, incontinence, LUTS, CPPS, transient penile numb-
ness, recto-urethral fistula (rare).
HIFU
HIFU allows the selective destruction of tissues at depth without damaging interven-
ing structures. Tissue is heated to the point of coagulative necrosis by high-energy 
US transmitted to the prostate using a transrectal device. The tissue temperature is 
raised locally at this point over 85°C. With each firing of the probe a “cigar shaped” 
volume of damage is produced. After one lesion is created, the focus is repositioned 
in order to create the next lesion with the same heating process. Lesions are placed 
side by side to create a continuous volume in which the tissue is necrosed. The rectal 
wall and the surrounding tissues are protecred. An anaesthetic is required. This is a 
day-case procedure which can be repeated. Long-term results are awaited.
Treatment .of .locally .advanced .non-metastatic .PC .(T3-T4 .N0M0)
EBRT in combination with hormone therapy has consistently demonstrated better 
outcomes compared to EBRT alone, which is associated with a low 10-year sur-
vival. There are potential advantages in starting hormone therapy prior to EBRT. 
Hormone therapy alone is another option in elderly patients or those unwilling 
to consider ERBT. In this setting, a non - steroidal anti-androgen (e.g. bicalut-
amide 150 mg) has equivalent efficacy to androgen deprivation by orchidectomy 
or LH-RH analogue, with potential advantages in terms of side-effects.
WW is also an option for non-metastatic T3 disease in an elderly asymptomatic 
man who may wish to avoid side- effects of treatment.
Palliative .treatment .of .locally .advanced .disease
Palliative TURP or medical therapy for LUTS or retention may be necessary. 
Incontinence can be due to sphincter involvement, though BOO and instability 
should be considered. Catheter may be required. PNS  tubes or ureteric stents are 
occasionally necessary for ureteric obstruction. Rarely, a colostomy is necessary 
to bypass a rectal stenosis.
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Treatment .of .advanced .prostate .cancer
Endocrine therapy
Metastatic disease is the cause of nearly all PC-related death. Currently incur-
able with 5-year survival is 25% and 10% survive <6 months. The mainstay of 
treatment is hormone therapy, with cytotoxic chemotherapy in reserve and novel 
treatments such as growth factor inhibitors, angiogenesis inhibitors, immuno-
therapy and gene therapy in development. The concept of hormone therapy was 
established in 1941 when Huggins and Hodges reported favourable responses in 
PC patients castrated or given oestrogens.
There is hormone dependence of PC. 95% of circulating androgen, mainly 
testosterone, is produced by the Leydig cells of the testes under the influence of 
LH. The anterior pituitary LH synthesis, stimulated by LH-RH, produced by the 
hypothalamus. The remaining 5% of circulating androgen is synthesized by the 
adrenal cortex from cholesterol, under the influence of pituitary ACTH. Testoster-
one is metabolized to the more potent DHT, by 1 and 2 types of 5-AR enzymes. 
DHT binds to the androgen receptor, travels to the cell nucleus and exerts its pos-
itive effect on cell growth and division. All prostate epithelial cells are dependent 
on androgens and fail to grow or undergo apoptosis in their absence. Similarly, 
most previously untreated PC are dependent on androgens.
Androgen deprivation results in a reduction in PSA and clinical improvement 
in >70% of PC patients. However, most will still die within 5 years due to the 
development of androgen-independent growth. This is considered to be due to 
growth of androgen-independent cell clones. The mean time to disease progres-
sion after androgen deprivation is 14 months in men with metastatic disease.
Types of androgen deprivation:
• Surgical castration: bilateral orchidectomy;
• Medical castration: using of the LH-RH agonists, oestrogens - also termed 
androgen ablation or androgen deprivation;
• Anti-androgens: androgen receptor blockade at target cell;
• MAB: medical or surgical castration plus anti-androgen;
• 5-ARI with finasteride or dutasteride.
Both forms of castration have equivalent efficacy, so patients should be given the 
choice. Estrogens are no longer used first-line, due to the significant cardiovascular 
morbidity. Anti-androgens alone are less effective in treating metastatic disease, 
but equivalent for non-metastatic disease. MAB has a theoretical advantage over 
castration in blocking the effects of the adrenal androgens, but significant clinical 
advantages have not been demonstrated. 5ARIs are not licenced for the treatment 
of PC, but appear to have a role in prevention. Bilateral orchidectomy is a simple 
procedure, usually carried out under general anaesthesia. Through a midline scrotal 
incision, both testes may be accessed. The tunica albuginea of each testis is incised 
and the soft tissue content is removed, after which the capsule is closed. The epi-
didymis is preserved. Serum testosterone falls within 8h to <0.2 nmol/l.
LH-RH agonists developed in the 1980s, giving patients an alternative to bi-
lateral orchidectomy, with which they are clinically equivalent. They are given by 
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subcutaneous or intramuscular injection, as 3-monthly depots. Examples include 
goserelin, triptorelin and leuprorelin acetates. If the anterior pituitary is over-
whelmed with an analogue of LH-RH, it switches off LH production, although 
serum testosterone rises in the first 2 weeks due to a surge of LH. This can result 
in “tumour flare”. To prevent this, cover with anti-androgens is recommended for 
a week before and two weeks after the first dose of LH-RH agonist.
Side effects of androgen deprivation are: loss of libido and ED, hot flushes and 
sweats, weight gain, gynaecomastia, anemia, ccognitive changes, osteoporosis and 
pathological fractures.
Anti-androgens are administered as tablets. Examples include bicalutamide 
(150 mg daily as monotherapy or 50mg daily for MAB, in combination with LH-
RH analogues or orchidectomy), flutamide and cyproterone acetate. The first two 
raise the serum testosterone slightly, so sexual interest and performance should 
be maintained, although many such patients have pre-existing ED due to the 
advancing disease. Side-effects include frequent gynaecomastia, breast tenderness 
and occasional liver dysfunction.
5-ARIs are used by treatment of PC patiens. Given that PC starts, in the main, 
as an androgen-dependent disease, interest in its prevention has also focused 
on antiandrogens. While non-steroidal antiandrogens would have unacceptable 
side-effects and cost, the 5-ARIs could be feasible chemoprevention agents. The 
Prostate Cancer Prevention Trial recruited 18,000 men who had no clinical or 
biochemical evidence of PC. They were randomized to placebo or finasteride 5mg 
daily for up to 7 years. The men were offered biopsy if they developed a rising 
PSA, an abnormality on DRE or at end of study. PC was detected in 24% and 
18% of participants in placebo and finasteride arms respectively, suggesting that fi-
nasteride reduces the risk of developing PC by 25%. However, Gleason >7 cancers 
were significantly more frequent in the finasteride arm. While this could be due to 
the effect of the 5-ARIs on tissue architecture, nobody is rushing to recommend 
this to their patients without full discussion of the implications.
Monitoring of the endocrine treatment
Typically, patients will have baseline PSA, full blood count, renal and liver func-
tion tests, a renal US and a bone scan. The PSA is repeated after 3 months, 6 
months and 6-monthly thereafter until it rises. Liver function is checked 3-month-
ly if anti-androgen monotherapy is used. Renal function should be checked on 
disease progression and bone imaging if clinically indicated. While PSA is very 
useful as a marker for response and progression, 15% of patients show clinical 
progression without PSA rise. This may occur in anaplastic tumours that fail to 
express PSA. Advice on exercise, diet and treatment of ED is often sought by 
patients during treatment.
Hormone therapy in the patients with androgen-independent disease
When the PSA rises from its lowest value or if symptomatic progression occurs 
despite a favorable biochemical response to first-line hormone therapy, the dis-
ease has entered its androgen-independent phase. In these circumstances, further 
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treatment with second-line hormonal therapy is usually considered. Most patients 
receiving anti-androgen monotherapy respond after switching to androgen ablation 
orchidectomy or LH-RH analogue. If there is relapse during androgen ablation, 
1/4 respond by adding an anti-androgen to establish MAB. If MAB was used from 
initiation of hormone therapy, withdrawal of the anti-androgen paradoxically elicits 
a favourable response in 1/4 of patients.
A further rise in PSA may require third-line hormonal therapy such as the ad-
dition of oestrogens or corticosteroids. 
The prognostic factors for survival with androgen-independent disease are identi-
cal to the factors predicting response to hormone therapy, plus time from initiation 
of hormone therapy to initiation of chemotherapy and visceral metastasis status.
Cytotoxic chemotherapy
Systemic chemotherapy is offered to appropriate patients with androgen-indepen-
dent metastatic disease. Men with low-volume disease who have failed radical lo-
cal treatment and hormone therapy are also candidates for chemotherapy. Elderly, 
frail and infirm patients with significant bone disease, renal impairment, haema-
tological and clotting abnormalities are unsuitable. Correction of renal and bone 
marrow dysfunction is necessary prior to treatment. Symptom improvements are 
reported with cytotoxic chemotherapy (mitoxantrone plus prednisolone, prednis-
olone alone, docetaxel plus prednisolone, estramustine phosphate plus docetaxel). 
The involvement of the acute pain team, palliative care physicians and nurses is 
often necessary in the terminal phase of the illness, to optimize quality of life.
5 2  .BLADDER .CANCER
Epidemiology, .etiology .and .risk .factors
Bladder cancer is the second most common urological cancer. This represents 3% 
of all cancer deaths. 
Risk factors:
• Chemical carcinogens due to smoking (30-50%) and exposure to chemical 
products, found in urine, are the major cause of BC. Cigarette smoke contains 
the carcinogens 4-aminobiphenyl and 2-naphthylamine. Slow hepatic detoxifi-
cation and renal excretion of chemical products appear to increase urinary car-
cinogenic exposure of the urothelium. Smokers have a 2-5 fold risk compared 
to non-smokers, with respect to development of BC and recurrences. There is 
a slow (20-year) reduction in risk following cessation of smoking;
• Men are 2.5 times more likely to develop the disease than women, which may 
be associated with greater urine residuals in the bladder in patients with BPH;
• Age increases risk, most commonly diagnosed in the 8th decade and rare <50 years;
• Black people have a lower incidence than White people, but inexplicably they 
appear to carry a poorer prognosis;
• Chronic inflammation of bladder mucosa due to bladder stones, long-term cath-
eters and bilharziasis are implicated in the development of SCC of the bladder;
• Occupational exposure to carcinogens, in particular aromatic hydrocarbons like 
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aniline, is a recognized cause of BC (rubber, dye, textile or leather manufac-
tures; plumbers, painters, drivers). A latent period of 25-45 years exists between 
exposure and carcinogenesis;
• Drugs: phenacitin and cyclophosphamide;
• Pelvic radiotherapy for other malignancies;
• Hereditary genetic etiology bacause of many somatic genetic abnormalities have 
been identified in TCC patients.
Pathology
• Benign tumours of the bladder are rare;
• The vast majority of primary BC are malignant and epithelial in origin and 
>90% are TCC, which may be single or multifocal. Because 5% of patients 
will have a synchronous upper tract TCC and metachronous recurrences may 
develop after several years the urothelial “field-change” theory of polyclonality 
is favoured over the theory of tumour monoclonality with implantation of the 
tumor cells.
• 1-7% of BC are SCC most common in areas where schistosomiasis is endemic. 
SCC is usually solid or ulcerative and muscle-invasive at presentation. SCC in 
the bladder is associated with chronic inflammation and urothelial squamous 
metaplasia, rather than CIS. 5% of paraplegics with long-term catheters devel-
op SCC. Smoking is also a risk factor for SCC.
• Adenocarcinoma is rare, usually solid/ulcerative, G3 and carries a poor prog-
nosis. 1/3 originate in the urachus, the remnant of the allantois, located deep to 
the bladder mucosa in the dome of the bladder. Adenocarcinoma is a long-term 
complication of bladder exstrophy and bowel implantation into the urinary 
tract, particularly bladder substitutions and ileal conduits after cystectomy.
• There are also phaeochromocytoma, melanoma, lymphoma and sarcoma aris-
ing within the bladder muscle.
• Secondary BC are mostly metastatic adenocarcinoma from GIT, prostate, kid-
ney or ovary.
Tumor .Node .Metastasis .classification .of .bladder .cancer .(2009)
T – Primary tumor
TX – Primary tumor cannot be assessed
T0 – No evidence of primary tumor
Ta – Non – invasive papillary carcinoma
Tis - Carcinoma in situ: “flat tumor”
T1 – Tumor invades subepitelial connective tissue
T2 – Tumor invades muscle
 T2a – Tumor invades superficial muscle (inner half)
 T2b - Tumor invades deep muscle (outer half)
T3 – Tumor invades perivesical tissue
 T3a – Microscopically
 T3b – Macroscopically (extravesical mass)
T4 – Tumor invades prostate, uterus, vagina, pelvic or abdominal wall
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N – Lymph nodes
NX – Regional lymph nodes cannot be assessed
N0 – No regional lymph node metastasis
N1 – Metastasis in a single lymph node in the true pelvis
N2 – Metastasis in multiple lymph nodes in the true pelvis
N3 – Metastasis in common iliac lymph node(s)
M – Distant metastasis
MX – Distant metastasis
M0 – No distant metastasis
M1 – Distant metastasis
Primary TCC is considered clinically as superficial (Ta, T1, CIS) or muscle-in-
vasive (T2-T3).
Flat, high – grade tumours that are confined to the mucosa are classified as 
CIS, which is a flat, high-grade, non-invasive urothelial carcinoma. It can be 
missed at cystoscopy or be considered as an inflammatory lesion if it is not biop-
sied. CIS is often multifocal and can occur in the bladder, but also in the upper 
urinary tract, prostatic ducts and prostatic urethra.
In 2004, the WHO published a new histological classification of urothelial 
carcinomas which provides a different patient stratification between individual 
categories compared to the older 1973 WHO classification. Recently an update of 
the WHO grading classification was published, but the following guidelines are still 
based on the 2004 WHO classification.
1973 WHO grading for urothelial papilloma
• Grade 1: well differentiated;
• Grade 2: moderately differentiated;
• Grade 3: poorly differentiated;
2004 WHO grading system for papillary lesions
• Urothelial papilloma (completely benign lesion);
• Papillary urothelial neoplasm of low malignant potential (PUNLMP);
• Low-grade (LG) papillary urothelial carcinoma;
• High-grade (HG) papillary urothelial carcinoma;
Symptoms .and .signs
• First, early and the most common presenting symptom is painless total hema-
turia. This may be initial or terminal if the lesion is at the bladder neck or in 
the prostatic urethra.
• Asymptomatic microscopic hematuria, found on routine urine stick-testing;
• Pain is unusual, even if the patient has obstructed upper tracts, since the ob-
struction and renal deterioration arise gradually. Pain may be observed by cys-
tits or muscle invasion;
• LUTS, such as urgency or suprapubic pain. This so-called “malignant cystitis” 
is typical in patients with CIS and SCC;
• Recurrent UTIs;
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• Advanced cases may present with lower-limb swelling due to lymphatic/venous 
obstruction, bone pain, weight loss, anorexia, confusion and anuria due to bi-
lateral ureteric obstruction;
• Urachal adenocarcinomas may present with a blood or mucus umbilical dis-
charge or a deep subumbilical mass;
• General examination may reveal pallor, indicating anemia due to chronic renal 
impairment or blood loss;
• Abdominal examination may reveal a suprapubic mass in the case of locally 
advanced disease;
• DRE and bimanual examination may reveal a mass above or involving the 
prostate;
• Although the likelihood of diagnosing BC in patients <50 years is low, all pa-
tients with these presenting features should be investigated.
Diagnosis
After a UTIs has been excluded or treated, all patients with hematuria require 
investigation of their upper tracts, bladder and urethra. Usually, renal US and 
cystoscopy, performed under local anaesthetic, are first-line investigations.
If these fail to find a cause, an IVU, CT and urine cytology are second-line 
investigations. CT before and after IV contrast is becoming the best investigation 
of hematuria. It is faster and more sensitive than US or IVU in the detection of 
renal and ureteric tumours. However, it carries a higher radiation dose and is 
more expensive. CT also detects some bladder tumours, but may overcall bladder 
wall hypertrophy as tumour and will miss flat CIS and urethral pathology and it 
cannot replace cystoscopy. If there is hydronephrosis in association with a bladder 
tumour, it is likely that the tumour is causing the obstruction to the distal ureter 
with muscle-invasive disease.
Patients with predominantly filling-type LUTS, suprapubic pain or recurrent 
UTIs should also have urine cytology and cystoscopy.
False negative cytology is frequent (40-70%) in patients with papillary TCC, 
but more sensitive (90-100%) in patients with high-grade TCC and CIS. False 
positive cytology can arise due to UTIs, inflammation, instrumentation and che-
motherapy.
If all investigations are normal, consideration should be given to nephrological 
disorders that may cause hematuria, such as glomerulonephritis. Cross-referral to 
a nephrologist is advised in patients with persisting microscopic hematuria, espe-
cially those with associated proteinuria, casts or hypertension.
Diagnostic .TUR .of .bladder .tumor
This provides definitive histological diagnosis and usually undertaken under gen-
eral or spinal anaesthesia. Bimanual examination is mandatory before and after 
bladder tumor resection, to assess size, position and mobility. The pathologist 
should report on the tumor type, grade and stage. In particular, the presence or 
absence of muscularis propria should be noted, since its absence will preclude 
reliable T staging. Red patches are biopsied separately, the prostatic urethra is 
UROLOGY 81
biopsied if radical reconstructive surgery is under consideration. Care is taken 
in resecting tumours at the dome, since intraperitoneal bladder perforation may 
occur, especially in women with thin-walled bladders.
Staging .investigations
This usually reserved for patients with biopsy-proven muscle-invasive BC unless 
clinically indicated, since superficial TCC and CIS disease are rarely associated 
with metastases. Pelvic CT or MRT may demonstrate extra - vesical tumour 
extension or iliac lymphadenopathy, reported if >8mm in maximal diameter. 
Chest X-ray is indicated for suspicion lesions of the lungs. Isotope bone scan is 
obtained in cases being considered for radical treatment. Open or laparoscopic 
lymphadenectomy may be indicated in the presence of CT-detected pelvic lymph-
adenopathy if radical treatment is under consideration.
Treatment .of .superficial .bladder .cancer
TUR
This is visually complete resection od bladder wall with tumor and is adequate 
treatment for 70% of newly presenting patients with Ta/Tl superficial disease. 
The remaining 30% of patients experience early recurrence, 15% with upstaging. 
Because of this, it is proposed that all new patients receive adjuvant treatment.
Complications are uncommon, including bleeding, urosepsis, bladder per-
foration, incomplete resection and urethral stricture. Alternatively, transure-
thral laser ablation is less likely to cause bleeding but histological sampling 
would be inadequate.
Most urologists perform review cystoscopy and second TUR at 1 months. If 
this demonstrates recurrence, 70% will further recur. If not, only 20% will further 
recur. If the bladder is clear at follow-up, further cystoscopies are performed at 
3-6 months and thereafter annually until the patient is no longer fit to undergo 
treatment. There is no accepted protocol for upper tract surveillance in patients 
with a history of bladder TCC, although some urologists recommend 2-yearly 
IVU, US and urine cytology.
Adjuvant intravesical chemotherapy
Intravesical chemotherapy with MMC (40 mg in 50 ml saline) is used for GI-2, 
Ta or T1 tumours and recurrent multifocal TCC. MMC is an antibiotic chemo-
therapeutic agent that inhibits DNA synthesis. In experimental studies, it may 
cause regression of small papillary TCC, so should be cytotoxic for microscopic 
residual disease post TURBT. It significantly reduces the likelihood of tumor 
recurrence compared to TUR BT alone, but has never been shown to prevent 
progression to muscle invasion and has no impact on survival.
It is used either as a single dose within 24 h of first TURBT or weekly for 6 weeks 
commencing up to 2 weeks post TUR BT. It is administered via a urethral catheter 
and held in the bladder for l h. Other agents include doxorubicin and epirubicin. 15% 
patients report transient LUTS. Occasionally a rash develops on the genitals or palms 
of the hands, so treatment must be stopped. Systemic toxicity is rare with MMC.
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Adjuvant intravesical BCG
BCG is an attenuated strain of Mycobacterium. It acts as an immune stimulant, 
upregulating cytokines such as IL-6 and IL-8 in the bladder wall. BCG is given as 
a 6-week course for G3T1 TCC and for CIS, starting at least 2 weeks post TURBT. 
It is administered via a urethral catheter, 80 mg in 50 ml saline and retained in the 
bladder for l h. BCG produces complete responses in 60-70% of patients? com-
pared  to TURBT alone and may delay tumor progression to muscle invasion. 30% 
do not respond and 30% of responders relapse within 5 years. It is more effective 
than MMC for adjuvant treatment of some types of BC, but is not often used be-
cause of the additional toxicity.
Though less expensive and more effective, BCG is more toxic than intravesical 
chemotherapy, causing LUTS in nearly all patients and low-grade fever with my-
algia in 1/4 cases. Up to 10% of patients develop a high persistent fever, requiring 
anti-tuberculous therapy for up to 6 months. Granulomatous prostatitis and epi-
didymo-orchitis are rare complications.
Contraindications: immunosuppressed patients, pregnant or lactating women, 
patients with hematological malignancy, traumatic catheterization.
Cystoscopy too early after BCG can look alarming, due to generalized inflam-
matory response. Review cystoscopy and biopsy 3 months after BCG may still 
reveal chronic granulomatous inflammation. The value of maintenance BCG is 
uncertain, although one study demonstrated a benefit for superficial TCC, exclud-
ing CIS, compared with a single 6-week course.
Treatment .of .muscle-invasive .bladder .cancer .(T2-T3a)
This is a poor type of BC, untreated 5-year survival is only 3%. For example 
5-years survival rates by T1 is 90% and by T2-T3 is 60-80%.
Partial cystectomy
This is a good option for well-selected patients with small solitary disease located 
near the dome and for urachal carcinoma. Morbidity is less than with radical cys-
tectomy. The surgical specimen should be covered with perivesical fat, with a 1.5 
cm margin of macroscopically normal bladder around the tumor. There should be 
no biopsy evidence of CIS elsewhere in the bladder. The bladder must be closed 
without tension and catheterized for 7-10 days to allow healing. Subsequent review 
cystoscopies ensure no tumor recurrence.
Radical cystectomy with urinary diversion
This is the most effective primary treatment for muscle-invasive TCC, SCC and 
adenocarcinoma and can be used as salvage treatment if RT has failed. It is also a 
treatment for G3T1 TCC and CIS, refractory to BCG treatment. Salvage radical 
cystectomy is technically a more difficult and slightly more morbid procedure.
The operation steps are described below. Through a midline abdominal trans-
peritoneal approach, the entire bladder is excised along with perivesical vascular 
pedicles, fat and urachus, plus the prostate or anterior vaginal wall. The anterior 
urethra is not excised unless there is prior biopsy evidence of tumor at the female 
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bladder neck or prostatic urethra. The ureters are divided close to the bladder, 
ensuring their disease-free status by frozen-section histology if necessary and anas-
tamosed into the chosen urinary diversion methods. A bilateral pelvic lymph-
adenectomy is undertaken at the time.
Major complications affect 1/4 of cystectomy patients. These include peri-op-
erative death (rare), re-operation, bleeding, thromboembolism, urosepsis, wound 
infection/dehiscence, intestinal obstruction or prolonged ileus (10%), cardio-pul-
monary morbidity and rectal injury. ED is likely after cystectomy due to cav-
ernosal nerve injury.
External beam radiotherapy
A good option for treating muscle-invasive (pT2/3/4) TCC in patients who are unfit 
or unwilling to undergo cystectomy, but who still wish to have the chance of cure. The 
5-year survival rates are inferior to those of surgery, but the bladder is preserved and 
the complications are less significant. Typically, a total dose of 70Gy is administered in 
30 fractions over 6 weeks. Higher-grade tumors tend to do less well, perhaps because 
of the undetected presence of disease outside the field of irradiation. Beyond this, pre-
diction of radiotherapy response remains difficult, relying on follow-up cystoscopy and 
biopsy. CIS, SCC and adenocarcinoma are poorly sensitive to ERBT.
Complications occur in 70% of patients, self-limiting in 90% of cases. These 
include radiation cystitis and proctitis with diarrhoea and rectal bleeding. These 
effects usually last few months. 
Treatment .of .locally .advanced .bladder .cancer .(pT3b/4)
Many patients treated with primary cystectomy or RT with curative intent will 
have metastatic disease due to incomplete tumor excision or micrometastases. At 
this stage, 5-year survival is only 5-10%. There is interest in augmenting primary 
treatment with help of adjuvant or neoadjuvant RT/chemotherapy in an effort to 
improve outcomes. Very low or no survival benefit has been demonstrated and it 
leads to unacceptably high morbidity or has no demonstrable advantages.
Treatment .of .metastatic .bladder .cancer
Systemic chemotherapy is routine for patients with unresectable, diffusely met-
astatic disease. Combination therapy (methotrexate, vinblastine, adriamycin and 
cisplatin - MVAC) is more effective than single-agent treatment. Gemcitobine has 
been used alone and in combination with cisplatin. Another new class of agents 
are taxanes paclitaxel and docetaxel. Long-term disease-free survival is rare. Roles 
for RT include palliation of metastatic pain and spinal cord compression.
Urinary .diversion .after .cystectomy
Ureterosigmoidostomy
The oldest form of urinary diversion, whereby the ureters drain into the sigmoid 
colon, either in its native form or following its detubularization and reconstruction 
into a low-pressure pouch. This diversion requires no appliance (stoma bag, cath-
eter), so remains popular in developing countries. In recreating a “cloaca”, the 
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patient may be prone to upper UTIs with the risk of long-term renal deterioration, 
metabolic hyperchloraemic acidosis and loose, frequent stools.
Ileal conduit
This was developed in 1950 and remains the most popular form of urinary diversion 
in EU. 15 cm of subterminal ileum is isolated on its mesentery and the ureters are 
anastomosed to the proximal end. The distal end is brought out in the right iliac 
fossa as a stoma. The ileum is anastomosed to gain enteral continuity.
Complications: prolonged ileus, urinary and enteral leak, pyelonephritis, ure-
tero-ileal stricture and stoma problems: skin irritation, stenosis and parastomal 
hernia.
Patients require stomatherapy support and some find difficulty in adjusting their 
lifestyle to cope with a stoma-bag. Metabolic complications are uncommon. A 
jejunal or colonic conduit are also used. The conduit may be brought out in the 
upper abdomen and patients require careful electrolyte monitoring due to sodium 
loss and hyperkalaemia.
Continent diversion
The advantage of such a diversion is the absence of an external collection device. 
A neobladder or pouch is fashioned from 60 cm of detubularized ileum or right 
hemicolon. The ureters drain into the neobladder, usually through an anti-reflux 
submucosal tunnel. This may be drained by the patient via a catheterizable stoma, 
such as the appendix or uterine tube (the “Mitrofanoff principle”) brought out 
in the right iliac fossa. Alternatively, the neobladder may be anastomosed to the 
patient’s urethra so that natural voiding can be established. Patients void by relax-
ing their external sphincter and performing a Valsalva maneuvre with abdominal 
walls straining. This orthotopic neobladder should require no catheter, unless the 
pouch is too large and fails to empty adequately. In this case, the patient must be 
prepared to perform CISC.
Popular ileal pouch include Studer operation. The distal 40-44 cm of resected 
ileum opened along the antimesenteric border with scissors. Spatulated ureters 
are anastomosed end-to-side with 4/0 running suture on either side of proximal 
end of afferent tubular ileal limb. Ureters are stented. The 2 medial borders of the 
U-shaped, opened, distal ileal segment are oversewn with a single-layer contin-
uous suture. The bottom of the U is folded between the 2 ends of the U. Before 
complete closure of the reservoir, a 8-10 mm hole is cut into the most caudal 
part of the reservoir. Six sutures are placed between the seromuscular layer of the 
anastomotic area of the reservoir and the membranous urethra. An 18F urethral 
catheter is inserted. Before complete closure of the pouch, a cystostomy tube is 
inserted and brought out suprapubically adjacent to the wound.
Which urinary diversions are chosen comes down to the surgeon’s preference. 
They carry similar complication risks. Previously irradiated bowel can safely be 
used to form pouches, though complications are more likely.
Complications relating to neobladders include: stone formation, urinary leak-
age and peritonitis, pelvic abscess, catheterizing difficulties and stomal stenosis, 
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urinary incontinence and nocturnal enuresis, pouch-ureteric reflux and UTIs, 
uretero-pouch anastomotic stricture, late neobladder rupture.
Metabolic abnormalities include early fluid and electrolyte imbalances, later, urinary 
electrolyte absorption may cause hyperchloraemic acidosis and loss of small bowel 
may result in vitamin B12 deficiency. Metabolic acidosis is less likely in patients with 
normal renal function. Treatment is with sodium bicarbonate and potassium citrate. 
Annual B12 monitoring should be undertaken, with supplementation if necessary.
Adenocarcinoma may develop in intestinal conduit (rare), neobladder or sig-
moid colon mucosa in the long term, due to the carcinogenic bacterial metabo-
lism of urinary nitrosamines. This tends to occur near to the inflow of urine. It is 
therefore advisable to perform annual visual surveillance of urinary diversions after 
10 years. If the urethra is in situ, annual urethroscopy and cytology is important.
5 3  .RENAL .PELVIC .AND .URETERAL .CANCERS
TCC accounts for 90% of upper urinary tract tumors. Renal pelvic TCC is un-
common, accounting for 10% of renal tumors and 4% of all TCC. Ureteric TCC 
is rare, accounting for only 1% of all new cases of TCC. Half are multifocal, 75% 
located distally, while only 3% are located in the proximal ureter. Risk factors are 
similar to those of TCC in the BC. Male:female ratio 3:1. Incidence increases with 
age. Smoking confers a two-fold risk and there are various occupational causes.
Pathology
The tumor usually has a papillary structure, but occasionally solid. It is bilateral 
in 2-4%. It arises within the renal pelvis, less frequently in one of the calyces or 
ureter. Histologically, features of TCC are present.
TNM .classification .2009 .for .upper .tract .urothelial .carcinoma
T – Primary tumor
TX – Primary tumor cannot be assessed
T0 – No evidence of primary tumor
Ta – Non-invasive papillary carcinoma
Tis – CIS
T1 – Tumor invades subepithelial connective tissue
T2 – Tumor invades muscle
T3 – Renal pelvis: Tumor invades beyond muscularis into peripelvic fat or renal 
parenchyma. Ureter: Tumor invades beyond muscularis into periureteric fat
T4 – Tumor invades adjacent organs or through the kidney into perinephric fat
N – Regional lymph nodes
NX – Regional lymph nodes cannot be assessed
N0 – No regional lymph node metastasis
N1 – Metastasis in a single lymph node <2 cm
N2 - Metastasis in a single lymph node >2 cm but <5 cm or multiple lymph 
nodes, none more than 5cm
N3- Metastasis in a lymph node >5 cm 
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M – Distant metastasis
M0 – No distant metastasis
M1 – Distant metastasis
Symptoms .and .signs
• Painless total hematuria;
• “Clot colic”: Loin pain, often caused by clots passing down the ureter;
• Asymptomatic when detected, associated with synchronous bladder TCC;
• At follow-up, ~50% of patients will develop a metachronous bladder TCC and 
2% will develop contralateral upper tract TCC.
Diagnosis
US is excellent for detecting the more common renal parenchymal tumors, but 
not sensitive in detecting tumors of the renal pelvis or ureter. Diagnosis is usually 
made on urine cytology and IVU or CT, respectively revealing malignant cells 
and a filling defect in the renal pelvis or ureter. If doubt exists, selective ureteric 
urine cytology, retrograde pyelo ureterography or URS are indicated. If US and 
cystoscopy are normal during the investigation of hematuria, an IVU or CT is 
recommended. Staging imaging is obtained by contrast-enhanced abdominal CT, 
chest X-Ray and isotope bone scan.
Treatment .
Nephroureterectomy
If staging indicates non-metastatic disease in the presence of a normal contralat-
eral kidney, the “gold standard” treatment with curative intent is nephroureterec-
tomy, open or laparoscopic. The open approach uses either a long transperitoneal 
midline incision or separate loin and iliac fossa incisions. The entire ureter is taken 
with a cuff of bladder, because of the 50% incidence of subsequent ureteric stump 
recurrence. Follow-up should include annual cystoscopy, IVU or CT to detect 
metachronous TCC development.
Percutaneous/ureterorenoscopic resection/ablation
For patients with a single functioning kidney, bilateral disease or those who are 
unfit, percutaneous or URS resection or ablation of the tumors are the minimally 
invasive options. Topical chemotherapy with MMC may subsequently be instilled 
through the nephrostomy or ureteric catheters. This nephron-sparing approach is 
less likely to be curative than definitive surgery.
Systemic combination chemotherapy for unresectable or metastatic disease 
using cyclophosphamide, methatrexate and vincristine is associated with a 30% 
total or partial response at the expense of moderate toxicity. Palliative surgery or 
arterial embolization may be necessary for troublesome hematuria. Radiotherapy 
is generally ineffective.
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5 4  .RENAL .TUMORS
5 4 1  .Benign .renal .masses
The most common are simple cysts, present in >50% of >50-year-olds. Rare-
ly symptomatic, treatment by aspiration under US or laparoscopic excision are 
seldom considered. Most benign renal tumors are rare. The two most clinically 
important are oncocytoma and AML.
Oncocytoma
This is uncommon, accounting for 3-7% of renal tumors. Male:female ratio is 2:1. 
They occur simultaneously with RCC in 7-32% of cases.
Oncocytomas are spherical, capsulated, brown/tan colour, mean size 4-6 cm. 
Half contain a central scar. They may be multifocal and bilateral and extend into 
perinephric fat. Histologically, they comprise aggregates of eosinophillic cells, 
packed with mitochondria. Mitoses are rare and they are considered benign, not 
known to metastasize. There is often loss of the Y chromosome.
Oncocytomas often present as an incidental finding or with loin pain or hema-
turia. Oncocytoma cannot often be distinguished radiologically from RCCs and 
may co-exist with RCC. Rarely, they exhibit a “spoke-wheel’s” pattern on CT 
scanning, caused by stellate central scar. Percutaneous biopsy is not recommended 
since it often leads to continuing uncertainty about the diagnosis. Radical or par-
tial nephrectomy is indicated, as for RCC. No follow-up is necessary.
Angiomyolipoma
80% of these benign clonal neoplasms (hamartomas) occur sporadically, mostly 
middle-aged females. 20% are in association with TS - an autosomal dominant 
syndrome characterized by mental retardation, epilepsy, adenoma sebaceum and 
other hamartomas. 50% of TS patients develop AMLs. Mean age 30 years, 66% 
female, frequently multifocal and bilateral.
AML is composed of blood vessels, smooth muscle and fat. They are always 
considered benign, although extrarenal AMLs have been reported in venous sys-
tem and hilar lymph nodes. Macroscopically, it looks like a well-circumscribed 
lump of fat. Solitary AMLs are more frequently found in the right kidney.
AMLs frequently present as incidental findings (>50%) on US or CT scans. 
They may present with flank pain, palpable mass or painless hematuria. Massive 
and life-threatening retroperitoneal bleeding occurs in up to 10% of cases.
US reflects from fat, hence a characteristic bright echo pattern. This does not 
cast an “acoustic shadow” beyond, helping to distinguish an AML from a calculus. 
CT shows fatty tumor as low-density is low in most of AMLs. If the proportion 
of fat is low, a definite diagnosis can not be made. Measurement of the diameter 
is relevant to treatment.
Many patients with AML >4 cm are symptomatic compared with only 1/4 
with smaller tumors. Therefore, asymptomatic AMLs can be followed with serial 
US. While those bleeding or >4cm should be treated with renal resection or by 
embolization. Emergency nephrectomy or selective renal artery embolization may 
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be life-saving. In patients with TS, in whom multiple bilateral lesions are present, 
conservative treatment should be attempted.
5 4 2  .Renal .cell .carcinoma
RCC - is the most common renal tumor, accounting for 85% of renal malignan-
cies and 2% of all cancer deaths. RCC is the most lethal of all urological tumors, 
app. 40% of patients dying of the condition. Incidence has increased since the 
1980s when US was introduced to clinical practice. It occurs in common sporadic 
and rare hereditary forms.
Etiology
Males are affected twice as commonly as females and peak incidence of sporadic 
RCC is 6th-8th decade.
Risk .factors:
• Urban dwelling;
• Tobacco chewing, smoking cigarettes, pipe or cigars;
• Renal failure and hemodialysis;
• Obesity and hypertension;
• Asbestos exposure;
• The analgesic phenacitin abuse;
• Renal injury;
• Nutrition with fatty products consumption is considered important. Asian mi-
grants to Western countries are at increased risk.
• Vitamins A, C, E and fruit/vegetable consumption are protective;
• 50% of individuals have genetic predisposition with autosomal dominant VHL 
syndrome characterized by phaeochromocytoma, renal and pancreatic cysts 
and cerebellar hemangioblastoma. They develop RCC, often bilateral and mul-
tifocal. VHL syndrome occurs due to loss of both copies of a tumor suppressor 
gene. This results in upregulation of vascular endothelial growth factor, the 
most prominent angiogenic factor in RCC, explaining why some RCCs are 
highly vascular.
Pathology
RCC is adenocarcinoma of the renal cortex, believed to arise from proximal convo-
luted tubule. Usually tan coloured and solid, 7-20% are multifocal, 10-20% contain 
calcification and 10-25% contain cysts. Rarely grossly infiltrative, they are usually 
circumscribed by a pseudocapsule of compressed tissue.
Histological .classification
• Conventional: arise from the proximal tubule, highly vascular, cells clear or gran-
ular;
• Papillary: papillary, tubular and solid variants. 40% multifocal, small incidental 
tumors could equate with “benign adenoma”;
• Chromophobe: arises from the cortical portion of the collecting duct, possess a 
perinuclear halo of microvesicles;
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• Collecting duct carcinoma: rare tumors in young patients with poor prognosis;
• Medullary cell: rare; arises from calyceal epithelium.
• The term “sarcomatoid” is used to describe an infiltrative, poorly differentiated 
variant of any type.
TNM .classification .system .(2009)
T – Primary tumor
T0 – Primary tumor cannot be assessed
T1 – Tumour <7 cm, limited to the kidney
 T1a – Tumor <4 cm, limited to the kidney
 T1b – Tumor >4 cm but <7 cm in greatest dimension
T2 – Tumour >7 cm, limited to the kidney
 T2a – Tumor >7 cm but<10 cm
 T2b – Tumor >10 cm, limited to the kidney
T3 – Tumor extends into major veinsor perinefric tissues but not into the ipsilat-
eral adrenal gland or beyond Gerota’s fascia
 T3a – Tumor grossly extends into the renal vein or invades perirenal 
and/or renal sinus fat (peripelvic), but not beyond Gerota’s fascia
 T3b – Tumor grossly extends into the vena cava below the diaphragm
 T3c- Tumor grossly extends into vena cava above the diaphragm or in-
vades the wall of the vena cava
T4 – Tumor invades beyond Gerota’s fascia (including contiquous extension into 
the ipsilateral adrenal gland)
N – Regional lymph nodes
NX – Regional lymph nodes cannot be assessed
N0 – No regional lymph node metastasis
N1 – Regional lymph node metastasis
M – Distant metastasis
MX – Distant metastasis
M0 – No distant metastasis
M1 – Distant metastasis
Grading .
is performed by the Fuhrman system (1 = well-differentiated; 2 = moderately differ-
entiated; 3 and 4 = poorly differentiated) based on nuclear size, outline and nucleoli.
Symptoms .and .signs
More than 50% of RCCs are now detected incidentally on abdominal US carried 
out to investigate vague or unrelated symptoms. Thus, the stage at diagnosis of 
RCC is lower than it was in the pre-US era.
Of the symptomatic RCCs diagnosed, 50% of patients present with hematuria, 
40% with loin pain, 30% of patients notice a mass and 25% have symptoms or signs 
of metastatic disease (night sweats, fever, fatigue, weight loss, hemoptysis). Less than 
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10% patients exhibit the classic triad: hematuria, pain and mass. Less common pre-
senting features include acute varicocele due to obstruction of the testicular vein by 
tumour within the left renal vein and lower limb edema due to venous obstruction. 
Paraneoplastic syndromes arise due to ectopic hormone secretion by the tumour. 
May be anemia due to hematuria and chronic disease. Polycythemia arises due to 
ectopic secretion of erythropoetin. Hypertension may be observed due to ectopic 
secretion of renin and renal artery compression. Hypoglycaemia is detected due to 
ectopic secretion of insulin, Cushing’s syndrome due to ectopic secretion of ACTH, 
hypercalcaemia due to ectopic secretion of parathyroid hormone-like substance. Gy-
naecomastia, amenorrhoea and reduced libido may be observed due to ectopic se-
cretion of gonadotrophins. Stauffer’s syndrome (hepatic dysfunction, fever, anorexia) 
occur in 10-40% of patients. These may be associated with any disease stage.
Diagnosis .
Full blood count may reveal polycythemia, anemia or high ESR. Serum Cr, BUN 
and electrolytes, calcium and liver function tests are essential.
Staging chest CT and bone scan will follow. Any suggestion of renal or IVC 
involvement on CT may be further investigated with MRT.
Angiography may be helpful in planning partial nephrectomy or surgery for ab-
normal kidneys. Contralateral kidney function is assessed by uptake and excretion 
of CT contrast, serum Cr measurement and an isotope renogram.
Abdominal US is first-line investigation for a patient with loin pain or a sus-
pected renal mass. The size resolution for renal masses is 1.5 cm, exhibiting vari-
able echo patterns. US may also detect renal cysts with smooth-walled, round or 
oval, without internal echoes and complete transmission with a strong acoustic 
shadow posteriorly. If the cyst has a solid intracystic element, septations, an irreg-
ular or calcified wall, further imaging with CT is indicated.
If a renal mass is detected, a thin slice CT scan before and after contrast is the 
most important investigation. In general, any solid enhancing renal mass is con-
sidered a RCC until proven otherwise. Even relatively avascular renal carcinomas 
enhance by 10-25 HU. Occasionally, an isodense but enhancing area of kidney is 
demonstrated (“pseudotumour”) and may correspond to a harmless hypertrophied 
cortical column of Bertini or dysmorphic segment. Lymphadenopathy >2 cm is 
invariably indicative of metastases.
Bosniak developed the following radiological classification of renal cysts:
1. Uncomplicated, simple and benign, no follow-up if asymptomatic;
2. Minimally complicated, septa, calcification, hyperdense, benign but require 
radiological follow-up;
3. Complicated, irregular margin, thickened septa, thick irregular calcification, 
indeterminate, surgical exploration may be indicated;
4. Large, irregular cyst margins with solid components internally, cystic renal 
carcinoma until proved otherwise, surgery required.
MRT may be used for imaging the IVC, locally advanced disease, CRF or for 
allegic patients. Renal arteriography may be helpful to delineate the number and 
position of renal arteries in preparation for nephron-sparing surgery.
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Treatment .of .localized .renal .cancer
Surgery is the good option for treatment for RCC. Increases in diagnosis of small-
er early-stage RCC and the concept of cytoreductive surgery for advanced disease 
has impacted on surgical treatment strategies of the disease.
Open radical nephrectomy
This remains the gold standard treatment of localized RCC. The aim is to excise 
the kidney with Gerota’s fascia, perhaps with ipsilateral adrenal gland and regional 
nodes, removing all tumour with adequate surgical margins. Surgical approach is 
transperitoneal with good access to hilar vessels or thoraco - abdominal for very 
large or T3c tumours. Following renal mobilization, the ureter is divided. Ligation 
and division of the renal artery or arteries should ideally take place prior to ligation 
and division of the renal vein to prevent vascular swelling of the kidney.
Excision of hilar or para-aortic/para-caval lymph nodes will improve patholog-
ical tumour staging. Lymph node involvement in RCC is a poor prognostic factor. 
Incidence ranges from 6% in T1-2 tumours, to 46% in T3a, to 62-66% in higher 
stage disease. Lymphadenectomy at time of nephrectomy will add prognostic in-
formation, especially if there is obvious lymphadenopathy, but therapeutic benefit 
remains unclear. Formal lymphadenectomy adds time and increases blood loss, 
while nodes are clear in about 95% of cases.
Complications include mortality up to 2% from bleeding or embolism of tu-
mour thrombus and maybe bowel, pancreatic, splenic or pleural injuries.
Laparoscopic approach
Well accepted for treating benign disease, this approach appears suitable for T1 
RCCs. Approaches are either transperitoneal or retroperitoneal. The kidney is 
removed whole or morselated in a bag through an iliac incision. Advantages over 
open surgery include less pain, reduced hospital stay and quicker return to normal 
activity. Morbidity is reported in 10-40% of cases. 5-year disease-specific survival 
may be >90% for T1 tumours.
Partial nephrectomy
Laparoscopic or open nephron-sparing surgery is the best option for multifocal, 
bilateral tumours, particularly if the patient has VHL syndrome or single function-
ing kidney. It has become acceptable to treat small tumours, even with a normal 
contralateral kidney, unless the tumour is close to the pelvicalyceal system. Arte-
riography or 3D CT reconstructions are helpful to the surgeon.
Open transperitoneal or loin approaches are used. Laparoscopic partial ne-
phrectomy may be performed. The renal artery is clamped and the kidney packed 
with crushed ice. Generally, results are comparable with open surgery.
Specific complications include failure of complete excision of the tumour(s) 
leading to local recurrence and urinary leak from the collecting system. Some pa-
tients develop acute renal failure. Local recurrence is more common after partial 
nephrectomy, where it can be treated by a further partial or total nephrectomy.
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Post-operative .follow-up
This aims to detect local or distant recurrence to permit additional treatment if 
indicated. After partial nephrectomy, concern will also focus on recurrence in the 
remnant kidney. Typically, stage-dependent 6-monthly clinical assessment and 
annual CT imaging of chest and abdomen for many years.
5-year survival by organ-confined T1 is 90-100%, T2 is 60-95%, T3 is 50-80%, 
N+ is 5-30%, by distant metastasis is 5-30%.
Alternatives to surgery:
• Observation: small solid, well-marginated renal masses may be safely followed 
with repeat scans in elderly or unfit patients. Growth is slow and metastasis rare.
• Cryosurgery is performed using intra-operative US by open, percutaneous or 
laparoscopic routes. This is an nephron-sparing treatment option.
• HIFU is extra-corporeal minimally invasive and highly accurate treatment is 
under evaluation.
Treatment .of .the .locally .advanced .RCC
Disease involving the IVC, right atrium, liver, bowel or posterior abdominal wall 
demands special surgical skills. In appropriate patients, an aggressive surgical ap-
proach will be needed to achieve negative margins. Pre- or postoperative ERBT 
or immunotherapy are used as adjuvant treatment.
Treatment .of .the .metastatic .RCC
~25-30% of patients with RCC exhibit metastatic disease at presentation and 20-
30% progress subsequently to this stage following nephrectomy. The prognosis is 
poor. Nephrectomy is undertaken to relieve local symptoms of pain or hematuria. 
If inoperable, arterial embolization can be helpful. A median survival benefit of 
10-12 months for patients with good performance status treated with cytoreductive 
nephrectomy prior to immunotherapy with interferons was reported.
Metastasectomy may be of benefit to the 1.5-3% of patients who develop a 
solitary metastases following nephrectomy. Resection of solitary metastases is an 
option for a few patients, usually a few months after nephrectomy, thereby ensur-
ing the lesion remains solitary.
Hormone therapy and chemotherapy have little role in RCC. Radiotherapy 
useful for palliation of metastatic lesions in bone and brain and in combination 
with surgery for spinal cord compression. The first cytokines to be used thera-
peutically, to activate anti-tumour immune response, were interferons and, sub-
sequently, interleukin-2. Randomized studies in the 1990-s demonstrated mod-
est response rates (10-20%) after systemic immunotherapy using these cytokines 
alone and in combination. Toxicity could be severe. Responses were more likely in 
patients with good performance status, prior nephrectomy and small-volume met-
astatic burden. The current first-line treatment of metastatic RCC is single-agent 
immunotherapy preceded by nephrectomy in selected patients.
As discussed earlier, most RCCs are highly angiogenic, so should be a good 
therapeutic target for angiogenesis inhibitors.
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5 5  .TESTICULAR .CANCER
Primary TC is the most common solid cancer in men aged 20-45. Constituting 1-2% 
of all male cancers, the lifetime risk of developing TC is 1 in 500. It is also considered 
the most curable cancer. Bilateral testicular cancer occurs in 1-5% of cases.
Etiology .and .risk .factors
• The most common affected age group is 20-45 years, with germ cell tumours. 
Rarely, infants and boys below 10 years develop yolk sac tumours and 50% men 
>60 years with TC have lymphoma.
• White:black peoples ratio is 3:1;
• 10% of TC occur in UDT. The risk increases by 5-18 times compared to men 
with normally descended testes. Because of ultrastructural changes are present 
in these testes by age 3 years, earlier orchidopexy does not completely eliminate 
the risk of developing TC. 5-10% of patients with a UDT will develop malig-
nancy in the normally descended contralateral testis.
• IGCN synonymous with CIS. 50% of cases develop invasive germ cell TC 
within 5 years. Risk factors include cryptorchidism, extra-gonadal germ cell tu-
mour, previous or contralateral TC, atrophic contralateral testis, 45XO karyo-
type and infertility.
• Patients infected with the HIV virus are developing TC more frequently;
• Genetic factors may play a role;
• Maternal estrogen ingestion during pregnancy increases the risk of cryptorchi-
dism and TC in the male;
• Traumatic and post-orchitis atrophy may be implicated as risk factors for TC.
Pathology
90% of TC are malignant GCT are divided into seminomatous and non- semino-
matous GCTs for clinical purposes. Seminoma appears pale and homogeneous. 
NSGCTs are heterogeneous and sometimes contain cartilage or hair.
WHO .histopathological .classification .of .testicular .tumours
Germ cell tumours
 Seminoma
  Spermatocytic, classical and anaplastic subtypes
 Non-seminomatous GCT
  Teratoma:
   Differentiated/mature
   Intermediate/immature 
   Undifferentiated/malignant
  Yolk sac tumour
  Choriocarcinoma
  Mixed NSGCT
  Mixed GCT
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Other tumours
 Epidermoid cyst (benign)
 Adenomatoid tumour
 Adenocarcinoma of the rete testis
 Carcinoid
 Lymphoma
 Metastatic, from another site
Sex cord stromal tumours
 Leydig cell
 Sertoli cell
 Mixed or unclassified
Mixed germ cell/sex cord tumours
The right testis is affected slightly more commonly than the left. Synchronous 
bilateral TC occurs in 2% of cases. TC spreads into the epididymis, spermatic cord 
and, rarely, the scrotal wall. Lymphatic spread occurs initially to the para-aortic 
nodes. Involvement of the epididymis, spermatic cord or scrotum may lead to 
pelvic and inguinal node metastasis. Blood-borne metastasis to the lungs, liver and 
bones may be observed.
TC is staged using various classifications, most recently the TNM (2009) sys-
tem. T stage is pathological, N stage involves imaging and M stage involves physi-
cal examination, imaging and biochemical investigations. An additional S category 
is appended for serum tumour markers.
TNM .classification .for .testicular .cancer .(2009)
pT – Primary tumor
pTX – Primary tumour cannot be assessed
pT0 – No evidence of primary tumour
pTis – IGCN
pT1 – Tumour limited to testis and epididymis without vascular/lymphatic inva-
sion: tumour may invade tunica albuginea but not tunica vaginalis
pT2 – Tumour limited to testis and epididymis with vascular/lymphatic invasion 
or tumour extending through tunica albuginea with involvement of tunica vaginalis
pT3 – Tumour invades sperm. cord with or without vascular/lymphatic invasion
pT4 – Tumour invades scrotum with or without vascular/lymphatic invasion
N – Regional lymph nodes
NX – Regional lymph nodes cannot be assessed
N0 – No regional lymph node metastasis
N1 – Metastasis with a lymph node/s <2 cm
N2 – Metastasis with a lymph node/s >2 but <5 cm
N3 – Metastasis with a lymph node/s >5 cm
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M – Distant metastasis
MX – Distant metastasis cannot be assessed
M0 – No distant metastasis
M1 – Distant metastasis
 M1a - Non-regional lymph nodes/or lung
 M1b – Other sites
S – Serum tumor markers levels
SX – Serum marker studies not available or not performed
S0 – Serum marker study levels within normal limits
S1-S2-S3: Pathological levels of LDH, hCG, AFP
Symptoms .and .signs
Testicular self-examination is indicated for young men. Most patients present with 
a scrotal lump, usually painless or slightly aching. There are patients with metastatic 
disease. This may be due to patient factors (fear, self-neglect, ignorance) or earlier 
misdiagnosis. Occasionally acute scrotal pain may occur, due to intratumoural hem-
orrhage, causing diagnostic confusion. The lump may have been noted by the patient, 
sometimes after minor trauma or by his partner. Symptoms suggestive of advanced 
disease include weight loss, lumps in the neck, chest symptoms and bone pain.
Examination of the genitalia should be carried out in a warm room with the 
patient relaxed. Using careful bimanual palpation, the normal side is first exam-
ined, followed by the abnormal side. This will reveal a hard, non-tender, irregular, 
non-transilluminable mass in the testis or replacing the testis. Care should be tak-
en to assess the epididymis, spermatic cord and overlying scrotal wall, which may 
be normal or involved. Rarely, a secondary hydrocele may be present. General 
examination may reveal cachexia, supraclavicular lymphadenopathy, chest signs, 
hepatomegaly, lower limb edema or abdominal mass all suggestive of metastatic 
disease. May be gynaecomastia due to endocrine manifestations of some tumours.
Differential diagnosis include testicular torsion, epididymo-orchitis, hydrocele, 
epididymal cyst, hernia, hematoma.
Diagnosis
US will confirm that the palpable lesion is within the testis, distorting its normally 
regular outline and internal echo pattern. Any hypoechoic area within the tunica 
albuginea should be regarded with suspicion. It may distinguish a primary from a 
secondary hydrocele. US may also be used to identify impalpable lesions as small 
as 1-2 mm tumour in a patient presenting with systemic symptoms and signs or 
an incidental finding.
Abdominal and chest CT scans are usually obtained for staging purposes if the 
diagnosis of TC is confirmed.
Tumour markers
Serum tumour markers are measured prior to any treatment of TC. GCTs may 
express and secrete into the blood measurable proteins. These tumour markers are 
useful in diagnosis, staging, prognosis and monitoring of response to treatment.
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AFP is expressed by trophoblastic elements within 50-70% of teratomas and 
yolk sac tumours. With respect to seminoma, the presence of elevated serum AFP 
strongly suggests a non-seminomatous element. Serum half-life is 3-5 days. Nor-
mal level is <10 ng/ml.
HCG is expressed syncytiotrophoblastic elements of choriocarcinomas (100%), 
teratomas (40%) and seminomas (10%). Serum half-life is 24-36h. Normal  level 
is <5 mIU/ml.
LDH is cellular enzyme, elevated in serum for various causes, therefore less spe-
cific. It is elevated in 10-20% of seminomas, correlating with tumour burden and is 
most useful in monitoring treatment response in advanced seminoma.
These markers are measured at presentation, 1-2 weeks after radical orchidec-
tomy and during follow-up to assess response to treatment and residual disease.
Normal markers prior to orchidectomy do not exclude metastatic disease. Nor-
malization of markers post orchidectomy cannot be equated with absence of dis-
ease. Persistent elevations of markers post-orchidectomy may occur with liver 
dysfunction and hypogonadotrophism, but usually indicate metastatic disease.
Treatment
Radical orchiectomy
The final investigation and the primary treatment for all TC. This involves excision 
of the testis, epididymis and cord through a groin incision. The cord is clamped, 
transfixed and divided near the internal inguinal ring before the testis is manipu-
lated into the wound, preventing inadvertent metastasis. A silicone prosthesis may 
be inserted at the time or at a later date. Fertility prophylaxis by freezing sperm 
should be offered to patients without a normal contralateral testis. Contralateral 
testis biopsy should be considered in patients at high risk for IGCN.
Treatment .of .non-seminomatous .germ .cell .tumours
Following radical orchidectomy and formal staging, the patient is normally man-
aged by the oncologist. Urologist may be asked to perform RPLND in selected 
cases. In the presence of elevated AFP, a seminoma would be managed as for 
teratoma. Combination chemotherapy, introduced in the 1980s, revolutionized 
the treatment of metastatic testicular teratoma.
In patients with non-metastatic disease (T1-4N0M0S0) are performed surveil-
lance or chemotherapy (bleomycin, etoposide, cisplatin) depending on risk factors 
for relapse.
In patients with metastatic disease and good prognosis, chemotherapy (bleo-
mycin, etoposide, cisplatin) is indicated. RPLND is performed for residual or 
recurrent mass. Salvage chemotherapy is indicated if histology confirms tumour.
In patients with metastatic disease, intermediate and poor prognosis, chemo-
therapy (bleomycin, etoposide, cisplatin) is indicated. RPLND for residual or 
recurrent mass. Salvage chemotherapy is indicated if histology confirms tumour.
In most countries RPLND remains the gold standard staging investigation fol-
lowing radical orchidectomy. RPLND is usually the first and only evidence of 
extra-gonadal metastasis of teratoma. Sometimes RPLND is used only to remove 
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or de-bulk residual mass post chemotherapy. RPLND may remove viable tumour 
in 10-30% of patients, taking para-aortic nodes up to the origin of the superior 
mesenteric artery and down to the iliac bifurcation.
Complications: 1% mortality and 25% morbidity includes lymphocele, pan-
creatitis, ileus and ejaculatory failure. Modified techniques reduce the risk of 
ejaculatory disturbance, by taking nodes on the unaffected side only down to the 
inferior mesenteric artery.
Treatment .of .seminoma .and .IGCN
Of all seminomas, 75% are confined to the testis at presentation and are cured 
by radical orchidectomy. 10-15% of patients harbour regional node metastasis 
and 5-10% have more advanced disease. Following radical orchidectomy and 
formal staging, the patient is managed by the oncologist. Treatment and follow-up 
depends largely on disease stage according to presence of metastases and size of 
nodal disease.
In patients with non-metastatic disease (T1N0M0) risk of subsequent para-aor-
tic node relapse is 20%. Adjuvant RT 20Gy in 10 fractions reduces risk to 1%. RT 
includes para-aortic nodes. Early results of a randomized MRC study comparing 
one cycle of carboplatin with radiotherapy suggest equivalence. In patients with 
metastatic disease chemotherapy and RT are indicated. 
5 6  .PENILE .NEOPLASMS
5 6 1  .Viral-related .and .premalignant .lesions
Viral - related lesions
• Condyloma acuminatum: also known as genital warts, related to HPV infec-
tion. Soft, usually multiple benign lesions on the glans, prepuce, shaft, genitalia 
or perineum. A biopsy is worthwhile prior to topical treatment with podophyl-
lin. 5% have urethral involvement, which may require diathermy. HPV infec-
tion (types 16,18,21) is potentially carcinogenic and condylomata have been 
associated with penile SCC.
• Bowenoid papulosis: a condition resembling CIS, but with a benign course. 
Multiple papules appear on the penile skin or flat glanular lesion. These should 
be biopsied. HPV is the suspected cause.
• Kaposi’s sarcoma is reticulo-endothelial tumour has become the second most 
common malignant PC. It presents as a raised, painful, bleeding violacious pap-
ule or as a bluish ulcer with local edema. It is slow-growing, solitary or diffuse. 
It occurs in immunocompromised men.
Premalignant cutaneous lesions
Some histologically benign lesions are recognized to have malignant potential or 
occur in close association with SCC of the penis.
• Cutaneous horn: rare, solid skin overgrowth, extreme hyperkeratosis, the base 
may be malignant;
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• Pseudoepitheliomatous micaceous and keratotic balanitis: unusual hyperker-
atotic growths on the glans. Require excision, histological examination and 
follow-up, as they may recur.
• Balanitis xerotica obliterans: also known as lichen sclerosus et atrophicus. This 
is a common sclerosing condition of glans and prepuce. It occurs at all ages and 
most commonly presents as phimosis. The meatus and fossa navicularis may be 
affected, causing obstructed and spraying voiding. The histological diagnosis is 
usually made after circumcision, with epithelial atrophy, loss of rete pegs and 
collagenization of the dermis.
• Leukoplakia: solitary or multiple whiteish glanular plaques that usually involve 
the meatus. Leukoplakia is associated with in situ SCC, follow-up is required.
• Erythroplasia of Queyrat: also known as CIS  of the glans, prepuce or penile shaft. 
A red, velvety, circumscribed painless lesion, though it may ulcerate resulting in 
discharge and pain. Histology reveals hyperplastic mucosal cells with malignant 
features.
• Bowen’s disease: this is CIS  of the remainder of the keratinizing genital or 
perineal skin.
• Buschke - Lewenstein tumour: also known as verrucous carcinoma or giant 
condyloma acuminatum, this is an aggressive locally invasive tumour of the 
glans. Metastasis is rare. Urethral erosion and fistulation may occur.
A chronic red or pale lesion on the glans or prepuce is a cause for concern. 
Note should be made of its colour, size and surface features. Early review fol-
lowing steroid, antibacterial or antifungal creams is recommended. If persistent, 
biopsy and excision are advised.
5 6 2  .Penile .cancer
SCC is the most common PC, accounting for 95% of penile malignancies. Others in-
clude Kaposi’s sarcoma and, rarely, basal cell carcinoma, melanoma, sarcoma, Paget’s 
disease. PC is rare, representing 1% of male cancers, most occurring in elderly men.
Risk .factors
• PC incidence rises during the 6th decade and peaks in the 8th decade. It is un-
usual <40 years, but has been reported in children.
• Many patients with penile SCC are reported about a pre-existing penile lesion 
and phimosis. PC is rare in men circumcised at a young age and it is non-ex-
istent in Israel. It is thought that chronic irritation with smegma and balanitis 
is contributory.
• HPV infection are suggested, especially with types 16, 18 and 21.
• Smoking.
Pathology
Believed to be preceded by CIS, SCC starts as a slow-growing papillary, flat or 
ulcerative lesion on the glans, prepuce, coronal sulcus or shaft. It grows locally 
beneath the foreskin before invading the corpora cavernosa, urethra and, eventu-
ally, the perineum, pelvis and prostate. Metastasis is initially to the superficial then 
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deep inguinal and, subsequently, iliac and obturator lymph nodes. Skin necrosis, 
ulceration and infection of the inguinal lymph nodes may lead to sepsis or hemor-
rhage from the femoral vessels. Metastasis to lungs and liver are rare.
SCC exhibits keratinization, epithelial pearl formation and mitoses. Grading is 
low, intermediate or high and correlates with prognosis.
TNM .classification .for .penile .carcinoma .(2009)
T – Primary Tumour
TX – Primary tumour cannot be assessed
T0 – No evidence of primary tumour
Tis – CIS
Ta – Non-invasive carcinoma
T1 – Tumour invades subepithelial connective tissue
T1a – Tumour invades subepithelial connective tissue without lymphovascular 
invasion and is not poorly differentiated or undifferentiated
T1b – Tumor invades subepithelial connective tissue with lymphovascular inva-
sion or is poorly differentiated or undifferentiated
T2 – Tumour invades corpus spongiosum and/or corpora cavernosa
T3 – Tumour invades urethra
T4 – Tumour invades other adjacent structures
N – Regional Lymph Nodes
NX – Regional lymph nodes cannot be assessed
N0 – No palpable or visibly enlarged inguinal lymph nodes
N1 – Palpable mobile unilateral inguinal lymph node
N2 – Palpable mobile multiple unilateral or bilateral inguinal lymph nodes
N3 – Fixed inguinal nodal mass or pelvic lymphadenopathy, unilateral or bilateral
M – Distant Metastasis
M0 - No distant metastasis
M1 – Distant metastasis
Symptoms .and .signs
Most common phimosis is present. A hard, painless lump on the glans penis is vis-
ible or palpable. Many patients delay presentation due to embarrassment, personal 
neglect, fear or ignorance. A bloody discharge may be confused with hematuria. 
Rarely, a groin mass or urinary retention are presenting symptoms.
Examination reveals a solid non-tender mass or ulcer beneath or involving the 
foreskin. There is usually evidence of local infection. In more advanced disease, 
prepuce, glans, shaft, scrotum and even perineum are replaced by tumour. The 
inguinal lymph nodes may be enlarged, fixed or even ulcerate overlying skin.
Diagnosis
A biopsy is indicated. Chest radiology, pelvic and abdominal CT scan, serum cal-




The first-line treatment of PC, regardless of the inguinal node status, is surgery. 
Circumcision is appropriate for preputial lesions, but may be local recurrences, if 
the excision margin is positive. Organ-preserving wide excision of glanular lesions 
with skin graft glanular reconstruction may be suitable for smaller G1-2 Ta-T1 
tumours, giving good cosmetic and functional results.
For G3T1 and more advanced tumours, partial or total penile amputation is 
required, depending on the extent of the tumour. Partial amputation is preferable, 
provided a 2 cm margin of palpably normal shaft can be obtained. The patient 
must be prepared for poor cosmetic and functional results: inability to have sexual 
intercourse and need to sit to void urine. Total amputation involves excision of 
the scrotum and its contents, with formation of a perineal urethrostomy. The most 
common complication is urethral stenosis. RT remains an alternative, but disad-
vantages include radio-resistance. Tissue necrosis and damage leading to urethral 
stricture, fistula and pain. Patients with Ml disease are offered palliative surgery.
Alternatives to surgery include laser or cryoablation, brachytherapy, photody-
namic therapy or topical 5-fluorouracil.
Lymphadenectomy
Six weeks of broad-spectrum antimicrobials are given after the primary tumour 
has been removed. Nodes become clinically insignificant in 50% of patients, who 
may then be followed-up.
For those with persistent inguinal lymphadenopathy, in the absence of demon-
strable pelvic or metastatic disease, bilateral inguinal lymphadenectomy should be 
considered, since 5-year survival is 80%. Even if lymphadenopathy is unilateral, 
>50% will have contralateral metastases. However, this is major surgery with a 
high morbidity including lymphedema, thromboembolism and wound breakdown, 
so it is not suitable for elderly or unfit men.
RT and chemotherapy are alternative or adjuvant treatments for metastatic 
nodal disease in unfit, elderly or inoperable patients. 5-year survival 25%. Rarely, 
lymphadenopathy ulcerates the skin, may encase the femoral vessels and invade 
the deeper musculature..
Prophylactic lymphadenectomy is currently practised for tumours exhibiting 
vascular invasion, high grade or stages T2-4, without evidence of benefit. It is ar-
gued that the risk of metastatic disease with palpably normal groins is greater than 
20% and delayed lymphadenectomy could reduce the chance of cure. 20-30% of 
patients with inguinal metastases will also have pelvic node involvement.
Metastatic disease is treated using single-agent or combination chemotherapy: 
cisplatin, bleomycin or methotrexate. Responses are partial and short-lived.
5 7  .URETHRAL .CANCER
Primary urethral cancer is rare, occurring in elderly patients.
Female:male ratio is 4:1.
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Risk .factors
Urethral stricture and STD are implicated. Direct spread from tumour in the 
bladder or prostate is more common.
Pathology
75% are SCC, occurring in the anterior urethra. 15% are TCC, occurring in 
the posterior/prostatic urethra. 8% are adenocarcinoma. The remainder include 
sarcoma and melanoma. Urethral cancer metastasises to the pelvic lymph nodes 
from the posterior urethra and to the inguinal nodes from the anterior urethra in 
50% of patients.
TNM .classification .for .urethral .cancer .(7th .edition)
T – Primary Tumour
TX – Primary tumour cannot be assessed
Tis – CIS
T0 – No evidence of primary tumour
Ta – Non-invasive papillary carcinoma
T1 – Tumour invades subepithelial connective tissue
T2 – Tumour invades any of the following structures: corpus spongiosum, pros-
tate, peri-urethral muscle
T3 - Tumour invades any of the following structures: corpus cavernosum,invasion 
beyond prostatic capsule, anterior vaginal wall, bladder neck
T4 – Tumour invades other adjacent organs
N – Regional Lymph nodes
NX – Regional lymph nodes cannot be assessed
N0 – No regional lymph-node metastasis
N1 – Metastasis in a single lymph node <2 cm
N2 – Metastasis in a single lymph node >2 cm or in multiple nodes
M – Distant Metastasis
MX – Distant metastasis cannot be assessed
M0 – No distant metastasis
M1 – Distant metastasis
Symptoms .and .signs
• Initial or terminal hematuria or a bloody urethral discharge;
• LUTS;
• Perineal pain;
• Periurethral abscess or urethro-cutaneous fistula;
• Past history of STD or stricture disease;
• Examination may reveal a hard palpable mass at the female urethral meatus or 
along the course of the male anterior urethra. Inguinal lymphadenopathy, chest 
signs and hepatomegaly may suggest metastatic disease.
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Diagnosis
Cysto-urethroscopy, biopsy and bimanual examination under anaesthesia will ob-
tain a diagnosis and local clinical staging. Chest X-Ray and abdomino-pelvic CT 
scans will enable distant staging.
Treatment
For localized anterior urethral cancer, surgery or EBRT are the options. Male 
patients would require perineal urethrostomy. Post-operative incontinence due to 
disruption of the external sphincter mechanism is minimal unless the bladder neck 
is involved, but the patient would need to sit to void. For posterior/prostatic ure-
thral cancer, cystoprostatourethrectomy should be considered for fit men. Anterior 
pelvic exenteration (excision of the pelvic lymph nodes, bladder, urethra, uterus, 
ovaries and part of the vagina) should be considered for women. In the absence of 
distant metastases, inguinal lymphadenectomy is performed if nodes are palpable. 
For locally advanced disease, a combination of preoperative RT and surgery is 
recommended. For metastatic disease, chemotherapy is the only option.
6 1  .RENAL .INJURIES
The kidneys are located retroperitonealy, surrounded by peri-renal fat, the verte-
bral column and spinal muscles, the lower ribs and abdominal contents. They are 
therefore relatively protected from injuries and a considerable degree of force is 
usually required to injure them. Injuries of spleen, liver and mesentery of bowel 
are therefore common.
Children’s kidneys are said to be more prone to injury in children because of 
the relatively greater size of the kidneys in children, the smaller protective muscle 
mass and cushion of peri-renal fat and the more pliable rib cage.
Classification
There are two categories: blunt and penetrating. Proportion depends on whether 
urban or non-urban community. Experience from large series shows that 95% of 
blunt injuries can be managed conservatively, whereas most of stab and gunshot 
wounds require exploration.
Blunt injures
Rapid deceleration or acceleration frequently causes renal pedicle injuries. Most 
common cause are motor vehicle accidents: pedestrian hit by a car, direct blow. 
Direct falls onto the flank or sporting injuries can lead to significant renal injuries.
Penetrating injuries
Stab or gunshot injuries to the flank, lower chest and anterior abdominal area 
may inflict renal injuries. 1/2 of patients with penetrating trauma and hematuria 
have grade III, IV or V renal injuries. Penetrating injuries anterior to the anterior 
axillary line are more likely to injure the renal vessels and renal pelvis, compared 
with injuries posterior to this line where less serious parenchymal injuries are more 
likely. There are iatrogenic injuries due to PCNL.
Staging .of .the .renal .injuries
Using CT, renal injuries can be staged according to the AAST Organ Injury Se-
verity Scale. Higher injury severity scales are associated with poorer prognosis.
• Grade I Contusion or subcapsular hematoma with no parenchymal laceration;
• Grade II <l cm deep parenchymal laceration of cortex, no extravasation of 
urine (i.e. collecting system intact);
• Grade III >l cm deep parenchymal laceration of cortex, no extravasation of 
urine;
• Grade IV Parenchymal laceration involving cortex, medulla and collecting sys-
tem oor renal artery/vein injury with contained hemorrhage;
• Grade V Completely shattered kidney or avulsion of renal hilum.
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Diagnosis
There are 2 types of patients: hemodynamically stable and unstable (SBP<90 
mmHg recorded at any time since the injury). While significant renal injury is 
more likely with macroscopic hematuria, in some cases of severe renal injury 
hematuria may be absent. Thus the relationship between the presence, absence 
and degree of hematuria and the severity of trauma is not absolute. In blunt 
trauma macroscopic hematuria predicts the likelihood of significant renal injury. 
Conversely, in penetrating trauma, hematuria may be absent in severe IV-V type 
renal injuries.
History is taken for nature of trauma (blunt, penetrating). Examination: pulse 
rate, SBP, respiratory rate, location of entry and exit wounds, flank bruising, rib 
fractures.
Hemodynamic instability may preclude standard imaging such as CT, the pa-
tient having to be taken to the operating theatre immediately to control the bleed-
ing. In this situation, an on-table IVU is indicated if a retroperitoneal hematoma 
is found and/or a renal injury is found which is likely to require nephrectomy. A 
single shot abdominal X-ray, taken 10 min after contrast administration (2 ml/kg), 
can establish the presence/absence of a renal injury and the presence of a normal-
ly functioning contralateral kidney where the ipsilateral kidney injury is likely to 
necessitate a nephrectomy.
The IVU has been replaced by contrast enhanced CT scan as the imaging study 
of choice in patients with suspected renal trauma. Compared with IVU, it provides 
clearer definition of the injury, allowing injuries to the parenchyma and collecting 
system to be more accurately graded. An arterial-venous phase scan is done within 
minutes of contrast injection, followed by a repeat scan 10-20 min after contrast 
administration to allow time for contrast to reach collecting system.
Imaging is designed to grade injury, to document presence and function of 




• Penetrating chest and abdominal wounds;
• Microscopic hematuria in a hypotensive patient;
• A history of a fall from a height, high speed motor vehicle accident. Falls from 
even a low height can cause serious renal injury in the absence of shock and 
of hematuria;
On contrast enhanced CT look for:
• Depth of parenchymal laceration;
• Parenchymal enhancement;
• Presence of urine extravasation;
• Presence, size and position of retroperitoneal hematoma;
• Presence of injuries to adjacent organs (bowel, spleen, liver, pancrea...);
• Presence of a normal contralateral kidney.
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While US can establish the presence of two kidneys and identify blood flow in 
the renal vessels with power Doppler, it cannot accurately identify parenchymal 
tears, collecting system injuries or extravasation of urine until a later stage when 
a urine collection occurs.
Treatment
Most blunt and many penetrating renal injuries can be managed non-operatively.
If SBP since injury has always been >90 mmHg, no history of acceleration or 
deceleration and hematuria is present, there is Grade I injury.
Cardiovascularly stable patient with macroscopic hematuria, having Grade II-
III injury admits for bed rest, observation, antibiotics and NSAID’s treatment, 
until the macroscopic hematuria, if present, resolves.
Indications for surgical exploration:
• The patient develops shock which does not respond to resuscitation with fluids 
and/or blood transfusion;
• The hemoglobin decreases <80;
• There is urinary extravasation;
• There are associated bowel or pancreatic injuries;
• Expanding and pulsatile peri-renal hematoma;
The finding of an expanding and/or pulsatile retroperitoneal hematoma at lapa-
rotomy will often indicate a renal pedicle injury and nephrectomy may be required 
to stop further hemorrhage. Controversy surrounds the correct management of the 
finding at laparotomy of a non-expanding, non-pulsatile retroperitoneal hemato-
ma. Most can be left alone, because of exploration, which increases the chances 
of kidney loss. It this cases bleeding can be controlled only by nephrectomy. This 
is a disaster if the contralateral kidney is absent or damaged.
If patient has Grade IV injury, this is an indication for exploration or drainage 
(JJ- stent or PNS). Sometimes these injuries will heal spontaneously. Operation 
is indicated if there are associated bowel or pancreatic injuries. In these situations 
the renal repair should be well drained and omentum interposed between the kid-
ney and bowel or pancreas.
Renal imaging is repeted if the patient develops a peritonitis or a fever, since 
these signs may indicate the development of a urinoma which can be drained per-
cutaneously. Renal exploration is required for a persistent leak and fistula formation.
Exploration is usually required for patients with Grade V injury with devitalized 
segments of kidney and urinary extravasation.
Technique of renal exploration
Midline incision allows exposure of renal pedicle, so allowing early control of the 
renal artery and vein and inspection for injury to other organs.
Lift the small bowel upwards to allow access to the retroperitoneum. Incise the 
peritoneum over the aorta, above the inferior mesenteric artery. A large perirenal 
hematoma may obscure the correct site for this incision. If this is the case, look 
for the inferior mesenteric vein and make your incision medial to this. Once on 
the aorta, the inferior vena cava may be exposed, then the renal veins and the 
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renal arteries. Pass slings around all of these vessels. Expose the kidney by lifting 
the colon off of the retroperitoneum. Bleeding may be reduced by applying pres-
sure to the vessels via the slings. Control bleeding vessels within the kidney and 
close any defects in the collecting system with 4/0 vicryl or monocryl sutures. If 
your sutures cut out, place a strip of Surgicel over the site of bleeding, place your 
sutures through the capsule on either side of this and tie them over the Surgicel. 
This will stop them from cutting through the friable renal parenchyma.
Complications
Arteriovenous fistulae can sometimes occur following renal inguries. Arteriog-
raphy with embolization can be used to stop the bleeding in these cases. The 
“second-stage” bleeding usually occurs over a longer time of injury, rather than as 
acute hemorrhage causing shock.
Excess renin excretion occurs following renal ischaemia from renal artery inju-
ry or thrombosis or renal compression by hematoma or fibrosis. This can lead to 
hypertension months or years after renal injury.
6 2  .URETERIC .INJURIES
External injuries are registered due to road traffic accidents and fall from a height. 
Penetrating injuries may be observed by knife or gunshot wounds. Iatrogenic in-
juries are detected during pelvic or abdominal surgery (hysterectomy, colectomy, 
aneurysm repair, URS). The ureter may be divided, ligated or angulated by a 
suture. A segment may be excised or damaged by diathermy.
Symptoms .and .signs .of .ureteric .injuries
• Urine peritonitis due to urine collection within the peritoneal cavity;
• Prolonged post-operative fever
• Urosepsis;
• Persistent drainage of fluid from drains, the abdominal wound or the vagina. Cr 
estimation of this fluid is indicated (Cr level higher than that of serum).
• Renal colic if the ureter has been ligated;
• Retroperitoneal mass, representing as a urinoma;
• The pathology report on the organ that has been removed may note the pres-
ence of a segment of ureter.
Diagnosis
IVU or CT can be used to determine the presence of a ureteric injury. If doubt 
remains, retrograde ureterography should be done.
The iatrogenic injury may be suspected at the time of surgery, but injury may 
not become apparent until some days or weeks post-operatively.
Intra-operative diagnosis
For ureteric contusions and perforations seen at the time of URS, JJ-stent is in-
serted. During abdominal or pelvic surgery direct inspection of the ureter - a good 
way of inspecting the ureter for injury, but requires exposure of a considerable 
length of ureter to establish that it has not been injured. Lower ureteric exposure 
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is more difficult than upper ureteric. Extravasation after injection of methylene 
blue into the ureter to look for leakage of dye from a more distant section of ure-
ter. On-table retrograde ureterography - a very accurate method of establishing 
the presence or absence of a ureteric injury. Both ureters can easily be examined.
Post-operative diagnosis
The diagnosis is usually apparent in the first few days following surgery, but it may 
be delayed by weeks, months or years. Symptoms and signs are UHN, flank pain 
and post-hysterectomy false incontinence. A continuous leak of urine from vagina 
suggests a ureterovaginal fistula. IVU and/or retrograde ureterogram are indicat-
ed. US may demonstrate UHN, but hydronephrosis may be absent when urine 
is leaking from a transected ureter into the retroperitoneum, peritoneal cavity or 
vagina. The IVU usually shows an obstructed ureter or occasionally a contrast leak 
from the site of injury.
Treatment
Generally, the best time to repair the ureter is as soon as the injury has been di-
agnosed. Delay definitive ureteric repair when there is evidence of active infection 
and urinoma at the site of proposed ureteric repair.
A PNS should be placed, i.v. antibiotics given and ureteric repair delayed until 
the patient is apyrexial.
Surgical repair should be delayed when the injury was diagnosed between day 7 
and day 14 after ureteric injury, the time when maximal edema and inflammation 
at the site of repair was believed to occur. However, favourable outcomes have 
been demonstrated after early repair.
The options of treatment depend on whether the injury is recognized immedi-
ately, level of injury and other associated problems.
The options are:
• Open JJ-stent for 3-6 weeks if there is injury recognized immediately;
• Primary closure of partial transection of the ureter with open JJ-stent;
• Direct end-to-end anastomosis if a tension-free anastomosis is possible;
• Re-implantation of the ureter into the bladder (ureteroneocystostomy) either 
using Boari flap;
• Replacement of the ureter with ileum where the segment of damaged ureter is 
very long (rare option);
• Permanent cutaneous ureterostomy (rare option).
General principles of ureteric repair:
• The ends of the ureter should be debrided and spatulated, so that the edges to 
be anastomosed are bleeding freely and to allow a wide anastomosis to be done;
• The anastomosis should be tension free;
• A JJ-stent should be placed across the repair;
• Watertight closure;
• Use 4/0 absorbable suture material;
• A drain should be placed around the site of anastomosis.
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6 3  .BLADDER .AND .URETERIC .INJURIES .ASSOCIATED .WITH .PELVIC .
FRACTURES
Pelvic fractures are observed usually due to run-over or crush injuries, where 
massive force is applied to the pelvis. Associated head, chest, intraabdominal, 
pelvic and genital injuries are common and these injuries plus the massive blood 
loss from pelvic veins and arteries account for the substantial mortality after pelvic 
fractures. 
Bladder .injuries .associated .with .pelvic .fractures
~10% of male and 5% of female pelvic fractures are associated with a bladder in-
juries. Fracture type leading to bladder injury is usually an antero-posterior pelvic 
compression fracture i.e. “open book” pelvic fracture. 60% of bladder ruptures 
are extra-peritoneal, 30% intraperitoneal and 10% combined extraperitoneal and 
intraperitoneal.
Urethral .injuries .associated .with .pelvic .fractures
The membranous urethra is injured with roughly the same frequency as the blad-
der in subjects who sustain a pelvic fracture, occuring in 5-15% of such cases. 
Most posterior urethral injuries occur in association with pelvic fractures.
Combined .bladder .and .posterior .urethral .injuries .following .pelvic .fractures
1/3 of patients with a traumatic bladder rupture have injuries to other urinary 
structures, most commonly the urethra. 10-20% of patients with a pelvic fracture 
and bladder rupture also have a posterior urethral rupture.
There are stable, where the fracture can withstand normal physiologic forces and 
unstable fractures, where the fracture cannot withstand normal physiologic forces.
Instability suggests a greater degree of trauma to the pelvis and increases the 
likelihood of serious associated injuries. In addition, fixation of an unstable frac-
ture reduces blood loss, mortality, hospital stay, leg length discrepancy and long-
term disability. It makes nursing care easier and reduces analgesic consumption.
Stability can be defined according to the Tile classification system of pelvic 
ring fractures:
• Type A stable: A1 - fracture of pelvis not involving the pelvic ring and A2 - 
minimal displacement of pelvic ring with no instability;
• “Open book” pelvic fracture (B1) caused by anteroposterior compression. A 
dramatic rise in pelvic volume stretches vessels, nerves and organs. This is hor-
izontally unstable pelvic fracture.
• “Closed book” pelvic fracture (B2 or B3) caused by a lateral compression force 
to the pelvis. The pubic rami fracture and overlap and the ilium and sacral 
wings may be fractured. Nerves and vessels are not stretched, but the urethra 
is more likely to be damaged by scissors like action of overlapping pubic rami. 
This is horizontally unstable pelvic fracture.
• Vertically and horizontally unstable pelvic fracture (C1,C2,C3), where vessels 
and nerves can be damaged by stretching.
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6 4  .BLADDER .INJURIES
Risk .factors
Risk factors are pelvic fracture, rapid acceleration/deceleration injuries with full 
bladder, iatrogenic bladder injuries by gynecologists, TUR, cystolitholapaxy, pen-
etrating trauma to the lower abdomen or back, caesarian section, spontaneous 
rupture after bladder augmentation.
Types .of .perforation
• Intraperitoneal perforation, where the peritoneum overlying the bladder is 
breached allowing urine to escape into the peritoneal cavity;
• Extraperitoneal perforation, where the peritoneum is intact and urine escapes 
into the space around the bladder with pelvic urinoma formation.
The .classic .symptoms .and .signs
• Difficulty or inability in passing urine;
• Suprapubic pain and tenderness if patient has extraperitoneal injury;
• Macrohematuria in patient with cathether;
• Abdominal distension and absent bowel sounds in patient with urine peritonitis 
due to intraperitoneal injury.
Diagnosis
During endoscopic urological operations the diagnosis is usually obvious on visual 
inspection alone. A dark hole is seen in the bladder and loops of bowel may be 
seen on the other side. No further diagnostic tests are required.
Abdominal/pelvic CT detects presence/absence of associated pelvic and ab-
dominal organ injury.
In pelvic fracture patients, if there is no blood present at the meatus, a gentle attempt 
at urethral catheterization may be made to do a retrograde cystogram, assess integrity 
of the bladder and detects signs of extraperitoneal or intraperitoneal bladder rupture.
Retrograde or CT cystography
The bladder must be adequately distended with a contrast. With inadequate dis-
tension a clot, omentum or small bowel may block the perforation, which may not 
therefore be diagnosed. At least 350-400 ml of contrast is used in an adult. Images 
are obtained before and after the contrast agent has been completely drained from 
the bladder (a post-drainage film). A whisper of contrast from a posterior perfo-
ration may be obscured by a bladder distended with contrast. In extraperitoneal 
perforations extravasation of contrast is limited to the immediate area surrounding 
the bladder. In intraperitoneal perforations, loops of bowel may be outlined by 
the contrast.
Treatment
Extraperitoneal bladder injuries are treated with a urethral catheter for ~2-3 weeks 
followed by a cystogram to confirm the perforation has healed.
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Indications for surgical repair of extraperitoneal bladder perforation:
• If the bladder is opened to place a suprapubic catheter for a urethral injury;
• A bone protruding into the bladder on CT;
• Associated rectal, vaginal or ureteral perforations;
• Where the patient is undergoing open fixation of a pelvic fracture, the bladder 
can be simultaneously repaired.
Intraperitoneal bladder injuries usually repaired surgically to prevent complica-
tions from urine peritonitis.
6 5  .URETHRAL .INJURIES
6 5 1  .Posterior .urethral .injuries .in .males
Mechanisms
• External, blunt: pelvic fracture, road traffic accidents, falls from a height, crush injury;
• External, penetrating: gunshot or stab wounds;
• Internal, iatrogenic: endoscopic surgery or radical prostatectomy;
• Internal, self-inflicted: foreign bodies inserted into urethra.
Symptoms .and .signs
Blood at meatus in 1/2 of patients. Next will be AUR and urinoma formation in 
pelvic cavity. In patients with partial injury may be hematuria. Perineal or scrotal 
bruising and edema may be observed by patients with urethral injury.
“High riding” prostate is palpated. The prostate and bladder become detached 
from the membranous urethra and are pushed upwards by the expanding pelvic 
urohematoma. The “high riding” prostate is said to be a classic sign of posterior 
urethral rupture. Traditional teaching states that a DRE should be done in cases 
of pelvic trauma to determine prostatic position. The pelvic hematoma may make 
it impossible to feel the prostate, so the patient may be thought to have a “high 
riding” prostate when, in fact, it is in a normal position. Conversely, what may 
be thought to be a normal prostate in a normal position may actually be the pal-
pable pelvic hematoma. In pelvic fracture, a DRE is done not to identify a “high 
riding” prostate, but rather to establish the presence of an associated rectal injury, 
where there is blood seen on the examining finger. However, rectal injury can still 
occur in the absence of rectal blood.
Diagnosis
Retrograde urethrography
This investigation detects urethral injury. Urethral injury is suspected in all pelvic 
fracture patients, where the pubic rami have been disrupted and there is blood at 
the meatus. 
Rules of retrograde urethrogram are presented below. This is aseptic technique. 
Position the patient at an oblique angle. Bottom leg flexed at the hip and knee. 
A 12-14 Ch catheter is placed in the fossa navicularis of the penis 1-2 cm from 
the external meatus, with the catheter balloon with 2 ml of water or with a pe-
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nile clamp applied to prevent contrast spilling out of the urethra and to hold the 
catheter in place. Continuous X-Ray imaging is done as contrast is instilled until 
the entire length of the urethra is demonstrated. Remember, as the membranous 
urethra passes through the pelvic floor, there is a normal narrowing and similarly 
the prostatic urethra is narrower than the bulbar urethra.
Treatment
Immediate open repair of posterior urethral injuries is not recommended and asso-
ciated with a high incidence of urethral strictures and subsequent re-stenosis after 
stricture repair, incontinence and impotence. The surrounding hematoma and tissue 
swelling makes it difficult to identify structures and to mobilize the two ends of the 
urethra to allow tension-free anastomosis. Immediate repair over urethral catheter is 
indicated where there is an only open wound.
One gentle attempt is performed to place a urethral catheter in suspected ure-
thral disruption. If any resistance is encountered, a retrograde urethrogram is 
indicated. If there is a urethral rupture, insert a suprapubic catheter via a formal 
open approach, to allow inspection of the bladder and repair of bladder injury.
Placement of the suprapubic catheter via an open approach is generally better 
than a percutaneous approach, because it allows inspection of the bladder for 
associated injuries which may require repair, but also because the catheter may 
inadvertently be placed into the large pelvic hematoma which always accompanies 
such fractures. In this case suprapubic can act as a potential source of infection of 
the pelvic hematoma, which can lead to life-threatening urosepsis.
In the majority of male posterior urethral injuries, treatment should be deferred 
for 3 months to allow the edema and hematoma to completely resolve. As this oc-
curs, the two distracted ends of the urethra come closer together, thereby reducing 
the amount of mobilization. Most such injuries can be repaired by an anastomotic 
urethroplasty. Optical urethrotomy using an endoscopic knife or laser, via a cysto-
scope inserted into the urethra is performed rare and has little benefit.
Management of combined urethral and bladder injuries associated with pelvic fractures:
• If a urethral catheter can be passed and a cystogram shows an extraperitoneal blad-
der rupture, a catheter will be in place until the bladder has healed (2-3 weeks).
• If a urethral catheter cannot be passed, because of a complete urethral rupture, 
a open cystostomy should be performed to allow inspection of the bladder and 
repair if the bladder has been injuried.
6 5 2  .Anterior .urethral .injuries .in .males
Mechanisms
• External, blunt: straddle injury by forceful contact of perineum with bicycle 
cross-bar. Most common bulbar urethra being crushed against pubic bone. Also 
may be kick to perineum and/or penile fracture.
• External, penetrating: gunshot and stab wounds;
• Internal, iatrogenic: inflated catheter balloon, endoscopic surgery, penile surgery.
• Internal, self-inflicted: foreign bodies inserted into urethra.
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Symptoms .and .signs
The patient usually presents with difficulty in passing urine and frank hematuria in 
the context of a straddle injury. Blood may be present at the end of the penis and 
a hematoma around the site of the rupture.
If the deep layer of the superficial fascia of the penis (Buck’s fascia) has been 
ruptured, urine and blood track into the scrotum causing swelling and a “butterfly 
wing” pattern of bruising, reflecting the anatomical attachments of Colles fascia.
Extravasation of urine can create a collection of urine around the urethra. This 
urinoma generates an inflammation, with subsequent stricture formation. Superadded 
infection can lead to abscess formation, which may burst onto the surface of the skin 
leading to a urethrocutaneous fistula. More rarely, Fournier’s gangrene supervenes.
Diagnosis
Retrograde urethrography delineates the extent of urethral injury.
Treatment
Urinary diversion with urethral or suprapubic catheter prevents further extravasa-
tion of urine and antibiotics may reduce the likelihood of superadded infection.
If there is anterior urethral contusion, but no extravasation of contrast on retro-
grade urethrogram a small urethral catheter (12 Ch) is inserted for 1 week.
Partial rupture of anterior urethra
This is leak of contrast from urethra with retrograde flow into bladder. Most can be 
managed by a period of suprapubic or urethral catheterization and heal without stric-
ture formation. Primary closure can be difficult because of edema and of hematoma at 
site of injury. A broad spectrum antibiotics are used to prevent infection of extravasated 
urine and blood. If a voiding cystogram 2 weeks later confirms urethral healing, supra-
pubic catheter is removed. If contrast still extravasates, leave it in place a little longer.
Suprapubic catheterization is preferred over urethral catheterization. If the 
bladder cannot be palpated, such that a suprapubic catheter cannot safely be in-
serted, then open suprapubic cystostomy is performed.
Complete rupture of anterior urethra
This is diagnosed, if there is lak of contrast from urethra on retrograde urethro-
gram, no filling of the posterior urethra or bladder. The urethra may either be 
immediately repaired or a suprapubic catheter can be placed with delayed repair.
Penetrating partial and complete anterior urethral injuries
Immediate surgical repair of anterior urethral injuries is only done in the context 
of penile fracture or where there is an open wound. If there is knife or gunshot 
wound, primary repair is recommended. Suprapubic diversion and subsequent 
repair may be indicated.
6 5 3  .Urethral .injuries .in .females
Rare, because the female urethra is short and its attachments to the pubic bone 
are weak, such that it is less prone to tearing during pubic bone fracture. When 
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they do occur, such injuries are usually associated with rectal or vaginal injuries. In 
developing countries, prolonged labour can cause ischaemic injury to the urethra 
and bladder neck, leading to urethrovaginal or vesicovaginal fistula formation.
6 6  .TESTICULAR .INJURIES
Mechanisms
There are blunt or penetrating injurues. Most in civilian practice are blunt, a 
blow forcing the testicle against the pubis or the thigh. Bleeding occurs into the 
parenchyma of the testis and if sufficient force is applied, the tunica albuginea 
of the testis is ruptured, allowing extrusion of seminiferous tubules and hemato-
cele formation. Penetrating injuries occur as a consequence of gunshot and knife 
wounds and from bomb blasts. Associated limb, perineal, pelvic, abdominal and 
chest wounds may occur.
Symptoms .and .signs
Where bleeding is confined by the tunica vaginalis, a hematocele is present. Intrat-
esticular hemorrhage and bleeding beneath the parietal layer of tunica vaginalis will 
cause the testis to enlarge slightly. The testis may be under great pressure as a con-
sequence of the intra-testicular hemorrhage confined by the tunica vaginalis. This 
can lead to ischaemia, necrosis and atrophy of the testis.
Severe pain is common, as are nausea and vomiting. If the testis is surrounded 
by hematoma it will not be palpable. If it is possible to palpate the testis, it is usu-
ally very tender. The resulting scrotal hematoma can be very large and the bruising 
and swelling so caused may spread into the inguinal region and lower abdomen.
Testicular .ultrasound .in .cases .of .blunt .trauma
A normal parenchymal echo pattern suggests there is no significant testicular in-
jury. Hypoechoic areas within the testis, indicating intraparenchymal hemorrhage, 
suggests testicular rupture. US will show hematocele.
Treatment
If patient has testicular rupture, exploration allows evacuation of the hematoma, 
excision of extruded seminiferous tubules and repair of the tear in the tunica al-
buginea. If patient has penetrating trauma, exploration allows repair to damaged 
structure.
6 7  .PENILE .INJURIES
6 7 1  .Penile .amputation
Blood loss can be severe. The shocked patient is resusciteted and cross-match of 
blood is performed. The penis is placed in a wet swab inside a plastic bag, which is 
then inserted inside another bag containing ice. It can survive for 24 hours.
By knife and gunshot wounds associated injuries are common. Most injuries, 
other than minor ones, should undergo primary repair. Debris is removed from 
wound, necrotic tissues are debrided and repair as for penile fractures is performed.
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Surgical reimplantation of amputated penis
By penile amputation the urethra s repaired first, over a catheter, to provide a sta-
ble base for subsequent neurovascular repair. The tunica albuginea of the corpora 
is closed with 4/0 absorbable suture. The dorsal artery of the penis is anastomosed 
with 11/0 nylon, then the dorsal vein with 9/0 nylon to provide venous drainage 
and, finally, the dorsal penile nerve with 10/0 nylon.
6 7 2  .Penile .fracture
This is rupture of the tunica albuginea of the erect penis. May be rupture of one 
or both corpora cavernosa ± rupture of corpus spongiosum with rupture of the 
urethra. The tunica albuginea is 2 mm thick in the flaccid penis. It thins during 
erection and is therefore vulnerable to rupture if the penis is forcibly bent during 
vigorous sexual intercourse.
Symptoms .and .signs
The patient usually reports a sudden “snapping” or “popping” sound and/or sen-
sation, with sudden penile pain and detumescence of the erection.
The penis is swollen and brusied, sometimes resembling an aubergine. If Buck’s 
fascia has ruptured, bruising extends onto the lower abdominal wall and into the 
perineum and scrotum. A tender, palpable defect may be felt over the site of the 
tear in the tunica albuginea. If the urethra is damaged, there may be blood at the 
meatus, hematuria and pain on voiding or urinary retention. Retrograde urethro-
gram is performed in such cases.
Treatment
Surgical repair is indicated due to lower complication rate e.g. reduced penile 
deformity, less chance of penile scar tissue and prolonged penile pain.
Surgical repair of penile fracture
The fracture site is exposed by degloving the penis via a circumcising incision 
around the subcoronal sulcus. A degloving incision allows better exposure of the 
urethra for associated urethral injuries and excellent exposure of both corpora 
cavernosa so that an unexpected bilateral injury can be repaired easily. Defect 
is closed in the tunica with absorbable sutures or by non - absorbable sutures. A 
urethral catheter is used for 1-2 days. Urethral rupture is repaired with a spatulated 
single or two-layer urethral anastomosis with a urethral catheter for 3 weeks. In 
postoperative period conservative treatment is used: application of cold compress-
es to the penis, analgesics and NSAIDs, abstinence from sexual activity for 6-8 
weeks to allow healing.
7 1  .ACUTE .URINARY .RETENTION
7 1 1  .Aсute .urinary .retention .in .male
This is painful inability to void, with relief of pain following drainage of the blad-
der by catheterization. Central to the diagnosis is the presence of a large volume 
of urine, which when drained by catheterization, leads to resolution of the pain. 
What represents “large” has not been strictly defined, but volumes of 500-800 ml 
are typical. Volumes <500 ml should lead one to question the diagnosis. Volumes 
>800 ml may be defined as acute-on-chronic retention.
Four broad mechanisms can lead to urinary retention:
• Increased urethral resistance (BOO);
• Low bladder pressure (i.e. impaired bladder contractility);
• Interruption of sensory or motor innervation of bladder;
• Central failure of coordination of bladder contraction with external sphincter 
relaxation.





Urinary retention in men is either spontaneous or precipitated by an event. Pre-
cipitated retention is less likely to recur once the event which caused it has been 
removed. Spontaneous retention is more likely to recur after TWC and therefore 
to require definitive treatment. Precipitating events include anaesthetic and oth-
er drugs (anticholinergics, sympathomimetic agents), non-prostatic abdominal or 
perineal surgery, immobility following surgical procedures, alcohol abuse.
Causes in either sex:
• Blood clots retention;
• Post-operative retention;
• Radical pelvic surgery damaging pelvic parasympathetic plexus;
• Pelvic fracture rupturing urethra;
• Neurogenic bladder (multiple sclerosis, transverse myelitis, diabetic cystopathy) 
• Spinal cord injuries (prolapsed discs, trauma, benign or metastatic tumours)
Causes in women:
• Pelvic prolapse (cystocele, rectocele);
• Urethral stricture;
• Urethral diverticulum;





Urethral catheterization is performed to relieve pain. Suprapubic catheterization 
is indicated if urethral route not possible. The volume drained is recorded. This 
confirms the diagnosis, determines subsequent management and provides prog-
nostic information with regard to outcome from this treatment. TWC is indicated. 
Urethral catheter for 3 days is inserted and alpha – blockers are used. Precipitated 
retention often does not recur. Spontaneous retention often does. 50% with spon-
taneous retention will experience a second episode of retention within the next 
week or so and 70% within the next year. Qmax <5ml/s and low voiding detrusor 
pressure predict subsequent retention. Thus, while most will require TUR or open 
operation, a substantial minority will get away without needing surgery. If there is 
success with TWC prostate shrinking drugs are used several months later. 5 ARIs 
are indicated for BPH patients. LHRH agonists are used in those with malignant 
prostates. If patient has CRF suprapubic catheter for several months is indicated. 
Most patients will require second operation (TUR or open prostatectomy).
Indications:
• Relief of urinary retention;
• Prevention of urinary retention in the postoperative period;
• Post-operative monitoring of urine output;
• Prevention of damage to the bladder during caesarian section;
• Bladder drainage following surgery to the bladder, prostate or urethra.
Technique is described below. Usually a 16-20Ch catheter is used, with a 10 ml 
balloon. For longer catheterization periods a silastic catheter is used to limit tissue 
reaction, thereby reducing risk of a catheter-induced urethral stricture. If there is 
clot retention, a 3 way catheter (22-24Ch or greater) is used to allow evacuation 
of clots and bladder irrigation to prevent subsequent catheter blockage. One gloved 
hand holds penis or separates labia to allow cleansing of urethral meatus. Sterile 
cleaning solution to prepare skin around meatus is used. Lubricant jelly is ap-
plied to urethra. Traditionally this contains local anaesthetic (e.g. 2% lignocaine), 
sterile glycerin and antiseptic which takes between 3-5 min to work. In male, gel 
is injected towards posterior urethra, while squeezing meatus to prevent it from 
coming back out of meatus. The catheter is inserted using another sterile hand, 
until flow of urine to confirm it is in bladder. Failure of urine flow may indicate 
that the catheter balloon is in the urethra. Intra-urethral inflation of balloon can 
rupture urethra. If no urine flows attempt aspiration of urine using a 50 ml bladder 
syringe. Absence of urine flow indicates either catheter is not in the bladder or 
there is anyria. If the catheter will not pass into the bladder and you are sure that 
the patient is in retention, proceed with suprapubic catheterization.
Suprapubic catheterization
Indications:
• Failed urethral catheterization in urinary retention;
• Preferred site for long-term catheters.
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Contraindications:
• Patients with clot retention, the cause of which may be an underlying bladder 
cancer;
• Patients with lower midline incisions (bowel may be fixed to the deep aspect of 
the scar, leading to the potential for bowel perforation);
• Pelvic fractures, where the catheter may inadvertently enter the large pelvic 
hematoma which always accompanies severe pelvic fracture. This can lead to 
infection of the hematoma and the resulting urosepsis can be fatal. Failure to 
pass a urethral catheter in a patient with a pelvic fracture usually indicates a 
urethral rupture confirmed by urethrography and is an indication for formal 
open, suprapubic cystotomy.
Technique is described below. Prior to insertion of trocar, be sure to confirm 
the diagnosis by abdominal examination. Palpation and percussion of lower ab-
domen are performed to confirm bladder is distended. US confirms diagnosis and 
US guided catheterization may be sensible. Wide-bore trocar is used. The catheter 
is inserted about 2 finger-breadths above the pubis symphysis. A few ml of local 
anaesthetic is instilled into skin of intended puncture site and down to rectus 
sheath. Location of bladder by aspiration of urine from bladder is confirmed. A 
1cm incision with a sharp blade through the skin is performed. Hold trocar handle 
in your right hand and steady needle end with your left hand. This hand helps 
prevent insertion too deeply. As soon as urine issues from the trocar, withdraw the 
latter, holding the attached sheath in place. Push the catheter in as far as it will 
go. Balloon is inflated. The sides of the sheath are removed.
7 1 2  .Bladder .outlet .obstruction .and .retention .in .women
It may be symptom-free and present with LUTS or as AUR. The causes are related 
to obstruction of the urethra (urethral stricture, compression by a prolapsing pelvic 
organs, post-surgery for stress incontinence) or have a neurological basis (injury to 
sacral cord or parasympathetic plexus, degenerative neurological disease e.g. MS, 
diabetic cystopathy).
Women have a higher Qmax, for a given voided volume, than do men. Women 
with BOO have lower Qmax than those without BOO.
By BOO in women the cause is treated. Where this it is not possible (because 
of a neurological cause), the options are:
• In woman CISC either until normal voiding function recovers or permanently 
if it does not;
• Indwelling catheter (preferably suprapubic rather than urethral);
• Mitrofanoff catheterizable stoma.
Where urethral CISC is technically difficult, a catheterizable stoma can be construct-
ed between the anterior abdominal wall and the bladder, using the appendix, Fallopian 
tube or a narrowed section of small intestine as a so called Mitrofanoff procedure.
It is simply a new urethra which has an abdominal location, rather than a per-
ineal one and is therefore easier to access for CISC.
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7 2  .TORSION .OF .THE .TESTIS .AND .TESTICULAR .APPENDAGES
A testicular torsion is a twist of the spermatic cord resulting in strangulation of 
the blood supply to the testis and epididymis. Testicular torsion occurs most fre-
quently between the ages 13-15 years of age, but any age group may be affected.
Symptoms .and .signs
Sudden onset of severe pain in the hemiscrotum, sometimes waking the patient 
from sleep. It may radiate to the groin, loin or epigastrium. There is sometimes a 
history of minor trauma to the testis. Some patients report previous episodes with 
spontaneous resolution of the pain. The testis is usually slightly swollen and very 
tender to touch. It may be “high- riding” and lying at a higher than normal posi-
tion in the testis and may be in a horizontal position due to twisting of the cord.
Differential .diagnosis .and .investigations
Epididymo-orchitis, torsion of a testicular appendage and testicular injuries are 
most common cases of “acute scrotum” syndrom. Colour doppler US with detec-
tion of reduced arterial blood flow in the testicular artery can be used to diagnose 
testicular torsion, but in many hospitals this test are not readily available and the 
diagnosis is based on symptoms and signs.
Emergent .surgical .management
Scrotal exploration should be undertaken as a matter of urgency. >6 hours of 
delay in relieving the twisted testis results in permanent ischaemic damage to the 
testis causing atrophy, loss of hormone and sperm production and, as the testis 
undergoes necrosis and the blood - testis barrier breaks down, an autoimmune 
reaction against the contralateral testicular tussue. Both testes are fixed since the 
“bell-clapper” abnormality which predisposes to torsion can occur bilaterally.
Torsion .of .testicular .appendages
The appendix of testis (hydatid of Morgagni a remnant of the Mullerian duct) 
and the appendix of epididymis (a remnant of a cranial mesonephric tubule of the 
Wolffian duct) can undergo torsion causing pain that mimicks a testicular torsion. 
At scrotal exploration they are easily removed with scissors or a diathermy probe.
7 3  .PARAPHIMOSIS
This is emergent situation, where the foreskin is retracted from over the glans of the 
penis, becomes edematous and cannot then be pulled back over the glans into its 
normal anatomical position. It occurs most commonly in teenagers or young men 
and also in elderly men, who have had the foreskin retracted during catheterization, 
but where it has not been returned to its normal position. Paraphimosis is usually 
painful. The foreskin is edematous and a small area of ulceration of the foreskin 
may have developed.
Treatment
The “iced-glove” method: topical lignocaine gel is applied to the glans and foreskin 
for 5 min. The penis is invaginated into the thumb of the glove and the edematous 
UROLOGY 119
paraphimosis is compressed. Squeeze the edema fluid out of the foreskin. This may 
reduce the swelling and allow reduction of the foreskin. Foreskin is returned to its 
normal position.
The Dundee technique is described below. A ring block is applied to the base 
of the penis using a 26G needle and 10-20 ml of 0.5% plain bupivicaine. Children 
usually require general anaesthesia. The skin of the foreskin and the glans is cleaned 
with cleaning solution. Using a 25G needle make approximately 20 punctures into 
the edematous foreskin. Squeeze the edema fluid out of the foreskin and return to its 
normal position. Approximately 1/3 of patients subsequently will require circumcision 
for an underlying phimosis.
If this fails, the traditional surgical treatment is a dorsal slit under general an-
aesthetic or ring block. A longitudinal incision is made in the tight band of con-
stricting tissue and the foreskin pulled back over the glans. The incision is closed 
transversely to lengthen the circumference of the foreskin and prevent recurrences.
7 4  .MALIGNANT .URETERIC .OBSTRUCTION
Locally advanced PC, bladder or ureteric cancer may cause unilateral or bilateral 
ureteric obstruction. Locally advanced non - urological malignancies (cervical 
cancer, rectal cancer, lymphoma) can also obstruct the ureters.
Unilateral obstruction is often asymptomatic. An incidental US finding that 
requires no specific treatment in the presence of a normal contralateral kidney. 
Occasionally, loin pain and systemic symptoms may develop due to infection 
of the obstructed upper urinary tract. In this circumstance, drainage by PNS or 
stenting is required.
Bilateral ureteric obstruction is a urological emergency. The patient presents 
with symptoms and signs of renal failure and has anuria.
Renal US will demonstrate bilateral UHN and an empty bladder. CT urography 
will confirm the presence of dilated ureters down to a mass at the bladder base.
Treatment
After treating any life-threatening hyperkalaemia, options include bilateral PNS 
or ureteric stenting. A clotting screen is required prior to nephrostomy insertion. 
Insertion of retrograde ureteric stents in this setting is usually unsuccessful because 
tumour involving the trigone obscures the location of the ureteric orifices. More 
successful is antegrade ureteric stenting following PNS tube insertion. The full-
length double-J silicone or polyurethane ureteric stents require periodic changes 
to prevent calcification or blockage.
Such emergent situations as renal colic, hematuria and anyria are discussed in 
other chapters.
Definitions
UTI is defined as the inflammatory response of the urothelium and tissue to bac-
terial invasion. This inflammatory response causes many symptoms, depending on 
what organ is inflamed (urethritis, cystitis, prostatitis, pyelonephritis...) or there is 
urosepsis with/without septic shock. The strict requirement for >105 bacteria/ml of 
urine is no longer required to make a diagnosis of UTI. In symptomatic patients 
many clinicians will now make a diagnosis of UTI with bacterial counts of >102/
ml. The low counts are due to irritation and frequent voiding caused by the infec-
tion and also represent the slow doubling time of acteria in urine.
An uncomplicated UTI is one occurring in a patient with a structurally and 
functionally normal urinary tract. The majority of such patients are women who 
respond quickly to a short course of antibiotics.
A complicated UTI is one occurring in the presence of an underlying anatomical 
or functional abnormality: functional problem causing incomplete bladder emptying 
(BOO), urinary stone disease, fistulas. Most UTIs in men occur in association with a 
structural or functional abnormality and are therefore defined as complicated UTIs. 
Complicated UTIs take longer to respond to antibiotic treatment than uncomplicated 
UTIs and they need removing of the underlying anatomical or structural abnormality.
Bacteriuria is the presence of bacteria in the urine. Bacteriuria may be asymp-
tomatic or symptomatic. Bacteriuria without pyuria indicates the presence of bac-
terial colonization of the urine, rather than the presence of active infection. Active 
implies an inflammatory response to bacterial invasion of the urothelium. Risk 
factors for bacteriuria: female sex, increasing age, low oestrogen states, pregnancy, 
DM, previous UTIs, indwelling catheters, stone disease, genitourinary malforma-
tion and obstruction.
Pyuria is the presence of WBC in the urine, implying an inflammatory response 
of the urothelium to bacterial infection or, in the absence of bacteriuria, some 
other pathology such as CIS , TB infection, bladder stones or other inflammatory 
conditions.
Isolated UTI: an interval of at least 6 months between infections.
Recurrent UTI: >2 infections in 6 months or 3 within 12 months. Recurrent 
UTI may be due to reinfection with infection by a different bacteria or bacte-
rial persistence with infection by the same organism originating from a focus 
within the urinary tract. Bacterial persistence is caused by the presence of 
bacteria within struvite calculi, within a chronically infected prostate, within 
an obstructed or atrophic infected kidney, occurs as a result of a vesicovaginal 
fistula or urethral diverticulum.
Etiology .and .microbiology
Most UTIs are bacterial and are caused by faecal-derived bacteria which are facul-
tative anaerobes, and can grow under both anaerobic and non-anaerobic conditions.
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The most common cause by uncomplicated UTIs is Escherichia coli (E. coli), 
a gram-negative bacillus, which accounts for 85% of community acquired and 
50% of hospital acquired infection. Other common causative organisms include 
Staphylococcus saprophyticus and Streptococcus faecalis (gram-positive), Neisse-
ria (gram-negative cocci).
By complicated UTI E. coli is responsible for up to 50% of cases. Other causes 
include Streptococcus faecalis, Staph. aureus, Staph. epidermidis (gram positive).
Nosocomial infections are: gram-negative Enterobacteria (Escherichia, Klebsi-
ella, Proteus), Pseudomonas aeruginosa.
Anaerobic infections of the bladder and kidney are uncommon. Anaerobes 
are normal commensals of the perineum, vagina and distal urethra. However, 
infections of the urinary system which produce pus (e.g. scrotal, prostatic or per-
inephric abscesses) are often caused by anaerobic organisms (e.g. Bacteroides 
species such as Bacteroides fragilis, Fusobacterium species, anaerobic cocci and 
Clostridium perfringens).
Other etiological factors: 
• Mycobacterium (M. tuberculosis acid-fast, aerobic, gram-positive);
• Chlamydia trachomatis;
• Candida albicans;
• Mycoplasma: Mycoplasma species and Ureaplasma urealyticum, which cause 
UTIs in patients with indwelling catheters and STD.
Route .of .infection
The vast majority of UTIs result from infection ascending retrogradely up the ure-
thra. The bacteria, derived from the large bowel, colonize the perineum, vagina and 
distal urethra. They ascend easily along the female urethra to the bladder causing 
cystitis and from the bladder they may ascend, via the ureters, to involve the kid-
neys. Presence of VUR will encourage ascending infection, as will any process that 
impairs ureteric peristalsis (e.g. ureteric obstruction, microorganisms, pregnancy). 
Infection which ascends to involve the kidneys is also more likely where the in-
fecting organism has factors increasing bacterial virulence - pili or fimbriae, which 
allow binding of bacteria to the surface of epithelial cells. There are many other 
factors of bacteria to avoid host defense mechanisms (toxins, enzyms).
Haematogenous route of infection is uncommon, but is seen with Staph. aureus, 
Candida and TB.
Infection via lymphatics is seen rarely in inflammatory bowel disease and ret-
roperitoneal abscess.
Host .defences
Factors which protect against UTIs are:
• Mechanical flushing effect of urine through the urinary tract;
• A mucopolysaccharide coating of bladder (Tamm - Horsfall protein) helps 
prevent bacterial attachment;
• Low urine pH and high osmolarity reduces bacterial growth;
• Urinary immunoglobulin (IgA) inhibits bacterial adherence.
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8 1  .CYSTITIS
This is infection and/or inflammation of the bladder. Cystits may be also due to 
pelvic radiotherapy as a radiation cystitis Bladder capacity by radiation cystitis 
is reduced and multiple areas of mucosal telangectasia are seen cystoscopically. 
Inflammation of the bladder may be as a drug-induced cystitis. Haemorrhagic 
cystitis may be as consequence of viral (Herpes zoster) infection.
Symptoms
Symptoms are: frequent voiding of small volumes, dysuria (urethral burning 
on voiding), urgency, claudy urine, suprapubic pain or discomfort, hematuria.
Diagnosis
Urinanalysis
Leukocyte esterase activity detects the presence of WBS in the urine with help of 
dipstick. Leukocyte esterase is produced by neutrophils and causes a colour change 
in a chromogen salt on the dipstick. Remember, there are many causes for pyuria 
and therefore a positive leukocyte esterase test occurring in the absence of bacteria 
on urine microscopy. This is so-called sterile pyuria and it occurs with TB infec-
tion, urinary stone disease, glomerulonephritis, interstitial cystitis, CIS. Thus, the 
leukocyte esterase dipstick test may be truly positive, in the absence of infection.
Nitrite testing
Nitrites are not normally found in urine and their presence suggests the pos-
sibility of bacteriuria. Many species of gram-negative bacteria can convert ni-
trates to nitrites and these are detected in urine by a reaction with the reagents 
on the dipstick. The specificity of the nitrite dipstick for detecting bacteriuria 
is >90%. Less accurate test may be in urine containing fewer than 105 organ-
isms/ml. So, if the nitrite dipstick test is positive, the patient probably has a 
UTI, but a negative test often occurs in the presence of infection.
Cloudy urine which is positive for WBCs on dipstick and is nitrite positive is 
very likely to be infected.
If this is a first episode of cystitis in an otherwise healthy individual, no further 
investigations are required. However, further investigations are required if:
• The patient develops symptoms and signs of upper tract infection (loin pain, 
malaise, fever) and therefore acute pyelonephritis, a pyonephrosis or peri-
nephric abscess is suspected;
• Recurrent UTIs develop;
• The patient is pregnant;
• Unusual infecting organism (e.g. Proteus), suggesting the possibility of an in-
fection stone or NSI
These further investigations will include a renal US in pregnant women and 
KUB X-ray or CT.
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Treatment
The aim is to eliminate bacteria from the urine. Empirical treatment involves the 
administration of antibiotics according to the clinical presentation and most likely 
causative organism, before culture sensitivities are available. Once urine or blood 
culture results are available, antimicrobial therapy should be adjusted according to 
bacterial sensitivities. Men are often affected by complicated UTI and may require 
imaging and longer treatments. Underlying abnormality should be corrected if 
feasible: extraction of infected calculus, removal of catheter, PNS of an infected 
or obstructed kidney.
There is one big problem: bacterial resistance to drug therapy. Organisms sus-
ceptible to concentrations of an antibiotic in the urine (or serum) after the rec-
ommended clinical dosing are termed “sensitive” and those that do not respond 
are “resistant”.
Recommended antimicrobial therapy in acute uncomplicated cystitis in pre-
menopausal women (EAU 2014)
Antibiotics → Daily dose → Duration of therapy
• Fosfomycin trometamol 3 g SD 1 day;
• Nitrofurantoin 50 mg q6h 7 days;
Alternatives
• Ciprofloxacin 250 mg bid 3 days;
• Levofloxacin 250 mg qd 3 days;
• Norfloxacin 400 mg bid 3 days;
• Ofloxacin 200 mg bid 3 days;
If local resistance pattern is known (E. coli resistance <20%)
• Trimethoprim-sulphamethoxazole 160/800mg bid 3 days;
• Trimethoprim 200 mg bid 5 days.
8 2  .URETHRITIS
This is inflammation of the urethra. Urethritis in men is a STD, which presents 
with dysuria and urethral discharge.
GU is caused by the gram-negative dipplococcus Neisseria gonorrhoea. Diag-
nosis is on cultures from urethral swab. Treatment involves a single dose of III- IV 
generation of cephalosporin (ceftriaxone or cefotaxime) or course of ciprofloxacin. 
Sexual contacts must be informed and treated.
NGU is mainly caused by Chlamydia trachomatis and Mycoplasma. Acute 
NGU is treated with a single dose of azithromycin, 7-10 days of doxycycline or 
macrolides. Transmission to females results in increased risk of pelvic inflamma-
tory disease, abdominal pain, ectopic pregnancy, infertility and perinatal infection. 
If NGU caused by Trichomonas vaginalis metronidazole is used. 
Urethral .syndrome
This is a condition of uncertain etiology that only affects women. It manifests 
as dysuria, frequency and urgency without evidence of infection, although some 
cases improve with antibiotics.
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8 3  .RECURRENT .URINARY .TRACT .INFECTION
Recurrent UTI is defined as >2 UTIs in 6 months or 3 within 12 months. It may 
be due to reinfection with infection by a different bacteria or bacterial persistence 
with infection by the same organism originating from the urinary tract
Re-infections
Usually occur after a prolonged interval from the previous infection and are often 
caused by a different organism than the previous infecting bacterium.
Women with reinfection do not usually have an underlying functional or ana-
tomical abnormality. Re-infections in women are associated with increased vag-
inal mucosal receptivity for uropathogens and ascending colonization of faecal 
flora from the perineum. 
Men with re-infection may have underlying BOO, which makes them more 
likely to develop a repeat infection, but between UTIs their urine is sterile. A ure-
throgram, US, cystoscopy, bladder US for PVR and, in some cases, urodynamics 
may be helpful in establishing the potential causes.
Bacterial .persistence
Bacterial persistence usually leads to frequent recurrence of infection within days 
or weeks and the infecting organism is usually the same organism as that causing 
the previous UTIs.
Presence of bacteria within a site in the urinary tract leads to repeated episodes 
of UTIs. Such sites include kidney stones, chronic bacterial prostatitis, bacteria 
within an obstructed or atrophic infected kidney, bacteria gaining access to the 
urinary tract via a fistula, bacteria within a urethral diverticulum.
As stated above, both men and women with bacterial persistence usually have 
an underlying functional or anatomical abnormality and they can potentially be 
cured of their recurrent UTIs, if this abnormality can be identified and corrected.
Management .of .women .with .recurrent .UTIs .due .to .re-infection
Most urologists will arrange a series of screening tests (KUB X-ray, renal US, 
cystoscopy) to double check there is no potential source of bacterial persistence.  
In the absence of finding an underlying functional or anatomic abnormality, 
these patients cannot be cured of their tendency to recurrent UTIs, but they can 
be managed in one of the following ways:
• Avoidance of spermicides used with the diaphragm or on condoms. Spermi-
cides reduce vaginal colonization with lactobacilli and may enhance E. coli ad-
herence to urothelial cells. Alternative form of contraception is recommended.
• Lack of estrogen in post-menopausal women causes loss of vaginal lactoba-
cilli and increased colonization by E.coli. Estrogen replacement can result in 
recolonization of the vagina with lactobacilli and eliminate colonization with 
bacterial uropathogens.
• Low-dose antibiotic prophylaxis. Oral antimicrobial therapy causes resistant 
strains in the faecal flora and subsequent resistant UTIs. However, trimetho-
prim, nitrofurantoin, low-dose cephalexin and the fluoroquinolones have a 
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minimal adverse effects on the faecal and vaginal flora. Prophylactic therapy 
requires only a small dose of an antimicrobial agent, generally given at bedtime 
for 6 to 12 months. Symptomatic reinfection during prophylactic therapy is 
managed with a full therapeutic dose with the same prophylactic antibiotic or 
another antibiotic. Prophylaxis can then be restarted. Symptomatic reinfection 
immediately after cessation of prophylactic therapy is managed by restarting 
nightly prophylaxis. 
• Sexual intercourse has been established as an important risk factor for acute 
cystitis in women and women who use the diaphragm have a significantly 
greater risk of UTI than women who use other contraceptive methods. Post-in-
tercourse therapy with antimicrobials such as nitrofurantoin or trimethoprim, 
taken as a single dose, effectively reduces the incidence of reinfection.
• Self-start therapy. Women keep a home supply of an antibiotic (e.g. trimetho-
prim, nitrofurantoin, a fluoroquinolone) and start treatment when they develop 
symptoms suggestive of UTIs.
Management .of .men .and .women .with .recurrent .UTIs .due .to .bacterial .
persistence
Investigations for identifying the potential causes of bacterial persistence:
• KUB X-ray to detect radio-opaque renal calculi;
• Renal US to detect hydronephrosis and renal calcul;
• Determination of PVR by bladder US;
• IVU or CT where a stone is suspected, but not identified on plain X-ray or US;
• Cystoscopy to identify possible causes of recurrent UTIs such as bladder stones, 
an underlying bladder cancer, urethral or bladder neck stricture or fistula.
Treatment of bacterial persistence depends on the functional or anatomical 
abnormality which is identified as the cause. If a stone is identified, this should be 
removed and if there is obstruction, this should be corrected.
8 4  .PYELONEPHRITIS
8 4 1  .Acute .pyelonephritis
There are many rsk factors: VUR, urinary tract obstruction, stone disease, neu-
rogenic bladder, DM, congenital malformations, pregnancy, indwelling catheters.
A clinical diagnosis based on the presence of fever, flank pain and tenderness, often 
with an elevated WBC count. It may affect one or both kidneys. There are usually 
accompanying LUTS suggestive of a lower UTI responsible for the ascending infection 
which resulted in the subsequent acute pyelonephritis. Nausea and vomiting are com-
mon. Differential diagnosis includes “acute abdomen” syndrome.
Pathogenesis .and .microbiology
Initially, there is infiltration of neutrophils and bacteria in the parenchyma. Later 
changes include the formation of inflammatory bands extending from renal papilla to 
cortex and small cortical abscesses. 80% of infections are secondary to E. coli. Other 
infecting organisms: Streptococcus faecalis, Klebsiella, Proteus and Pseudomonas.
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Urine culture will be positive for bacterial growth, but the bacterial count may 
not necessarily be >105 cfu/ml of urine. Thus, if a diagnosis of acute pyelonephritis 
is suspected from the symptoms of fever and flank pain, but there are <105 cfu/ml 
of urine, this case is treated as acute pyelonephritis.
Diagnosis .and .treatment
• For those patients who have a fever but are not systemically unwell, outpa-
tient management is reasonable. Culture the urine and start oral antibiotics 
according to local antibiotic policy, which will be based on the likely infecting 
organisms and their likely antibiotic sensitivity.
• If the patient is systemically unwell, culture urine and blood, start i.v. fluids and 
antibiotics, again selecting the antibiotic according to local antibiotic policy.
• A KUB X-ray and renal US are used, to see if there is an underlying upper tract 
abnormalities such a ureteric stone or hydronephrosis.
• If the patient does not respond within 3 days to this regimen of appropriate i.v. 
antibiotics, CT is performed. The lack of response to treatment suggests the pos-
sibility of a pyonephrosis or a perinephric abscess. The CT may demonstrate an 
obstructing ureteric calculus that may have been missed on the KUB X-ray and 
may show a perinephric abscess. A pyonephrosis should be drained by insertion 
of a PNS tube. A perinephric abscess should also be drained by insertion of a 
drain percutaneously.
• If the patient responds to i.v. antibiotics, these are changed to an oral antibiot-
ics of appropriate sensitivity when they become apyrexial and continue this for 
approximately 10-14 days.
Recommended .initial .empirical .antimicrobial .therapy .in .acute .
uncomplicated .pyelonephritis .in .premenopausal .women
1. Oral therapy in mild and moderate cases:
Antibiotics → Daily dose → Duration of therapy
• Ciprofloxacin 500-750 mg bid 7-10 days;
• Levofloxacin 250-500 mg qd 7-10 days;
• Levofloxacin 750 mg qd 5 days;
Alternatives
• Ceftibuten 400 mg qd 10 days;
• Amoxiclav 0.5/0.125 g tid 14 days;
2. Initial parenteral therapy in severe cases:
After improvement, the patient can be switched to an oral regimen using one of 
the above-mentioned antibacterials to complete the 1-2-week course of therapy.
Antibiotics → Daily dose
• Ciprofloxacin 400 mg bid;
• Levofloxacin 250-500 mg qd;
• Levofloxacin 750 mg qd;
Alternatives:
• Cefotaxime 2 g tid;
• Ceftriaxone 1-2 g qd;
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• Ceftazidime 1-2 g tid;
• Cefepime 1-2 g bid;
• Amoxiclav 1.2 g tid;
• Piperacillin/tazobactam 2.5-4.5 g tid;
• Gentamicin 5 mg/kg qd;
• Amikacin 15 mg/kg qd;
• Ertapenem 1 g qd;
• Imipenem/cilastatin 0.5/0.5 g tid;
• Meropenem 1 g tid;
• Doripenem 0.5 g tid.
8 4 2  .Emphysematous .pyelonephritis
A rare, severe form of acute pyelonephritis caused by gas-forming organisms. It 
is characterized by fever and abdominal pain, with radiographic evidence of gas 
within and around the kidney on plain X-Ray or CT. It usually occurs in DM 
patients and in many cases is precipitated by urinary obstruction. The high glucose 
levels of the poorly controlled diabetic provides an ideal environment for fermen-
tation by Enterobacteria, carbon dioxide being produced during this process.
It presents as a severe acute pyelonephritis, which fails to respond within 2-3 
days with conventional treatment in the form of i.v. antibiotics. Commonly caused 
by E.coli, less frequently Klebsiella and Proteus. On KUB X-ray a crescent or 
kidney-shaped distribution of gas may been seen around the kidney. Renal US 
often demonstrates focal echoes, indicating gas within the kidney. Intra-renal gas 
is seen on CT scan.
Patients with emphysematous pyelonephritis are usually very unwell and mor-
tality is high. In selected cases, it can be managed conservatively, by i.v. antibiotics 
and fluids, drainage and careful control of diabetes. In those where urosepsis is 
poorly controlled, emergency nephrectomy is required.
8 4 3  .Purulent .forms .of .pyelonephritis
Pyonephrosis
This is an infected hydronephrosis. Pus accumulates within the renal pelvis and 
calyces. The causes are essentially those of hydronephrosis, where infection has 
supervened.
Patients with pyonephrosis are usually very unwell, with a high fever, flank pain 
and tenderness. Again, patients with this combination of symptoms and signs will 
usually be investigated by a renal US, where the diagnosis of a pyonephrosis is 
usually obvious. Treatment consists of PNS witn i.v. antibiotics and fluids. By loss 
of function nephrectomy is indicated.
Perinephric abscess
Perinephric abscess develops as a consequence of extension of infection outside 
the parenchyma of the kidney in acute pyelonephritis or from hematogenous 
spread of infection from a distant site. The abscess develops within Gerota’s fascia. 
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These patients are often diabetic and associated conditions such as an obstructing 
ureteric calculus may be the precipitating event leading to development of the 
perinephric abscess.
Failure of acute pyelonephritis to respond to i.v. antibiotics within a few days 
arouses the suspicion that there is an accumulation of pus in or around the kidney 
or obstruction with infection.
Imaging studies, such as US and more especially CT will establish the diagnosis 
and allow radiographically controlled percutaneous drainage of the abscess. If the 
pus collection is large, formal open surgical drainage under general anaesthetic 
will provide more effective drainage.
Maintaining a degree of suspicion in all cases of presumed acute pyelonephritis 
is the single most important thing in allowing an early diagnosis of complicated 
renal infection, such as a pyonephrosis, perinephric and kidney abscess or em-
physematous pyelonephritis. If the patient is very unwell, diabetic or has a history 
suggestive of stones, they may have something more than just a simple acute py-
elonephritis. Specifically ask about a history of sudden onset of severe flank pain a 
few days earlier, suggesting the possibility that a stone passed into the ureter, with 
later infection supervening. Arranging a KUB X-ray and renal US in all patients 
with suspected renal infection, which will demonstrate the presence of hydrone-
phrosis, pus or stones.
Clinical indicators suggesting a more complex form of renal infection are length 
of symptoms prior to treatment and time taken to respond to treatment. Most 
patients with uncomplicated acute pyelonephritis have been symptomatic for <5 
days. Most patients with a perinephric abscess have been symptomatic for >5 
days prior to hospitalization. Patients with acute pyelonephritis became afebrile 
within 4-5 days of treatment with an appropriate antibiotic, whereas those with 
perinephric abscesses remain pyrexial.
8 4 4  .Chronic .pyelonephritis
It can be a radiological or pathological diagnosis (renal scarring) or description. The 
scarring can be due to previous infection or it can occur from the long-term effects 
of VUR. A child with VUR, particularly where there is reflux of infected urine, will 
develop reflux nephropathy. which if bilateral may cause CRF. An adult may also 
develop radiological and pathological features of chronic pyelonephritis, due to the 
presence of VUR or obstruction combined with high bladder pressures, again partic-
ularly where the urine is infected. This was a common occurrence in male patients 
with neurogenic bladder before the advent of effective treatments for this condition.
The scars are closely related to a deformed renal calyx. Distortion and dilata-
tion of the calyces is due to scarring of the renal pyramids. These scars typically 
affect the upper and lower poles of the kidneys, because these sites are more prone 
to intrarenal reflux. The cortex and medulla in the region of a scar is thin.
The kidney may be so scarred that it becomes small and atrophic. Scars can be 
seen on a renal US, an IVU, renal isotope scan or a CT.
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8 5  .FOURNIER’S .GANGRENE
A necrotizing fascitis of the genitalia and perineum, causing necrosis and subse-
quent gangrene of infected tissues. Culture of infected tissue reveals a combination 
of aerobic (E. coli, enterococcus, Klebsiella) and anaerobic organisms (Bacteroi-
des, Clostridium, microaerophilic streptococci), which are believed to grow in a 
synergistic fashion. Conditions which predispose to the development of Fournier’s 
gangrene include DM, local trauma to the genitalia and perineum (e.g. zipper 
injuries to the foreskin, periurethral extravasation of urine following traumatic 
instrumentation of the urethra) and surgical procedures such as circumcision.
Symptoms
A previously well patient may become systemically unwell over a very short time 
following a seemingly trivial injury to the external genitalia. A fever is usually 
present, they may have marked pain in the affected tissues and the developing 
urosepsis may alter their mental state. The genitalia and perineum are edematous 
and on palpation of the affected area, tenderness and crepitus may be present 
indicating the presence of subcutaneous gas produced by gas-forming organisms. 
As the infection advances, bullae appear in the skin and, within a matter of hours, 
areas of necrosis may develop which spread to involve adjacent tissues. The con-
dition advances very rapidly.
Diagnosis
The diagnosis is a clinical one and is based on awareness of the condition and a 
low index of suspicion.
Treatment
While i.v. access is obtained, blood taken for culture, i.v. fluids started and oxygen 
administered, broad spectrum antibiotics are given to cover both gram-positive and 
negative aerobes and anaerobes (e.g. ampicillin, gentamicin and metronidazole or 
clindamycin). Make arrangements to transfer the patient to the operating room as 
quickly as possible so that debridement of necrotic tissue can be carried out. Ex-
tensive areas of tissue may have to be removed, but it is unusual for the testes or 
deeper penile tissues to be involved and these can usually be spared. A suprapubic 
catheter is inserted to divert urine and allow monitoring of urine output.
Where facilities allow, consider treatment with hyperbaric oxygen therapy. 
There is some evidence that this may be beneficial. Repeated debridements to 
remove residual necrotic tissue are not infrequently required. Mortality is in the 
order of 20-30%.
8 6  .EPIDIDYMITIS .AND .ORCHITIS
This is an inflammatory condition of the epididymis, often involving the testis 
and caused by bacterial infection. It has an acute onsent and a clinical course 
lasting <6 weeks. It presents with pain, swelling and tenderness of the epididymis. 
It should be distinguished from chronic epididymitis where there is longstanding 
pain in the epididymis, but usually no swelling.
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Infection ascends from the urethra or bladder. In men aged <35 years, the in-
fective organism is usually N. gonorrhoeae, C. trachomatis. In children and older 
men, the infective organisms are usually coliforms. Mycobacterium tuberculosis is 
a rarer cause of the epididymis.
Differential .diagnosis
Torsion of the testicle is the main differential diagnosis. A preceding history of 
symptoms suggestive of urethritis or urinary infection, LUTS suggest that epididy-
mitis is the cause of the scrotal pain, but these symptoms may not always be pres-
ent in epididymitis. In epididymitis pain, tenderness and swelling may be confined 
to the epididymis, whereas in torsion, the pain and swelling are localized to the 
testis. However, there may be overlap in these physical signs.
Where doubt exists, exploration is the safest option. Though radionuclide scan-
ning can differentiate between a torsion and epididymitis, this is not available in 
many hospitals. Colour doppler US, which provides a visual image of blood flow, 
can differentiate between a torsion and epididymitis, but its sensitivity for diagnos-
ing torsion is only 80%. These 20% have torsion but normal findings on doppler 
US of the testis. Again, if in doubt, scrotum is explored.
Treatment
This consists of antibiotics, bed rest and analgesia. Where C. trachomatis is a 
possible infecting organism, a 10-14 day course of doxycycline 100 mg twice 
daily is prescribed. If gonorrhoeae is confirmed on a gram stain of the ure-
thral discharge and on culture, ciprofloxacin or ceftriaxon is used. For non-
STD related epididymitis, antibiotics are prescribed empirically (until cul-
ture results are available) according to local microbiology department advice. 
Fluoroquinolones, cefalosporins and aminoglycosides are used for empirical 
treatment (2-4 weeks).
Complications of acute epididymitis: abscess formation, infarction of the testis, 
chronic pain and infertility.
Chronic .epididymitis
is diagnosed in patients with long-term pain in the epididymis and testicle. It can 
result from recurrent episodes of acute epididymitis. Clinically, the epididymis is 
thickened and may be tender. Treatment is with the appropriate antibiotics and 
NSAIDs or epididymectomy in severe cases.
Orchitis
is inflammation of the testis, although it often occurs with epididymitis (epi-
didymo-orchitis). Causes include mumps, M. tuberculosis, syphilis, autoimmune 
processes as a granulomatous orchitis. The testis is swollen and tense, with edema 
of connective tissues and inflammatory cell infiltration. The underlying cause is 
treated.
Mumps orchitis occurs in 30% of infected post-pubertal males. It manifests 3-4 
days after the onset of parotitis and can result in tubular atrophy. 10-30% of cases 
are bilateral and are associated with infertility.
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8 7  .PROSTATITIS
This is infection and/or inflammation of the prostate. Overall prevalence in men 
is 5-11%. Age groups at increased risk are 20-50 and >70 years old.
Etiology .and .pathogenesis
The tissues surrounding the prostatic acini become infiltrated with lymphocytes. 
The most common infective agents are gram-negative Enterbacteriacae (Esch-
erichia coli, Pseudomonas aeruginosa, Klebsiella, Serratia, Enterobacter aero-
genes). 5-10% of infections are caused by gram - positive bacteria (Staphylococcus 
aureus and saprophyticus, Streptococcus faecalis). The etiology of inflammatory 
and non-inflammatory forms of prostatitis is not well understood.
Risk factors: UTI and intraprostatic ductal reflux, urethral catheters, transure-
thral surgery, prostatic stones, which can provide a nidus of infection for chronic 
prostatitis, venous and secretory stasis.
Classification .of .prostatitis
I. Acute bacterial prostatitis;
II. Chronic bacterial prostatitis;
III. Chronic pelvic pain syndrome;
IIIA Inflammatory CPPS: WBC in EPS, VB3 or semen. Where cultures are nega-
tive, increased leucocytes per HPF (>10) favor a diagnosis of inflammatory CPPS;
IIIB Non-inflammatory CPPS (prostatodynia): no WBC in EPS, VB3 or semen; 
IV. Asymptomatic inflammatory prostatitis (histological prostatitis or male infer-
tility cases).
Diagnosis
• Segmented urine cultures localize bacteria and WBC to a specific part of the 
urinary tract with (EPS) or without (VB3) prostatic massage.
VB1 - first 10 mls of urine voided. Positive culture and WBC indicates urethritis 
or prostatitis.
VB2 - midstream urine. Positive culture and WBC indicates cystitis.
VB3 - first 10 mls of urine voided following prostatic massage. Positive culture 
indicates prostatitis.
EPS - positive culture indicates prostatitis.
• NIH-CPSI questionnaire (National Institute of Health Chronic Prostatitis 
Symptom Index). This scores 3 main symptom areas: pain (location, frequency, 
severity), voiding (LUTS) and impact on quality of life.
Acute .bacterial .prostatitis
ABP is infection of the prostate associated with lower UTIs and generalized uro-
sepsis. E. coli is the most common cause. Pseudomonas, Serratia, Klebsiella and 
enterococci are less common causes.
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Acute onset of fevers, chills, nausea and vomiting, perineal and suprapubic 
pain, LUTS. Signs of systemic toxicity (fever, tachycardia, hypotension) may be 
present. Suprapubic tenderness and a palpable bladder will be present if there is 
AUR. On DRE the prostate is extremely tender.
Treatment includes an oral fluoroquinolone (ciprofloxacin 500mg bd) for 2-4 weeks. 
For a patient who is systemically unwell, i.v. antibiotics (aminoglycosides, fluoroquino-
lones and/or 3rd generation cephalosporins). NSAIDs are used for pain relief. Cath-
eterization or suprapubic cateter are used for relief of retention. Traditional teaching 
was that a suprapubic  catheter should be inserted to avoid the potential obstruction 
of prostatic urethral ducts by a urethral catheter. However, in-and-out catheterization 
or short periods with an indwelling catheter probably does no harm and is certainly an 
easier way of relieving retention than suprapubic catheterization.
Prostatic .abscess
Failure to respond to this treatment regimen with persistent symptoms and fever 
while on antibiotic therapy suggests the development of a prostatic abscess. A 
TRUS or CT scan is the best way of diagnosing a prostatic abscess. This may be 
drained by a TUR.
Chronic .bacterial .prostatitis
History of recurrent UTIs. Chronic episodes of pain and voiding dysfunction may 
be a feature. DRE may show a tender, enlarged and boggy prostate. Treatment as 
for acute bacterial prostatitis.
Chronic .pelvic .pain .syndrome
Both inflammatory (IIIA) and non-inflammatory (IIIB) types present with >3 
month history of localized pain (perineal, suprapubic, penile, groin or external gen-
italia) or pain with ejaculation, There are LUTS and ED. Symptoms can recur over 
time and severely affect patient’s quality of life.
Treatment options for inflammatory and non-inflammatory CPPS are not fully 
understood. NSAIDs and alfa – blockers are used. Alfa – blokers acts on prostate 
and bladder neck alfa -receptors, causing smooth muscle relaxation, improved 
urinary flow and reduced intraprostatic ductal reflux. Sometimes patients need 
antibiotics, biofeedback and psychological support.
Asymptomatic .inflammatory .prostatitis
Incidental histological diagnosis of prostatic inflammation from prostate tissue 
taken for other indications (i.e. biopsy for raised PSA) or male infertility. Treat-
ment options: oral fluoroquinolone, alpha-blockers, NSAIDs as a suppositoria, 
physiotherapy, phytotherapy.
8 8  .INTERSTITIAL .CYSTITIS
IC is a refractory bladder disorder of unknown etiology. Predominantly affects 
females. Patients suffer from chronic urinary frequency, nocturia, urgency and 
bladder/suprapubic pain, in the absence of any obvious cause.
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Possible contributing factors:
• Studies have demonstrated increased mast cells in bladder smooth muscle. Activat-
ed mast cells release histamine, which can cause symptoms and fibrosis in tissues;
• Defective bladder epithelium: an abnormal GAG layer may allow urine to leak 
past the luminal surface, causing inflammation in muscle layers;
• Neurogenic mechanisms: abnormal activation of sensory nerves causes release 
of neuropeptides, resulting in neurogenic inflammation;
• Reflex sympathetic dystrophy of the bladder due to excessive sympathetic activity;
• Urinary toxins or allergens;
• Bladder autoimmune response.
Diagnosis
A higher prevalence of allergies, irritable bowel syndrome, fibromyalgia, focal 
vulvitis and Segren’s syndrome has been reported in IC.
History, pelvic examination, DRE, urinalysis and culture are mandatory. IC 
symptom index questionnaire, voiding diaries and urodynamics are useful.
Diagnostic studies:
• Cystoscopy: 10% of patients will have pink ulceration of bladder mucosa. This 
is Hunner’s ulcer. Under anaesthesia, the bladder should be distended twice (to 
80-100 cm H20 for 1-2 min) and then inspected for diffuse glomerulations (>10 
per quadrant in 3/4 bladder quadrants). Bladder biopsy is only indicated to rule 
out other pathologies. Bladder filling causes pain and reproduces symptoms.
• Intravesical KCl challenge In 75% of IC patients, installation of KCl into the 
bladder will provoke pain and symptoms.
Exclusion criteria:
• Bladder capacity >350 ml, measured by cystometry;
• Lack of urgency with a 150 ml injection in cystometry;
• Uninhibited contractions during cystometry;
• <9 months from onset;
• Absence of nocturia;
• Symptoms improved by antibiotics, anticholinergics or antispasmodics;
• Daytime voids <8;
• Bacterial cystitis or prostatitis within 3 months;
• Bladder or ureteral calculi;
• Genital herpes;
• Uterine, cervical, vaginal or urethral cancer;
• Urethral diverticulum;





• <18 years old.
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Treatment
• Tricyclics have anticholinergic, antihistamine and sedative effects;
• Pentosan polysulphate (Elmiron) is an anti-inflammatory synthetic GAG analogue;
• Long-term analgesia with NSAIDs or paracetamol;
• Opiates may be prescribed and monitored via pain clinics;
• Repeated intravesical drug installation of dimethyl sulphoxide (DMSO) ± local 
anaesthetic (Lidocain), GAG analogues (pentosan polysulphate and hyaluronic 
acid), BCG, capsaicin, resiniferotoxin;
• Transcutaneous electrical nerve stimulation (TENS) and neuromodulation;
• TUR, laser coagulation or diathermy of Hunner’s ulcers;
• Bladder hydrodistention;
• Bladder aufmentation should be considered after failed conservative treatments;
• As a last option surgery urinary diversion ± cystectomy may be required.
8 9  .UROSEPSIS
Bacteraemia is the presence of pathogenic organisms in the blood stream. In the hos-
pital setting, the most common causes are the presence of or manipulation of indwell-
ing urinary catheters, urinary tract endoscopic surgery and urinary tract obstruction. 
Diabetic patients, patients in ICUs and patients on chemotherapy and steroids are 
more prone to urosepsis. From a urological perspective, the clinical scenario is usually 
a post-operative patient or patients with obstruction or purulent forms of UTIs. Con-
sider the possibility of a non-urological source of sepsis (e.g. pneumonia).
Causative organisms in urosepsis: E. coli, Streptococcus faecalis, Staphylococ-
ci, Pseudomonas aeruginosa, Klebsiella and Proteus mirabilis.
Sepsis is the clinical syndrome caused by bacterial infection of the blood, con-
firmed or most common not confirmed by positive blood cultures for a specific 
organism and accompanied by a systemic response to the infection known as SIRS.
SIRS is defined by at least two of the following:
• Fever (>38°C) or hypothermia (<36C);
• Tachycardia (>90 beats/min);
• Tachypnoea (respiratory >20/min or PaCO2 < 4.3 kPa or a requirement for 
mechanical ventilation);
• WBC count >12000 cells/mm3, <4000 cells/mm3 or 10% immature forms.
Septicemia is often accompanied by endotoxemia. This is the presence of cir-
culating bacterial endotoxins.
Severe sepsis is a state of altered organ perfusion or evidence of dysfunction of 
one or more organs, with at least one of the following: hypoxemia, lactic acidosis, 
oliguria or altered mental status.
Septic shock is severe sepsis with hypotension, hypoperfusion and organ dys-
function. It results from gram-positive bacterial toxins or gram-negative endotox-
ins which trigger release of cytokines, vascular mediators and platelets, resulting in 
vasodilatation, which manifest as hypotension and DIC.
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Diagnosis
• Urine culture: gram-stain may aid in deciding which antibiotic to use;
• Full blood count. The WBC count is usually elevated. The platelet count may 
be low. This is a possible indication of impending DIC.
• Coagulation screen is important if surgical or radiological drainage of the source 
of infection is necessary;
• Urea and electrolytes as a baseline determination of renal function;
• Arterial blood gases to identify hypoxia and the presence of metabolic acidosis;
• Blood cultures;
• Thorax X-Ray for pneumonia, atelectasis and effusions;
• Depending on the clinical situation, a renal US may be helpful to demonstrate 
hydronephrosis or pyonephrosis and CT urography may be used to establish the 
presence or absence of a ureteric stone.
Treatment
The principles of management include early recognition, resuscitation, localiza-
tion of the source of sepsis, early and appropriate antibiotic administration and 
removal of the primary source of sepsis.
• A (Airway), B (Breathing), C (Circulation);
• 100% oxygen via a face-mask;
• Establish i.v. access with a wide-bore i.v. cannula;
• I.v. crystalloid (e.g. normal saline or colloid);
• Catheterize to monitor urine output;
• If there is septic shock, the patient needs to be transferred to ICU. Inotro-
pic support may be needed. Steroids may be used as adjunctive therapy in 
gram-negative infections. Naloxone may help revert endotoxic shock.
• Treat the underlying cause. Drain any obstruction and remove any foreign body. 
If there is a stone obstructing the ureter, JJ-stent or PNS tube is inserted to relieve 
the obstruction. Send any urine specimens obtained for microscopy and culture.
• Empirical antibiotic treatment. This is blind use of antibiotics based on an 
educated guess of the most likely pathogen that has caused the urosepsis. 
Gram-negative aerobic rods are common causes of urosepsis (e.g. E. coli, Kleb-
siella, Citrobacter, Proteus and Serratia). The enterococci (gram-positive aer-
obic non-haemolytic streptococci) may sometimes cause urosepsis. In urinary 
tract operations involving the bowel, anaerobic bacteria may be the cause of 
urosepsis and in wound infections, staphylococci (e.g. Staph. aureus and Staph. 
epidermidis) are the usual cause.
• Antibiotic therapy should be adjusted later when cultures are available;
Recommendations for antibacterial therapy of urosepsis
• A IIIrd-generation cephalosporins (e.g. i.v. cefotaxime or ceftriaxone). These are 
active against gram-negative bacteria, but have less activity against gram-positive 
bacteria. Ceftazidime also has activity against Pseudomonas aeruginosa.
• Fluoroquinolones are an alternative to cephalosporins. They exhibit good ac-
tivity against enterobactaria and P. aeruginosa, but less activity against staph-
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ylococci and enterococci. GIT absorption of ciprofloxacin is good, so oral 
administration is as effective as i.v.;
• Use metronidazole if there is a potential anaerobic source of sepsis;
• Aminoglycosides are used in conjunction with other antibiotics. It has a rel-
atively narrow therapeutic spectrum against gram-negative organisms. Close 
monitoring of therapeutic levels and renal function is important. It has good 
activity against enterobacteria and Pseudomonas, with poor activity against 
streptococci and anaerobes and, therefore, should ideally be combined with 
beta-lactam antibiotics or ciprofloxacin.
• If no clinical response to the above antibiotics, consider a combination of 
piperacillin/tazobactam, which s active against enterobacteria, enterococci and 
Pseudomonas.
• If there is clinical improvement, i.v. treatment should continue for at least 48-
72 h and then be changed to oral medication. Make appropriate adjustments 
when sensitivity results are available from urine cultures.
8 10  .UTIS .AND .PREGNANCY
Pregnancy does not alter the incidence of UTI, which remains at 4% for women 
of reproductive age. However, physiological and anatomical changes associated 
with pregnancy alter the course of infection, causing an increased risk of recurrent 
UTIs and progression to acute pyelonephritis up to 1/4 cases. A common caus-
ative organism of gestational pyelonephritis is E.coli.
Risk .factors:
• Renal size is enlarged, secondary to increased interstitial volume and distended 
renal vasculature;
• RPF increases early in the 1st trimester;
• GFR increases by 50%, related to an increased cardiac output;
• Renal function and biochemical parameters are affected by changes in RPF 
and GFR. Cr clearance increases and serum levels of Cr, urea and urate fall in 
normal pregnancy. Raised GFR causes an increased glucose load at the renal 
tubules and results in glucose excretion (glycosuria) in most pregnancies. Urine 
output increases.
• Plasma renin activity is increased 10-fold and levels of angiotensinogen and angio-
tensin are increased 5-fold. Osmotic thresholds for ADH and thirst decrease.
• Serum bicarbonate is reduced. Increased progesterone stimulates the respiratory 
centre resulting in reduced PCO2;
• Bladder displacement occurs due to the enlarging uterus. The bladder becomes 
hyperaemic and raised oestrogen levels cause hyperplasia of muscle and connective 
tissues.
• LUTS: urinary frequency (>8 voids during the day) and nocturia (>1 void at 
night) increases over the duration of gestation. Urgency and urge incontinence 
also increase secondary to pressure effects from the enlarging uterus.
• Previous history of recurrent UTIs and pre-existing VUR;
• Physiological changes in pregnancy include hydronephrosis with decreased ureteral 
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peristalsis causing urinary stasis. Up to 75% of pyelonephritis occurs in the 3rd 
trimester, when these changes are most prominent. Hydronephrosis develops from 
week 6 to week 10 of gestation. By week 28 of gestation, 90% of pregnant women 
have hydronephrosis. It has usually resolved within 2 months of birth. It is due to a 
combination of the smooth muscle relaxant effect of progesterone and to mechan-
ical obstruction from the enlarging fetus and uterus, which compress the ureter.
• UTI increases the risk of pre-term delivery, low fetal birth weight and maternal 
anemia.
Diagnosis
MSU should be obtained at the first antenatal visit and sent for urinalysis and cul-
ture to look for bacteria, protein and blood. A second MSU investigation is rec-
ommended at later visits (week 16) to examine for bacteria, protein and glucose.
The hydronephrosis of pregnancy poses diagnostic difficulties in women pre-
senting with flank pain thought to be due to a renal or ureteric stone. Renal US 
is often used as the initial imaging technique in those presenting with flank pain. 
In the non-pregnant patient, the presence of hydronephrosis is taken as surrogate 
evidence of ureteric obstruction. Because hydronephrosis is a normal finding in 
the majority of pregancies, its presence cannot be taken as a sign of a possible 
ureteric stone. US is an unreliable way of diagnosing the presence of stones in 
pregnant women.
Treatment
All proven episodes of UTIs should be treated (asymptomatic bacteriuria or symp-
tomatic UTIs), guided by urine culture sensitivities. Antibiotics which are safe to 
use during pregnancy include amoxicillin/clavulonic acid and cephalosporins. Ni-
trofurantoin may be used in 1st and 2nd trimesters only. Repeat urine cultures after 
treatment to check bacteria have been eliminated. Acute pyelonephritis requires 
hospital admission for i.v. antibiotics until apyrexial, followed by oral antibiotics 
for 14 days and repeated cultures for the duration of pregnancy.
Antibiotics to avoid in pregnancy: tetracyclines (fetal malformation, maternal 
hepatotoxicity, dental discolouration), fluoroquinolones (arthropathy), trimetho-
prim (folate antagonist), aminoglycosides (auditory or vestibular nerve damage), 
sulphonamides (neonatal hemolysis, methemoglobinaemia), nitrofurantoin (ma-
ternal or neonatal hemolysis).
Acute renal failure is a common problem in the current time. Prospective studies 
have demonstrated that 2% to 5% of all patients admitted to a general medical/
surgical hospital unit will develop ARF. In the ICUs after cardiovascular or ab-
dominal vascular surgery, the incidence may be >20%. ARF is defined as a rapid 
reduction in renal function characterized by progressive azotemia and creatinin-
amia, which may or may not be accompanied by oliguria. This abrupt decline in 
renal function occurs over the course of hours to days and results in the failure 
to excrete nitrogenous wastes from the plasma or to maintain normal volume 
and electrolyte homeostasis. The ARF can be diagnosed with certainty when the 
patient’s prior renal function is known and the reduction in renal function is 
documented.
Сlassification .of .acute .renal .failure
Clinically, it is very useful to separate the causes of ARF into three major cat-
egories: prerenal, renal and postrenal. Assigning a patient to one of the three 
categories usually requires a combination of clinical, laboratory evaluations 
and imaging studies of the GUT. The importance of differentiating the major 
causes of ARF must be stressed, because the initial evaluation and manage-
ment are tailored to the particular cause.
9 1  .PRERENAL .ARF
Etiology .of .prerenal .ARF
Volume depletion:
• Surgical: hemorrhage, shock;
• GIT losses: vomiting, diarrhea, fistulas;
• Renal: overdiuresis, salt-wasting disorders;
Cardiac causes with primary decrease in cardiac output:
• Acute disorders: myocardial infarction, arrhythmias, malignant hypertension, 
tamponade, endocarditis;
• Chronic disorders: valvular diseases, chronic cardiomyopathy (ischemic heart 
disease, hypertensive heart disease);
Redistribution of extracellular fluid
• Hypoalbuminemic states: nephrotic syndrome, advanced liver disease, malnutrition;
• Diseases: peritonitis, burns, crush injury;
• Peripheral vasodilatation: sepsis, antihypertensive agents;
• Renal artery stenosis (bilateral).
Prerenal ARF is caused by transient renal hypoperfusion that may induce a fall 
in GFR and produce urinary sodium avidity. The hallmark of prerenal ARF is 
its reversibility with treatment of the underlying cause and the lack of structural 
damage to the kidney. The “gold standard” is the response to appropriate fluid 
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repletion: return of renal function to the previous baseline within 24 to 72 hours 
is usually considered to represent prerenal disease.
Under normal circumstances, the kidney can maintain normal RBF and GFR 
down to perfusion pressures of approximately 60 mm Hg. The phenomenon of au-
toregulation requires a complex interaction of physiologic factors to maintain RBF 
and GFR. In some hospitalized patients with disordered autoregulation, a reduction 
in RBF and GFR may occur with modest or even no discernable fall in SBP. In the 
setting of decreased renal perfusion, angiotensin II and vasodilatory prostaglandins 
play an important role in maintaining glomerular hydrostatic pressure and GFR.
Prerenal ARF may be encountered in both the volume-depleted and vol-
ume-overloaded patient. True volume depletion may result from renal or extra-
renal losses that result in systemic hypotension and renal hypoperfusion. In the 
volume-overloaded patient, with edematous states such as cirrhosis and congestive 
heart failure, prerenal ARF may occur because the kidney perceives that the vas-
cular tree is underfilled (i.e., “ineffective arterial blood volume”). This results in 
renal hypoperfusion. Prerenal ARF may also occur owing to high-grade bilateral 
renal artery stenosis or in states of renal hypoperfusion due to redistribution of 
extracellular fluid with peripheral vasodilation as seen with sepsis. 
The pathophysiology of prerenal ARF relates to the reduction in RBF. Renal 
hypoperfusion stimulates both the sympathetic nervous system and renin-angio-
tensin system to cause renal vasoconstriction and sodium avidity. Furthermore, 
hypotension is a powerful stimulus to the release of antidiuretic hormone, which 
mediates water reabsorption. Hence, urine production is characterized by low vol-
ume, decreased concentration of urinary sodium, increased urinary excretion of Cr 
and a high urine osmolality. Microscopy of the urinary sediment is usually bland.
Therapy for prerenal ARF is directed at optimizing volume status with isotonic 
fluids. In patients with the edematous disorders who have prerenal ARF, special 
efforts are directed at treating the underlying disease states (i.e., heart failure, cir-
rhosis) and optimizing systemic hemodynamics and renal perfusion.
9 2  .POSTRENAL .ARF
Obstruction of the urinary tract may cause ARF. To be the cause of ARF, urinary 
tract obstruction must involve the outflow tract of both kidneys, unless preexisting 
renal dysfunction is present, in which case the obstruction may involve only a sin-
gle kidney. Patients with acute urinary tract obstruction may present with hematu-
ria, flank or abdominal pain or signs of uremia. Lesions that may cause obstruction 
can be either intrinsic (stones) or extrinsic (periureteral metastatic disease or ret-
roperitoneal fibrosis) to the GUT. Although anuria suggests complete obstruction, 
partial obstruction may exist in the presence of adequate urinary output. 
If urinary tract obstruction is a diagnostic consideration, the renal US is indi-
cated in confirming the diagnosis of UHN or hydronephrosis. Renal radionuclide 
studies or retrograde pyelography may be helpful in this circumstance.
Iatrogenic causes should additionally be considered. Urinary extravasation or 
fistula formation are signs of iatrogenic injuries and can be confirmed with help of 
excretory urography or retrograde ureterography. Other ways to confirm urinary 
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extravasation during the time of operation are by i.v. administration of a vital dye 
excreted by the kidneys (e.g., indigo carmine or methylene blue).
Obstruction represents a potentially reversible cause of ARF. Any drainage de-
vice such as a urethral catheter, ureteral stent or PNS tube should be inserted for 
treatment of postrenal ARF.
9 3  .RENAL .ARF
The major causes of ARF due to renal disease include acute glomerulonephritis, 
acute interstitial nephritis and acute tubular necrosis.
Acute .Glomerulonephritis .
The presence of proteinuria, hematuria and RBC casts is pathognomonic of AGN. 
The importance of the urinalysis in the evaluation of patients with ARF cannot be 
overemphasized and the physician must develop skill and expertise in interpreting 
the microscopic findings.
Acute .Interstitial .Nephritis .
The diagnosis of ARF secondary to AIN may be suggested by the urinalysis find-
ings of sterile pyuria, WBC casts and eosinophiluria. AIN is most often induced 
by drug therapy, although infections may also be responsible. Most common 
causes of AIN are: NSAIDs, penicillins and cephalosporins, rifampicin, fu-
rosemide, thiazide-type diuretics,  trimethoprim-sulfamethoxazole, cimetidine, 
allopurinol, ciprofloxacin, 5-aminosalicylates.
The major histologic changes are interstitial edema and marked interstitial in-
filtrate of T lymphocytes and monocytes. Eosinophilic plasma cells and polymor-
phonuclear cells may also be detected. 
The clinical presentation, although variable, usually involves an abnormal urine 
sediment, fever and a rising serum Cr value associated with the administration of 
the offending drug. Rash is seen in about 25% of cases. Eosinophilia and eosin-
ophiluria are present in more than 75% of cases, with the exception of AIN due 
to NSAIDs, in which fever, rash and eosinophilia are typically absent. Proteinuria 
with most drugs is usually modest, with less than 0,5-1 g/day. The development 
of AIN is not dose dependent and recurrence can occur with second exposures to 
the same or related drug. The onset of AIN may occur from 3-5 days to several 
weeks after drug therapy. The diagnosis is usually suspected in the ARF patient 
with characteristic urinary sediment abnormalities and a history of an offending 
drug therapy. The diagnosis is confirmed only by renal biopsy.
Initial therapy consists of discontinuing the offending drug with the expectation that 
renal function will begin to improve in 3 to 7 days. There is some experimental and 
suggestive clinical evidence that corticosteroid and/or cytotoxic therapy may be bene-
ficial to hasten recovery of renal function and reduce interstitial fibrosis.
Acute .tubular .necrosis
The majority of all hospital-acquired ARF is secondary to ATN. Renal hypoperfu-
sion and renal ischemia are the most common causes of ATN, although nephro-
toxins  from various agents are being recognized with increasing frequency. 
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Endogenous nephrotoxinsc products:
• Pigment nephropathy (myoglobin, hemoglobin, methemoglobin);
• Intrarenal crystal deposition (uric acid, calcium, oxalate);
• Tumor-specific syndromes (tumor lysis syndrome, myeloma kidney);
Exogenous nephrotoxins:
• Antibiotics (aminoglycosides, co-trimoxazole, amphotericin B, polymyxin, 
colistin, vancomycin, acyclovir;




• Chemotherapeutic and immunosuppressive agents;
• NSAIDs;
• HIV Protease inhibitors;
• Organic solvents;
• Heavy metals;
• Poisons (mushrooms, snake bites, bacterial toxins)
• Chemicals (aniline, hexol, cresol, chlorates, potassium bromated);
• Other drugs (dextrans, EDTA, radiation).
A patient who develops ATN while receiving medications should have each 
medication reviewed for the possibility of nephrotoxicity.
Stages .and .symptoms
After the inciting incident (Ist phase), the oligoanuric IInd phase usually begins less 
than 24 hours and may last for 1 to 3 weeks. Urine volume averages 150 to 300 mL/
day and may be absent. The II-nd phase may be prolonged in the elderly. During 
this phase, the clinician must be alert for the expected complications, with special 
emphasis on metabolic consequences, gastrointestinal bleeding and infection.
The diuretic (polyuric) IIIrd phase is characterized by a progressive increase in 
urine volume, a harbinger of renal recovery. However, the serum Cr may continue 
to rise for another 24 to 48 hours before it reaches a plateau and falls. Severe poly-
uria during this phase is seen less frequently now. Careful management during this 
phase is crucial, because up to 25% of deaths with ARF may occur in this phase, 
usually related to fluid and electrolyte abnormalities, as well as infection. Finally, 
the recovery IVth phase ensues. Renal function returns to near baseline, but ab-
normalities of urinary concentration and dilution may persist for weeks or months.
Uremic signs and symptoms:
• Gastrointestinal: nausea, vomiting, upper gastrointestinal bleeding;
• Neurologic: mental status changes, encephalopathy, coma, peripheral neuropathy;
• Cardiac: pericarditis, uremic cardiomyopathy;
• Pulmonary: pleuritis;
• Hematologic: bleeding, anemia;
• Immunologic: impaired granulocyte and lymphocyte function.
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Complications:
• Fluid overload: hypertension, edema, acute pulmonary edema;
• Electrolyte disturbances: hyperkalemia, hyponatremia, hypermagnesemia, hyper-
phosphatemia, hypocalcemia or hypercalcemia, hyperuricemia, metabolic acidosis.
Differential .diagnosis .of .acute .renal .failure
Distinguishing between prerenal, renal and postrenal causes of ARF may be com-
plex. A thorough history and physical examination to assess volume status, cardio-
vascular hemodynamics, potential nephrotoxins and evidence of systemic disease 
should be undertaken in ARF patients. All interventions and drug therapies sur-
rounding an ARF event should be outlined. Therefore, it is critical to know the 
level of preexisting renal function. One should identify the presence of risk factors 
and diseases known to be associated with ARF. 
On examination, the vital signs and hemodynamic parameters should be assessed. 
Hypotension, particularly orthostatic hypotension, suggests volume depletion and 
prerenal ARF. Hypertension with advanced CRF can be an indicator of volume 
overload, suggesting the need for diuretics or dialysis. A patient’s weight is helpful 
information and its daily measurement is important in the diagnosis and manage-
ment of ARF. After major urologic procedures (e.g., cystectomy, nephrectomy, 
transplantation), measurement of the central venous pressure or pulmonary artery 
wedge pressure is the most accurate method to assess volume status. Other clinical 
parameters that correlate with volume status include neck vein distention, lung rales 
and peripheral edema.
The urine output may be a clue to the diagnosis of ARF. The presence of marked 
oligoanuria suggests urinary tract obstruction, renovascular occlusion or cortical ne-
crosis. In contrast, nonoliguric ARF is being recognized with increased frequency and 
careful monitoring of serum Cr levels in patients at risk is of paramount importance.
Examination of the urinalysis results is fundamental to the evaluation of the 
patient with ARF. The simple urinalysis may distinguish the cause of ARF among 
the various possibilities. For example, proteinuria, hematuria and RBC casts are 
pathognomonic of AGN. The classic sediment of ATN includes pigmented gran-
ular casts and renal tubular epithelial cells, which may be seen in nearly 80% of 
cases of oliguric ARF. Normal urinalysis will be by prerenal and postrenal ARF. 
Eosinophils may be seen by AIN.
For diagnosis of ARF there are a variety of imaging modalities.The most widely 
used is renal US. This noninvasive and readily available study is fairly sensitive for 
the identification of hydronephrosis. Duplex US of the renal artery is useful for 
the identification of renal artery stenosis or thrombosis. The absence of a Doppler 
signal from the artery is a noninvasive sign to confirm renal artery thrombosis. 
Another common imaging study in ARF is the abdominal plain radiograph to 
identify the presence or location of renal calculi or both. Additionally, the abdom-
inal plain radiograph is particularly helpful to discern the proper position of the 
stents and drains. The radionuclide renal scan is a useful imaging study in selected 
clinical circumstances. The renal scan is a simple way to evaluate for renal flow in 
situations in which renal artery thrombosis is a serious consideration, such as after 
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partial nephrectomy or renal transplantation. It is especially useful when there is 
renal insufficiency that prohibits the use of iodinated contrast media.
Radiocontrast studies (IVP, CT, angiography) are of limited value during ARF 
because of their ability to worsen renal insufficiency. Angiography is used to con-
firm renal artery thrombosis, stenosis or dissection. Studies such as an IVP yield 





• Carefully monitor intake/output and weights;
• Restrict fluids;
Electrolytes and acid-base balance:
• Prevent and treat hyperkalemia;
• Avoid hyponatremia;
• Keep serum bicarbonate >15 mEq/L;
• Minimize hyperphosphatemia;
• Treat hypocalcemia only if symptomatic or if i.v. bicarbonate is required;
Uremia and Nutrition:
• Administer protein (1.0–1.8 g/kg/day) and maintain caloric intake, consider 
forms of nutritional support;
• Keep carbohydrate intake at least 100 g/day to minimize ketosis and endoge-
nous protein catabolism;
Drugs:
• Diuretics, dopamine and calcium channel blockers;
• Stop magnesium-containing medications;
• Adjust dosage of all other medications for renal failure.
Management of ARF is based on its cause. When ARF is identified as prerenal, 
correction of the precipitating factors and restoration of renal perfusion usually 
lead to its resolution. Nephrotoxic drugs should be eliminated when clinically 
appropriate. Maintaining normal volume status is essential. In the postoperative 
setting, this implies judicious replacement of crystalloid, colloid and blood with 
close monitoring of the central venous pressure. The management of postrenal 
ARF will depend on its etiology. Any obstruction needs appropriate drainage and 
urinary extravasation needs to be controlled. 
The management of ATN focuses on the prevention of complications and providing 
an treatment options that will lead to renal recovery. During the initial evaluation it is 
imperative to search for reversible causes, such as volume depletion and obstruction. 
During the initial stages, a trial of parenteral hydration with isotonic fluids may correct 
ARF secondary to prerenal causes. Thereafter, fluid status should be monitored. In 
a patient with oliguria, special attention must be given to avoiding excessive hydra-
tion that might precipitate the need for dialysis. Consideration may be given to using 
pharmacologic intervention to convert the patient from an oliguric to a nonoliguric 
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state.Increases in urinary volume make it easier to treat problems of volume overload, 
hyperkalemia and metabolic acidosis. The morbidity, need for dialysis and mortality 
lower in the nonoliguric patients.
Once the clinical diagnosis of ATN is made, conservative treatment is in order. 
This would include attempts to minimize further renal parenchymal injury, ensure 
provision of nutrition, maintain the metabolic balance and promote recovery of 
renal function. Pharmacologic intervention have the goal to convert oliguric ATN 
to nonoliguric ATN.
It is suggested that patients who respond to mannitol, furosemide or dopamine 
with an increased urine output have better outcomes than nonresponders. Both 
loop diuretics and mannitol administration have been proved to minimize the 
degree of renal injury if given at the time of the ischemic insult. Diuretics are 
capable of inducing a diuresis to wash out obstructive debris and casts. It is rea-
sonable to give a trial of a loop diuretic in escalating doses and if the patient does 
not respond, the drug should not be readministered because large doses of loop 
diuretics may be ototoxic and the large infusion volume may cause pulmonary 
edema. Mannitol, an osmotic diuretic, theoretically ameliorates ARF by flushing 
intratubular casts, increasing RBF, increasing urine flow, reducing hypoxic cell 
swelling, protecting mitochondrial function and scavenging free radicals. Man-
nitol use continues to be promoted prophylactically or within a short time after 
an ischemic or nephrotoxic insult in certain high-risk patient groups. Dopamine 
has selective renal vasodilator properties that cause natriuresis and increased urine 
output. Low-dose “renal-dose” dopamine activates dopamine-1 receptors, which 
induce renal vasodilation and increased RBF. 
Calcium channel blockers inhibit voltage-gated calcium entry into cells and are 
reported to reverse vascular constriction, increase GFR and improve renal plasma 
flow. The clinical benefit of calcium channel blockers most widely studied has 
been the effect on graft function in renal transplant recipients.
Adequate nutrition is important for the recovery of the critically ill patient 
with ARF. Preexisting or hospital-acquired malnutrition is an important factor 
contributing to high mortality seen in patients with ARF. ARF not only affects 
water, electrolyte and acid-base metabolism but also induces specific alterations 
in protein and amino acid, carbohydrate and lipid metabolism. The metabolic al-
terations in ARF patients are determined not only by acute loss of renal function 
but also by the underlying disease process (i.e., sepsis, trauma or multiple-organ 
failure) and by the type and intensity of renal replacement therapy. Ntritional 
therapy in patients with ARF may be beneficial in promoting recovery. Caloric intake 
should be maintained and carbohydrate intake should be at least 100 g/day to mini-
mize ketosis and endogenous protein catabolism. A moderate protein intake of about 
1.0 to 1.8 g/kg/day may be required to maintain positive nitrogen balance. Higher 
protein intakes of up to 2.5 g/kg/day have been needed to improve nitrogen balance in 
critically ill ARF patients on continuous dialysis, although no survival advantage was 
noted. Hence, it should be stressed that a low-protein intake (<0.5 g/kg/day) may be 
unnecessary and protein intake should not be severely restricted in ARF to limit the 
need for dialysis. In terms of types of amino acids utilized, diet or solutions including 
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both essential and nonessential amino acids in standard proportions is recommended. 
Dietary phosphorus, potassium and sodium chloride may be restricted. In the critically 
ill patient, nutritional support via total parenteral nutrition or enteral feedings should 
be considered. Prior studies demonstrate that provision of adequate nutrition to the 
ARF population may improve survival. Patients with ARF are candidates to develop 
significant electrolyte abnormalities such as hyperkalemia, metabolic acidosis, hyper-
phosphatemia and hypocalcemia. These problems may be minimized by the prophy-
lactic institution of a low-potassium diet accompanied by fluid restriction and oral 
phosphate binders.
Hyperkalemia is the most common and most dangerous electrolyte abnormality 
in the ARF setting. If the serum potassium level exceeds 6.0 mEq/L, an electro-
cardiogram should be performed with subsequent therapy based on the findings. 
With hyperkalemia, the earliest changes demonstrate peaked T waves with subse-
quent broadening of the PR interval and eventual QRS broadening, which may 
mature into a sine wave form. Stabilizing the membrane of the cardiac conduction 
system may be accomplished with i.v. calcium salts, which have an immediate 
effect and a rather short duration of action. Shifting potassium into cells may be 
accomplished by a combination of i.v. glucose and insulin or i.v. sodium bicar-
bonate. Elimination of potassium from the body in a patient with ARF may be 
accomplished via the GIT with a cationic binding resin. If severe hyperkalemia 
exists, dialysis may be required.
Dialysis
Despite adequate medical therapy, dialysis may be required for patients with se-
vere ARF. The indications for the initiation of dialysis include:
• Volume overload;
• Severe hyperkalemia;
• Severe metabolic acidosis;
• Pericarditis, selected poisonings;
• Uremic symptomatology.
HD is the standard dialytic modality for hemodynamically stable patients with 
ARF. To perform acute HD, access to the circulation is required and usually involves 
placement of a venous catheter in the jugular, subclavian or femoral vein. Blood is 
transported by a blood pump to the dialyzer, where it comes into close proximity 
with the dialysate solution across a semipermeable membrane. Contact of the blood 
with dialysate allows the removal of solutes by the process of diffusion, driven by a 
concentration gradient from blood to dialysate. Fluid may also be removed by the 
process of ultrafiltration driven by a pressure gradient across the dialyzer.
PD permits the removal of solutes and fluid by using the peritoneal membrane as 
the dialyzer. This process does not require access to the circulation and is generally 
less stressful hemodynamically than standard HD. For this procedure, dialysate is 
instilled into the peritoneal space via a catheter, which is percutaneously placed. 
Fluid is allowed to dwell for a period of time and is then removed, taking with it 
uremic solutes by diffusion, as well as accomplishing ultrafiltration of fluid from an 
osmotic pressure gradient induced by high concentrations of glucose in the dialysate. 
The diagnosis of CKD implies a persistent abnormality in GFR with a wide 
spectrum of causes. It is recommended that “chronic kidney disease” should be 
defined as sustained kidney damage greater than 3 months resulting in a GFR 
<60 mL/min/1.73 m2. After an initial kidney insult, if the acute injury does not 
completely resolve, a continuing diminishing of functional nephrons occurs over 
time. The renal failure consists of 4 stages, associated with specific clinical and 
biochemical abnormalities. Small changes in the SCr measurement correlate with 
significant alterations in the GFR when renal function is > 60 mL/min. This is 
especially true in CKD as the GFR decreases to levels <30 mL/min. Although 
an initial disease may decrease an individual’s renal reserve, biochemical abnor-
malities are uncommon before the “renal insufficiency” stage. Once severe “renal 
failure” occurs, clinical symptoms become more common. The rate of progression 
throughout the delineated stages depends on many factors. 
When kidney function is minimally impaired, physiologic adaptation is com-
plete. As the GFR falls usually below 20% of normal, progressive anorexia with 
nausea, salt retention, acidosis, anemia, muscle fatigue and worsening blood pres-
sure control may occur. Structurally, after the GFR in humans falls below 1/2 
of normal, a relentless progressive loss of function ensues even when the initial 
disease becomes inactive.
The clinical course of progressive renal disease moves through several different 
phases, which include: decreased renal reserve, renal insufficiency, renal failure, 
uremia.
Etiology
There are a number of diseases involve the kidney and can lead to progressive renal 
insufficiency. Progressive deterioration in renal function can occur in tubulointer-
stitial disease, hematopoietic disease, ureteral obstructions, VUR, BPH, vascular 
disease (hypertension, atheroemboli), metabolic disease (cystinosis, oxalosis, uric 
acid nephropathy, hypercalcemia), toxic injuries (analgesic, NSADs, chemother-
apy, lead, lithium), cystic disease (ADPKD, medullary cystic disease), glomerular 
diseases (glomerulonephritis, IgA nephropathy), systemic diseases (DM, systemic 
lupus erythematosus, systemic sclerosis, systemic vasculitis).
Urologic diseases can result in CKD. Urinary stone disease, obstructive urop-
athy involving the ureter, bladder or urethra can lead to progressive CRF. Un-
detected PUJO and PUVs are the most common types of congenital causes for 
progressive CRF. The percentage of ESRD population attributable to reflux ne-
phropathy and nonreflux nephropathy has increased. VUR may result in CKD 
from renal scarring. VUR may be either unilateral or bilateral and progression to 
CRF is related to the severity of reflux.
10 CHRONIC RENAL FAILURE
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Diagnosis
Once the GFR decreases to <60 mL/min for 3 months or more, patients are 
classified as having CKD. The adjusted relative risk from a population survey 
adjusted for age, proteinuria, hematuria and hypertension found that changes in 
GFR occurred at a cutoff SCr clearance value of 1.2-1.4 mg/dL. Other measure-
ments that complement the SCr value may give a better index to the underlying, 
predicted GFR. Cr clearance, Cr clearance plus urea clearance divided by 2, GFR 
measurements - all provide information on the level of renal dysfunction. The 
Cockcroft-Gault formula [Cr clearance = (140 - age) Ѕ weight Ѕ (0.85 if female) 
divided by 72 Ѕ plasma Cr] is widely used throughout the world to estimate RRF.
Most forms of CKD gradually and inevitably progress to ESRD over a 2-10 yeare, 
depending on the underlying renal lesion responsible for the CKD, combined with 
patient-specific factors. Staging and the approach to treatment of CKD depend on 
the assessment of GFR (function assessment), level of proteinuria and clinical co-
morbidities.
Function Assessment 
The SCr level is widely used as an index of RRF, the measured value is affected 
by factors other than the GFR. At any given GFR the SCr concentration is sig-
nificantly higher in men than in women and in blacks than in whites. The mean 
of the Cr and the urea clearance is a more accurate estimate of the GFR than 
either is separately.
Radiographic Assessment 
The radiographic assessment of CKD patients should take into account the impact of 
contrast on RRF. Contrast material can induce worsening of underlying renal disease 
to the point of requiring RRT. All patients with abnormal SCr greater than 2 mg/
dL should be considered for alternative diagnostic testing and prophylactic preventive 
strategies to avoid worsening renal function. Specific measures may help lower the risk 
for ARF in patients with CKD undergoing radiographic assessment. These include 
volume expansion, hydration with i.v. administration of sodium chloride 0.9%, sodium 
bicarbonate solution, infusion of mannitol, loop diuretics, calcium antagonists, the-
ophylline, dopamine.
Urinalysis
The urine sediment examination is helpful in detection of CKD and the identification 
of the type of kidney disease. Cells can originate from the kidney or from other sites 
within the urinary tract. The presence of a RBC cast strongly suggests glomerulone-
phritis especially if the RBCs are dysmorphic. Urinary eosinophils are usually associat-
ed with allergic tubular interstitial nephritis. If the urinalysis is negative, despite the pa-
tient’s having apparent CKD, a second specimen should be examined at another time. 
Increased excretion of albumin is a sensitive marker for CKD attributable to DM, 
glomerular disease, interstitial disease and hypertension. It is recommended screening 
assessment using proteinuria measurement to detect CKD. Traditionally the cut-off 
value indicating a urinary albumin excretion >30 mg/24 hr has been 3 mg/L.
Chapter 10. CHRONIC RENAL FAILURE148
Kidney biopsy
A US-guided renal biopsy is not usually performed to evaluate asymptomatic 
hematuria but is warranted if the GFR is <60 mL/min and the urinalysis is ab-
normal. The structural severity of glomerular injury and the immunopathologic 
category of disease are helpful in predicting renal outcome.
Conservative .treatment
Regardless of the disease, once a critical number of nephrons is destroyed, a 
steady decline in GFR occurs as the progressive loss in viable nephrons occurs. 
Well-designed renal assessment and management programs are feasible and can 
be systematically applied to large numbers of CKD patients to decrease the rate of 
progression. The list are: lifestyle modifications, blood pressure control, glycemic 
control, reduction of proteinuria, protein restriction, lipid control, avoidance of 
nephrotoxins, correction of anemia, optimization of calcium-phosphorus product, 
correction of acidosis and maintenance of fluid balance.
Optimal renal care begins with the early detection of CRF. It means screening 
high-risk patients with serum Cr >1.2 mg/dl. Next will be initiation of interven-
tions that delay progression (using of ACE inhibitors to control blood pressure, 
blood sugar target of HbA1C less than 7%, glucose before meals of 80 to 120 
mg/dl, hyperlipidemia control, protein restriction), prevent uremic complications 
(malnutrition, abnormal body composition, osteodystrophy, anemia, edema, aci-
dosis), modification of comorbidities (DM, vascular, pulmonary and cardiac dis-
ease) and preparation of the patients for RRT (referral to nephrologist for evalua-
tion, dialysis) to optimize patient survival.
Various pharmacologic trials comparing different medications have shown that 
patients with better blood pressure control have significantly slower rates of de-
teriorating kidney function. Clinical trials have suggested that reducing mean ar-
terial pressure to 125/75 mm Hg provides more optimal renal function stability 
in patients with diabetes and proteinuria, compared with mean arterial pressure 
targets of 140/90 mm Hg. Aggressive blood pressure control should also be a goal 
for patients on dialysis. Angiotensin II is critical in causing progressive renal disease 
by both hemodynamic and nonhemodynamic mechanisms. Blockade of the renin-an-
giotensin system contributes to preservation of renal function by decreasing glomerular 
pressure and proteinuria. Because proteinuria plays a sentinel role in renal scarring, 
a reduction in proteinuria correlates with slowing of disease progression. For optimal 
control of blood pressure a combination regimen that includes a diuretic and ACE 
inhibitors is essential.
Protein restriction can ameliorate many symptoms of CRF and prevent its pro-
gression. However, without regular dietary consultation, patients on a low-protein 
diet may experience a decrease in protein intake and deterioration of several nu-
tritional parameters. A number of different diets have been used to help slow the 
progression of CKD. The overall dietary requirement in CKD is approximately 
0.6 g of protein/kg/day.
Decreased GFR is associated with complications in most organ systems. The 
most important complications include high blood pressure, anemia, malnutri-
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tion, bone disease, neuropathy and alterations in quality of life. As the patient 
moves from stage to higher stages, additional comorbidities are more likely to 
develop. Atherosclerotic risk factors are frequently present in CKD. Patients at high 
risk for cardiovascular events warranting lipid-lowering therapy and close cardiovascular 
screening. Both statin and fibric acid derivatives have proven effective, although indi-
vidual differences mandate periodic monitoring of fasting lipid levels and liver function 
tests. Cigarette smoking is universally recognized as an independent risk factor for 
cardiovascular disease and should be discouraged with this disease. If GFR <60 
ml/min there is a higher prevalence of abnormalities of bone metabolism. Treatment 
of calcium-phosphorus abnormalities or reduction in the use of calcium-based phos-
phate binders reduces the risk of cardiovascular disease outcomes. Obese patients 
are associated with increasing risks for a variety of cardiovascular complications 
and with higher all-cause mortality. Weight reduction is an important lifestyle 
modification for overweight patients. There are associations between anemia and 
adverse cardiovascular outcomes in CKD patients. The treatment goal should be 
to achieve hemoglobin of ∼12 g/dl with erythropoetin.
Treatment .of .the .patients .with .end-stage .renal .disease
Multiple different RRTs are available for treatment of ESRD patients. The most 
commonly utilized RRTs are HD, PD and renal transplantation. HD is the predom-
inant form of therapy for adults with ESRD. Transplantation, however, is the pre-
dominant mode of care for patients younger than 20 years. ESRD patients are treated 
also with chronic PD. A desire for self-care, a long distance from a HD unit, diffi-
culties with HD therapy, serious cardiac disease, DM and small stature are charac-
teristics of patients especially suited for PD. Unsuitable characteristics of patients for 
chronic PD are considered to be obesity, hernias, poor hygiene, inflammatory bowel 
disease and obliterated peritoneal space. Outcome comparison suggests that renal 
transplantation is still the best overall treatment for ESRD patients, despite advances 
in dialytic options. Therefore, patients who reach ESRD should undergo transplan-
tation as soon as possible, once on dialysis. The estimated number of patients starting 
renal replacement therapy each year for ESRD is elevated. The increase in living 
renal donation has been further facilitated by the widespread adoption of minimal-
ly invasive donor nephrectomy techniques, the increased use of living, biologically 
unrelated renal donors and the development of protocols for transplantation across 
alloantibody barriers, including ABO blood group incompatibility.
The purposes of RRT are to prolong and to maintain the quality of life. Per-
manent renal failure in adults is commonly defined as an irreversible glomerular 
filtration rate <10 mL/min or a serum Cr level of greater than 8 mg/dL. A rea-
sonable goal for ESRD treatment programs is the transplantation of all patients in 
whom the risk is equal to or less than that of remaining on maintenance dialysis. 
Renal transplantation is the preferred method of therapy for most patients with 
ESRD because it is more cost effective and allows a return to a more normal 
lifestyle than maintenance dialysis does. Data indicate that survival after renal 
transplantation is significantly better than that of patients treated with dialysis.
The survival of kidney grafts has steadily improved and those for the current era 
are quite remarkable. Kidney transplant 5 year survival rates for HLA-identical 
sibling is 80-87%, for one-haplotype sibling is 75-81%, for spouse is 78%, for oth-
er biologically unrelated is 70-78%, for deceased is 60-66%, for standard criteria 
is 60-70%, for expanded criteria is 40-52%.
Indications for RRT:
• Anuria or extreme oliguria (urine output < 50 mL/12 hr);
• Hyperkalemia (K > 6.5 mmol/l);
• Severe acidemia (pH <7.1);
• Azotemia (urea > 30 mmol/l);
• Clinically significant organ edema;
• Uremic encephalopathy, pericarditis, neuropathy/myopathy;
• Severe dysnatremia (Na > 160 or < 115 mmol/l).
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Selection .and .preparation .of .kidney .transplant .recipients
The pretransplantation evaluation is a multidisciplinary process that is performed 
well in advance of the renal transplantation operation and immunosuppression. 
The purposes of the evaluation are generally considered to be to diagnose the 
primary renal disease and its risk of recurrence in the kidney graft and to rule out 
active invasive infection.
The process of evaluating the transplantation candidate is initiated by identifying 
the presence or absence of the risk factors. Candidates with a history of substance 
abuse must have unannounced drug screens with negative results before continuing 
the process. Candidates with morbid obesity must demonstrate weight reduction 
before continuing the process because of the risks associated with renal transplanta-
tion in obese patients. Candidates considered to be at risk for noncompliance must 
demonstrate contract satisfaction. Cigarette smoking increases the risks of surgery, 
post-transplantation malignancy, cardiovascular disease and renal allograft loss. It 
must be stopped before transplantation in patients who already have clinical evi-
dence of vasculopathy or cardiopulmonary disease. Compliance issues are extremely 
important in the long-term management of kidney transplant recipients. Transplan-
tation candidates with chemical dependency need to have an objectively document-
ed drug- or alcohol-free period of at least 6 months before transplantation. 
It is recommended that patients >50 years or with a history of coronary artery 
disease, cardiac symptoms or insulin-dependent DM undergo stress cardiac testing 
with further diagnosis and treatment of significant cardiac disease.
Patients with focal segmental glomerulosclerosis, hemolytic-uremic syndrome, 
primary oxalosis, renal amyloidosis, cystinosis should be counseled about the sig-
nificant probability of disease recurrence and the risk of secondary graft failure. 
DM and IgA nephropathy are examples of diseases that commonly recur in the 
transplanted kidney but rarely result in graft failure. ADPKD, renal dysplasia and 
Alport’s syndrome without antiglomerular basement membrane antibodies are ex-
amples of renal diseases that do not recur in the transplanted kidney.
Infections must be detected and treated before transplantation or prevented with 
immunizations. Potential sources of dental sepsis must be treated. Dialysis access sites 
must be clear of infection. Pulmonary infections or tuberculin skin test conversions 
require treatment before immunosuppression. Reasonable indications for pretransplan-
tation cholecystectomy are considered to be symptomatic cholecystitis, multiple small 
gallstones and polyps. Segmental colectomy is reasonable for patients with recurrent 
diverticulitis because of the morbidity and mortality of bowel perforation in the immu-
nosuppressed kidney transplant recipient. Diabetic foot ulcers must be healed before 
transplantation and UTIs should be inactive at the time of engraftment. Serologic 
testing for CMV is important because this disease is a major cause of morbidity in 
immunosuppressed patients. Patients with herpes simplex virus need antiviral therapy 
during intense immunosuppression. Recipient HIV infection has been considered to be 
a contraindication to renal transplantation. The treatment of chronic active hepatitis B 
and C is evolving and patients with active hepatitis C infection may benefit from anti-
viral therapy before transplantation. Сorticosteroids enhance viral replication and these 
infections should be inactive at the time of transplantation. Unless the patient is pro-
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tected by antibody development after infection or prior immunizations, the following 
immunizations are given to transplantation candidates: hepatitis A, hepatitis B, pneu-
mococcus, diphtheria, tetanus, pertussis, polio, varicella, measles, mumps and rubella.
To reduce the risk of cancer recurrence, a waiting time of 2 to 5 cancer-free years 
from the time of the last cancer treatment is recommended for patients who have 
had invasive malignancies. Shorter intervals from cancer treatment to transplantation 
are generally accepted for patients who have had low-grade, noninvasive cancers.
Heart disease is the predominant cause of death after renal transplantation 
and it is common for kidney transplantation candidates with a history of cardiac 
disease, cerebrovascular disease or DM or who are older than 50 years to undergo 
a cardiac evaluation. Further testing and treatment are based on the results of a 
screening evaluation. Cerebrovascular disease, peptic ulcer disease and significant 
pulmonary disease must be detected and treated.
Evaluations of the vascular system and the urinary tract are necessary to identify 
problems that need to be corrected before transplantation or addressed at the time of 
transplantation. Patients with symptoms and signs of lower extremity arterial disease 
or a history of abdominal or pelvic vascular surgery need to undergo a diagnostic 
evaluation to be certain that revascularization of a kidney graft is possible. If signif-
icant arteriosclerosis or venous disease is detected, it may be necessary to perform 
angiography to select alternative sites, such as the aorta or splenic artery, for renal 
revascularization or to plan corrective vascular surgery before renal transplantation. 
Thrombosis is a significant cause of kidney transplant loss. Renal transplanta-
tion patients at risk for graft thrombosis are those with previous vascular problems. 
A decision can be made about intermediate- or long-term anticoagulation with 
low-molecular-weight heparin or warfarin.
The purposes of the urologic evaluation are to determine the suitability of the 
urinary bladder or its substitute for urinary tract reconstruction and to determine 
the necessity for removal of the native kidneys before or at the time of renal 
transplantation. Patients need the urologic evaluation and treatment before or 
after transplantation if there is a history for urologic disease, abnormalities and 
operations on the urinary tract.
Indications for nephrectomy:
• Renal stones not cleared by minimally invasive techniques;
• Solid renal tumors;
• Polycystic kidneys that are symptomatic, have been infected or have tumors;
• Significant not controlled proteinuria;
• Recurrent pyelonephritis;
• Nephroslerosis or terminal hydronephrosis.
Pretransplantation nephrectomy is usually performed 6 weeks before trans-
plantation or active wait-listing for deceased donor renal transplantation to allow 
wound healing and the detection and treatment of surgical complications. It is 
common to perform kidney removal at the time of renal transplantation in chil-
dren. It is common to do preliminary nephrectomies in adults.
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Donor .selection .and .preparation
The basic criteria for a renal donor are an absence of renal disease, active infection 
and an of transmissible malignancy. Whether the kidney is removed from a living 
donor or a deceased donor, the surgical goals are to minimize warm ischemia 
time, to preserve renal vessels and to preserve ureteral blood supply. In the de-
ceased donor, it is also necessary to obtain histocompatibility specimens.
Living Donor 
On the basis of the preoperative evaluation, one must be able to assure the living 
donor of nearly normal renal function after unilateral nephrectomy. On evalua-
tion, if one of the potential donor’s kidneys is better than the other, the better 
kidney is left with the donor.
A living renal donor is considered to be unsuitable when one of the following 
is present: significant renal disease, mental dysfunction, high risk of perioperative 
mortality or morbidity and significant transmissible disease. ABO incompatibility 
and a positive crossmatch between donor lymphocytes and recipient serum were 
usually considered to be contraindications to directed living renal donation. Sero-
logic testing is performed for HIV, hepatitis, CMV infection and syphilis. DM is 
excluded in the donor. Abdominal US can be performed to exclude donors with 
significant renal abnormalities and to detect incidental intra-abdominal abnor-
malities. 3D CT angiography followed by plain X-Ray of the abdomen has been 
widely accepted because it satisfactorily excludes stone disease, demonstrates renal 
and vascular anatomy and defines the urinary collecting system.
The mortality of kidney donation has been estimated to be 0.02%, the risk of a 
potentially life-threatening or permanently debilitating complication has been es-
timated to be 0.23%. The short- and long-term risks of living donor nephrectomy 
are generally considered to be low enough and the probability of successful graft 
outcome high enough, to make the risks acceptable for fully informed donors. 
Live donor nephrectomy can be performed either as an open or laparoscopical-
ly assisted procedure. Laparoscopic donor nephrectomy has become the preferred 
technique for live donor nephrectomy. The kidney is then taken in an ice bath into 
the recipient’s operating room or cold-stored until the time of transplantation.
5-year graft survival for living biologically unrelated donor kidney transplants is 
better compared with primary deceased kidney transplants.
Deceased Donor 
The criteria for an ideal deceased kidney donor are normal renal function, no hy-
pertension requiring treatment, no DM, no malignancy other than a primary brain 
tumor or treated superficial skin cancer, no generalized viral or bacterial infection, 
acceptable urinalysis, age between 6 and 50 years and negative assays for STD, 
hepatitis, HIV and human T-lymphoproliferative virus. Exceptions are made in 
an effort to expand the donor pool, resulting in the adoption of the “expanded 
criteria donor”. ECDs are defined as donors >50 years old with any two of the 
following risk factors: cerebrovascular death, hypertension and serum Cr level >1.5 
mg/dl. ECD kidney transplant survival rates and those from donors younger than 
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the age of 6 years and older than the age of 50 years are significantly inferior to 
those from ideal deceased donor kidney transplants.
The initial goals of resuscitation of the brain-dead deceased donor are SBP of 
90 mm Hg or mean arterial pressure of 60 mm Hg and urinary output exceeding 
0.5 mL/kg/hr. Monitoring of central venous pressure, capillary wedge pressure 
or pulmonary artery pressure is helpful for managing fluid administration. Se-
rum electrolyte levels are checked every 2 to 4 hours. In some cases dopamine 
or dobutamine can be infused without causing renal vasospasm. If intravascular 
volume expansion and vasopressors are unsuccessful in promoting a diuresis, 
furosemide, 1 mg/kg, with or without mannitol, 0.5 to 1 g/kg, can be infused. 
Because hypothermia can cause cardiac irritability and coagulopathy, the 
head can be wrapped, i.v. fluids can be warmed and the body can be placed 
on a warming blanket. Tissue typing and crossmatching can be performed on 
a peripheral blood sample or groin lymph nodes before organ retrieval. The 
deceased donor is maintained in the operating room by the anesthesiology 
team to ensure ventilation and circulatory support and to administer drugs 
such as diuretics, heparin and α-adrenergic blocking agents.
The principles of deceased donor organ retrieval are adequate exposure, control 
of the vessels above and below the organs to be removed, initiation of preservation 
in situ, the removal of the organs, separation of the organs, completion of preserva-
tion, removal of histocompatibility specimens, removal of iliac vessels for vascular 
reconstruction of pancreas and liver grafts and organ packaging. The kidneys are 
the last transplantable organs to be removed. A total midline incision with splitting 
of sternum and diaphragm exposes all transplantable organs in the chest and abdo-
men. For multiple abdominal organ retrieval, the aorta is controlled above the ce-
liac axis. The IVC is controlled above the liver. The aorta and IVC are controlled 
below the renal vessels, heparin is administered to the donor and the great vessels 
are cannulated. The proximal aorta is occluded, the IVC is vented into the chest 
or through the distal IVC cannula and in-situ flushing with an ice-cold preserva-
tion solution is performed through the aortic cannula. The gastrocolic ligament is 
divided, the small bowel mesentery is divided along with the superior mesenteric 
artery and vein and the small bowel is divided at the ligament of Treitz. The 
esophagus is divided and, with further dissection, the en bloc specimen consisting 
of the liver, stomach, spleen, pancreas, both kidneys, aorta and IVC is removed. 
The specimen is placed down in a pan of slush and is separated.
Kidney .preservation .and .preparation
Warm ischemic injury of organs for transplantation is caused due to failure of 
oxidative phosphorylation and cell death due to ATP depletion. ATP is required 
for the function of the cellular sodium-potassium pump. When the sodium-po-
tassium pump is impaired, sodium chloride and water passively diffuse into the 
cells, resulting in cellular swelling and the “no-reflow” phenomenon after renal 
revascularization. Lysosomal enzymes are activated and this results in cell death. 
During reperfusion, hypoxanthine is oxidized to xanthine with the formation of 
free radical scavengers that cause further cell damage.
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Cellular energy requirements are significantly reduced by hypothermia. This 
is done by surface cooling, hypothermic pulsatile perfusion or flushing with an 
ice-cold solution followed by cold storage. Making the flush solution slightly hy-
perosmolar with impermeant solutes helps prevent endothelial cell swelling. When 
the sodium-potassium pump is impaired, there is passive transfer of ions across 
the cell membrane. If the electrolyte composition of the flush solution is nearly 
the same as that inside the cell, electrolyte balance will be maintained. Calcium 
channel blockers, xanthine oxidase inhibitors, free-radical scavengers, vasoprotec-
tive agents and lysosome stabilizers such as methylprednisolone have all been used 
to reduce ischemic injury.
The basic methods of kidney preservation are pulsatile machine perfusion with a 
protein-based solution or hypothermic flushing followed by simple cold storage. In 
current time after demonstration that the two methods provided equivalent results, 
simple cold storage became more widely used for human kidney preservation. The 
commonly used solutions (UW solution or Euro-Collins) minimizes cellular swelling. 
A kidney graft removed from a living renal donor by an open technique re-
quires little preparation by the kidney transplant recipient team because most of 
the preparation has been done in situ by the donor team. Because of the presence 
of significant amounts of perirenal fat, stapled vessels and retraction of the renal 
vein into the renal hilum, significantly more bench work is required for kidneys 
removed laparoscopically. It is needed prompt identification of the renal artery 
and vein, removal of the staple lines and rapid flushing of the kidney with ice-cold 
preservation solution is the initial priority, followed by the final dissection. For a 
deceased donor kidney, the short right renal vein can be extended with a variety 
of techniques that use the inferior vena cava or donor external iliac vein. The left 
kidney may be preferred because of its longer renal vein. There are techniques for 
the management of multiple renal arteries from deceased and living donors.
Recipient .operation
Just before surgery a prophylactic antibiotic is administered and continued postop-
eratively until the results of cultures are known. Immunosuppression is started just 
before or during surgery in the deceased kidney graft recipient. After the induction 
of anesthesia and the placement of central venous catheter, the genitalia and skin 
are prepared and a Foley catheter is placed in the bladder. The bladder is filled 
before the ureteroneocystostomy. A self-retaining ring retractor attached to the 
operating table that has been flexed and rotated toward the surgeon allows the 
operation to be performed by a surgeon and one assistant. Most common kidney 
is transplanted into right iliac fossa. Placement of the kidney on the right side will 
allow access to a wider choice of arteries and veins for vascular reconstruction. In 
men, the spermatic cord is preserved and in women, the round ligament is divided. 
The recipient’s target blood vessels are dissected. Lymphatic vessels are divided 
between ligatures to prevent the development of postoperative lymphocele. Before 
temporary vascular occlusion, heparin, is commonly given i.v. to the recipient. 
During the vascular anastomosis, an infusion of mannitol and fluids are begun to 
act as a free-radical scavenger and as an osmotic diuretic. The addition of an albu-
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min infusion has been found to be helpful in promoting early renal function in the 
deceased donor kidney transplant. The renal artery is usually anastomosed to the 
end of the internal iliac artery or to the side of the external or common iliac artery. 
The renal vein, with or without an extension, is usually anastomosed end to side to 
the external iliac vein or to the junction of the external and common iliac veins. 
Furosemide is commonly infused just before release of the vascular clamps. Uri-
nary tract reconstruction is usually by antireflux ureteroneocystostomy, of which 
there are several techniques. Double-pigtail ureteral stents are used. The routine 
use of a ureteral stent for all cases has been shown to reduce the incidence of 
ureteral complications. Stent is left in place for several weeks. The uncomplicated 
renal transplantation can be closed by a variety of running or interrupted suture 
techniques with retroperitoneal drain. A closed suction drain is recommended in 
the subcutaneous tissue of an obese patient.
Renal .allograft .rejection
There are two histocompatibility systems of greatest importance in renal trans-
plantation: the ABO blood group and the MHC. Most common the donor and 
recipient must be ABO compatible because A and B substances are present on 
endothelial cells and most individuals have antibodies to the RBC antigens they 
lack. The MHC antigens are glycoproteins on the cell membrane. They are en-
coded by MHC genes on the short arm of chromosome 6. Autosomal class I 
antigens are known as the HLA-A, HLA-B and HLA-C antigens and they are 
present on nearly all nucleated cells. They are detected by tissue typing T lym-
phocytes, usually with a DNA polymerase chain reaction amplification technique. 
HLA-DR, HLA-DQ and HLA-DP antigens are class II antigens present on B 
lymphocytes, activated T lymphocytes, monocytes, macrophages, dendritic cells 
and some endothelial cells. HLA-DR antigens are detected by tissue typing B 
lymphocytes. Testing for HLA-DQ and HLA-DP antigens is not routinely done. 
Recipient circulating cytotoxic antibodies against the MHC antigens of a specific 
donor are detected by pretransplantation crossmatching techniques and a posi-
tive complement-dependent T-cell lymphocytotoxicity crossmatch is considered 
to be a contraindication to renal transplantation when the serum used is recently 
obtained from the transplantation candidate. Protocols have been developed to 
use kidney transplants when the recipient has a positive crossmatch to the donor 
and the crossmatch is rendered negative by plasmapheresis and immunoglobulin 
administration to permit an otherwise prohibited transplant to take place.
Because of inheritance patterns of the HLA antigens, each potential kidney graft 
recipient is a “half-match,” or haploidentical, with his or her parents and children 
and has a 0.25 probability of HLA identity, a 0.50 probability of haploidentity and 
a 0.25 probability of a total HLA mismatch with a sibling. Within the past 5 years, 
the influence of histocompatibility matching on graft survival has decreased in the 
presence of more effective and less toxic immunosuppressive regimens.
Incompatibility with MHC antigens on donor tissue stimulates the very com-
plex immune response.
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Classification of Rejection 
Hyperacute rejection occurs immediately after renal revascularization. It is an 
irreversible process mediated by preformed circulating cytotoxic antibodies that 
develop after pregnancy, blood transfusions or an earlier failed transplantation. 
It is very rare when the microlymphocytotoxicity crossmatch between recipient 
serum and donor lymphocytes is negative.
Accelerated rejection is mediated by humoral and cellular components of the 
immune response. It occurs within days to weeks and often does not respond to 
antirejection therapy.
Acute rejection can occur any time after transplantation. The symptoms of 
acute kidney transplant rejection are those of “the flu,” accompanied by pain over 
an enlarged kidney graft, hypertension, decreased urinary output, fluid retention, 
increased serum Cr levels and radioisotope renography indicating decreased renal 
blood flow, glomerular filtration and tubular function. Acute pyelonephritis must 
be ruled out by urinalysis and, subsequently, negative urine culture. Needle biopsy 
of the kidney graft is the standard to confirm the diagnosis of acute rejection. The 
typical histologic findings of acute renal allograft rejection are mononuclear cellu-
lar infiltration, tubulitis and vasculitis.
Chronic rejection is characterized by a gradual decline in renal function asso-
ciated with interstitial fibrosis, vascular changes and minimal mononuclear cell 
infiltration. A positive B-cell crossmatch or a positive flow crossmatch against 
donor B or T cells is considered by some to be predictive of chronic rejection and 
poorer long-term graft survival.
Immunosuppression
Immunosuppressive drug regimens commonly include a corticosteroid in com-
bination with other drugs such as cyclosporine or tacrolimus (calcineurin inhibi-
tors), azathioprine or mycophenolate mofetil (purine antagonists) and sometimes 
antilymphocyte antibody preparations. Triple maintenance immunosuppression 
with prednisone, cyclosporine or tacrolimus and azathioprine or mycopheno-
late mofetil is common. Corticosteroid therapy (reduce transcription of cytokine 
genes) is usually started at high doses and then rapidly tapered during the first few 
weeks after engraftment. Cyclosporine and tacrolimus have similar mechanisms of 
action (inhibit calcineurin and interleukin-2 production), effectiveness and cost, 
but slightly different side effect profiles and they are not used together. A determi-
nation of cyclosporine or tacrolimus blood levels is helpful when toxicity or insuf-
ficient immunosuppression is suspected. Azathioprine and mycophenolate mofetil 
have similar mechanisms of action (inhibit purine synthesis), but mycophenolate 
mofetil is more effective, more toxic and more expensive.
Urinary incontinence is the complaint of any involuntary leakage of urine. It 
results from a failure to store urine during the filling phase of the bladder due to 
abnormality of bladder smooth muscle or the urethral sphincter.
Urine loss is either urethral or extra-urethral or secondary to anatomical abnor-
malities including ectopic ureters, rectovesical or vesicovaginal fistulae is defined 
as a false UI.
Overflow incontinence is leakage of urine when the bladder is abnormally dis-
tended with large residual volumes. Typically, men present with chronic urinary 
retention and dribbling incontinence. This can lead to back pressure on the kid-
neys and CRF.
Nocturnal enuresis describes any involuntary loss of urine during sleep. The 
prevalence in adults is 0.5%. Childhood enuresis can be further classified into pri-
mary types (never been dry for longer than a 6-month period) or secondary (the 
re-emergence of bed wetting after a period of being dry for at least 6-12 months).
Risk .factors
• Gender (female > males) and genetic predisposition;
• Neurological disorders (spinal cord injury, stroke, MS, Parkinson’s disease), 
radical pelvic radiotherapy) and estrogen deficiency for UUI;
• Anatomical disorders (vesicovaginal and uretero-vaginal fistulas, ectopic ureter, 
urethral injuries) for false UI;
• Childbirth, weakness in collagen tissue, pelvic and prostate surgery (radical 
hysterectomy, radical prostatectomy, TURP) leading to injury of sphincter in 
the case of SUI.
Diagnosis .of .UI
History
LUTS and triggers for incontinence (cough, sneezing, exercise, position, urgen-
cy), frequency and severity of symptoms are discussed. Risk factors are established 
(see above). A validated patient completed questionnaire may be helpful.
Physical examination
A pelvic examination is performed in the supine with a Sim’s speculum. The patient is 
asked to cough or strain and inspection for vaginal wall prolapse (cystocele, rectocele, 
enterocele) is performed. Uterine or perineal descent and urinary leakage during the 
stress test are detected. Urethral hypermobility is assessed with this test. A lubricated 
cotton- tipped applicator is introduced through the urethra to bladder neck level. Hy-
permobility is defined as a resting or straining angle of >30 from horizontal.
The abdomen is examined for a palpable bladder, indicating urinary retention. 
A neurological examination should include assessment of anal tone and reflex, 
perineal sensation and lower limb function.
12 INCONTINENCE
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Bladder diaries: the frequency and volume of urine, incontinent episodes, pad 
usage, fluid intake and degree of urgency are recorded. Alternatively, pads can be 
weighed to estimate urine loss (pad testing).
Urinalysis can exclude UTIs. Blood tests, X-Ray imaging and cystoscopy are 
indicated for persistent or severe symptoms, bladder pain and voiding difficulties.
Uroflowmetry measures the velocity of voided urine. A low rate indicates BOO 
or reduced bladder contractility. PVR is also useful (<50ml is normal; >200ml is ab-
normal; 50-200ml requires clinical correlation). Urodynamic investigations are also 
performed.
12 1  .STRESS .URINARY .INCONTINENCE
SUI is involuntary urinary leakage on effort, exertion, sneezing or coughing, due 
to hypermobility of the bladder and urethra and/or ISD.
Urethral hypermobility is due to a weakness of pelvic floor support causing a rota-
tional descent of the bladder neck and proximal urethra during increases in intra-ab-
dominal pressure. If the urethra opens concomitantly, there will be urinary leaking.
ISD describes an intrinsic malfunction of the sphincter, regardless of its ana-
tomical position, which is responsible for type III SUI. Causes include inadequate 
urethral compression (previous urethral surgery, ageing, menopause, radical pelvic 
surgery, anterior spinal artery syndrome) or deficient urethral support (pelvic floor 
weakness, childbirth, pelvic surgery, menopause).
Classification
• Type I - leakage that occurs during stress with <2cm descent of the bladder base 
below the upper border of the symphysis pubis.
• Type II - leakage on stress accompanied by marked bladder base descent 
(>2cm) that occurs only during stress (IIa) or is permanently present (IIb).
• Type III - bladder neck and proximal urethra are already open at rest with or 
without descent. Also known as ISD.
In males, the urethral sphincter may be damaged after prostatic or pelvic sur-
gery (TURP; prostatectomy).
Treatment .of .SUI
The injection of bulking materials 
This treatment option is used to increase outlet resistance. Indications are SUI 
I-II type secondary to demonstrable ISD with normal bladder muscle function. 
Contraindications are UTI, untreated bladder dysfunction, bladder neck stenosis.
Suburethral injections are given by a transurethral route using a cystoscope and 
injection needle. Requires either a local block or a general anaesthetic, with full 
antibiotic cover. In men, the injection should be proximal to external sphincter to 
avoid sphincter spasm or in the proximal membranous urethra beside verumon-
tanum. In women, a periurethral technique can also be used, with endoscopic or 
US guidance. In women, 2 injections are recommended. In men 3 or 4 circum-
ferential injections are administered, with the aim of achieving urethral muscosal 
apposition and closure of the lumen. Overall success rate ~50-70%.
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Complications are urinary urgency, urinary retention (which may need drainage), 
hematuria, cystitis, granuloma formation. Often, repeat treatments are needed.
Retropubic suspension procedures
Surgery is considered after conservative methods have failed. These prosedures 
are used to treat female SUI caused by urethral hypermobility. The aim of sur-
gery is to elevate and fix the bladder neck and proximal urethra in a retropubic 
position, to support the bladder neck and regain continence. These procedures 
are contraindicated in the presence of significant ISD. All operations done via a 
Pfannenstiel or lower midline abdominal incision to approach the bladder neck 
and develop the retropubic space. Better results are seen in patients with pure SUI 
and primary repair.
By Marshall – Marchetti - Krantz procedure sutures are placed either side of the 
urethra around the level of the bladder neck and then tied to the hyaline cartilage 
of the pubic symphysis. Short-term success is about 90%, but declines over time.
Burch colposuspension requires good vaginal mobility, to allow vaginal wall to 
be elevated and attached to the lateral pelvic wall where the formation of adhesions 
over time secures its position. Paravaginal fascia is exposed and approximated to the 
iliopectineal (Cooper’s) ligament of the superior pubic rami. Initial success rates are 
90%. Better long-term results compared to other retropubic repairs. A laparoscopic 
approach can also be performed, but long-term results have proven to be poor.
By vagino-obturator shelf/paravaginal repair sutures are placed by the vaginal 
wall and paravaginal fascia and then passed through the obturator fascia to attach to 
part of the parietal pelvic fascia below the tendinous arch. Cure rates are up to 85%.
Complications are osteitis pubis, may be urinary retention and OAB.
Sling procedures are mainly used for female SUI associated with poor urethral 
function (type III or ISD) or when previous surgical procedures have failed. Also 
used for incontinence due to urethral damage in male patients. It is essential that 
urethral and bladder function is evaluated prior to surgical repair.
At present time synthetic monofilament polypropylene such as TVT or TOT 
are used most common. The TVT is a popular procedure as it is less invasive, it 
can be inserted under local anaesthetic as a day case and it has few complications. 
The tape has long trocars on each end, which are inserted either side of the ure-
thra through a vaginal approach (TVT) or trocars are inserted through obturator 
membranes (TOT). They perforate soft tissues and are pushed out onto the lower 
abdominal wall. Once the tape is positioned loosely behind the mid-urethra, its 
covering is removed and the ends cut flush to the abdomen. Both techniques 
use cystoscopy to assist prevention of bladder perforation during sling placement. 
Post-operatively, patients may temporarily require CISC until PVR are <100ml.
Overall, long-term cure rates for slings are 80%, with improvement seen in 
90%. Complication rates are voiding disorders (urinary retention, de novo OAB), 
may be vaginal, urethral and bladder erosions. Sometimes bowel, bladder perfora-
tion and pelvic bleeding are detected.
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The artificial urinary sphincter
AUS consists of an inflatable cuff placed via a lower abdominal incision around 
the bladder neck in both men or women or the bulbar urethra in men, a pres-
sure-regulating balloon placed extraperitoneally and an activating pump placed in 
the scrotum or labia majora. The cuff provides a constant pressure to compress 
the urethra. To void, the pump is squeezed, which transfers fluid to the reservoir 
balloon, thereby deflating the cuff. The cuff then automatically refills within 3 
minutes. Voiding takes place in the interval taken for the cuff to refill.
Indications are incontinence III type secondary to ISD in patients with normal 
bladder capacity and compliance. It is used for sphincter damage due to prosta-
tectomy, TUR, pelvic radiotherapy, pelvic fracture and following urethral recon-
struction. In women it is used after other treatments for incontinence have failed. 
It can be used for neuropathic sphincter weakness if the incontinence is not due 
to OAB. If there is combined bladder overactivity and sphincter weakness, treat 
the bladder first with help of anticholinergics, intravesical botulinum injections 
and augmentation. In some cases this will be enough to achieve continence. If 
incontinence persists, proceed with AUS at a later date.
Patients should undergo urodynamics, cystoscopy and upper tract imaging to 
evaluate voiding function and identify anatomical abnormalities that might affect 
the efficacy of the sphincter. Good manual dexterity is required to manipulate the 
pump and perform CISC if needed. The patient must also have sufficient cognitive 
function to operate the sphincter themselves, several times daily.
Complications are recurrent incontinence secondary to urethral atrophy under-
neath the cuff, mechanical failure, urethral erosion, OAB or reduced compliance 
causing reflux, hydronephrosis and renal failure. Recurrent incontinence is inves-
tigated by cystoscopy to exclude erosion, X-Ray isused to determine leaks from 
the system and urodynamics to detect high bladder pressures. Primary implant 
infection rates are 1-3%. With infection or erosion, entire device is removed and 
wait 3-6 months before reinsertion. Hematoma, late urinary retention may signify 
obstruction from urethral stricture or bladder neck contracture.
AUS can function well for many years. Overall long-term success with contin-
ued continence and no device malfunction is 80%. Revision rates are about 20%
12 2  .URGE .URINARY .INCONTINENCE
UUI is involuntary urine leakage accompanied by or immediately preceded by a 
sudden, strong desire to void. It is a component of the OAB. OAB is a syndrome 
which includes urgency, with or without urge incontinence, frequency and noctu-
ria. The symptoms are usually caused by OAB, but can be due to other forms of 
voiding dysfunction. This diagnosis is common for the population >40 years old.
The underlying etiology for UI can only be absolutely determined by urody-
namic studies. Detrusor overactivity is a urodynamic observation characterized by 
involuntary bladder muscle contractions during the filling phase of the bladder, 
which may be spontaneous or provoked and can consequently cause UI. The un-
derlying cause may be neurogenic, where there is a relevant neurological condition 
or idiopathic, where there is no defined cause.
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Low bladder compliance is characterized by a decreased volume to pressure 
relationship, where there is a high increase in bladder pressure during filling due 
to alterations in elastic properties of the bladder wall or changes in muscle tone 
(neurogenic bladder or microcyst).
Treatment .of .OAB
Conservative treatment
Any underlying cause is treated: urethral obstruction, bladder stones, spinal dis-
ease or tumor. TUR for BPH can provide symptomatic relief in >2/3 of pa-
tients. Treatment of SUI component includes pelvic floor exercises, biofeedback 
and high-frequency electrical stimulation, which strengthens the pelvic floor and 
sphincter by increasing tone through sacral neural feedback systems. Behavioural 
modification involves modifying fluid intake, avoiding stimulants (caffeine, al-
cohol) and bladder training for urgency. This is delay micturition for increasing 
periods of time by inhibiting the desire to void.
Anticholinergic drugs act to inhibit bladder contractions and increase capacity 
(oxybutynin, tolterodine, trospium, solifenacin). Oxybutynin also exerts a direct 
muscle effect and can be administered intravesically in patients performing inter-
mittent catheterization (5 mg in 30 ml normal saline 8 hourly after emptying the 
bladder). Contraindication is closed angle glaucoma. Side-effects are dry mouth, 
constipation, blurred vision.
Tricyclic antidepressants exert a direct relaxant effect on bladder muscle as well 
as producing sympathomimetic and central effects.
Desmopressin is a synthetic vasopressin analogue which acts as an antidiuretic. 
It is used intranasally to alleviate nocturia in adults.
Baclofen is a GABA receptor agonist, which is used orally or via intrathecal 
pump in patients with bladder dysfunction and limb spasticity.
Botulinum toxin A injection therapy acts by inhibiting calcium-mediated release 
of acetylcholine at the neuromuscular junction, reducing muscle contractility. It is 
used predominantly for neuropathic bladder dysfunction, but increasingly is being 
used for failed medical therapy of the OAB in non-neuropaths. It is injected directly 
into detrusor muscle under cystoscopic guidance with help of flexible  or rigid cys-
toscopy under regional or general anaesthetic at 20-30 random sites, excluding the 
trigone. Repeat treatments are required with 6-12 months between injections and 
CISC may be needed to empty residuals. Side-effects lasting a week or so can occur.
Neuromodulation involves electrical stimulation of the bladder’s nerve supply 
to suppress reflexes responsible for involuntary bladder muscle contraction. The 
“Interstim” device stimulates the S3 afferent nerve which then inhibits detrusor 
activity at the level of the sacral spinal cord. An initial percutaneous nerve evalua-
tion is performed, followed by surgical implantation of permanent electrode leads 
into the S3 foramen, with a pulse generator which is programmed externally.
Surgery of the OAB
The aim is to increase functional bladder capacity, decrease maximal detrusor 
pressure and protect the upper urinary tract.
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Auto-augmentation may be used. Detrusor muscle is excised from the dome 
of bladder, leaving the underlying bladder endothelium intact. A large epithelial 
bulge is created which augments bladder capacity.
Augmentation ileocystoplasty relieves intractable frequency, urge and UUI in 
90% of patients. The bladder dome is cut open (bivalved) and a detubularized 
segment of ileum is anastomosed, creating a larger bladder volume.
Conduit diversion may be indicated as a non-continent urinary outlet. Typical-
ly, both ureters are anastomosed and connected to a short ileal pouch, which is 
brought out cutaneously as a stoma.
12 3  .MIXED .INCONTINENCE
This is involuntary urinary leakage associated with urgency and also with exertion, 
effort, sneezing or coughing. 30-50% of women with SUI also have symptoms of 
frequency, urgency or UUI. Underlying etiologies and evaluation remain the same 
as for SUI and UUI.
Risk factors for women include frequent and severe childbirth, ageing, estrogen 
withdrawal, previous pelvic surgery and obesity. There also appears to be an intrin-
sic loss of urethral strength, often associated with urethral hypermobility. In men, 
damage occurs to the external sphincter from pelvic fractures, after prostatectomy 
or TUR. Neurological disorders also cause sphincter weakness.
This mixed UI patient group needs further investigation to rule out pathologies 
such as BC, stones and interstitial cystitis. Voiding records and urodynamic studies 
are most useful. Female examinations are stress test, pelvic organ prolapse investi-
gation. In male patients a palpable bladder and penile abnormalities are examined. 
Imaging (prostate size, flow rate, PVR) are indicated.
When SUI appears to be the predominant symptom, initially start with con-
servative methods and then review. Behavioural and pelvic floor exercises with 
vaginal weights (Kegel’s exercises) are important and can improve symptoms in 
1/3 of women with mild SUI. When no success with conservative treatment of 
SUI, surgical repair can alleviate remaining symptoms. Surgical procedures for SUI 
in women include colposuspension, vagino - obturator shelf procedure, slings for 
bladder neck support and tension- free vaginal tape (TVT or TOT). Urethral bulk-
ing agents and artificial urinary sphincters can be used in both sexes. Pelvic organ 
prolapse is corrected with a pessary or surgery.
In mixed UI electrostimulation is used to reduce OAB, which can alleviate the 
urge and UUI component. However, if UUI is the most marked symptom, surgery 
will be less helpful and behavioural therapy with pharmacotherapy for UUI should 
be used first for minimally 3 months.
12 4  .POST-PROSTATECTOMY .INCONTINENCE
This type of incontinence is diagnosed slightly <1% after TUR and 0.5% after 
BPH-ectomy. Results after RP are variable up to 40% suffer from mild UI,  but this 
usually improves over 12-18 months post-surgery, severe UI persisting in 2-10%.
Risk–factors are increasing age, pre-existing bladder dysfunction, previous ra-
diotherapy, prior TURP, advanced stage of disease and surgical technique. Earlier 
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recovery of continence after RP is achieved using a perineal approach, nerve-spar-
ing techniques, sphincter and bladder neck preserving procedures.
The proximal sphincter mechanism is removed at prostatectomy and TUR. 
Post-prostatectomy continence therefore requires a functioning distal urethral 
sphincter mechanism and low bladder pressure during bladder filling. Nerve-spar-
ing RP produces better continence rates. The main cause of post-radical prosta-
tectomy incontinence is sphincter dysfunction. A substantial proportion of men 
also have OAB before prostatectomy and this may remain so after prostatectomy. 
History detects stress-induced leakage. Cough, standing from a sitting position 
suggests sphincter dysfunction. There is leakage on coughing. PVR volume mea-
surement on US is used to exclude retention with overflow. Urodynamic studies 
allow determination of OAB and sphincter function. Cystoscopy allows identifi-
cation of strictures.
12 months for spontaneous improvement is needed unless incontinence is se-
vere. Pelvic floor exercises, insertion of urethral bulking agents, bulbourethral sling 
to compress the urethra are treatment options. AUS insertion is usually deferred 
until 1 year post-prostatectomy and is the most effective long-term treatment.
If OAB exists, conservative treatment includes behavioural therapy, pelvic floor 
exercises and anticholinergic medication. Surgery for intractable cases includes 
augmentation cystoplasty or urinary diversion. Catherization may be considered 
in the older patient.
12 5  .ENURESIS
Enuresis is any involuntary loss of urine in the absence of any demonstrable 
abnormality of the urinary tract. It may occur at an inappropriate time or social 
setting, during the day, night or diurnally. Nocturnal enuresis describes loss of 
urine occurring during sleep. Monosymptomatic nocturnal enuresis is a term used 
to describe bedwetting in children with no daytime urinary symptoms to suggest 
an underlying voiding disorder.
Nocturnal enuresis is estimated to affect up to 15% of 5-years olds and 10% of 
7-year old children. There is 15% spontaneous resolution of symptoms per year. 
The prevalence in adults is ~0.5%. There are primary nocturnal enuresis (never 
been dry for more than a 6-month period) and secondary (the re-emergence of 
bed wetting after a period of being dry for at least 6 months).
Risk .factors
• An abnormal decrease in ADH levels at night causes increased urine production;
• Altered sleep/arousal mechanism with impaired “arousal from sleep” response 
to a full bladder;
• Reduced nocturnal functional bladder capacity;
• OAB during sleep;
•  Familial predisposition, psychological factors and UTIs are also considered to 
contribute to nocturnal enuresis.
The aim of the evaluation is to establish the underlying pathophysiological fac-
tors to guide treatment. In the patients with enuresis it is helpful to discuss about 
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the frequency of episodes, daytime symptoms, new or recurrent problems, family 
history, symptoms of UTIs, bowel problems and psychosocial history. Abdomen 
is examined for palpable bladder. Neurological exam include investigation of the 
perineal sensation, anocutaneous reflex and lower limb sensation. The spine is in-
spected for sacral agenesis. The voiding diary is investigated to assess for nocturnal 
polyuria and functional bladder capacity. Urinalysis is used to assess for infection, 
the presence of glucose (DM) or protein (UTIs, renal disease).
Treatment
• Reassurance and counselling with motivational techniques to improve child’s 
self-esteem;
• Bladder training: regular daytime toileting, emptying the bladder before bed, 
avoiding bladder stimulants (i.e. blackcurrant drinks, caffeine), reduced fluid 
intake in the hours before sleep;
• Conditioning therapy: an enuretic alarm is connected to the child’s underwear, 
which is triggered with the first few drops of urine, waking the child from sleep 
with 60-70% successful response;
• Synthetic analogue of ADH (desmopressin) given intranasally or orally just be-
fore bedtime to exert an antidiuretic response in the patients with nicturia and 
normal bladder function;
• Imipramine, a tricyclic antidepressant with anticholinergic and antispasmodic 
properties;
• Patients with OAB benefit most from a combination of options: enuretic alarm, 
bladder training and anticholinergic drugs (oxybutynin, trospium chloride, so-
lifenacin) with/without desmopressin.
Infertility is failure of conception after at least 12 months of unprotected inter-
course. The chance of a normal couple conceiving is estimated at 20-25% per 
month, 75% by 6 months and 85-90% at 1 year.
It is estimated that up to 50% of infertility is due to male factors. Defects of 
the spermatozoa will lead to failure of fertilization of the normal ovum due to 
defective sperm development, function or inadequate numbers.
There may be abnormalities of morphology (teratozoospermia), motility (as-
thenozoospermia), low sperm numbers (oligozoospermia) or absent sperm (azo-
ospermia).
Male .reproductive .physiology
Hypothalamic – pituitary - testicular axis
The hypothalamus secretes LHRH, which causes pulsatile release of anterior pitu-
itary gonadotrophins, called FSH and LH, which act on the testis. FSH stimulates 
the seminiferous tubules to produce spermatozoa. LH acts on Leydig cells to pro-
duce testosterone. It promotes development of the male reproductive system and 
secondary sexual characteristics. Steroidogenesis is stimulated by a cAMP-protein 
kinase C mechanism, which converts cholesterol to pregnenolone. Further steps in 
the biosynthesis pathway produce intermediary substances (dehydroepiandrosterone 
and androstenedione) prior to producing testosterone. In the blood, testosterone is 
attached to SHBG and albumin. At androgen-responsive target tissues, testosterone 
is converted into a potent androgen, DHT, by intracellular 5-AR.
Spermatogenesis and conception
Seminiferous tubules are lined with Sertoli cells, which surround developing germ 
cells (spermatogonium) and provide nutrients and stimulating factors, as well as 
secreting androgen-binding factor and inhibin. Germ cells divide to form primary 
spermatocytes. These undergo a first meiotic division to create secondary sper-
matocytes with 46 chromosomes, followed by a second meiotic division to form 
spermatids with 23 chromosomes. Finally, these differentiate into spermatozoa. 
This process with transport of spermatozoa takes app. 70 days. Spermatozoa that 
are not released are reabsorbed by phagocytosis. Mature spermatozoa have a head, 
middle piece and tail. The head is composed of a nucleus covered by an acrosome 
cap, containing vesicles filled with lytic enzymes. The middle piece contains mi-
tochondria and contractile filaments, which extend into the tail to aid motility. 
After deposition at the cervix, sperm penetrate cervical mucus and travel through 
the uterus to the site of fertilization in the fallopian tube, during which time they 
undergo functional maturation (capacitation). Sperm start to penetrate the oo-
cyte and bind to the zona pellucida. The activation phase is initiated, triggering 
hyperactivated motility and the acrosomal reaction, leading to enzyme release, 








• Functional disorders: immunological infertility (sperm antibodies), head or tail 
defects, Kartagener’s syndrome (immotile cilia), dyskinetic cilia syndrome;
• Erectile or ejaculatory problems;
• Testicular injuries: orchitis, testicular torsion, trauma, radiotherapy;
• Endocrine disorders: Kallmann’s syndrome (isolated gonadotrophin deficiency 
causing hypogonadism), hyperprolactinemia, hyper- or hypothyroidism, hyper-
ostrogenia, anabolic steroids abuse, congenital adrenal hyperplasia;
• Genetic disorders: Kleinfelter’s syndrome (47XXY), XX male, XYY syndrome, 
presence of AZF factor;
• Male genital tract obstruction: congenital absence of vas deferens, epididymal 
obstruction or infection, Mullerian prostatic cysts, groin or scrotal surgery;
• Systemic disease: renal failure, liver cirrhosis;
• Drugs: chemotherapy, sulphasalazine;
• Environmental factors: alcohol, smoking, toxic substances, hot baths.
Diagnosis
• Sexual history: duration of problem, frequency and timing of intercourse, previous 
successful conceptions, previous birth control, erectile or ejaculatory dysfunction;
• Endocrinological status: age at puberty, history of cryptorchidism, gynaecomas-
tia, hypogonadism;
• Medical and surgical anamnesis: detailed assessment for risk factors, recent 
febrile illness, post-pubertal mumps orchitis, varicocele, testicular torsion, trau-
ma, tumour, STD, genitourinary surgery, radiotherapy, respiratory diseases as-
sociated with ciliary dysfunction, DM;
• Drugs and environmental: previous drug consumption, exposure to substanc-
es which impair spermatogenesis or erectile function, alcohol abuse, smoking 
habits, hot baths.
Examination
A full assessment of all systems is performed, with attention to general appearance 
(signs of hypogonadism, gynaecomastia). Urogenital examination should include as-
sessment of the penis, measurement of testicular consistency, tenderness and volume 
with a Prader orchidometer (normal >15ml), palpate epididymis (tenderness, swelling) 
and spermatic cord (vas deferens present or absent, varicocele), DRE of the prostate.
Semen analysis 2-3 specimens over several weeks, collected after 3-4 days of 
sexual abstinence. Specimens are delivered to the laboratory within 1h. Ejaculate 
volume, liquefaction time and pH are noted. Microscopy techniques measure sperm 
concentration, total numbers, morphology and motility. The mixed agglutination 
reaction (MAR test) is used to detect antisperm antibodies. The presence of leu-
cocytes (>1x106/ml of semen) suggests infection and cultures should be requested.
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Semen analysis: normal parameters (WHO 1999, 2010)
Semen volume >1,5-2.0ml
pH 7.2-7.8
Time to liquefy <60 min 
Total sperm count >40 x 106/ejaculate
Sperm concentration >15-20 x 106/ml
Sperm motility >32-50% with progressive motility (A+B)
 >25% grade A
Sperm morphology >4-14% normal forms (Kruger)
Viability >75% viable sperm
White blood cells <1 x 106 WBC/ml
MAR test <10% with adherent particles
Screening of STD, investigations of urethral discharges and prostatic secretions, 
bacteriological exam of ejaculate are performed. 
Hormone measurement for serum FSH, LH and testosterone, prolactin, estra-
diol, inhibin B levels are indicated. In cases of isolated low testosterone level, it is 
recommended to test free testosterone levels. Raised prolactin is associated with 
sexual dysfunction and may indicate pituitary disease.
Chromosome analysis is indicated for clinical suspicion of an abnormality (azo-
ospermia or severe oligospermia, small atrophic testes with high FSH level). De-
tecting of AZF and CFTR mutations are used for patients with azoospermia.
Testicular biopsy is performed for azoospermic patients, to differentiate be-
tween non-obstructive and obstructive causes. It is also used for sperm retrieval.
Functional sperm tests
• Post coital (in vivo) test: cervical mucus is taken just before ovulation and 
within 8 hours of intercourse and microscopy performed. Normal results shows 
>10 sperm per HPF, the majority demonstrating progressive motility. Abnor-
mal results indicate inappropriate timing of the test, cervical mucus antisperm 
antibodies, abnormal semen, inappropriately performed coitus.
• Sperm penetration (in vitro) test: a sample of semen is placed directly onto 
pre-ovulatory cervical mucus on a slide and the penetrative ability of sperma-
tozoa is observed.
• Sperm-cervical mucus (in vitro) test: a specimen of semen (control) and one 
mixed with cervical mucus are placed separately on a slide and observed for 30 
minutes. More than 25% exhibiting jerking movements in the mixed sample 
(but not the control) is a positive test for antisperm antibodies.
Imaging
• Scrotal US scan is used to confirm a varicocele and testicular abnormalities;
• TRUS is indicated for low ejaculate volumes, to investigate seminal vesicle ob-
struction (>1.5 cm width) or absence and ejaculatory duct obstruction (>2.3 mm);
• Vasography: Vas deferens is punctured at the level of the scrotum and injected 
with contrast. A normal test shows the passage of contrast along the vas deferens, 
seminal vesicles, ejaculatory duct and into the bladder, which rules out obstruction.
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Oligozoospermia





• Testicular cancer or lymphoma;
• Drug and toxin exposure;
• Cryptorchidism.
It is often associated with abnormalities of morphology and motility. The com-
bined disorder is called oligoasthenoteratozoospermia (OAT) syndrome.
If sperm counts <5 million/ml (severe form) this require hormone investi-
gation, including FSH and testosterone. Severe oligospermia is associated with 
seminiferous tubular failure, small soft testes and high FSH.
Treatment
Correct the underlying cause. Idiopathic cases may respond to empirical medical 
therapy or require assisted reproductive techniques.
Azoospermia
Defined as an absence of sperm in the ejaculate fluid.
Etiology
• Obstructive: absent or obstructed vas deferens; epididymal or ejaculatory duct 
obstruction (related to infection, iatrogenic injury, cystic fibrosis);
• Non-obstructive: hypogonadism (Kallmann’s syndrome, pituitary tumour), 
abnormalities of spermatogenesis (chromosomal anomalies, toxins, idiopathic, 
varicocele, orchitis, testicular torsion).
Diagnosis
• Hormone assay (raised FSH indicates non-obstructive cause, normal FSH with 
normal testes indicates increased likelihood of obstruction);
• Chromosomal analysis may be used to exclude Kleinfelter’s syndrome in pa-
tients presenting with azoospermia, small soft testes, gynaecomastia, high FSH/
LH and low testosterone;
• Testicular biopsy is performed to assess if normal sperm maturation is occurring 
and for sperm retrieval for later IVF.
• TRUS assesses absence or blockage of vas deferens and ejaculatory duct ob-
struction. Cystic fibrosis may be observed in patients with vas deferens defects.
Treatment for azoospermia
• Bilateral absence of vas deferens: MESA or consider donor insemination.
• Primary testicular failure with testicular atrophy: TESE or in vitro fertilization (IVF).
• Obstructive cause with normal testis: epididymovasostomy or vasovasostomy 
or IVF.
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Treatment .options .for .male .factor .infertility
• General: modification of life style factors (reduce alcohol consumption, avoid 
smoking and hot baths);
• Medical treatment: correct any reversible causative factors;
• ED is treated with oral, intracavernosal drugs, vacuum devices or prostheses;
• Ejaculatory failure may respond to sympathomimetic drugs (desipramine) or 
electroejaculation (used in spinal cord injury), where an electrical stimulus is 
delivered via a rectal probe to the postganglionic sympathetic nerves that inner-
vate the prostate and seminal vesicles;
• Antisperm antibodies: assisted conception methods are usually required.
Hormonal causes
• Hypogonadotropic hypogonadism may respond to HCG 2000IU subcutaneous-
ly 3 times a week, which stimulates an increase in testosterone and testicular 
size. If the patient remains azoospermic after 6 months of treatment, recombi-
nant FSH is added. Alternatively, pulsatile LHRH can be administered subcu-
taneously via a minipump.
• Hyperhonadotropic hypergonadism: testosterone deficiency requires testoster-
one replacement therapy;
• Hyperprolactinaemia is treated with dopamine agonists;
• Anti-estrogens (clomiphene citrate or tamoxifen) are often used empirically to 
increase LHRH, which stimulates endogenous gonadotrophin secretion.
Surgical treatment by genital tract obstruction
• Epididymal obstruction can be overcome by microsurgical anastomosis between 
the epididymal tubule and vas (epididymovasovasostomy);
• Vas deferens obstruction is treated by microsurgical reanastomosis of ends of 
the vas and is used for vasectomy reversal;
• Ejaculatory duct obstruction requires transurethral resection of the ducts;
• Varicocele: repaired by open/laparoscopic surgical ligation or embolization.
Assisted reproductive techniques
Sperm extraction used for obstructive azoospermia. Sperm are removed directly 
from the epididymis by MESA or by PESA. If these methods fail, TESE or TESA 
may be tried. Spermatozoa are used as a “fresh” or undergo cryopreservation until 
required. Later, they are separated from seminal fluid by dilution and centrifuge 
methods with further selection of motile sperm and normal forms using Percoll 
gradiant techniques and used for assisted conception. By IUI following ovarian 
stimulation, separated spermatozoa are injected across catheter directly into the 
uterus. By IVF controlled ovarian stimulation produces oocytes which are then 
retrieved under transvaginal US-guidance. Oocytes and sperm are placed in a 
Petri dish for fertilization to occur. Embryos are transferred to the uterine cavity. 
Pregnancy rates are 15-20% per cycle. By ICSI a single spermatozoon is injected 
directly into the oocyte cytoplasm. Pregnancy rates are 15-22% per cycle.
This is the persistent (during 3 months) inability to achieve or maintain a penile 
erection sufficient for sexual intercourse.
Mechanism .of .erection
Neuroendocrine signals from the brain, created by audiovisual or tactile stimuli, activate 
the autonomic nuclei of the spinal erection centre (T11-L2 and S2-S4). Signals are 
relayed via the cavernosal nerve to the erectile tissue of the copora cavernosa with help 
of NO and PGE1 activating smooth muscle relaxation and induce the veno-occlusive 
mechanism. This triggers increased arterial blood flow into sinusoidal spaces secondary 
to arterial and arteriolar dilatation, relaxation of cavernosal smooth muscle and opening 
of the vascular space. The result is expansion of the sinusoidal spaces against the tunica 
albuginea, which compresses the subtunical venous plexuses, decreasing venous outflow. 
Maximal stretching of the tunica albuginea acts to compress the emissary veins which lie 
within its inner circular and outer longitudinal layers, reducing venous flow even further. 
Rising intracavernosal pressure and contraction of the ischiocavernosus muscles produces 
a rigid erection. Following orgasm and ejaculation, vasoconstriction (due to increased 
sympathetic activity and many secondary messengers) produces detumescence.
Phases .of .erection
• Flaccid phase (0) - cavernosal smooth muscle contracted, sinusoids empty, 
minimal arterial flow;
• Latent (filling) phase (I) - increased pudendal artery flow, penile elongation;
• Tumescent phase (II) - rising intracavernosal pressure, forming of the erection;
• Full erection phase (III) - increased cavernosal pressure causes penis to become 
fully erect;
• Rigid erection phase (IV) - further increases in pressure + ischiocavernosal 
muscle contraction;
• Detumescence (V) - following ejaculation, sympathetic discharge resumes, 
there is smooth muscle contraction and vasoconstriction, reduced arterial flow, 
blood is expelled from sinusoidal spaces.
Etiology
ED is generally divided into psychogenic and organic causes, although it is often 
multifactorial.
Causes of erectile dysfunction
• Psychological (depression, anxiety, relationship difficulties, stress);
• Arteriogenic factors: hyperlipidaemia and hypercholesterolemia, hypertension, 
smoking, DM, peripheral vascular disease;
• Venogenic: impairment of veno-occlusive mechanism (due to anatomical or 
degenerative changes), spinal cord injury, penile trauma;
• Iatrogenic: pelvic surgery, prostatectomy;
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• Endocrine: hypogonadism, hyperprolactinaemia, hypo and hyperthyroidism, DM;
• Neurological: multiple sclerosis, parkinson’s disease, multi-system atrophy, tu-
mours, spina bifida, syringomyelia, pelvic surgery or radiotherapy, peripheral 
neuropathy (DM, alcohol- related);
• Drug-induced (antihypertensives, anti-arrhythmics, antidepressants, anti-an-
drogens, statins);
• Other: CRF, cirrhosis, prostatitis, peyronie’s disease.
Diagnosis
History
• Sexual: onset of ED (sudden or gradual), duration of problem, presence of 
erections (nocturnal, early morning, spontaneous), ability to maintain erections 
(early collapse, not fully rigid), loss of libido, relationship issues (frequency of 
intercourse and sexual desire, relationship problems);
• Medical and surgical: hypertension, cardiac disease, peripheral vascular disease, 
DM, endocrine or neurological disorders, pelvic surgery, radiotherapy, trauma 
with damaging innervation and blood supply to the pelvis and penis;
• Drugs: enquire about current medications and ED treatments already tried, 
smoking, alcohol consumption.
An organic cause is more likely with gradual onset, unless associated with an 
acute obvious cause such as surgery, loss of spontaneous erections, intact libido 
and ejaculatory function, existing medical risk factors and older age groups. The 
IIEF scale can be used to quantify severity.
Examination
Full physical examination (CNS, abdomen, neurological), DRE to assess prostate 
and external genitalia assessment to document phimosis and Peyronie’s disease. 
Confirm presence, size and location of testicles. The bulbocavernosus reflex can 
be performed to test integrity of spinal segments S2-S4 (squeezing the glans causes 
anal sphincter and bulbocavernosal muscle contraction).
Investigation
• Blood tests: fasting glucose, PSA, serum testosterone, SHBG, LH/FSH, pro-
lactin, thyroid function test, fasting lipid profile;
• Nocturnal penile tumescence testing: rigiscan device contains 2 rings which are 
placed around base and distal penile shaft to measure tumescence and number, 
duration and rigidity of nocturnal erections;
• Colour Doppler US measures arterial peak systolic and end diastolic velocities, 
pre and post intracavernosal injection of PGE1;
• Cavernosometry: intracavernosal injection of vasoactive drug followed by saline 
infusion, the rate of which is proportional to the degree of any venous leaking;
• Cavernosgraphy: imaging and measurement of blood flow of the penis after 
intracavernosal injection of contrast and induction of artificial erection, which 





Aims to understand and address underlying psychological issues and provides in-
formation and treatment in the form of sex education, instruction on improving 
partner communication skills, cognitive therapy and behavioural therapy with pro-
grammed re-learning of couple’s sexual relationship.
Oral medication
PDE-5 inhibitors: sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra). PDE5 
inhibitors enhance cavernosal smooth muscle relaxation and erection by blocking 
the breakdown of cGMP. Sexual stimulus is still required to initiate events. Side-ef-
fects are eadache, flushing, visual disturbance. Contraindications are nitrates, recent 
myocardial infarction, recent stroke, hypotension, unstable angina.
Dopamine receptor agonist is apomorphine (Uprima). This drug is adminis-
tered sublingually and acts centrally on dopaminergic receptors in the paraventric-
ular nucleus of the hypothalamus to enhance and co-ordinate the effect of sexual 
stimuli. Adverse effects: nausea, headache, dizziness.
Androgen replacement therapy
Testosterone replacement is indicated for hypogonadism. It is available in oral, 
intramuscular, pellet, patch and gel forms. In older men, it is recommended that 
PSA is checked before and during treatment.
Intracavernosal therapy
Alprostadil/Caverjet (synthetic PGE1), papaverine (smooth muscle relaxant), 
phentolamine. Training of technique and first dose is given by health professional. 
Needle is inserted at right angles into the corpus cavernosum on the lateral aspects 
of mid-penile shaft. Adverse effects are pain, priapism, hematoma.
Vacuum erection device
It contains 3 components: vacuum chamber, pump and constriction band. The 
penis is placed in the chamber and the vacuum created by the pump increases 
blood flow to the corpora cavernosa to induce an erection. The constriction band 
is placed onto the base of the penis to retain blood in the corpora and maintain 
rigidity. Adverse effects are penile coldness and bruising.
Penile prosthesis
Semi-rigid, malleable and inflatable penile prostheses are available for surgical 
implantation into the corpora to provide penile rigidity and sufficient erectile size 
for sexual intercourse. Side-effects are mechanical failure, erosions, infections.
GENITOURINARY TUBERCULOSIS
Tuberculosis of the GUT is caused by Mycobacterium tuberculosis. Urinary TB is 
a disease of young adults and is a little more common in males than in females.
Etiopathogenesis
Mycobacterium tuberculosis reaches the genitourinary organs by the hematogenous 
route from the lungs. The primary site is often not symptomatic or apparent. The kid-
ney and possibly the prostate are the primary sites of tuberculous infection in the GUT.
The primary granulomatous lesion forms in the lung. It consists of a central 
area of caseation surrounded by epitheloid and Langhans’ giant cells, accompa-
nied by caseous lesions in the regional lymph nodes. There is early spread of bacilli 
via the bloodstream to the GUT, but immunity rapidly develops and the infection 
remains quiescent. Acute diffuse systemic dissemination of tubercle bacilli can 
result in symptomatic miliary ТВ.
Reactivation of infection is so called post primary TB, which triggered by im-
mune compromise. When a shower of tubercle bacilli hits the renal cortex, the 
microorganisms may be destroyed by normal tissue resistance and this is common-
ly seen in autopsies of persons who have died of TB. Only scars are found in the 
kidneys. However, if enough bacteria of sufficient virulence become lodged in the 
kidney and are not overcome, a clinical infection is established. TB of the kidney 
progresses slowly during 15-20 years. As a rule, there is no renal pain and little or 
no clinical disturbance of any type until the lesion has involved the calyces or the 
pelvis, at which time pus and organisms may be discharged into the urine. Symp-
toms of cystitis are manifested. The infection then proceeds to the pelvic mucosa 
and the ureter. This may lead to stricture and obstruction with hydronephrosis. 
As the disease progresses, a caseous breakdown of tissue occurs until the entire 
kidney is replaced by cheesy material. Calcium may be laid down in the reparative 
process. The ureter undergoes fibrosis and tends to be shortened and therefore 
straightened. This change leads to a “golfhole” ureteral orifice, typical of an in-
competent valve. Vesical irritability develops as an early clinical manifestation of 
the disease as the bladder is bathed by infected material. Tubercles in the field of 
involved ureteral orifice finally coalesce and ulcerate with bleeding. With severe 
involvement, the bladder becomes fibrosed and contracted. This leads to marked 
frequency. VUR or stenosis and, therefore, UHN may develop. The passage of 
infected urine through the prostatic urethra ultimately leads to invasion of the 
prostate and one or both seminal vesicles. There is no local pain. On occasion, the 
primary hematogenous lesion in the GUT is in the prostate. Prostatic infection 
can ascend to the bladder and descend to the epididymis. Because this is a slow 
process, there is usually no pain. If the epididymal infection is extensive and an 
abscess forms, it may rupture through the scrotal skin, thus establishing a perma-




Tuberculosis of the GUT may be present in the following situations: 
• Chronic cystitis that not respond to adequate therapy;
• Sterile pyuria;
• Macro or microhematuria;
• Presence of enlarged epididymis with a beaded or thickened vas;
• A chronic draining scrotal sinus;
• Induration or nodulation of the prostate and thickening of one or both seminal 
vesicles especially in a young man; 
• A history of present or past TB elsewhere in the body;
• Presence of tubercle bacilli in the urine by culture or positive PCR.
 The extent of the infection is determined by:
• The palpable findings in the epididymis, vasa, prostate and seminal vesicles; 
• Specific renal and ureteral lesions as revealed by imaging;
• Involvement of the bladder as seen through the cystoscope; 
• The degree of renal damage as measured by loss of functio.
There are no no classic symptoms of renal TB. Generalized malaise, fatigabil-
ity, low-grade but persistent fever and night sweats are some of the non-specific 
complaints. Even vesical irritability may be absent, in which case only proper col-
lection and examination of the urine will afford the diagnosis. Active TB elsewhere 
in the body is found in less than half of patients with GUT. Because of the slow 
progression of the disease, the affected kidney is usually completely asymptomat-
ic. On occasion, however, there may be a dull ache in the flank. The passage of 
a blood clot, secondary calculi or a mass of debris may cause renal and ureteral 
colic. Rarely, the presenting symptom may be a painless mass in the abdomen. 
Perinephric abscess may cause an enlarging mass in the flank. A plain film of the 
abdomen shows obliteration of the renal and psoas shadows. US and CT scans 
may be more helpful. Renal stones may develop if secondary nonspecific infection 
is present. Uremia is the end stage if both kidneys are involved. 
The earliest symptoms of renal TB may arise from secondary vesical involve-
ment. These include burning, frequency and nocturia. Hematuria is occasionally 
found and is of either renal or vesical origin. At times, particularly in a late stage 
of the disease, the vesical irritability may become extreme. If ulceration occurs, 
suprapubic pain may be noted when the bladder becomes full. When severe-
ly damaged, the bladder wall becomes fibrosed and contracted. Stenosis of the 
ureters or VUR occurs, causing hydronephrotic atrophy. Scarring with stricture 
formation is one of the typical lesions of TB and most commonly affects the jux-
tavesical portion of the ureter. Complete ureteral obstruction may cause complete 
nonfunction of the kidney. 
TB of the prostate and seminal vesicles usually causes no symptoms. Prostate 
and seminal vesicles may be normal to palpation. Ordinarily, however, the TB 
prostate shows areas of induration, even nodulation. The involved seminal vesi-
cle is usually indurated, enlarged and fixed. The first clue to the presence of TB 
infection of these organs is the onset of a TB epididymitis. TB of the epididymis 
usually presents as a painless or only mildly painful swelling. A thickened, non-
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tender or only slightly tender epididymis may be discovered. The vas deferens often 
is thickened and beaded. In the more advanced stages, the epididymis cannot be 
differentiated from the testis on palpation. This may mean that the testis has been 
directly invaded by the epididymal abscess. Hydrocele occasionally accompanies 
TB epididymitis. The idiopathic hydrocele should be tapped so that underlying 
pathologic changes, if present, can be evaluated (epididymitis, testicular tumor). 
An abscess may drain spontaneously through the scrotal wall. A chronic draining 
sinus should be regarded as TB until proved otherwise. In rare cases, the onset is 
quite acute and may simulate an acute nonspecific epididymitis. If epididymitis is 
present, the ipsilateral seminal vesicle usually shows changes as well. The ducts of 
the involved epididymis become occluded. If this is bilateral, sterility results. Ab-
scess of the epididymis may rupture into the testis, through the scrotal wall or both. 
Signs of extragenital TB may be found (lungs, bones, lymph nodes, tonsils, 
intestines). Involvement of the penis and urethra is rare. 
Diagnosis
Urinalysis
Persistent pyuria without organisms on culture means TB until proved otherwise. 
Acid-fast stains done on the concentrated sediment from a 24-hour specimen are 
positive in at least 2/3 of cases. However, this must be corroborated by a positive 
culture. If clinical response to adequate treatment of bacterial infection fails and 
pyuria persists, TB must be ruled out by bacteriologic and imaging.
Cultures for tubercle bacilli from the first morning urine are positive in a very 
high percentage of cases of TB infection. If positive, sensitivity tests should be or-
dered. In the face of strong presumptive evidence of TB, negative cultures should 
be repeated. Three to five first morning voided specimens are needed. It can also 
be infected with tubercle bacilli or it may become hydronephrotic from fibrosis 
of the bladder wall or VUR. If TB is suspected, the tuberculin test should be per-
formed. A positive test, particularly in an adult, is hardly diagnostic, but a negative 
test in an otherwise healthy patient speaks against a diagnosis of TB.
Imaging 
A plain X-Ray of the abdomen may show enlargement of one kidney or obliter-
ation of the renal and psoas shadows due to perinephric abscess. Punctate calci-
fication in the renal parenchyma may be due to TB. Renal stones are found in 
10% of cases. Calcification of the ureter may be noted, but this is rare. IVP can 
be diagnostic if the lesion is moderately advanced. The typical changes include:
• A “moth-eaten” appearance of the involved ulcerated calyces;
• Obliteration of calyces;
• Dilatation of the calyces due to ureteral fibrosis;
• Abscess cavities;
• Single or multiple ureteral strictures;
• Absence of function of the kidney. 
US and CT also show the calcifications, renal contractions and scars, ureteral 
and calyceal strictures suggestive of genitourinary TB. US has the advantage of low 
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cost and low invasiveness. Contrast CT is highly sensitive for calcifications and the 
characteristic anatomic changes.
Cystoscopic study is indicated even when the offending organism has been 
found in the urine and IVP show the typical renal lesion. This study clearly 
demonstrates the extent of the disease. Cystoscopy may reveal the typical tubercles 
or ulcers of TB. Biopsy can be done if necessary. Severe contracture of the bladder 
may be noted. A cystogram may reveal VUR.
Treatment
The primary treatment is medical therapy. Surgical excision of an infected organ, 
when indicated, is an adjunct to overall therapy.
If patient has renal TB, a strict medical regimen should be instituted. A combi-
nation of drugs is usually desirable. The following drugs are effective in combina-
tion: isoniazid, rifampin, ethambutol, streptomycin, pyrazinamide. It is preferable 
to begin treatment with a combination of isoniazid, rifampin and ethambutol. It is 
recommended 2 or 3 months of intensive triple drug therapy daily followed by 3 
months of continuation therapy with isoniazid and rifampin two or three times per 
week. If resistance to one of these drugs develops, one of the others listed should 
be chosen as a replacement. 
TB of the bladder always secondary to renal or prostatic TB. It tends to heal 
promptly when definitive treatment for the “primary” genitourinary infection is 
given. Vesical ulcers that fail to respond to this regimen may require transurethral 
electrocoagulation. Should extreme contracture of the bladder develop, it may be 
necessary to divert the urine from the bladder or perform augmentation cystoplasty 
after subtotal cystectomy (ileocystoplasty, ileocecocystoplasty, sigmoidocystoplas-
ty) to increase bladder capacity.
In patients with TB of the epididymis, the prostate is always involved and usu-
ally the kidney as well. Only rarely does the epididymal infection break through 
into the testis. Treatment is medical. If after months of treatment an abscess or a 
draining sinus exists, epididymectomy is indicated.
Although a few urologists advocate removal of the entire prostate and the vesi-
cles when they become involved by TB, the majority opinion is that only medical 
therapy is indicated. Control can be checked by culture of the semen for bacilli.
Perinephric abscess usually occurs when the kidney is destroyed, but this is 
rare. The abscess must be drained and nephrectomy should be done either then or 
later to prevent development of a chronic draining sinus. Prolonged antimicrobial 
therapy is indicated. If ureteral stricture develops on the involved side, ureteral 
dilatations are indicated. The severely involved bladder may cause incompetence 
of the ureterovesical junction on the uninvolved side. Ureteroneocystostomy can-
not be done in such a bladder. Some form of urinary diversion may be required.
16 1  .SCHISTOSOMIASIS .(BILHARZIASIS)
Etiopathogenesis
Schistosomiasis, caused by a blood fluke, is a disease of warm climates. In its 3 
forms (Schistosoma mansoni, Schistosoma japonicum, Schistosoma hematobium) 
it affects about 350 million people. Schistosomiasis is on the increase in endem-
ic areas because of the construction of modern irrigation systems that provide 
favorable conditions for the intermediate host, a freshwater snail. This disease 
principally affects the urogenital system, especially the bladder, ureters, seminal 
vesicles and the male urethra and prostate gland. Infection with S. mansoni and 
S. japonicum mainly involves the colon.
Humans are infected when they come in contact with larva-infested water in 
canals, ditches or irrigation fields during swimming, bathing or farming proce-
dures. Forktailed larvae, the cercariae, lose their tails as they penetrate deep under 
the skin. They are then termed schistosomules. They cause allergic skin reactions 
that are more intense in people infected for the first time. These schistosomules 
enter the general circulation through the lymphatics and the peripheral veins and 
reach the lungs. If the infection is massive, they may cause pneumonitis. They pass 
through the pulmonary circulation, to the left side of the heart and to the general 
circulation. The worms that reach the vesicoprostatic plexus of veins survive and 
mature, whereas those that go to other areas die.
The adult S. hematobium worm, a digenetic trematode, lives in the prostatove-
sical plexus of veins. The male is about 10Ѕ1 mm in size, is folded upon itself and 
carries the long, slim 20Ѕ0.25 mm female in its “schist,” or gynecophoric canal. In 
the smallest peripheral venules, the female leaves the male and partially penetrates 
the venule to lay her eggs in the subepithelial layer of the affected viscus, usually 
in the form of clusters that form tubercles. The ova are seen only rarely within 
the venules. They are almost always in the subepithelial or interstitial tissues. The 
female returns to the male, which carries her to other areas to repeat the process. 
The living ova, by a process of histolysis and helped by contraction of the detrusor 
muscle, penetrate the overlying urothelium, pass into the cavity of the bladder and 
are extruded with the urine. If these ova reach fresh water, they hatch and the 
contained larvae—ciliated miracidia - find a specific freshwater snail that they pen-
etrate. There they form sporocysts that ultimately form the cercariae, which leave 
the snail hosts and pass into fresh water to repeat their life cycle in the human host. 
The fresh ova excite little tissue reaction when they leave the human host 
promptly through the urothelium. The contents of the ova trapped in the tissues 
and the death of the organisms cause a severe local reaction, with infiltration of 
round cells, monocytes, eosinophils and giant cells that form tubercles, nodules 
and polyps. These are later replaced by fibrous tissue that causes contraction of 
different parts of the bladder and strictures of the ureter. Fibrosis and massive de-
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posits of eggs in subepithelial tissues interfere with the blood supply of the area and 
cause chronic bilharzial ulcerations. Epithelial metaplasia is common and SCC is 
a frequent sequela. Secondary infection of the urinary tract is a common compli-
cation and is difficult to overcome. The trapped dead ova become impregnated 
with calcium salts and form sheets of subepithelial calcified layers in the ureter, 
bladder and seminal vesicles.
Symptoms .and .signs
Penetration of the skin by the cercariae causes allergic reactions, with cutaneous 
hyperemia and itching that are more intense in people infected for the first time. 
During the stage of generalization or invasion, the patient complains of symptoms 
such as malaise, fatigue, lowgrade fever, excessive sweating, headache and backache. 
When the ova are laid in the bladder wall and begin to be extruded, the patient 
complains of terminal, slightly painful hematuria that is occasionally profuse. This 
may remain the only complaint for a long time until complications set in, when 
vesical symptoms become exaggerated and progressive. Increasing frequency, supra-
pubic and back pain, urethralgia, profuse hematuria and pyuria are likely to occur, 
with secondary UTIs, ulceration or malignancy. Renal pain may be due to ureteral 
stricture, VUR or secondary stones obstructing the ureter. Fever, rigor, toxemia and 
uremia are manifestations of renal involvement.
In early uncomplicated cases, there are essentially no clinical findings. Later, a 
fibrosed, pitted, bilharzial glans penis, a urethral stricture or fistula or a perineal 
fibrous mass may be found. A suprapubic bladder mass or a renal swelling may be 
felt abdominally. DRE may reveal a fibrosed prostate, an enlarged seminal vesicle 
or a thickened bladder walls.
Diagnosis
Urinalysis usually reveals the terminal-spined dead or living ova, blood and pus 
cells and bacteria. SCC cells may be seen. The hemogram usually shows leukocy-
tosis with eosinophilia and hypochromic normocytic anemia. Serum Cr and BUN 
measurements may demonstrate some degree of CRF. A variety of immunologic 
methods have been used to confirm the diagnosis of schistosomiasis. Positive 
immunologic tests indicate previous exposure but not whether schistosomiasis is 
currently present. The cercariae, schistosomules, adult worms and eggs are all 
potentially antigenic. Adult worms, however, acquire host antigen on their integ-
ument that circumvents the immunologic forces of the host. Antibody production 
may be manifested as hypergammaglobulinemia.
A plain X-Ray of the abdomen may show enlarged hydronephrotic kidney or 
large tumor in the bladder area. Calcifications or stones may be noted in the kid-
ney, ureter or bladder. Linear calcification may be seen in the ureteral and bladder 
walls. Punctate calcification of the ureter and a honeycombed calcification of 
the seminal vesicle may be obvious. IVP may show either normal or diminished 
renal function and varying degrees of pathology of the upper urinary tracts. These 
changes include hydronephrosis, dilated and tortuous ureters, ureteral strictures or 
a small contracted bladder having a capacity of only a few milliliters. Gross irreg-
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ular defects of the bladder wall may represent cancer. Abdominal and pelvic CT 
is replacing IVP as the initial imaging of choice. Retrograde urethrography may 
reveal a bilharzial urethral stricture. Cystograms often reveal VUR, particularly if 
the bladder is contracted.
Cystoscopy may show fresh conglomerate, grayish tubercles surrounded by a 
halo of hyperemia, old calcified yellowish tubercles, sandy patches of mucous 
membrane and a lusterless ground-glass mucosa that lacks the normal vascular 
pattern. Other obvious lesions include bilharzial polyps, chronic ulcers on the 
dome that bleed when the bladder is deflated, vesical stones, malignant lesions, 
stenosed or patulous ureteric orifices and a distorted, asymmetric trigone. All are 
signs of schistosomal infection.
Bilharzial cystitis is unmistakable in endemic areas. The presence of schistoso-
mal ova in the urine, together with radiographic and cystoscopic findings, usually 
confirms the diagnosis. Nonspecific cystitis usually responds to medical treatment 
unless there is a complicating factor. Tuberculous cystitis may mimic bilharzial cys-
titis. The detection of tubercle bacilli, together with the radiographic picture, is con-
firmatory, but TB may occur in a bilharzial bladder. Vesical calculi and malignancy 
should be diagnosed by thorough urologic examination, although both conditions 
are common in association with bilharzial bladder. Complications of schistosomi-
asis are the result of fibrosis, which may be extreme and causes contraction of the 
bladder neck as well as of the bladder itself. It also causes strictures of the urethra 
and ureter that are usually bilateral. VUR is a frequent sequela. Secondary persistent 
infection and stone formation usually complicate the picture still further. SCC of 
the bladder is  common.
Treatment
Praziquantel, metrifonate and oxamniquine are the drugs of choice in treating 
schistosomiasis. These drugs do not have the serious side effects associated with 
the older drugs. Cure rates are 70-95%. Niridazole, a nitrothiazole derivative, is 
effective in treating S. mansoni and S. hematobium infections. It may be tried 
against S. japonicum infections. Side effects may include nausea, vomiting, an-
orexia, headache, T-wave depression and temporary suppression of spermatogene-
sis. Antibiotics or urinary antiseptics are needed to overcome or control secondary 
infection. Supportive treatment in the form of iron, vitamins and a high-calorie 
diet is indicated in selected cases.
Surgical treatment may be needed sometimes. Juxtavesical ureteral strictures re-
quire resection of the stenotic segment with ureteroneocystostomy. If the ureter is not 
long enough to reimplant, a tube of bladder may be fashioned, turned cephalad and 
anastomosed to the ureter. VUR requires a suitable surgical repair. A contracted blad-
der neck may need TUR. A chronic “weeping” bilharzial bladder ulcer necessitates 
partial cystectomy. The contracted bladder is treated by enterocystoplasty with placing 
a segment of bowel as a patch on the bladder. This procedure, which significantly 
increases vesical capacity, is remarkably effective in lessening the severity of symp-
toms associated with contracted bladder. SCC requires total cystectomy with urinary 
diversion if the lesion is deemed operable. Unfortunately, late diagnosis is common.
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16 2  .FILARIASIS
Filariasis is endemic in the countries bordering the Mediterranean, in south China 
and Japan, the West Indies and the South Pacific islands.
Etiopathogenesis
Wuchereria bancrofti is a threadlike nematode about 0.5 cm or more in length that 
lives in the human lymphatics. In the lymphatics, the female gives off microfilariae, 
which are found in the peripheral blood, particularly at night. The intermediate host is 
a mosquito, which bites an infected person and becomes infected with microfilariae, 
which develop into larvae. These are in turn transferred to another human, in whom 
they reach maturity. Mating occurs and microfilariae are again produced. The adult 
nematode in the human host invades and obstructs the lymphatics. This leads to 
lymphangitis and lymphadenitis. In long-standing cases, the lymphatic vessels be-
come thickened and fibrous and there is a marked reticuloendothelial reaction.
Symptoms .and .signs
In mild cases, the patient suffers recurrent lymphadenitis and lymphangitis with 
fever and malaise. Not infrequently, inflammation of the epididymis, testis, scro-
tum and spermatic cord occurs. These structures then become edematous, boggy 
and at times, tender. Hydrocele is common. In advanced cases with many ex-
posures, obstruction of major lymph channels may cause chyluria and elephan-
tiasis. Varying degrees of painless elephantiasis of the scrotum and extremities 
develop as obstruction to lymphatics progresses. Lymphadenopathy is common. 
Diagnosis
Chylous urine may look normal if minimal amounts of fat are present, but in an ad-
vanced case or following a fatty meal, it is milky. On standing, the urine forms layers: 
the top layer is fatty, the middle layer is pinkish and the lower layer is clear. In the 
presence of chyluria, large amounts of protein are to be expected. Hypoproteinemia 
is found and the albumin-globulin ratio is reversed. Both WBC and RBC are found. 
Marked eosinophilia is the rule in the early stages. Microfilariae may be demonstrated 
in the blood, which should be drawn at night. The adult worm may be found by bi-
opsy. When filariae cannot be found, an indirect hemagglutination titer of 1/128 and 
a bentonite flocculation titer of 1/5 in combination are considered diagnostic. Fol-
lowing a fatty meal, endoscopy to observe the efflux of milky urine from the ure-
teral orifices may differentiate between unilateral and bilateral cases. Retrograde 
urography and lymphangiography may reveal the renolymphatic connections in 
patients with chyluria.
Treatment
Diethylcarbamazine (Hetrazan) is the drug of choice, but it is toxic. This drug 
kills the microfilariae but not the adult worms. Several courses of the drug may be 
necessary. Antibiotics may be necessary to control secondary infection.
Prompt removal of recently infected patients from the endemic area almost 
always results in regression of the symptoms and signs in early cases.
Elephantiasis of the external genitalia may require surgical excision.
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Mild cases require no therapy. Spontaneous cure occurs in 50% of cases. If 
nutrition is impaired, the lymphatic channels may be sealed off by irrigating the 
renal pelvis with 2% silver nitrate solution. Should this fail, renal decapsulation 
and resection of the renal lymphatics should be performed. This can now be per-
formed laparoscopically with diminished morbidity.
16 3  .ECHINOCOCCOSIS .(HYDATID .DISEASE)
Hydatid disease is common in Australia, South America, Africa, Asia and Europe. 
Livestock are the intermediate hosts. Canines, especially dogs, are the final hosts.
Etiopathogenesis
The adult tapeworm, which is Echinococcus granulosus, inhabits the intestinal 
tracts of carnivorous animals. Its eggs pass out with the feces and may be ingested 
by such animals as sheep, cattle, pigs and occasionally humans. Larvae from these 
eggs pass through the intestinal wall of the various intermediate hosts and are dis-
seminated throughout the body. In humans, the liver is principally involved, but 
about 3% of infected humans develop echinococcosis of the kidney. If a cyst of the 
liver should rupture into the peritoneal cavity, the scoleces may directly invade the 
retrovesical tissues, thus leading to the development of cysts in this area.
Symptoms, .signs .and .diagnosis
If renal hydatid disease is closed and not communicating with the pelvis, there 
may be no symptoms until a mass is found. With communicating disease, there 
may be symptoms of cystitis and renal colic may occur as cysts are passed from 
the kidney. X-Ray films may show calcification in the wall of the cyst and IVP 
often reveal changes typical of a space-occupying lesion. The cystic nature of the 
lesion may be demonstrated on US and CT scans. Calcification in the cyst wall 
may be noted. Scintillation scanning or angiography can also suggest the pres-
ence of a cyst. Serologic tests that should be done include immunoelectrophoresis 
and indirect hemagglutination. The Casoni intracutaneous procedure is unreliable. 
Retroperitoneal and perivesical cysts may cause symptoms of cystitis or AUR may 
develop secondary to pressure. The presence of a suprapubic mass may be the only 
finding. It may rupture into the bladder and cause hydatiduria, which establishes 
the diagnosis. 
Treatment
Nephrectomy is generally the treatment of choice for renal hydatid disease. As-
piration of the cyst is dangerous. Leakage or rupture may occur. Retroperitoneal 
cysts are best treated by marsupialization and curettage.
17 1  . .VARICOCELE
A varicocele is defined as dilated and tortuous veins within the pampiniform 
plexus of scrotal veins most common on the left side. It is the most surgically 
correctable cause of male subfertility. The varicocele is a disease of puberty and is 
only rarely detected in boys <10 years of age. Found in 15% of men in the general 
population, 20-40% of males presenting with primary infertility and 45-80% of 
men with secondary infertility. Bilateral varicoceles are uncommon in healthy men 
(<10%) but are palpated in up to 20% of subfertile men.
Pathogenesis
Several anatomic features contribute to the predominance of left-sided varicoce-
les. The left internal spermatic vein is longer than the right. In addition, it usually 
joins the left renal vein at right angles. The right internal spermatic vein has a 
more oblique insertion into the IVC. This particular anatomy in the standing man 
may cause higher venous pressures to be transmitted to the left scrotal veins and 
result in retrograde reflux of blood into the pampiniform plexus. Varicoceles are 
associated with testicular atrophy and varicocele correction can reverse atrophy 
in adolescents. There is indisputable evidence that the varicocele affects semen 
quality. A classic semen analysis pattern has been attributed to varicoceles in 
which low sperm count and motility is found in conjunction with abnormal sperm 
morphology. The finding of semen abnormalities constitutes the main indication 
for varicocele surgery in infertile men. Precisely how a varicocele exerts an effect 
on the testicle remains unclear. Several theories have been postulated. It is likely 
that a combination of effects results in infertility. Pituitary-gonadal hormonal 
dysfunction, internal spermatic vein reflux of renal or adrenal metabolites and an 
increase in hydrostatic pressure associated with venous reflux are also postulated 
effects of a varicocele. The most intriguing theory of how varicoceles affect testis 
function invokes an inhibition of spermatogenesis through the reflux of warm 
corporeal blood around the testis, with disruption of the normal countercurrent 
heat exchange balance and elevation of intratesticular temperature. Although most 
men with varicoceles are fertile, but the association of varicoceles with infertility 
is well established. 
Symptoms .and .signs
Possible clinical manifestations of a varicocele:
• Inguinal, scrotal or testicular pain;
• Testis damage: fibrosis with impaired spermatogenesis, testicular atrophy;
• Infertility: the classic semen abnormalities include decreased motility, low 
sperm count and increased abnormal forms.
Examination of the scrotum with the patient in the supine and upright positions 
and while he performs a Valsalva maneuver in the standing position: a varicocele 
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feels like a “bag of worms “ and should become more prominent when the patient 
is standing or performing a Valsalva.
• Grade I is small, not grossly visible and palpated only during Valsalva;
• Grade II is moderate size, not grossly visible, but easily palpable in the standing 
position;
• Grade III is large and grossly visible.
Scrotal Doppler US is diagnostic, when venous diameter >3.5 mm with reflux 
of the blood.
Semen analysis: varicoceles are associated with low or absent sperm counts, re-
duced sperm motility and abnormal morphology, either alone or in combination.
Treatment
Several treatment modalities, both surgical and nonsurgical, are available for vari-
coceles. These include incisional ligation of the veins through the retroperitoneal, 
inguinal or subinguinal approaches, percutaneous embolization and laparoscopy. 
The common goal of all treatments is to eliminate the retrograde reflux of venous 
blood through the internal spermatic veins. Treatments can be compared in terms 
of expected success rates (semen improvement and pregnancy), cost and outcomes 
(pain pills, return to work or other activity) and their relative merits can be analyzed.
If watchful waiting is chosen, a pregnancy rate of 16% can be expected. If IVF 
is chosen, a pregnancy rate of 35% can be expected. An overall complication rate 
of 1% is associated with the incisional approach, compared with a 4% compli-
cation rate for laparoscopy and 10-15% for radiologic occlusion. A significant 
problem with the radiologic approach is technical failure, meaning the inability 
to access and occlude the spermatic vein. After varicocele repair in an infertile 
male, perform semen analysis every three months until either one year has passed 
or pregnancy occurs.
17 2  .HYDROCELE
A hydrocele is an abnormal quantity of peritoneal fluid between the parietal and 
visceral layers of the tunica vaginalis, the double layer of peritoneum surround-
ing the testis and which was the processus vaginalis in the foetus. Normally the 
processus vaginalis becomes obliterated along its entire length, apart from where 
it surrounds the testis where a potential space remains between the parietal and 
visceral layers. The adult hydrocele is caused by excessive fluid secretion by the 
visceral tunica albuginea without adequate reabsorption of this fluid by the parietal 
peritoneum around the testis. 
Pathogenesis
May be primary or secondary. Primary hydroceles develop slowly over the course 
of years and there is no precipitating event such as epididymoorchitis or trauma 
and the underlying testis appears normal on US. Secondary hydroceles may be due 
to infection, tumor, trauma and represent an effusion between the layers of the 
tunica vaginalis, analogous to a pleural or peritoneal effusion. In filariasis, obstruc-
tion of the lymphatics of the spermatic cord give rise to the hydrocele.
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Hydrocele formation is the most common complication reported after nonmi-
croscopic varicocelectomy with an average incidence of about 7%. Analysis of the 
protein concentration of hydrocele fluid indicates that hydrocele formation after 
varicocelectomy is due to lymphatic obstruction. At least half of postvaricocelec-
tomy hydroceles grow to a size large enough to warrant surgical excision due to 
the discomfort and growth of the hydrocele to a large size. The effect of hydrocele 
formation on sperm function and fertility is uncertain. The development of a large 
hydrocele creates an abnormal insulating layer that surrounds the testis. Use of 
magnification to identify and preserve lymphatics can virtually eliminate the risk 
of hydrocele formation after varicocelectomy. The management of postvaricoce-
lectomy hydrocele is identical to that for other forms of hydrocele. 
Symptoms .and .signs
Usually painless, unless the underlying testicular disease is painful. A hydrocele 
has a smooth surface and it is difficult or impossible to feel the testis which is 
surrounded by the tense, fluid collection. The superior margin can be palpated. It 
is possible to transilluminate a hydrocele. The light from a torch applied on one 
side can be seen on the other side of the hydrocele. 
Treatment
Men diagnosed with hydroceles, where there is suspicion for concomitant ma-
lignancy, should undergo high-resolution scrotal US. If malignancy is suspected, 
an inguinal approach should be used to allow control of the spermatic cord in 
preparation for radical orchiectomy. If this approach is taken and no malignancy 
is encountered, the testis can be spared and the hydrocele can be repaired by one 
of the techniques.
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